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Pleiotropic drug resistance (PDR) ATP-binding cassette (ABC) transporters are 
abundant eukaryotic membrane proteins that pump a vast array of different compounds 
across organelle and cell membranes. Overexpression of the archetype fungal PDR 
transporter Cdr1 is the main cause of azole drug resistance in Candida albicans, a major 
fungal pathogen that can cause serious, life threatening, invasive fungal infections in 
immunocompromised individuals. Fluconazole, an azole antifungal, is commonly used to 
treat these infections. Azole resistance of C. albicans isolates, however, is of serious clinical 
concern with often fatal outcomes. An attractive approach to overcome azole resistance is 
the use of efflux pump inhibitors in combination with azoles. In order to achieve this result, 
understanding how these efflux pumps work and obtaining high-resolution structures will 
help to develop suitable inhibitors that do not easily give rise to resistance. Yet, to date, no 
structure for any PDR ABC transporter has been solved. PDR transporters are one of the 
largest membrane protein superfamilies. Many plants and fungi have more than ten, some 
up to 50, different PDR transporters; which indicates that they are likely to be important 
for their survival in complex, frequently changing, environments. As such, they are of great 
importance to human fungal disease, and in agriculture.  
The objectives of this project were to: i) investigate the role of cysteine amino acids 
in the stability, trafficking and function of C. albicans Cdr1; ii) hyperexpress Cdr1 in the 
eukaryotic model organism, Saccharomyces cerevisiae, and optimise the isolation and 
purification of Cdr1; and iii) attempt to determine the structure of Cdr1 with X-ray 
crystallography or cryo-EM.  
In this PhD project, a successful workflow was developed that led to the purification 
of 0.5 mg Cdr1 per litre of the culture medium in pure, stable, monodisperse form that was 
used to perform structural investigations of Cdr1 with X-ray crystallography and cryo-EM. 
In addition, 21 cysteine-deficient Cdr1 mutants were created, and biochemically 
characterised, which revealed that the six conserved extracellular cysteines were most 
critical for proper Cdr1 expression, localisation, and function. One fully functional ‘almost 
Cys-less’ version of Cdr1, Cdr1P-CID, with all but the six conserved extracellular cysteines 
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replaced with serine, alanine or isoleucine was constructed. Cdr1P-CID will be critical in 
cysteine-crosslinking studies that will help confirm the biological significance of any future 
structure of Cdr1. An additional four mutants were constructed to generate catalytically 
inactive transporters. Two conserved nucleotide binding domain residues (D327 and 
E1027) contributing catalytic bases for ATP-hydrolysis, were replaced with asparagine or 
glutamine. In addition to those three mutants (Cdr1-D327N, -E1027Q, and -D327N-
E1027Q), a fourth catalytically inactive Cdr1 mutant (Cdr1-K901A) was also generated.  
Detergent screening, using 31 detergents with different chemistries, revealed that 
n-dodecyl-β-D-maltopyranoside (DDM) and lauryl maltose neopentyl glycol (LMNG) 
worked best for Cdr1 solubilisation and/or purification. They provided purified monomeric 
Cdr1 molecules for crystallography and electron microscopy. Crystal trials using four 
different commercial crystal screens identified some conditions that resulted in small 
crystal formations that need to be optimised in order to grow bigger crystals. Protocols for 
negative stain EM and cryo-EM were optimised which resulted in the first very low-
resolution (~18 Å) structures of negative stained detergent-purified Cdr1, however more 
work is needed to resolve ambiguities between the structures. This study has revealed 
important insights into the structure-function relationship of C. albicans Cdr1 and laid the 
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Preface 
This doctoral thesis represents a four-year research study performed at the Sir John 
Walsh Research Institute (SJWRI) of the University of Otago, Dunedin, New Zealand. It 
contributed to the project “Fungal drug resistance – not as simple as A-B-C” (supported by 
Marsden Grant UOO1305) that was led by Prof. R. D. Cannon and Dr. E. Lamping. 
The thesis comprises six chapters with Chapter 1 being a general introduction that 
provides the background and describes the objectives of the study. Chapter 2 covers the 
materials and general methods used throughout this study. However, the next three 
chapters contain additional methods specific for the experimental focus of those chapters. 
Chapters 3, 4 and 5 describe the research results separated into three distinct aspects of 
the project: 
• Chapter 3 - Mutagenesis and biochemical characterisation of Cdr1 mutants  
• Chapter 4 - Expression and purification of Cdr1  
• Chapter 5 - X-ray crystallography and cryo-EM studies of Cdr1 
Chapter 6 contains my concluding remarks. 
This project was performed in collaboration with two research groups, one at the 
University of Auckland, New Zealand, and the other at the Max Planck Institute (MPI) of 
Molecular Physiology in Dortmund, Germany. Most research (i.e. molecular biology, 
biochemical characterisation, expression and purification of Cdr1) was conducted at the 
MBL (Molecular Biosciences Laboratory, SJWRI, University of Otago). X-ray crystallography 
was performed in the Crystallography Facility, Department of Biochemistry, University of 
Otago. Parts of the negative stain EM experiments were performed at the Cryo-EM Facility 
of the University of Auckland under the supervision of Associate Prof. A. K. Mitra and later 
experiments at the Otago Micro- and Nano-Scale Imaging Centre under supervision of Dr. 
Mihnea Bostina at the University of Otago. Some purification experiments and the 
structural characterisation of Cdr1 (negative stain EM, and cryo-EM), supported by the 
German Academic Exchange program (DAAD), were performed by me at the MPI of 
Molecular Physiology, Dortmund, Germany, under the supervision of Prof. S. Raunser. The 
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SEC-MALS experiments were performed at the School of Biological Sciences of the 
University of Auckland, at Prof. C. Day’s laboratory in the University of Otago Department 
of Biochemistry, and later also at the Wyatt Technology Corporation, Dernbach, Germany. 
Permission to reprint figures taken from journals and books in this Doctoral Thesis 
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2D Two-dimensional 
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Cryo-EM Cryo-electron microscopy 
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CTF Contrast transfer function 
CV Column volume 
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DDD Direct electron detection device 
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DRI Differential refractive index 
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EDs Extracellular domains 
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EF Elongation factor 
ELs Extracellular loops 
EM Electron microscopy 
EtBr Ethidium bromide 
FCC Frozen competent cells 
FEGs Field emission guns 
FFT Fast fourier transform 
FLC Fluconazole 
For/Rev Forward/reverse 
FPLC Fast protein liquid chromatography 
FSEC Fluorescence-detection size exclusion chromatography 
 xiii 
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h Hour(s) 
HB Homogenising buffer 
His Histidine 
HIV Human immunodeficiency virus 
HOG High osmolarity glycerol 
HPLC High performance liquid chromatography 
Hsp70 Heat shock protein 70 
IFIs Invasive fungal infections 
IL Interleukin 
ILs Intracellular loops 
IMAC Immobilised metal ion affinity chromatography 
ISAC Iterative stable alignment and clustering 
ITC Itraconazole 
kDa Kilodaltons 
keV Kilo electron volts 
KTZ Ketoconazole 
kV Kilo volts 
LCP Lipid cubic phase 
LDM Lanosterol 14α-demethylase 
LOH Loss of heterozygosity 
MALDI-TOF  Matrix-assisted laser desorption/ionisation- time-of-flight  
MALS Multiangle light scattering 
MDR Multidrug resistance 
MES 2-(n-morpholino)ethane-sulphonic acid 
MFS Major facilitator superfamily 
mg/ml Milligram/millilitre 
mGFP Monomeric green fluorescent protein 
MIC Minimum growth inhibitory concentration 
Min Minute(s) 
mM Millimolar 
MP Membrane protein 
mRNA Messenger ribonucleic acid 
MRPs Multidrug resistance-associated proteins 
MS Mass spectrometry 
MW Molecular weight 
MWCO Molecular weight cut-off 
NAC Non-albicans Candida 
NBDs Nucleotide binding domains 
Ni-NTA  Nickel-nitrilotriacetic acid 
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nm Nanometre 
NOSC Normalised oligomycin-sensitive Cdr1 ATPase activity 
NYS Nystatin 
o/n Overnight 
OC Oral candidiasis 
OD600nm Optical density at a wavelength of 600 nm 
ODU Optical density units 
ORF Open reading frame 
OS Oligomycin-sensitive 
OSC Corrected oligomycin-sensitive Cdr1 ATPase activity 
PAMPs Pathogen-associated molecular patterns 
PCR Polymerase chain reaction 
PDB Protein databank 
PDR Pleiotropic drug resistance 
PEG Polyethylene glycol 
PGK 3-phosphoglycerate kinase 
Pi Inorganic phosphate 
PMSF Phenylmethanesulphonyl fluoride 
POS Posaconazole 
PRRs Pattern recognition receptors 
rDNA Ribosomal deoxyribonucleic acid 
RPM Revolutions per minute 
RT Room temperature 
rVVC Recurrent vulvovaginal candidiasis 
s Second(s) 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SEC Size exclusion chromatography 
SNPs Single-nucleotide polymorphisms 
TEM  Transmission electron microscopy 
TEMED N,N,N’,N’-tetramethyl-ethylenediamine 
TF Transcription factor 
Th T-helper cell 
TMDs Transmembrane domains 
TMSs Transmembrane segments  
UA Uranyl acetate 
Ura Uracil 
UV Ultraviolet 
VIPER Validation of individual parameter reproducibility 
VPP Volta phase plate 
VRC Voriconazole 
YOLO You only look once 
 
Detergent abbreviations are presented separately in Chapter 2 (Table 2.2).  
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1 General Introduction 
1.1 Candida and Candida Infections 
Fungal infections are silent killers (Brown et al., 2012a). An estimated 1.6 million 
people die of fungal diseases each year (Leading International Fungal Education-(LIFE) , and 
millions more suffer from irritating superficial fungal infections (Global Action Fund for 
Fungal Infections-(GAFFI) . Those numbers are higher than the number of people dying of 
tuberculosis and three-times that of people dying of malaria (Bongomin et al., 2017). Of 
the estimated 2.2 to 3.8 million fungal species distributed worldwide (Hawksworth et al., 
2017), only ~300 are human pathogens (Taylor et al., 2001). The most common human 
fungal pathogens are species of the Candida, Cryptococcus, Pneumocystis, Aspergillus and 
Fusarium genera and species of the Mucorales order of fungi (Miceli et al., 2011; Bongomin 
et al., 2017). 
Candida species are ubiquitous polymorphic yeast of the Ascomycota division of 
fungi (Calderone et al., 2012). This genus of sexually ‘imperfect’ fungi was first described 
by the Dutch mycologist, Christine Marie Berkhout, in 1923 (Barnett, 2004). Candida 
infections emerged as a significant medical concern with the rise of the AIDS epidemic in 
the late 80s and early 90s (Pfaller, 1996). Candida species are a normal part of the 
microflora of skin and mucous membranes of the oral cavity and the respiratory, 
gastrointestinal, and genitourinary tracts (Sardi et al., 2013). Occasionally, however, they 
can cause superficial fungal infections of the skin or mucous membranes (i.e. oral thrush 
or vaginal candidiasis), that, if left untreated, can lead to serious life-threatening invasive 
fungal infections (Calderone et al., 2012). It is estimated that 75% of women will experience 
at least one episode of vaginal thrush in their reproductive years (Powell, 2010). The global 
rates of recurrent vulvovaginal candidiasis (rVVC), defined as more than three episodes of 
symptomatic vaginal candidiasis within one year, are shown in Figure 1.1. 
Immunodeficiencies related to age or caused by disease, medication or hormonal 
imbalances of the body are common predisposing factors for candidiasis.  
 3 
 
Figure 1.1. Global burden of recurrent vulvovaginal candidiasis (rVVC). The colours 
indicate the global estimates of women aged between 15 and 54 who experience rVVC in 
each country. Modified from (Denning, et al. 2018); used with permission from Elsevier, 
licence no. 4885790128582 (Appendix A4). 
The number of immunocompromised individuals is rising steadily, not the least 
because of a steady increase in the number of elderly people and certain advances in 
modern medicine. The immunocompromised include HIV-AIDS patients, premature babies, 
the elderly, cancer patients undergoing chemo- or radio-therapy, organ transplant patients 
and many more (Underhill et al., 2014; Raje et al., 2015). C. albicans is by far the most 
frequently (46.4%) isolated Candida species collected from medical centres of different 
countries (Garber, 2001; Pfaller et al., 2019), but the proportion of non-albicans Candida 
(NAC) species seems to be steadily increasing due to the over- or mis-use of antifungals 
(Papon et al., 2013; Sardi et al., 2013). The list of NAC species includes C. glabrata (19.6%), 
C. parapsilosis (14.4%), and C. tropicalis (8.3%) and the less frequently clinically isolated 
species C. krusei (2.8%) (Pfaller et al., 2019), and the only recently emerged multidrug 
resistant species, Candida auris (Satoh et al., 2009; Lee et al., 2011; Calvo et al., 2016; 
Schelenz et al., 2016; Jeffery-Smith et al., 2018; Kordalewska et al., 2019; Pfaller et al., 
2019).  
1.2 Candida albicans 
C. albicans is a very adaptable microorganism, arguably the most important human 
fungal pathogen of immunocompromised individuals (Kabir et al., 2012). The name 
Candida albicans is derived from the Latin words Candida, which means white, or pure, and 
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albicus, with a similar meaning, whitish, referring to their whitish round-shaped colony 
morphology when grown on agar plates. The genomic plasticity of C. albicans is very 
dynamic, it can transition between being haploid, diploid, and aneuploid. The variations in 
chromosome organisation and copy number can generate rapid diversity which is 
advantageous in responses to stressful growth conditions (Selmecki et al., 2010). 
C. albicans is a polymorphic organism able to grow in different forms in different 
environments, and numerous cell morphologies have been recognised. These include 
ovoid, unicellular, yeast cells (sometimes referred to as blastospores), filamentous hyphae, 
pseudo-hyphae, and chlamydospores (Odds, 1988) and three recently reported yeast-like 
cell morphotypes named opaque, grey and gastro-intestinally induced transition (GUT) cell 
types (Noble et al., 2017). The pathogenicity and virulence of C. albicans in both superficial 
and systemic infections is related to its spectacular morphological plasticity (Calderone et 
al., 2000; Noble et al., 2017). This proposition has been supported by molecular genetic 
analyses. It has been shown that the genes involved in cellular morphology are coregulated 
with typical virulence factors such as proteases and adhesins. So, producing both hyphae 
and virulence factors, concurrently, results in cells that are tailored for invading the host 
tissues and makes the hyphae pivotal for the process of infecting the host (Kumamoto et 
al., 2005).  
The ability of Candida cells to adhere to different surfaces and to other microbial 
cells (Calderone et al., 2000) facilitates biofilm formation of either mono- or mixed-species 
communities (Cannon et al., 1999; de Groot et al., 2013) which has been established as one 
of the main virulence factors that contributes to fungal pathogenicity (de Groot et al., 
2013). Biofilms have been found on different tissues and prosthetic device surfaces, such 
as endothelial and epithelial cells, urinary and central venous catheters, artificial heart 
valves, contact lenses, orthopaedic implants, ocular prostheses, dentures, and many more 
(Bryers, 2008; Lyons et al., 2019). Formation of Candida biofilms comprises four stages: 1) 
adherence of cells to the surface; 2) proliferation to make a basal layer of cells on the 
surface; 3) hyphal and pseudo-hyphal growth accompanied by production of extracellular 
matrix material; and 4) gradual dispersal of yeast-form cells to colonise new sites (Nobile 
et al., 2015). 
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1.2.1 Pathogenicity 
C. albicans pathogenicity depends on both the host and C. albicans virulence 
factors. The infection process starts with the adhesion of C. albicans cells to host cell 
surfaces (Calderone et al., 2000) followed by penetration of the host tissue and invasion of 
the bloodstream by Candida hyphae. C. albicans yeast cells adhere to a variety of cell 
surfaces and foreign implant materials (Calderone et al., 1991; Calderone, 1993; Hostetter, 
1994; Cannon et al., 1999). Adhesins are a family of extracellular molecules (Douglas, 1995; 
de Groot et al., 2013) that include proteins of the agglutinin-like sequence (Als) family (Liu 
et al., 2011), hyphal wall protein (Hwp) family (Staab et al., 2013), enhanced adherence to 
polystyrene (Eap) (Li et al., 2008), and some more (Fukazawa et al., 1997; Calderone et al., 
2001; Kempf et al., 2009; Zipfel et al., 2011). In addition to adhesins, secreted hydrolytic 
enzymes are important virulence factors that contribute to the cell damage of invaded host 
tissue. The list of hydrolytic virulence factors includes phospholipases (Ghannoum, 2000), 
and secreted aspartyl proteinases (SAPs) (Hube et al., 1997; Naglik et al., 2003; Schaller et 
al., 2005). The polymorphic phenotype of C. albicans (Soll, 1992), and its ability to form 
biofilms on biotic and abiotic surfaces (Ganguly et al., 2011) are also implicated as virulence 
factors (Kabir et al., 2012). Although growth of C. albicans as hyphae is a key virulence 
factor required for penetrating the host epithelium and escaping phagocytes, its yeast form 
is also required for spreading the infection at a later stage of the infection process (Cheng 
et al., 2012). 
1.2.2 Host Immune Response to C. albicans Infection 
C. albicans has evolved effective strategies to escape the host’s innate immune 
defence system. The innate immune system of healthy individuals recognises C. albicans 
yeast cells with the help of specific surface receptors that, upon binding of yeast cells, 
induce an immune response in the host that includes the activation of a signal transduction 
cascade which is followed by the release of certain cytokines and chemokines (Wang et al., 
2014). Thus, in healthy individuals, C. albicans cells are eliminated quickly through a 
complex network of interactions between the innate (Qin et al., 2016) and adaptive 
(Richardson et al., 2015) immune systems. Imbalances in this web of interactions can lead 
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to the spread of the yeast through the bloodstream causing life-threatening systemic 
fungal infections (Brown et al., 2012a; Brown et al., 2012b).  
To neutralise invading C. albicans cells, the host first recognises the pathogen by 
detecting evolutionarily conserved cell wall components, mainly carbohydrate polymers 
and proteins. Pattern recognition receptors (PRRs) recognise these small pathogen-
associated molecular patterns (PAMPs) as microbial signatures, that, upon binding, activate 
signalling cascades that stimulate the innate immune response and help establish adaptive 
immunity (Netea et al., 2010). The mucosal epithelium usually provides a physical barrier 
against invading C. albicans cells. Epithelial cells also secret antimicrobial peptides called 
defensins and histatins to control the potential pathogen (Cheng et al., 2012), and they also 
play a crucial role in producing cytokines that recruit host immune cells (Steele et al., 2002). 
Once the yeast cells have successfully crossed the epithelium and entered the blood, 
endothelial cells engulf the organism by surrounding them with pseudopods to remove the 
invading fungus (Phan et al., 2005). Although epithelial and endothelial cells are not 
classical immune cells, they provide crucial barriers for infectious agents (Naglik et al., 
2011).  
The adaptive immune response comprises of a plethora of specialised immune cells. 
Phagocytes are immune cells modulated by both the innate and acquired immune systems. 
Neutrophils are one of the main types of phagocytes. They have intra- and extra-cellular 
antifungal activities and can either kill invading pathogens by phagocytosis or hinder them 
in the extracellular space by releasing chromatin fibres as extracellular traps (Urban et al., 
2006; Urban et al., 2009). Monocytes and macrophages are important for the detection of 
PAMPs and to attract neutrophils to the site of infection. The arrival of neutrophils leads to 
the engagement of even more monocytes and the modulation of cytokine release by 
activated macrophages (Amulic et al., 2012).  
Dendritic cells are essential components of the innate host immune system. They 
have PRRs for pathogen detection, they can secrete cytokines, and they can phagocytose 
fungal pathogens. They are also essential for inducing the adaptive T-cell-mediated 
immune response to C. albicans invasion (Ramirez-Ortiz et al., 2012). 
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Natural killer cells are a type of lymphocyte vital for both the innate and adaptive 
immune responses which have direct and indirect antifungal activities against Candida and 
other fungi through production of cytotoxic compounds and cytokines and interferons 
(Zucchini et al., 2008; Schmidt et al., 2013). T-lymphocytes (T-cells) are an important 
component of the adaptive immune response to invading C. albicans cells. Naive CD4+ T-
cells can differentiate into a number of different T-helper (Th) cell types (e.g. Th1, Th2, Th9, 
Th17, Th22) via antigen recognition and cytokine secretion (Igyarto et al., 2011). Th1 and 
Th17 cells are part of the innate immune response that enable the host to maintain tissue 
homeostasis in the presence of colonising C. albicans cells (Pandiyan et al., 2011; van de 
Veerdonk et al., 2011; Hernandez-Santos et al., 2013; Conti et al., 2014). IL-17 in candidiasis 
has been established as a key mediator of host protection at mucosal surfaces; most 
probably through inducing the antimicrobial peptide production that helps to manage 
overgrowth and morphotype switching of Candida (Conti et al., 2015). 
1.3 Clinical Manifestations of Candidiasis 
Candidiasis is the term for fungal infections caused by Candida species, that may 
occur as a superficial or systemic disease. C. albicans is a commensal microorganism that 
colonises many parts of the body asymptomatically, but it can become pathogenic in 
immunocompromised individuals. Superficial mucosal infections of the skin and of mucosal 
membranes of the oral cavity, the pharynx, and the genitourinary tract are quite common 
in healthy individuals. If untreated, however, these infections can turn into serious invasive 
fungal infections (haematogenously disseminated candidiasis) in individuals with 
weakened immune systems.  
1.3.1 Oral Candida Infections 
Oral candidiasis (OC) has been classified into two categories; primary, and 
secondary OC (Singh et al., 2014). Primary OC is subdivided based on clinical, mycological, 
histological, serological and therapeutic criteria (Lehner, 1964) into acute (includes 
pseudomembranous and erythematous candidiasis), chronic (includes 
pseudomembranous, erythematous and hyperplastic candidiasis), Candida-associated 
lesions (denture-induced stomatitis, angular cheilitis, and median rhomboid glossitis), and 
 8 
keratinised primary lesions with Candida super-infection (includes leukoplakia, lichen 
planus, and lupus erythematosus) (Singh et al., 2014). Secondary OC is an oral 
manifestation of a generalised systemic mucocutaneous candidiasis (Singh et al., 2014; 
Patil et al., 2015).  
1.3.1.1 Pseudomembranous Candidiasis 
Pseudomembranous candidiasis (thrush) is the most common type of candidiasis 
which is often seen in extremes of age, immunocompromised patients, patients on 
corticosteroids, and those on prolonged broad-spectrum antibiotic therapy (Burgdorf, 
2008; Farah et al., 2010; Lalla et al., 2013; Patil et al., 2015). It can occur on the soft palate, 
oropharynx, labial and buccal mucosa, tongue, and gingiva. It presents as superficial white 
to whitish-yellow creamy plaques (Figure 1.2-A). These non-adherent plaques can be wiped 
off gently, leaving behind an erythematous base that bleeds easily (Farah et al., 2010; Lalla 
et al., 2013). This condition may be acute or chronic; the acute form has rather mild 
symptoms with slight taste alteration, whereas the chronic form may lead to dysphagia and 
chest pains (Patil et al., 2015).  
1.3.1.2 Erythematous Candidiasis 
Acute erythematous candidiasis, also known as “antibiotic sore mouth” (Farah et 
al., 2010), is relatively rare (Patil et al., 2015). Clinically, it manifests as a painful localised 
erythematous area and the lesions (Figure 1.2-B) are well-demarcated erythematous areas, 
or depapillated areas of the tongue (Williams et al., 2011; Patil et al., 2015).  
1.3.1.3 Chronic Hyperplastic Candidiasis 
Chronic hyperplastic candidiasis is also known as plaque-like/nodular candidiasis. It 
usually appears as one of two forms: homogeneous adherent white plaque-like lesions or 
erythematous multiple nodular/speckled type (Figure 1.2-C) and the plaques are not easily 
removed (Patil et al., 2015). 
1.3.1.4 Candida-Associated Lesion  
Denture-induced stomatitis (Figure 1.2-D), angular cheilitis (Figure 1.2-E), and 
median rhomboid glossitis (Figure 1.2-F) are three types of Candida-associated lesions 
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(Singh et al., 2014; Patil et al., 2015). Denture stomatitis, also known as “chronic atrophic 
candidiasis”, or “chronic erythematous candidiasis”, as the names suggest is a chronic 
infection that usually presents as an erythematous area of the fitting surface of denture 
and is commonly associated with poor denture hygiene (Pereira-Cenci et al., 2008; Patil et 
al., 2015). Clinically, the lesions could be seen as pinpoint hyperaemia, diffuse 
erythematous or a granular/papillary type and it is frequently accompanied with angular 
cheilitis and median rhomboid glossitis (Patil et al., 2015).  
Angular cheilitis appears as erythematous or ulcerated fissures, normally affecting 
the commissures at the corners of the mouth. Median rhomboid glossitis manifests as 
papillary atrophy at the centre of the tongue and presents as a symmetric, depapillated 
area anterior to the circumvallate papillae (Patil et al., 2015). Most cases have no 
symptoms, however, some patients experience persistent pain, and irritation (Lago-
Mendez et al., 2005).  
1.3.1.5 Chronic Mucocutaneous Candidiasis  
This condition consists of a heterogeneous group of disorders, which are usually 
superficial infections of the oral cavity (Figure 1.2-G), skin, nail beds (Figure 1.2-H), genital 
mucosa, and occasionally face and scalp, due to underlying immunologic conditions. Oral 
cavity involvement is reported in more than 90% cases (Williams et al., 2011; Lalla et al., 
2013; Patil et al., 2015). Vaginal candidiasis is characterised by itching, burning, curd-like 
whitish non-offensive vaginal discharge, oedema, dysuria and dyspareunia (Eckert et al., 








Figure 1.2. Different presentations of candidiasis. A) Pseudomembranous candidiasis of 
the tongue, B) erythematous candidiasis of the palate, C) hyperplastic candidiasis at the 
lateral border of the tongue, D) denture stomatitis of the palate, E) angular cheilitis 
(Stoopler et al., 2013); used with permission from Canadian Dental Association (Appendix 
A4), F) median Rhomboid glossitis, G) chronic mucocutaneous candidiasis (Kopáčová et al., 
2005) of the mouth and H) the nails (Kopáčová et al., 2005); used with permission directly 
from the author (Appendix A4). All, except E, G, and H, taken from (Patil et al., 2015); CC-
BY licence (Appendix A4).  
 
1.3.2 Diagnosis 
Correct identification of the symptom-causing pathogen within hours of 
presentation is critical for successful treatment, especially for invasive fungal infections 
(Pappas et al., 2004; Pfaller et al., 2016). Clinical signs and symptoms guide a quick, but 
rather superficial, diagnosis and must be complemented with either culture-based 
methods, microscopy, or, ideally, with faster and more reliable biochemical and 
molecular techniques (Madhavan et al., 2011; Coronado-Castellote et al., 2013). 
Culture media used for isolating Candida species include blood agar, potato 
dextrose, Sabouraud dextrose, or yeast peptone dextrose media in either solid (agar 
plates) or liquid (broth) form. More selective media like CHROMagar (Bernal et al., 
1996; Horvath et al., 2003), bird-seed agar (Pasligh et al., 2010), and CandiSelect4 
(Gaschet et al., 2008) are available to presumptively differentiate between various 
Candida species, but these culture-based methods generally take a long time (one or two 
days) and they are quite unreliable in distinguishing closely related species. Biochemical 
methods are also routinely used. Oxygen requirement combined with biochemical tests 
such as catalase, oxidase, and coagulase, and mixed techniques that combine enzymatic 
A                                     B                                      C                                      D 
                                     F                                        
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and nutrient assimilation tests can provide preliminary species identification (Rodrigues 
et al., 2004; Aslanzadeh, 2006; Coronado-Castellote et al., 2013). However, commercially 
available biochemical kits vary in accuracy (Sahand et al., 2009; Coronado-Castellote et al., 
2013) and still require rather long cultivation times (4 – 72 h), after which it is often too 
late to improve outcomes for seriously ill patients. Molecular techniques using PCR 
amplification and DNA sequencing have been used effectively to identify Candida to the 
species level. Examples include using specific primers based on the sequences of the DNA 
topoisomerase II genes (Kanbe et al., 2003) and several PCR-based methods that have 
emerged for the diagnosis of bloodstream infection directly from whole blood (Opota et 
al., 2015). A very common method involves amplification and sequencing of the rDNA 
internal transcribed spacer region ITS2 (Hoggard et al., 2018). 
Mass spectrometry-based methods are also very useful to identify Candida species. 
For instance, C. albicans and non-albicans Candida species can be identified directly from 
a blood culture by MALDI-TOF Mass Spectrometry within half an hour (Spanu et al., 2012). 
Although modern molecular techniques are fast and reliable, unfortunately, many 
diagnostic laboratories are not equipped, or simply cannot afford, to carry out such tests.  
1.3.3 Treatment 
Successful treatment of patients with candidiasis requires correct diagnosis, 
otherwise the treatment may only result in a temporary relief of the symptoms and 
ultimately lead to a relapse (Pappas et al., 2015; Pfaller et al., 2016). Oral candidiasis 
typically responds to topical antifungal therapy, such as gels or pastilles. In severe cases of 
candidiasis, or if topical treatment of superficial candidiasis is ineffective, treatment with 
orally administered antifungals is used. Cutaneous infections, including vaginal candidiasis, 
are also routinely treated with topical antifungal agents (including azoles or nystatin). 
However, serious invasive bloodstream infections are treated with orally or intravenously 
administered antifungal drugs (Pappas et al., 2004; Pappas et al., 2015). Candidiasis can be 
treated successfully with a number of antifungal medications including the azole 
antifungals fluconazole (FLC), itraconazole (ITC), posaconazole (POS) and voriconazole 
(VRC), the polyenes nystatin (NYS) and amphotericin B (AMB) and the echinocandins 
micafungin or caspofungin (Garcia-Cuesta et al., 2014; Pappas et al., 2015; Ben-Ami, 2018). 
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1.4 Antifungals 
Fungal pathogens are eukaryotes and, as such, they share many essential cellular 
processes with the human host. This significantly limits the number of structures or 
processes that can be targeted by drugs without affecting the health of the human host. 
Liu et al., 2006, found that ~80% of 240 essential fungal genes had highly conserved (> 40% 
identity) structural homologs in the human genome (Liu et al., 2006). This is why treatment 
options remain rather limited with only three major classes of antifungal drugs available to 
treat patients with life-threatening invasive fungal infections. The drug classes include the 
azole antifungals that target ergosterol biosynthesis, the echinocandins that target cell wall 
biosynthesis and polyene antifungals that bind to the fungal-specific sterol, ergosterol 
(Figure 1.3).  
1.4.1 Polyene Antifungals 
The polyenes are broad-spectrum antifungal agents produced by the bacterial 
genus Streptomyces (Vartak et al., 2014). The AMB deoxycholate formulation was 
introduced as an antifungal agent in 1959. It is effective against a wide variety of fungi 
(Chandrasekar, 2008), and its primary mode of action is binding to ergosterol, an essential 
membrane lipid component only found in fungi. Binding of ergosterol by AMB or NYS is 
thought to cause pore formation and changes to the permeability of fungal plasma 
membranes that lead to cell depolarisation and cell death (Ermishkin et al., 1976; 
Traunmuller et al., 2011). However, a recent study suggests that binding ergosterol by AMB 
alone is sufficient to kill yeast and pore formation is only a secondary effect of the AMB 
action (Gray et al., 2012). Another proposed mechanism for polyenes is the ergosterol 
extraction from the lipid bilayer (Figure 1.3 - reviewed by (Revie et al., 2018)). The polyene 
antifungal NYS is mostly used in topical applications to treat superficial Candida infections 
of the skin and mucosa of various body parts, but it can also be administered orally 
(Bondaryk et al., 2013). 
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Figure 1.3. Modes of action of antifungal drugs. A) Azoles target lanosterol 14α-
demethylase (LDM), an ergosterol biosynthesis enzyme encoded by ERG11 (yeast) or CYP51 
(mould), causing the accumulation of toxic sterol intermediates, produced by ERG3. This 
toxic sterol intermediate induces severe membrane stress, but the lack of ergosterol 
ultimately inhibits cell growth. It is important to note that azoles are fungistatic and not 
fungicidal agents. B) A proposed mechanism of action of the fungicidal polyenes is the 
extraction of ergosterol from the plasma membrane lipid bilayer. C) The echinocandins act 
as non-competitive inhibitors of β 1,3-glucan synthase, encoded by FKS1, leading to the 
loss of cell wall integrity and causing severe cell wall stress. Echinocandins are fungicidal 
for various Candida species, but they appear to have only fungistatic activities for 
Aspergillus spp. and Cryptococcus neoformans. Figure from (Revie et al., 2018); used with 
permission from Elsevier, licence no. 4753390085403 (Appendix A4). 
 
Unfortunately, polyenes have only limited selectivity for ergosterol over cholesterol 
which leads to serious toxic side-effects in mammalian cells (Brajtburg et al., 1990). Thus, 





high-risk patients, and infusion related difficulties are reasons why AMB is no longer 
recommended as the primary therapy for most patients suffering fungal infections 
(Ostrosky-Zeichner et al., 2003a; Patterson, 2006; Petrikkos et al., 2007). AMB formulations 
with significantly reduced cell toxicities have been created by incorporating AMB into 
liposomes or other lipid formulations (Walsh et al., 2000; Groll et al., 2003). The discovery 
of AMB derivatives with greater selectivity for ergosterol and, thus, less toxic side-effects 
than AMB, confirmed in a mouse model of systemic candidiasis (Davis et al., 2015), have 
provided hope for improved polyene antifungal therapies.  
1.4.2 Echinocandin Antifungals 
Although discovered in the 1970s (Benz et al., 1974), these semi-synthetic cyclic 
lipo-hexapeptides were only introduced into the clinic in the 2000s (Denning, 2002). Since 
then, no other class of antifungal has found its way into the clinical setting (Richardson et 
al., 2012). The echinocandins non-competitively inhibit β-1,3-glucan synthase, an essential 
plasma membrane protein that catalyses fungal cell wall β-1,3-glucan biosynthesis. 
Reduced β-1,3-glucan content in cell walls causes osmotic fragility leading to cell lysis 
(Figure 1.3). Caspofungin, micafungin and anidulafungin are three registered echinocandins 
that can be used to treat a number of fungal infections including candidiasis. However, 
their clinical use is somewhat restricted because they are expensive and their limited oral 
bioavailability means that they must be delivered intravenously (Denning, 2003; Denning 
et al., 2010). 
Even though Candida biofilm-related infections are extremely difficult, if not 
impossible, to treat, the only antifungals with demonstrated in vitro activity against C. 
albicans biofilms are AMB and the echinocandins (Kuhn et al., 2002; Sardi et al., 2013). 
1.4.3 Azole Antifungals 
The azoles are the largest and most frequently used class of antifungal. They inhibit 
the growth of a wide range of fungi. There are two major groups of currently used azole 
antifungals:  
1. Imidazoles - containing an imidazole ring with two nitrogen atoms. They include 
econazole, clotrimazole, miconazole, ketoconazole, and tioconazole. 
 15 
2. Triazoles - containing a triazole ring with three nitrogen atoms. They include FLC, 
VRC, POS, and ITC (Figure 1.4). 
The imidazoles are mostly applied as topical agents to treat superficial mucosal or 
skin infections while triazoles are mostly used, either orally or intravenously, to treat 
invasive fungal infections (IFIs). Azoles inhibit the cytochrome P450 enzyme, lanosterol 
14α-demethylase encoded by ERG11 (also known as CYP51), an enzyme of the ergosterol 
biosynthesis pathway (Warrilow et al., 2013). Inhibition of Erg11 results in ergosterol 
depletion which makes fungal cells susceptible to further membrane damage (Lupetti et 
al., 2002) and also affects cell growth and proliferation (White et al., 1998; Sanglard et al., 
2009). Accumulation of toxic methylated sterols (produced by Erg3) also occurs due to 
inhibition of Erg11 and leads to membrane stress (Shapiro et al., 2011; Prasad et al., 2016; 
Revie et al., 2018) as shown in Figure 1.3. 
Ketoconazole was the first orally bioavailable azole. Although it revolutionised the 
treatment of oral candidiasis and other fungal infections, its clinical use was limited due to 
hepatotoxicity, inhibition of cortisol synthesis and a large number of undesirable drug 
interactions (Fromtling, 1988).  
The second generation, triazole antifungals, exhibit much improved 
pharmacokinetic properties because they interact with fewer mammalian P450 enzymes 
and, therefore, have far fewer undesirable drug interactions. FLC has the additional 
advantage that it has greater water-solubility, which is why it is still the most frequently 
used antifungal for the prevention and treatment of superficial and invasive candidiasis. 
Unfortunately, many other fungal pathogens like C. glabrata, C. krusei, Aspergilli and other 
medically important moulds are often resistant to FLC (Rex et al., 1994; Slavin et al., 1995). 
ITC is another triazole antifungal that is useful for the treatment of vulvovaginal or oral 
candidiasis, although its toxicology is rather unfavourable for prolonged therapeutic use 
(Lestner et al., 2009). The triazole antifungal VRC was introduced in the early 2000s. It has 
improved antifungal activities against a number of fungi that do not respond to FLC 
therapy. It can be orally administered to treat species like C. krusei that are less-susceptible 
to FLC (Ostrosky-Zeichner et al., 2003b) as well as FLC resistant moulds like Aspergillus 
(Walsh et al., 2008; Rambach et al., 2011) or fungi of the Fusarium solani species complex 
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(Troke et al., 2013). POS is another broad spectrum antifungal with activities against 
Candida spp., Aspergillus and various Mucorales spp. (Torres et al., 2005).  
Apart from considering the type of fungus causing the infection, a clinician choosing 
an appropriate antifungal needs to consider a number of additional factors, including the 
drug’s toxicity, potentially deleterious drug-drug interactions (Hines et al., 2011), and 
genetic and patient-to-patient pharmacokinetic variabilities (Desta et al., 2002). For 
example, having the same fixed daily dose of VRC does not mean that it has the same effect 
in different patients, as there are three populations based on polymorphisms in the 
CYP2C19 drug metabolising gene that have markedly different VRC success rates (Desta et 
al., 2002). Another consideration is that echinocandins are safer than azoles for treatment 
of the elderly due to differences in the cumulative nephrotoxicity risk (Flevari et al., 2013). 
Short-term treatment versus long-term prophylaxis (Raad et al., 2006), oral versus 
intravenous delivery (Perea et al., 2004), and antifungal availability and cost (Walsh et al., 
2000), also need to be considered as well.  
 
Figure 1.4. Triazole antifungals. Fluconazole (FLC), voriconazole (VRC), itraconazole (ITC) 
and posaconazole (POS).  
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1.5 Antifungal Drug Resistance 
Treatment of patients with antifungal agents triggers a plethora of possible 
responses in the fungal pathogen to overcome the effects of the antifungal agent (Cannon 
et al., 2009). Thus, it is usually only a matter of time until a fungal pathogen develops 
resistance against an antifungal agent. Resistance has been shown to be increasing against 
different antifungal drugs in different fungal pathogens, however, the resistance rates 
differ between institutions and geographic regions. For instance, an increase was reported 
in FLC resistance in C. glabrata from 9% (1992-2001) to 14% (2001-2007) in the USA, while 
in some institutions the rate was as high as 12%-18%. Another report in 2013, similarly 
showed that among 1846 clinical isolates from 31 countries, 12% of C. glabrata isolates 
were FLC resistant. In contrast, 41% of Candida infections were resistant to FLC in some 
intensive care units in China (reviewed by (Perlin et al., 2017; Wiederhold, 2017)). Thus, 
antimicrobial drug resistance, which threatens the lives of millions (de Kraker et al., 2016), 
is of serious concern (Lawrence et al., 2013) and we must be vigilant in the proper use of 
antimicrobials, carefully monitor possible outbreaks of drug resistant fungi, avoid the 
spread of resistant microorganisms, and develop an arsenal of alternative treatment 
options (Lawrence et al., 2013; Laxminarayan et al., 2013) to stay ahead in this constant 
game of cat and mouse.  
Because of the limited number of antifungal agents, and the constant threat of 
multidrug resistance (MDR), it is paramount that we understand the resistance 
mechanisms to the drugs so that novel, improved, therapies can be developed (Pfaller, 
2012; Cowen et al., 2015). There is primary (i.e. inherent or intrinsic) drug resistance of 
strains or species and then there is secondary, acquired, drug resistance that can develop 
during prolonged therapy. The mechanisms of resistance are, however, similar in nature 
(Figure 1.5). They include drug target alterations (Rodero et al., 2003; Park et al., 2005; 
Niimi et al., 2012b; Spettel et al., 2019) or overexpression (Dunkel et al., 2008b), 
upregulation of multidrug transporters (Mahe et al., 1996), activation of stress responses 
(Cowen et al., 2009), alterations in cellular metabolic pathways (Kelly et al., 1997), and the 
formation of biofilms (Mateus et al., 2004), aspects of which have been recently reviewed 
(Srinivasan et al., 2014; Perlin et al., 2017; Robbins et al., 2017; Revie et al., 2018). Azole 
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and echinocandin resistance is relatively common and the mechanisms have been well-
documented, however, polyene resistant strains remain rare, quite possibly because 
polyenes interact primarily with an essential lipid component rather than a protein target 
and they are fungicidal rather than fungistatic (Table 1.1 and Table 1.2). Some Candida 
strains, such as many C. lusitaniae and some C. guilliermondii strains, display primary 
resistance to amphotericin B (Eliopoulos et al., 2002). Table 1.1 summarises the different 
types of resistance mechanisms reported for the different classes of antifungal agents, and 
Table 1.2 provides a more detailed indication of the resistance mechanisms. During 
exposure of C. albicans to antifungal treatment (both in vivo or in vitro), or to host tissues, 
there can be microevolution of strains that enable them to adapt to the host niche or 
antifungal drug (Table 1.3, extracted from (Pais et al., 2019)). 
Table 1.1. Summary of the major antifungal drug resistance mechanisms. Modified from 
(Perlin et al., 2017). For more details, check the Table 1.2. 
Resistance mechanism Azoles Echinocandins Polyenes 
Target overexpression Yes   
Drug pump upregulation Yes   
Target site modification Yes Yes  
Target abundance Yes  Yes 
Biofilm formation Yes Yes Yes 
Non-target effects Yes Yes Yes 
Mode of action Fungistatic Fungistatic or fungicidal Fungicidal 
 
 
1.5.1 Candida albicans Azole Resistance Mechanisms 
Azole compounds are the most commonly used drugs to treat human fungal 
infections (Cowen et al., 2005). Widespread use of azole drugs, however, coupled with their 
fungistatic nature has led to the emergence of azole resistant clinical isolates (Sanglard et 
al., 1995). Resistance arises through multiple mechanisms, some involve the drug target, 
and some involve off-target effects (Shapiro et al., 2011).  
1.5.1.1 Alteration of the Drug Target 
Alteration of the drug target, through overexpression (Cowen et al., 2000) or 
mutation (Marichal et al., 1999), is one of the mechanisms of azole resistance. Some 
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common substitutions in ERG11 that result in fluconazole resistance, for instance, are 
A114S, Y132H, Y132F, Y257H, G464S, and F72S (Xiang et al., 2013; Wang et al., 2015). 
Mutations in the transcription factor (Zucchini et al.) regulating ERG11 expression, Upc2, 
leads to Erg11 overexpression (Dunkel et al., 2008b; Lohberger et al., 2014). Some specific 
point mutations in Upc2 can lead to a hyper-active TF which, as a consequence, induces 
over-expression of ergosterol biosynthesis genes (Heilmann et al., 2010). Increasing gene 
dosage of ERG11 through genomic alterations is another cause of target overexpression. 
For example, azole resistant clinical isolates frequently have an isochromosome – a 
duplication of the left arm of chromosome 5. This arm includes the MTL locus, ERG11, and 
TAC1 – encoding a transcription factor that regulates the expression of drug efflux pump 
genes CDR1 and CDR2 (Selmecki et al., 2006). Increasing the copy number of ERG11 and 
hyperactive TAC1 alleles have been shown to increase azole resistance (Selmecki et al., 
2008). Aneuploidy (more than two copies of particular chromosomes) is another adaptive 
mechanism in C. albicans by which the pathogen responds to drug-induced stress in order 
to upregulate gene expression important for survival (Selmecki et al., 2006). 
 
Figure 1.5. Mechanisms responsible for intrinsic and acquired antifungal drug resistance. 
The effects of any combination of these mechanisms can lead to the selection of 
 20 
increasingly resistant strains over prolonged periods of treatment. Figure from (Revie et 
al., 2018); used with permission from Elsevier, licence no. 4753390085403 (Appendix A4). 
 
Table 1.2. Mechanisms of resistance to major antifungal agents. 





Efflux pump upregulation  
     (e.g. encoded by either MDR or CDR genes) 
Mutations in pump gene transcription factors  
     (e.g. C. albicans TAC1 [CDR1, CDR2, RTA2, etc], C. albicans MRR1 
     [MDR1, etc], S. cerevisiae PDR1 [PDR5, etc], C. glabrata PDR1 
     [CDR1, CDR2, etc]) 
Target alteration  
     (e.g. ERG11 in yeast and Cyp51 in moulds) 
Target overexpression  
     (e.g. C. albicans ERG11 regulated by UPC2) 
Bypass pathways 
     (e.g. ERG3 which reverses the membrane-disruptive effects of 
     azole drugs) 
(Lopez-Ribot et 
al., 1998; 
Sanglard et al., 
1998) 
Stress responses 
     (e.g. molecular chaperone Hsp90) 
Chromosomal abnormalities and high genomic plasticity 
     (e.g. loss of heterozygosity (LOH), increased chromosomal copy 
     number, aneuploidy, or isochromosome formation; especially  
     among Cryptococcus neoformans and C. albicans) 
(Cowen et al., 
2005; Selmecki 
et al., 2006; 
Cannon et al., 
2007; Cowen et 
al., 2008) 
Enhanced mRNA stability 
     (e.g. the half-life of CDR1 mRNA was threefold higher in resistant 
     isolates)  
(White, 1997a) 








s Point mutations in FKS1 “hot-spot”  
Adaptive stress response 
     (e.g. molecular chaperone Hsp90, cell wall integrity signalling, the 
     high osmolarity glycerol (HOG) pathway, and chitin biosynthesis) 
Biofilm formation  
     (leading to poor drug penetration) 
(Park et al., 
2005; Perlin, 







Less target accessibility 
     (by reduction in the membrane ergosterol content, or 
     accumulation of other sterols (by defects in the ERG3 gene) 
Increased catalase activity 
     (leading to decreased oxidative damage)  
(Ghannoum et 
al., 1999; 
Peman et al., 
2009; 




Table 1.3. Response of C. albicans upon exposure to antifungal drugs or to host tissues. 







Observed changes Reference 
Fluconazole 
treatment 
 X Overexpression of azole resistance genes 
     (CDR1, CDR2, MDR1, ERG11) 








X  ERG11 mutations (White, 1997b) 
Fluconazole 
treatment 
X  UPC2 GOFb, leading to ERG11 
     upregulation 
(Dunkel et al., 
2008b; Heilmann 
et al., 2010; Hoot 
et al., 2011) 
Fluconazole 
treatment 








X  TAC1 GOF, MRR1 GOF leading to MDR1 
     upregulation 
(Popp et al., 2017) 
Fluconazole 
treatment 
X X MRR1 GOF + LOH, leading to MDR1 
     upregulation 








X  (Several) mutations + LOH (Ford et al., 2015) 
Murine kidney X  Resistance to oxidative stress and high 
     temperature 
(Luttich et al., 
2013) 
Murine spleen  X  Uncoupling of oxidative phosphorylation 
     + resist phagocyte killing 
(Cheng et al., 
2007) 
Murine kidney X  Chromosome rearrangement + altered 
     colony morphology 




X  Increased competitive fitness + loss of 
     hyphae formation 
(Tso et al., 2018) 
Sputum (cystic 
fibrosis patients)  
X  NRG1 mutation (Kim et al., 2015b) 
Macrophage 
escape 
 X SSN3 mutation (Wartenberg et 
al., 2014) 
a Evolved in patients, not in vitro in the laboratory  
b Gain-of-function 
 
1.5.1.2 Upregulation of Multidrug Transporters 
Another key mechanism of resistance to azoles, shown in Table 1.2, is the 
overexpression of drug efflux proteins. There are two major types of multidrug efflux 
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pumps, the major facilitator superfamily (MFS) and the ATP-binding cassette (ABC) 
transporter superfamily, that contribute to azole resistance in C. albicans and related 
Candida spp. (Table 1.2; and see section 1.6). 
ABC transporters are primary transporters that couple drug efflux to ATP hydrolysis, 
and MFS transporters are secondary transporters that use the free energy provided by the 
flow of protons or ions down an electrochemical concentration gradient to efflux 
compounds across biological membranes (Cannon et al., 2007). Multidrug efflux proteins 
transport a vast array of compounds and there are often overlapping substrate specificities 
between different transporters. The C. albicans genome is predicted to encode 19 ABC 
transporters (Gaur et al., 2005; Prasad et al., 2015) and between 85 to 95 MFS transporters 
(Gaur et al., 2008; Coleman et al., 2009), far fewer than some other fungal species that 
inhabit a larger range of environments. Moulds of the Aspergillus genus have 40–60 ABC 
(Coleman et al., 2009; Kovalchuk et al., 2010; Meneau et al., 2016) and between 275 and 
356 MFS transporters (Coleman et al., 2009; Meneau et al., 2016). Prolonged exposure to 
azole antifungals often causes mutations in TFs that lead to the overexpression of ABC or 
MFS transporters. Clinically significant azole resistance in C. albicans is usually 
accompanied by the over-expression of the ABC proteins Cdr1 and Cdr2 or MFS protein 
Mdr1 (Morschhauser, 2002; Cannon et al., 2009). Upregulation of CDR1, CDR2 and a 
number of additional factors that are necessary to enable the overexpression of these 
plasma membrane efflux pumps is induced by gain-of-function mutations in transcription 
factor Tac1 (Coste et al., 2004; Coste et al., 2007). Similarly, mutations of the transcription 
factor Mrr1 were found to be responsible for the upregulation of MDR1 and a network of 
additional factors causing the increased drug resistance phenotype in some clinical azole 
resistant strains (Morschhauser et al., 2007; Dunkel et al., 2008a; Lohberger et al., 2014).  
1.5.1.3 Cellular Stress Responses 
The resistance mechanisms, mentioned above, show how the fungal cell is able to 
bypass the effect of the drug by either blocking binding of the drug to the target - ensuring 
the target is not saturated with drug, or removing the drug from the cell. Beside these 
mechanisms, C. albicans has developed stress response pathways that enable the cell to 
manage different environmental stresses, including exposure to drugs. A mutation in the 
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ERG3 gene, encoding the sterol Δ-5,6-desaturase, which reverses the membrane-disruptive 
effects of azole drugs by blocking production, and accumulation, of the toxic 14-α-methyl-
3,6-diol sterol, when Erg11 is inhibited (Martel et al., 2010) is one such stress response. The 
role of the stress response proteins calcineurin, casein kinase 2, cAMP-protein kinase A, 
and Hsp90 in azole drug resistance has been considered in several reviews (Cannon et al., 
2007; Shapiro et al., 2011; Perlin et al., 2017).  
1.5.1.4 Biofilms  
The ability of C. albicans to form biofilms that are intrinsically resistant to the host 
immune system, makes biofilm-induced Candida infections a serious clinical challenge 
(Nobile et al., 2015). C. albicans biofilms are also extremely resistant to most antifungals, 
including the azoles (Mathe et al., 2013), and this resistance phenotype is evident just a 
couple of hours after adherence of the yeast to surfaces (Mateus et al., 2004). Resistance 
can be caused by reduced levels of ergosterol in yeast membranes. Mukherjee, et al., 2003, 
clearly showed 40% and 50% reduced ergosterol levels between intermediate- and mature- 
as opposed to early-phase biofilms, respectively (Mukherjee et al., 2003). They also 
determined that increased expression of CDR1 and MDR1 after surface contact of yeast is 
important as well (Mukherjee et al., 2003). However, efflux pump expression plays a pivotal 
role in azole resistance in early-phase biofilm formation (Mukherjee et al., 2003). Another 
crucial factor of biofilm-associated azole resistance is the membrane sterol composition 
that could change the membrane permeability leading to reduced entry of azoles into 
fungal cells (Mukherjee et al., 2003). Biofilms formed from calcineurin mutants were more 
susceptible to fluconazole (Uppuluri et al., 2008) suggesting a role for calcineurin in biofilm 
resistance. Also, an increased (1,3)-β-D-glucan content of biofilms has been shown to 
contribute to biofilm azole resistance (Nett et al., 2007). One explanation for this could be 
the physical interactions of glucan (as an important cell wall component) with the 
antifungal that prevents penetration of drug, or it could be because of structural changes 
to the cell wall protecting the cell from external insults (Nett et al., 2007). 
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1.6 Multidrug Efflux Transporters of C. albicans  
One of the main mechanisms responsible for high-level azole resistance in clinical 
C. albicans isolates is overexpression of plasma membrane efflux pumps in the two main 
families, the ABC pumps and the MFS transporters (White, 1997a; Cannon et al., 2009). 
1.6.1 MFS Transporters 
MFS transporters catalyse the active uptake or export of sugars, oligosaccharides, 
metabolites, amino acids, oxyanions and a number of small molecule drugs. They usually 
utilise the electrochemical gradient of protons (H+), cations (e.g. Na+, K+) or anions (Cl-) to 
transport the movement of substrates against concentration gradients (Madej, 2014). MFS 
transporters have either 12- or 14-transmembrane spans (TMSs) that are connected to 
each other via short intracellular or extracellular loops (Pao et al., 1998; Law et al., 2008; 
Reddy et al., 2012). The C. albicans MFS transporter family comprises sugar porters (SP), as 
well as members of the DHA1 (drug:H+ antiporter 1), DHA2 and ACS (anion:cation 
symporter) families (Gaur et al., 2008; Costa et al., 2014). Among the 95 MFS transporters 
(Gaur et al., 2008), only Mdr1, a DHA1 protein with 12 predicted TMSs, also known as Benr 
(for benomyl resistance), has been implicated in azole resistance (Pasrija et al., 2007). 
MDR1 was identified by its ability to confer benomyl and methotrexate resistance in 
Saccharomyces cerevisiae (Fling et al., 1991). Hydrophilic and less branched substrates like 
FLC and KTZ are preferred Mdr1 efflux pump substrates (Lamping et al., 2007; Puri et al., 
2010). Generally, MFS-type multidrug efflux pumps transport a narrower range of 
substrates than ABC-type multidrug efflux transporters (Puri et al., 2010). Up-regulation of 
MDR1 due to gain-of-function mutations in the transcription factor Mrr1 (Morschhauser et 
al., 2007; Dunkel et al., 2008a) was detected in several clinical azole-resistant C. albicans 
isolates (Sanglard et al., 1995; Wirsching et al., 2000; White et al., 2002). 
1.6.2 ABC Transporters 
ATP-binding cassette (ABC) transporters are one of the largest protein super-
families that are found in all kingdoms of life (Higgins, 1992; Dassa et al., 2001) including in 
bacteria (Fath et al., 1993), yeast (Paumi et al., 2009), plants (Kang et al., 2011) and humans 
(Dean et al., 2001). ABC transporters use the energy released by ATP-hydrolysis at the 
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nucleotide binding domains (NBDs - which contain highly conserved motifs) to actively 
transport substrates against their concentration gradients (Rees et al., 2009). However, not 
all ABC proteins are transporters, rather some are soluble proteins with no transmembrane 
domains (TMDs) (Xiong et al., 2015; Ofori et al., 2018).  
There are nine subfamilies (A-I; Figure 1.6) of ABC proteins (Vasiliou et al., 2009; 
Kretzschmar et al., 2011; Jeong et al., 2014; Jeong et al., 2017; Lefevre et al., 2018). 
Members of the eighth ABC protein subfamily, ABCH, were first identified in the Drosophila 
genome (Dean et al., 2001) and later also in some other taxa (Sheps et al., 2004; Annilo et 
al., 2006; Sturm et al., 2009; Liu et al., 2013; Jeong et al., 2014; Jeong et al., 2017) but not 
in plants (Kretzschmar et al., 2011; Lefevre et al., 2018). The predicted topologies of all nine 
subfamilies are presented in Figure 1.6. ABC transporters having two TMDs and two NBDs 
are called ‘full size transporters’ but those ABC transporters with only one TMD and one 
NBD are called ‘half transporters’. 
ABC proteins can be divided into three major functional categories, importers - only 
found in prokaryotes, exporters - found in all organisms, and soluble ABC proteins (without 
TMDs) involved in various other biological processes. There are three types of ABC 
importers (type I, type II and energy-coupling-factor (ECF); Figure 1.7), and two, but quite 
possibly more than two, types of ABC exporters (type I and type II exporters; Figure 1.8). 
Importers and exporters transport a large variety of biological molecules, while soluble ABC 
proteins of the ABCE and ABCF subfamilies are involved in the core biological processes of 
transcription and translation (Zhao et al., 2004) or ribosome assembly (Tyzack et al., 2000).  
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Figure 1.6. Predicted topologies of different subfamilies of ABC proteins. IN refers to the 
cytosol and OUT refers to the outside of the cell or organelle. NBDs are in red, TMDs in 
blue, and extracellular loops (ELs) in green. The N-terminal extension found in some 
subfamily C members is depicted in purple. Taken from (Lefevre et al., 2018); used with 
permission from the American Society of Plant Biologists, Licence no. 1014527-1 (Appendix 
A4). 
Many genetic disorders of humans such as cystic fibrosis (CF) (Cohn et al., 1998), 
diabetes (Ortiz et al., 2015), adrenoleukodystrophy (ALD) (Wiesinger et al., 2015) and 
hypercholesterolemia (Rudkowska et al., 2008) are associated with mutations in ABC 
transporters. Genetic disorders involving ABC transporters that are associated with disease 
are described in the following reviews (Mosser et al., 1993; Gottesman et al., 2001; Borst 
et al., 2002; Rees et al., 2009; Zhao et al., 2017; Robey et al., 2018). The importance of 
these ABC mutations in human disease has led to the establishment of mutation databases 
such as DisGeNET which is “one of the largest available collections of genes and variants 
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involved in human diseases” (Pinero et al., 2017) and the ABCA4-Database where “ABCA4 
modelled structure provides a molecular basis on which to analyse protein sequence 
mutations related to genetic retinal disease in order to predict the risk of retinal disease” 
(Trezza et al., 2017).  
 
 
Figure 1.7. Nucleotide-free conformations of type I, type II and ECF-type ABC importers. 
All structures were prepared with PyMOL Molecular Graphics System (DeLano, 2002). The 
lipid bilayer is indicated with dashed grey lines. A) Type I Archaeoglobus fulgidus molybdate 
ABC importer ModAB2C2 (pdb: 2ONK; (Hollenstein et al., 2007a; Hollenstein et al., 2007b)). 
B) Type II Escherichia coli vitamin B12 ABC importer BtuC2D2F (pdb: 2QI9; (Hvorup et al., 
2007)). C) Lactobacillus brevis energy-coupling factor (EFC) ABC importer Ecf-folate 
transporter (pdb: 4HUQ; (Xu et al., 2013)). Type I, and type II each consist of an additional 
periplasmic high-affinity substrate binding protein domain shown in yellow. The N- and C-
terminal NBDs and TMDs are shown respectively in magenta, red, green, and pale blue. 
Taken from (Lamping et al., 2017a); used with permission from Springer Nature, licence 





Figure 1.8. Nucleotide-free conformations of a typical type I and type II ABC exporter. A) 
Type I Mus musculus multidrug efflux pump MmABCB1 (pdb: 3G5U; (Aller et al., 2009)); 
and B) Type II Homo sapiens cholesterol ABC exporter HsABCG5-G8 (pdb: 5DO7; (Lee et al., 
2016)). MmABCB1 is a single polypeptide, but HsABCG5-G8 is a heterodimer of two 
separate polypeptide chains. Their N- and C-terminal TMDs are shown in green and blue 
and their N- and C-terminal NBDs in magenta and red, respectively. Large extracellular 
loops are coloured yellow and are a main distinguishing feature between the two types of 
ABC exporters. Extracted from (Lamping et al., 2017a); used with permission from Springer 
Nature, licence no. 4885751453645 (Appendix A4). 
 
The 26 predicted C. albicans ABC proteins do not include any ABCA family member, 
but comprise four ABCB proteins (previously known as the multidrug resistance (MDR) 
proteins), four ABCC proteins, also known as multidrug resistance-associated proteins 
(MRPs), two ABCD or adrenoleukodystrophy proteins (ALDps), one ABCE protein or RNase 
L inhibitor (RLI), four ABCF proteins or the elongation factor EF-3 (EF3) proteins and eleven 
ABCG or ABCG-other proteins, also commonly known as the pleiotropic drug resistance 
(PDR) subfamily of ABC proteins (Gaur et al., 2005; Prasad et al., 2015) (Table 1.4). Thus, C. 
albicans has seven soluble ABC proteins [ABCE (1), ABCF (4) and ABCG-other (2) proteins] 
and 19 transmembrane ABC transporters of the ABCB (4), ABCC (4), ABCD (2) and ABCG (9) 
families (Figure 1.6 and Table 1.4). 
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Type of ABC 
transporter 
ABCB/MDR 
MDL1 685 Involved in regulating cellular resistance to oxidative stress Half 
MDL2 783 Involved in regulating cellular resistance to oxidative stress Half 
ATM1 750 Export of mitochondrially synthesised precursors of iron-sulphur clusters Half 
HST6 1323 Putative sex pheromone transporter Full 
ABCC/MRP 
YCF1 1580 Vacuole fusion; heavy metal detoxification Full 
BPT1 1490 Unconjugated bilirubin transport and heavy metal detoxification Full 
MLT1 1606 Phosphatidylcholine import Full 
YOR1 1488 Organic anion export including oligomycin  Full 
ABCD/ALDP 
PXA1 768 Peroxisomal long-chain fatty acid import  Half 
PXA2 667 Peroxisomal long-chain fatty acid import Half 
ABCE/RLI RLI1 622 Ribosome biogenesis and translation initiation/termination  
ABCF/YEF3 
CEF3 1050 Polystyrene adherence induced  
ELF1 1195 Putative mRNA export protein  
GCN20 751 Positive regulator of Gcn2p kinase  
KRE30 609 Mutation confers hyper-sensitivity to amphotericin B  
Other CAF16 320 
Part of evolutionarily-conserved CCR4-
NOT regulatory complex  
MODF 545 Similar to S. cerevisiae YDR061w  
ABCG/PDR 
orf19.3120 579 
Repressed by fluphenazine and in azole-
resistant strains overexpressing 
CDR1/CDR2 
Half 
ADP1 1038 Gene used for strain identification by multi-locus sequence typing  Half 
ROA1 1274 Involved in azole sensitivity  Full 
CDR1 1501 Drug efflux and lipid translocation Full 
CDR2 1499 Drug efflux and lipid translocation Full 
CDR11 1512 Responds to extracellular pH Full 
CDR3 1501 Lipid translocation Full 
CDR4 1490 Lipid translocation Full 
SNQ2 1495 Multidrug resistance and resistance to singlet oxygen species Full 
Data taken from the Candida genome database (CGD, (Skrzypek et al., 2017)) and the Saccharomyces 
genome database (SGD, (Cherry, 2015)), based on (Prasad et al., 2015). 
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1.6.2.1 ABC Transporter Topology 
Full size ABC transporters share a highly conserved domain architecture comprising 
four core domains: two transmembrane domains (TMDs) each containing six 
transmembrane segments (TMSs) that provide the substrate transport channel through 
which compounds are transported across the lipid bilayer and two cytoplasmic nucleotide-
binding domains (NBDs) that hydrolyse ATP (Cannon et al., 2009). Full-size fungal PDR 
transporters are type II ABC transporters of the large ABCG sub-family (Lamping et al., 
2017a). They are defined by two large extracellular loops (EL3 and EL6) that contain PDR 
family-defining motifs near the exit of TMS5 and TMS11, respectively, and by two large 
intracellular loops (IL1 and IL3) connecting predicted TMS2 with TMS3 and TMS8 with TMS9 
(Figure 1.6), respectively. In addition, the two large EL3 and EL6 of fungal PDR transporters 
contain six conserved cysteine residues (Lamping et al., 2010). Unlike these type II ABCG 
transporters (Lee et al., 2016; Taylor et al., 2017), type I ABCB transporters like human 
ABCB1 have four equally large ILs (IL1-IL4) that extend deep into the cytosol, and they also 
lack large extracellular domains (EDs) (Aller et al., 2009; Li et al., 2014; Kim et al., 2018; 
Thonghin et al., 2018). The NBDs consist of highly conserved Walker A, Walker B (Walker 
et al., 1982) motifs and the hallmark ABC signature motif or the C-loop (Bianchet et al., 
1997), but the TMD sequences are variable; possibly reflecting the large diversity of 
substrates transported by this transporter superfamily ranging from ions to 
macromolecules (Locher, 2004; Jones et al., 2009; Rees et al., 2009; Kerr et al., 2010). It 
should be noted that NBDs of the type II PDR exporters have asymmetric NBDs (Ernst et al., 
2008) with one core conserved motif set and one with atypical Walker and ABC motifs, that 
will be discussed later, in Chapter 3 (Section 3.1.1.2). 
Some ABC transporters possess additional subdomains that are involved in 
regulating transport activity or in targeting the transporter to the correct organelle. ABC 
importers, for instance, use a high-affinity binding protein component (yellow; Figure 1.7 
A and B) that delivers the ligand to the TMD of the ABC import machinery. ABC exporters, 
conversely, recruit their solutes directly from the cytoplasm (Hollenstein et al., 2007a; Rees 
et al., 2009) or from the inner leaflet of the lipid bilayer (Locher, 2016). 
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The five bacterial ABC importer domains are encoded as separate genes (e.g. 
ModB2C2 (Hollenstein et al., 2007b)), whereas most prokaryotic and eukaryotic ABC 
exporters are expressed as half-size transporters that form functional homo- (e.g. ABCG2 
(Taylor et al., 2017), and Sav1866 (Dawson et al., 2006)) or hetero-dimers (e.g. ABCG5-G8 
(Lee et al., 2016)) or full size transporters (e.g. ABCB1 (Aller et al., 2009)). 
1.6.2.2 ABC Transporter Motifs and Structures 
ABC protein NBDs can be divided into two core sub-domains, the catalytic, Rec-A 
like, sub-domain and a helical sub-domain containing the canonical ABC signature motif, 
LSGGQ, also known as the C-loop. The catalytic sub-domain comprises a canonical P-loop 
motif, GXXGXGK(S/T), commonly known as Walker A (Walker et al., 1982), a Q-loop, a 
canonical beta-sheet motif, hhhhDE (h refers to a small hydrophobic amino acid), 
commonly known as Walker B (Walker et al., 1982) with a conserved glutamate (E) that 
mediates the nucleophilic attack on the bound ATP-γ-phosphate molecule by a water 
molecule, an H-motif or switch region that also contributes to ATP-hydrolysis (Hollenstein 
et al., 2007a; Rees et al., 2009) and a D-loop region (Figure 1.9) that provides critical contact 
points between the two NBDs (Rees et al., 2009) and is also important for the crosstalk 
between the NBDs and the TMDs of PDR transporters (Furman et al., 2013). Typically, in 
type I ABC exporters, IL1 of TMD1 and IL3 of TMD2 are in close contact with their proximal 
Q-loop1 and Q-loop2 regions, respectively, whereas IL2 of TMD1 and IL4 of TMD2 reach 
across to the opposite NBD providing contact to Q-loop2 and Q-loop1, respectively. In their 
closed, ATP-bound, state (i.e. open to the outside) the Walker-A and Walker B motifs of 
one NBD (e.g. NBD1) form an ATP-binding site with the ABC signature motif of the opposite 
NBD (e.g. NBD2), thus creating two functional ATP-binding and hydrolysis sites (Jones et 
al., 2009; Rees et al., 2009; Mehmood et al., 2012). Type II ABC exporters (Figure 1.9) on 
the other hand have one canonical NBD [i.e. composite NBD2 (CNBD2) comprising 
canonical Walker A2, Walker B2 and ABC1 signature motifs] and one non-canonical CNBD1 
with the catalytic Walker A1 K residue replaced by a C (C193 in Cdr1), the Walker B1 
catalytic E replaced by an N (N328 in Cdr1), the conserved H residue of the H-loop of NBD1 
replaced by a Y (Y361 in Cdr1) and a non-canonical ABC2 signature motif (LNVEQ in Cdr1). 
Unlike type I ABC transporters, type II PDR transporters have characteristically high, but 
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non-inducible, ATPase activities (Ernst et al., 2008). The molecular mechanisms of these 
transporters will be discussed in more detail in Chapter 3 (section 3.1.1). 
 
 
Figure 1.9. A schematic view of the conserved NBD motifs of Cdr1/Pdr5. Different motifs 
and loops of Cdr1/Pdr5 are shown in the graphic image, and underneath, the sequences of 
the highlighted sections are listed. Red residues are the critical ones for ATP-binding and/or 
hydrolysis (reviewed by (Lamping et al., 2017a)). * stands for the typical non-canonical NBD 
motifs for PDR transporters. Taken from (Lamping et al., 2017a); used with permission from 
Springer Nature, licence no. 4885751453645 (Appendix A4). 
 
1.6.2.3 PDR Transporters Cdr1 and Cdr2 
The two major ABC transporters that cause high level azole antifungal drug 
resistance in clinical C. albicans isolates are Cdr1 (for Candida drug resistance) (Prasad et 
al., 1995) and Cdr2 (Sanglard et al., 1995; Maebashi et al., 2001). CDR1 and CDR2 encode 
full-size PDR transporters of the ABCG sub-family characterised by its unique inverted 
domain topology [NBD-TMD]2 (ABCG subfamily in Figure 1.6). Full-size PDR transporters 
are only found in plants (Crouzet et al., 2006; Kang et al., 2011) and fungi (Lamping et al., 
2010). Full-size PDR transporters also have an unusual ~150 amino acid N-terminal 
extension rich in hydrophilic (S, T, N, Q) and charged (D, E, R, K) amino acid residues 
(Lamping et al., 2010) that may be important for protein–protein interactions that regulate 
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their function, expression and/or localisation. C. albicans has some additional full-size PDR 
transporter genes, such as CDR3 (Balan et al., 1997), CDR4 (Franz et al., 1998), CDR11 
(Prasad et al., 2014), and SNQ2 (Gaur et al., 2005). Although Cdr3 and Cdr4 have been 
implicated in phospholipid flip-flop across the lipid bilayer (Prasad et al., 2014), rather little 
is known about the function of these additional PDR transporters. Recently, it has been 
suggested that SNQ2 is involved in azole resistance (Sanglard, 2016). Cdr1 and Cdr2, 
however, are multidrug efflux pumps that are frequently up-regulated in azole-resistant C. 
albicans isolates (Sanglard et al., 2009). Upregulation of CDR1 and CDR2 is often caused by 
point mutations in TAC1, a gene that encodes the Tac1 transcription factor. Tac1 normally 
binds to the drug-responsive element CGGN4CGG (de Micheli et al., 2002; Coste et al., 2004; 
Liu et al., 2007) in the promoters of genes that are co-ordinately upregulated in response 
to stress like exposure to azole antifungals. However, in azole resistant C. albicans isolates 
that have TAC1 point mutations, this network of genes is constitutively overexpressed. 
Although Cdr1 and Cdr2 are equally efficient efflux pumps (Lamping et al; 2007), Cdr1 is 
the major contributor to the azole resistance of clinical isolates (Holmes et al., 2008; Tsao 
et al., 2009). 
1.7 Membrane Proteins  
There are three types of membrane proteins: integral, peripheral and lipid 
anchored membrane proteins. Integral membrane proteins are embedded in the lipid 
bilayer via strong hydrophobic interactions with membrane lipids. The less hydrophobic 
peripheral membrane proteins are attached to biological membranes primarily through 
hydrophilic interactions with the polar headgroups of lipids or the hydrophilic parts of a 
membrane protein (Figure 1.10).  
A third class of membrane proteins, lipid anchored membrane proteins, are soluble 
proteins that are covalently attached to certain types of lipids. The most prominent of them 
are GPI-anchored membrane proteins that are covalently attached to 
glycosylphosphatidylinositol (GPI). GPI-anchored proteins are exclusively located on the 
extracellular leaflet of the plasma membrane where they frequently associate with lipid 
raft microdomains (Figure 1.11). Integral membrane proteins like transporters or sensory 
molecules reside permanently in membranes while peripheral membrane proteins often 
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attach only temporarily to biological membranes in response to various cell or 
environmental stimuli (Alberts et al., 2002b; Lomize et al., 2007).  
 
 
Figure 1.10. Schematic diagram of a typical biological membrane. There are two layers of 
amphipathic lipid molecules that self-assemble to form a lipid bilayer. In each lipid layer, 
the hydrophilic head groups (red circles) of lipids form a hydrophilic boundary layer that 
interacts with the cytosol or the extracellular fluid, and the hydrophobic tails (yellow lines) 
form the hydrophobic interior of a biological membrane. The membrane protein and lipid 
composition differ significantly between the many different types of biological membranes 
and membrane sub-compartments. A typical biological membrane is composed of 
hundreds of different types of lipids that provide a 2-dimensional hydrophobic matrix for 
many different types of surface, peripheral or integral membrane proteins and a complex 
set of carbohydrate molecules is predominantly attached to lipids or proteins of the 
extracellular side of the plasma membrane (derivative work: Wikimedia, (Dhatfield); 
Licenced with CC-BY-sa-3.0, (Appendix A4)). 
 
Biological membranes are fluid, two-dimensional, bilayers of a complex mix of 
amphiphilic phospholipids and sterols, such as cholesterol or ergosterol, in which proteins 
can move freely resulting in a mosaic of lipids and proteins to which carbohydrates can be 
attached on the extracellular side of a plasma membrane bilayer, as illustrated in Figure 
1.11. The Fluid Mosaic Model was first proposed by Singer and Nicolson in 1972 (Singer et 
al., 1972), and since then it has stood the test of time (Nicolson, 2014). The fluidity of 
biological membranes is critical for proper functioning of membrane proteins and must be 
maintained. Cells usually respond to changes in membrane fluidity caused by temperature 
fluctuations by fine-tuning the mixture of lipids and the saturation level of fatty acid side 
 35 
chains. Despite its usefulness to help us understand how membrane proteins act in their 
natural environment, the Fluid Mosaic Model of biological membranes provides a rather 
simplistic view that does not take into account the existence of complex membrane 
microdomains. The concept of membrane microdomains or lipid rafts was first introduced 
by Kai Simons and colleagues in 1997 (Simons et al., 1997). Lipid-rafts are slightly thicker, 
rigid, membrane sub-compartments of certain types of lipids and proteins that ‘swim’ like 
rafts in a sea of a fluid lipid bilayer (Figure 1.11).  
 
Figure 1.11. Lipid raft heterogeneity of cell membranes. A) Dynamic nanoscale assemblies 
of sterols, sphingolipids (e.g. sphingomyelin and glycosphingolipids; GSLs), 
glycosylphosphatidylinositol (GPI) and proteins in the plasma membrane fluctuate in 
composition. GPL: glycerophospholipids. Lipid-raft associated lipids and proteins are 
orange and non-lipid-raft proteins and lipids are blue. B) Certain cellular events can trigger 
clustering of nanoscale structures into larger, more stable, lipid-raft platforms that are 
important for many cellular signalling and trafficking events (Simons et al., 2010); used with 
permission from Springer Nature, licence no. 4753250550579 (Appendix A4). 
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Lipid-rafts are enriched in sphingolipids, sterols and phospholipids with mostly 
saturated fatty acid side chains (Calder et al., 2007). Their existence was first suggested by 
the simple observation that some membrane proteins resisted extraction with mild 
detergent (1% Triton X100) at low (4 ˚C) temperature (Simons et al., 1997). Since then the 
concept of detergent resistant lipid rafts has matured and their existence is almost 
universally accepted. We now know that all biological membranes are organised into 
various microdomains of specific lipids interacting with certain types of proteins and 
carbohydrates in a manner far more complex and colourful (Figure 1.11) than the Fluid 
Mosaic Model would allow. Clearly, lipids are more than passive passengers that provide a 
fluid ‘platform’ to enable proteins to function (Simons et al., 2010).  
Lipid rafts have been studied in several fungal species, including the budding yeast 
S. cerevisiae, as well as the pathogens C. albicans and Cryptococcus neoformans. Raft 
domains in yeast mainly contain ergosterol and complex sphingolipids (Bagnat et al., 2000), 
including inositol-phosphoceramide (IPC), mannose-inositol-phosphoceramide (MIPC), and 
mannose-(inositol phosphate)2-ceramide (M(IP)2C) (Dickson et al., 2006). The rafts vary in 
size depending on the membrane composition, and their lipid composition varies between 
different cell types. For instance, yeasts do not have sphingomyelin (present in the 
mammalian cell plasma membrane), but instead they have similar inositol 
phosphosphingolipids (Matmati et al., 2008; Mollinedo, 2012). In addition, fungal 
membranes are generally more negatively charged than human cell membranes, due to a 
lower ratio of neutral versus anionic phospholipids. There are also differences between 
fungal and mammalian saccharide moieties and the lengths of fatty acids attached to 
various lipid species; i.e. yeast ceramides have longer fatty acids than their animal 
counterparts (Dickson et al., 1999; Kodedova et al., 2019). C. albicans lipid rafts house many 
biologically important proteins involved in lipid metabolism, cell wall biogenesis, protein 
metabolism, electron transport, and ATP synthesis (Insenser et al., 2006). The lipid profiles 
of C. albicans biofilms and planktonic cells are also quite different; biofilms contain higher 
levels of phospholipids and sphingolipids (Mollinedo, 2012). There is also evidence that 
lipid rafts are involved in biofilm formation (Mollinedo, 2012) and hyphal growth of C. 
albicans. In fact, monitoring raft location during hyphal growth confirmed that lipid rafts 
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were only present in actively growing sites, such as the hyphal tips and a highly polarised 
ergosterol-rich domain present only during hyphal growth (Martin et al., 2004). 
It is estimated that ~30% of all proteins (Wallin et al., 1998; Krogh et al., 2001; Liu 
et al., 2002) and ~50% of all drug targets are membrane proteins (Overington et al., 2006). 
Yet, our knowledge of their structure and mechanism of action lags far behind that of 
soluble proteins (Liszewski, 2015). Of the more than 140,000 structures deposited in the 
protein databank (https://www.rcsb.org) only ~5,700 (< 4%) structures are for membrane 
proteins. Complex membrane protein-lipid interactions are one of the reasons why 
membrane protein research is so challenging. Unlike soluble proteins, integral membrane 
proteins must first be extracted from their natural lipid environment without affecting their 
native conformation and also hopefully keeping them biologically active during that 
process. Detergents commonly used for the extraction of membrane proteins cannot 
substitute for their native lipid environment which is why detergent extractions often cause 
membrane protein aggregation and/or misfolding. The heterologous expression of a 
correctly folded and functional membrane protein at quantities that are required for their 
structural characterisation can also be quite challenging. There are many factors that could 
affect the heterologous expression of a correctly folded and functional membrane protein. 
They include the lack of protein or lipid cofactors (Opekarova et al., 2003; Rosano et al., 
2014), an incorrect bilayer thickness (Kubyshkin et al., 2019), the lack of the correct 
membrane microenvironment (Opekarova et al., 2003), or the incorrect post-translational 
modification of the membrane protein of interest (Carpenter et al., 2008; Junge et al., 2008; 
Gomes et al., 2016) in the chosen heterologous expression host. 
1.7.1 Membrane Protein Structural Studies 
The structure of proteins and protein complexes in different conformational states 
of their transport cycle can provide important clues about their detailed transport 
mechanism. There are different techniques that can produce structural information at 
atomic or near-atomic resolution including X-ray crystallography and cryo-electron 
microscopy (cryo-EM). X-ray crystallography provides structures with the highest 
resolution of ~1.5-2 angstrom (Å) down to almost sub-atomic resolution. However, 
achieving such high-resolution structures remains a challenge for membrane proteins 
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because of the difficulties of obtaining well-ordered three-dimensional crystals that are 
suitable for X-ray crystallography. Cryo-EM (Vinothkumar, 2015; Quentin et al., 2018; Vilas 
et al., 2018) is a promising technique that could potentially overcome some of these major 
limitations. The past decade has seen a number of breakthroughs in electron microscopy, 
ultra-stable and coherent beam microscope, detector technology and powerful image-
processing software (Rigaud et al., 2000; Scheres, 2012; Nannenga et al., 2013; Cheng et 
al., 2015; Delmar et al., 2015; Henderson, 2015; Vinothkumar, 2015) that have significantly 
increased the pace of solving membrane protein structures. Particle size remains a limiting 
factor, and presently cryo-EM can only be used to solve structures of larger membrane 
proteins or membrane protein complexes. However, achieving high-resolution structures 
of sub-100 kDa proteins will soon be possible due to recent technical advances. Although 
X-ray crystallography remains the gold-standard for solving high-resolution structures of 
smaller membrane proteins, cryo-EM has recently been used successfully to solve some 
ABC transporter structures at sub-nanometre resolutions (Kim et al., 2015a; Frank et al., 
2016; Taylor et al., 2017; Zhang et al., 2018) as will be discussed in the Chapter 5. 
1.8 Aims of This Project 
The emergence of azole resistant C. albicans strains is a global health threat, 
especially for immunocompromised individuals, that calls for either the development of 
more effective drugs or inhibitors to combat the resistance. We know that one of the main 
mechanisms of azole drug resistance in clinical C. albicans isolates is overexpression of 
plasma membrane ABC transporter Cdr1. However, despite recent progress in the 
structural analysis of membrane proteins, no 3D structure for Cdr1, or any other PDR 
transporter, is currently available. It is important to gain knowledge of the Cdr1 structure 
and its biochemical features as this will not only provide insight into rational design of novel 
drugs to overcome efflux-mediated resistance, but also provide insight into the mechanism 
of function of an important subfamily of ABC proteins.  
Therefore, the overall objective of this study was the overexpression of C. albicans 
membrane protein Cdr1 in S. cerevisiae and its purification in order to perform biochemical 
studies and to initiate the approach for 3D structural studies. Since the study of integral 
membrane proteins is still limited by many factors, one goal of this work was to establish 
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procedures that enable the optimisation of expression and purification of Cdr1 in a pure 
stable, and monodisperse, state that facilitates structural studies via crystallography, 
negative stain electron microscopy and/or cryo-EM. Furthermore, as unique features of 
PDR ABC proteins are large extracellular loops that contain conserved cysteines, their role 
in pump expression and function was investigated. In order to determine the most critical 
cysteines essential for Cdr1 expression, membrane localisation, and/or function, different 
Cys-deficient mutant versions of Cdr1 were created and tested functionally and 
biochemically. The specific aims of this project were to: 
• Determine how removing the conserved Cys residues from Cdr1 might 
affect the function and/or expression of the transporter.  
• Overexpress and purify detergent solubilised Cdr1 to determine the 
oligomeric state of Cdr1 in detergent micelles and to obtain protein of 
sufficient quantity and quality for structure determination. 







2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals 
Chemicals and detergents used in this study are listed in Table 2.1 and Table 2.2, 
respectively. All chemicals were of analytical grade.  
Table 2.1. Chemicals used in this study. 
Chemical Manufacturera 
Acetic acid (glacial) Merck Life Science, Auckland, NZ 
40% Acrylamide/Bis-acrylamide (37.5:1) Bio-Rad Laboratories Pty Ltd, Auckland, 
NZ 
Agar Formedium™, Hunstanton, UK 
Agarose (ultra-pure) Invitrogen NZ Ltd, Auckland, NZ 
Ammonium molybdate Sigma-Aldrich NZ, Auckland, NZ 
Ammonium persulphate (APS)  Bio-Rad 
Amphipol A8-35 Anatrace Inc, Maumee, OH, USA 
ATP disodium salt (cat#A-6419) Sigma-Aldrich 
Bromophenol blue  SERVA Electrophoresis GmbH, 
Heidelberg, Germany 
Bovine serum albumin (BSA) Thermo Fisher Scientific™, Auckland, NZ 
Collodion solution Sigma-Aldrich 
Dimethyl sulphoxide (DMSO) Merck 
Dithiothreitol (DTT) Roche Diagnostics, Auckland, NZ 
Enniatin Sigma-Aldrich 
Ethanol Merck 
Ethidium bromide (EtBr) Thermo Fisher 
Ethylenediaminetetraacetic acid disodium salt 
(EDTA; Titriplex III) 
Merck 
FK506 (Tacrolimus) Sigma-Aldrich 
Fluconazole (FLC) Sigma-Aldrich 
Glucose Formedium™ 




Lithium acetate Sigma-Aldrich 
Magnesium chloride hexa-hydrate Sigma-Aldrich 
2-(N-Morpholino)ethane-sulphonic acid (MES) Fluka, Fisher Scientific, Auckland, NZ 
Oligomycin Sigma-Aldrich 
Phenylmethanesulphonyl fluoride (PMSF)  Roche Diagnostics 
Polyethylene glycol 3350 (PEG-3350) Sigma-Aldrich 
Potassium nitrate  Sigma-Aldrich 
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Chemical Manufacturera 
Sodium L-ascorbate BioXtra Sigma-Aldrich 
Sodium azide Sigma-Aldrich 
Sodium chloride Merck 
Sodium dodecyl sulphate (SDS) Merck 





(Tris base; ultra-pure) 
Invitrogen 
Uranyl acetate Agar Scientific, Stansted, Essex, UK 
Uranyl formate Polysciences Inc, Warrington, PA, USA 
Xylene cyanol  Sigma-Aldrich 
a The full manufacturer’s name and address are listed only the first time they are encountered. 
 
Table 2.2. Detergents used in this study. Abbreviations for the detergent (Sol-grade) have 
been listed here rather than in the list of Abbreviations. 
Type Group Name Abbreviation 
Non-ionic 
General purpose Sodium dodecyl sulphate  SDSab 
Octylphenoxypolyethoxyethanol TRITON X-100b  
polyoxyethylenesorbitan monooleate TWEEN 80b  
Digitonin  
Glucosides n-Octyl-β-D-gucopyranoside OG 
n-Nonyl-β-D-glucopyranoside NG 
Glucamides n-Decanoyl-N-hydroxyethyl-glucamide HEGA-10 
n-Decanoyl-N-methyl-glucamide MEGA-10 
Maltosides n-Nonyl-β-D-maltopyranoside NM 
 n-Decyl-β-D-maltopyranoside DM 
 n-Undecyl-β-D-maltopyranoside  UM (UDM) 
 n-Dodecyl-β-D-maltopyranoside  β-DDM 
 n-Dodecyl-α-D-maltopyranoside α-DDM 
 n-Tridecyl-β-D-maltopyranoside - 













































Sterol derivatives  CHAPS 
 CHAPSO 
a SDS is an Ionic detergent. 
All detergents were from Anatrace (Maumee, OH, USA) except for b Merck Life Science (Auckland, NZ) and 
c Glycon Biochemicals GmbH (Luckenwalde, Germany). 
 
2.1.2 Additional Materials 
Additional materials used in this study are listed in Table 2.3. 
Table 2.3. Additional miscellaneous materials used in this study. 
Material Manufacturer  
0.45 µm Ahlstrom ReliaPrep™ Syringe Filter 
Single Use 
Thomas Scientific, Swedesboro, NJ, USA 
1 kb Plus DNA Molecular Ladder New England Biolabs (Vasiliou et al.), 
Melbourne, Australia 
4-15% Mini-PROTEAN® TGX Stain-Free™ 
Precast Gels 
Bio-Rad 
96-well Corning 3550 Crystallisation Plate Corning Inc, Rio de Janeiro, Brazil 
Bio-Beads SM-2 Resin Bio-Rad 
EDTA-Free Protease Inhibitor Cocktail Tablets Sigma-Aldrich 
MbClass I and II Suite (Screens) QiaGen Ltd, Venlo, Netherlands 
MemGold™ and MemGold2™ (Screens) Molecular Dimensions Inc., Maumee, OH, 
USA 
Molecular Weight Cut-off (MWCO) Amicon® 
Ultra-Centrifugal Filters  
Merck Millipore Ltd, Auckland, NZ 
PageRuler™ Prestained Protein Ladder Thermo Fisher 
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Material Manufacturer  
Pre-stained, Strep-tagged Recombinant 
Proteins (10–250 kDa) - Protein Ladder 
Bio-Rad 
Prism Ultra Protein Ladder (10-245 kDa) Abcam Australia Pty Ltd, Melbourne, 
Australia 
QC Colloidal Coomassie Stain Bio-Rad 
 
2.1.3 Instruments 
Instruments used in this study are listed in Table 2.4. 
Table 2.4. Instruments used in this study. 
Instrument (type) Manufacturer  
Automated crystal imaging (Rock Imager 1,000) Formulatrix Inc, Bedford, MA, USA 
Cell disrupter (Bead-beater) BioSpec Products Inc, Bartlesville, OK, 
USA 
Confocal microscope (LSM 710) Carl Zeiss Microscopy GmbH, Jena, 
Germany 
CryoPlunger (FEI Vitrobot™ Mark IV) Thermo Fisher 
Electron microscope (JEM-1400) Jeol USA Inc, Peabody, MA, USA 
Electron microscope (Talos™ Arctica) Thermo Fisher 
FPLC (ÄKTA™ Pure) GE Healthcare Life Sciences Ltd, 
Auckland, NZ 
FPLC (NGC® Discover) Bio-Rad 
Gel imaging (ChemiDoc® MP) Bio-Rad 
Gel imaging (GelDoc™ EZ Imager) Bio-Rad 
High vacuum carbon coater (Leica EM ACE600) Leica Micro Systems Ltd, Milton Keynes, 
UK 
Microplate reader (Synergy™ 2 Multi-Detection)  BioTek Instruments, Inc, Winooski, VT, 
USA 
Mosquito LCP crystal pipetting robot  TTP Labtech Ltd, Melbourne, UK 
Nanophotometer (P360) IMPLEN GmbH, Munich, Germany 
PCR thermal cycler (C1000 Touch™) Bio-Rad 
Plasma discharger (Femto Version A)  Diener Electronic GmbH + Co KG, 
Ebhausen, Germany 
Power supply (PowerPac) Bio-Rad 
SDS PAGE (Mini-PROTEAN® Tetra) Bio-Rad 
Shaking incubator (Multitron) Infors HT, Bottmingen, Switzerland 
Simplicity® UV water purification system Merck Millipore 
UV/Visible spectrophotometer (Ultraspec 6300 
pro) 
Amersham BioSciences UK Ltd, 
Buckinghamshire, UK 
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2.1.4 Protein Chromatography Columns 
Protein chromatography columns were purchased from GE Healthcare Life Sciences 
Ltd, Auckland, NZ (Table 2.5).  
Table 2.5. Pre-packed chromatography columns used in this study. 
 
2.1.5 Buffers and Solutions 
Buffers and solutions used in this study are listed in Table 2.6. For preparing the 
solutions either deionised distilled water (ddH2O) or ultrapure water (ASTM type 1 water; 
defined by the American Society for Testing and Materials) was used. Ultrapure water was 
obtained by purifying the ddH2O using the Simplicity® UV water purification system.  
Table 2.6. Buffers and solutions used in this study. 
Buffer/Solutiona Components Amounta Concentration Storage 
2× Protein loading dye 
(10 ml) 
Tris-Cl, pH 6.8 145 mg 120 mM -20 ˚C 
Bromophenol blue 2 mg 0.02% 
SDS 0.40 g 4% 
Glycerol 2 ml 20% 
DTT 309 mg 200 mM 
4× Protein gel  
    separating buffer 
(100 ml) 
Tris-Cl, pH 8.8 18.15 g 1.5 M 4 ˚C 
SDS 0.40 g 0.4% 
4× Protein gel 
    stacking buffer 
(100 ml) 
Tris-Cl, pH 6.8 6.06 g 0.5 M 4 ˚C 
SDS 0.40 g 0.4% 
10× Protein gel 
    electrophoresis buffer 
Tris 30 g 248 mM RT 
SDS 10 g 1% 
Glycine 144 g 1.9 M 





Recommended sample volumes 
or protein binding capacity 
Superose® 6 
Increase 10/300 GL 
24 ml 5,000-5 × 106 Da 25-500 μl 
HiLoad 16/600 
Superdex® 200 pg  
120 ml 1 × 104-6 × 105 Da <5 ml 
HisTrap™ HP  1 ml 
5 ml 
 40 mg/ml 
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Buffer/Solutiona Components Amounta Concentration Storage 
10× DNA loading dye 
(10 ml) 
Xylene cyanol 25 mg 0.25% 
Glycerol 5 ml 50% 
50× Tris-acetate EDTA 
(TAE; pH 8.5) 
Tris 242 g 2 M 4 ˚C 
Disodium EDTA 18.61 g 100 mM 
Glacial acetic acid 57.1 g 1 M 
ATPase assay cocktail 
(250 ml) 
MES-Tris pH 7.5b 3.67 g 75 mM -20 ˚C 
Potassium nitrate 1.90 g 75 mM 
Ammonium molybdate 93 mg 0.3 mM 
Sodium azide 0.12 g 7.5 mM 
ATPase assay 
    development reagent 
(50 ml) 
Sodium L-ascorbate 0.8 g 1.6% Make 
fresh, RT SDS 0.5 g 1% 
Ammonium molybdate 
in 6 M sulphuric acidc 
5 ml 12% 
  
Cell homogenising buffer 
(HB; pH 7.5) 
Tris-Cl, pH 7.5 6.06 g 50 mM 4 ˚C 
EDTA 186 mg 0.5 mM 
Glycerol 200 g 20% 
PMSFd  1 mM 
GTED-20 (pH 7.5) Tris-Cl, pH 7.5 1.21 g 10 mM 4 ˚C 
EDTA 186 mg 0.5 mM 
Glycerol 200 g 20% 
PMSFd  1 mM 
Imidazole (pH 8.0) 
(100 ml) 
Imidazole 6.808 g 1 M 4 ˚C 
Mg-ATP (pH 7.0) 
(50 ml)  
ATP disodium salt 0.793 g 28.8 mM -20 ˚C 
1 M MgCl2.6H2O 1.44 ml 28.8 mM 
Ni-NTA affinity buffer 
    (IMAC buffer) 
(pH 7.5)e 
Tris-Cl, pH 7.5 2.42 g 20 mM 4 ˚C 
NaCl  5.84 g 100 mM  
Glycerol 100 g 10% 




Protein gel fixing  
    solution 
Ethanol 400 ml 40% RT 
Acetic acid 100 ml 10% 
Protein size exclusion 
    chromatography buffer 
    (SEC buffer) 
(pH 7.5)e 
Tris-Cl, pH 7.5 1.21 g 10 mM 4 ˚C 




Yeast frozen competent cell 
     (FCC) solution (100 ml) 
Glycerol 5 ml 5% 4 ˚C 
 DMSO 10 ml 10% 
a Unless otherwise stated in brackets, the amounts listed are for one litre. 
b 75 mM MES adjusted to pH 6.0-7.0 with a few drops of 1 M Tris; and then above pH 7.0, pH adjusted to 
7.5 using 75 mM Tris. 
c 87 ml concentrated sulphuric acid slowly and carefully added to 120 ml ddH2O in a phosphate-free 500 ml 
Schott bottle. To this, 30 g ammonium molybdate was added to make up to 250 ml with ddH2O, and stored 
at RT. 
d PMSF added just before use. For a 100 mM stock solution, 1.74 g PMSF was dissolve in 100 ml isopropanol. 
e The buffer was filtered and degassed, with a vacuum manifold, through a 0.22 μm filter (Merck Millipore). 
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2.1.6 Culture Media 
Culture media were prepared in ddH2O and autoclaved at 121 °C for 15 min (Table 
2.7). 
Table 2.7. Culture media. 
Culture Media Component a  % (w/v) 
YPD  Yeast extract  1% 
Peptone 2% 
Glucose 2% 
With or without agar 2% 
2× YPCD 2× YPD  
CSM (complete supplement mixture) 0.079% 





With or without agar 2% 
CSM-URA Yeast nitrogen base without amino acids 0.67% 
CSM minus uracil 0.077% 
Glucose 2% 
With or without agar 2% 
a All components were obtained from Formedium™, Hunstanton, UK. 
 
2.1.7 Yeast Strains 
The Saccharomyces cerevisiae strains ADΔ (Lamping et al., 2007) or ADΔΔ (Sagatova 
et al., 2015) were used as the host to overexpress Candida albicans Cdr1 and Cdr1 variants. 
The strains generated and/or used in this study are listed in  
Table 2.8. 
Table 2.8. S. cerevisiae strains used in this study. 
Strain Genotype Developed 
by 
MBLa 
ADΔ MATα his1 Δura3::dpl200 PDR1-3 
Δyor1::hisG Δycf1::hisG Δsnq2::hisG 
Δpdr3::hisG Δpdr5::hisG Δpdr10::hisG 








Strain Genotype Developed 
by 
MBLa 
AD∆-CaCDR1A-GFP AD∆, ∆pdr5::CaCDR1A-GFP  (Lamping et 
al., 2007) 
771 
ADΔΔ ADΔ, Δhis1:dpl200 (Sagatova et 
al., 2015) 
1857 








AD∆∆-CaCDR1P-GFP  AD∆∆, ∆pdr5::CaCDR1P-GFP E. Lamping 2310 
AD∆∆-CaCDR1PC-GFP AD∆∆, ∆pdr5::CaCDR1PC-GFP E. Lamping 2311 
AD∆∆-CaCDR1PC-GFP-N2 AD∆∆, ∆pdr5::CaCDR1PC-N2-GFP E. Lamping 2312 
AD∆∆-CaCDR1PC-GFP-NT1 AD∆∆, ∆pdr5::CaCDR1PC-NT1-GFP E. Lamping 2313 
AD∆∆-CaCDR1PC-GFP-NT2 AD∆∆, ∆pdr5::CaCDR1PC-NT2-GFP E. Lamping 2314 
AD∆∆-CaCDR1PC-GFP-N1 AD∆∆, ∆pdr5::CaCDR1PC-N1-GFP G. Madani 2386 
AD∆∆-CaCDR1PC-GFP-TS1 AD∆∆, ∆pdr5::CaCDR1PC-TS1-GFP G. Madani 2387 
AD∆∆-CaCDR1PC-GFP-EL3 AD∆∆, ∆pdr5::CaCDR1PC-EL3-GFP G. Madani 2388 
AD∆∆-CaCDR1PC-GFP-T1 AD∆∆, ∆pdr5::CaCDR1PC-T1-GFP G. Madani 2389 
AD∆∆-CaCDR1PC-GFP-NTS1 AD∆∆, ∆pdr5::CaCDR1PC-NTS1-GFP G. Madani 2390 
AD∆∆-CaCDR1PC-GFP-TS2 AD∆∆, ∆pdr5::CaCDR1PC-TS2-GFP G. Madani 2391 
AD∆-CaCDR1PC-GFP-EL6 AD∆, ∆pdr5::CaCDR1PC-EL6-GFP E. Lamping 2392 
AD∆-CaCDR1PC-GFP-T2 AD∆, ∆pdr5::CaCDR1PC-T2-GFP E. Lamping 2393 
AD∆∆-CaCDR1PC-GFP-NTS2 AD∆∆, ∆pdr5::CaCDR1PC-NTS2-GFP G. Madani 2394 
AD∆∆-CaCDR1PC-GFP-N12 AD∆∆, ∆pdr5::CaCDR1PC-N12-GFP G. Madani 2395 
AD∆∆-CaCDR1PC-GFP-TS12 AD∆∆, ∆pdr5::CaCDR1PC-TS12-GFP G. Madani 2396 
AD∆∆-CaCDR1PC-GFP-NTS12 AD∆∆, ∆pdr5::CaCDR1PC-NTS12-GFP G. Madani 2397 
AD∆∆-CaCDR1PC-GFP-T12 AD∆∆, ∆pdr5::CaCDR1PC-T12-GFP G. Madani 2398 
AD∆∆-CaCDR1PC-GFP-EL36 AD∆∆, ∆pdr5::CaCDR1PC-EL36-GFP G. Madani 2399 
AD∆-CaCDR1A-GFP-∆EL3 AD∆∆, ∆pdr5::CaCDR1A-∆EL3-GFP E. Lamping 2400 
AD∆-CaCDR1A-GFP-∆EL6 AD∆∆, ∆pdr5::CaCDR1A-∆EL6-GFP E. Lamping 2401 
AD∆∆-CaCDR1A-GFP-∆∆EL36 AD∆∆, ∆pdr5::CaCDR1A-∆∆EL36-GFP G. Madani 2402 
AD∆∆-CaCDR1A-K901A-GFP AD∆∆, ∆pdr5::CaCDR1A-K901A-GFP G. Madani 2410 
AD∆∆-pABC3 AD∆∆, ∆pdr5::pABC3 G. Madani 2411 
AD∆∆-CaCDR1PC-GFP-NTS12-S1b AD∆∆, ∆pdr5::CaCDR1PC-NTS12-S1-GFP G. Madani 2429 















G. Madani 2615 
a Strain numbers correspond to those in the University of Otago Sir John Walsh Research Institute 
Molecular Biosciences Laboratory fungal collection. 




Desalted lyophilised oligonucleotides were obtained from Sigma-Aldrich NZ Ltd, 
Auckland, NZ (Table 2.9). 
2.2 Molecular and Cellular Biology 
2.2.1 DNA Agarose Gel Electrophoresis  
Agarose gel electrophoresis was used to size-separate, visualise and quantify DNA 
fragments. A set of six 0.7% agarose gels was prepared by adding 0.98 g agarose to 140 ml 
1x TAE buffer (Table 2.6) and bringing the solution to the boil for about 1 min using a 
microwave oven. The melted agarose solution was cooled to ~45 °C and 0.5 µl ethidium 
bromide (EtBr; 2 mg/ml) was added before the solution was poured into a DNA mini-gel 
cast system consisting of six individual gel trays. Suitable combs were inserted, and the 
agarose gel was allowed to solidify at RT for at least one hour before use. For loading DNA 
onto an agarose gel, DNA samples were mixed with one tenth their volume 10x DNA 
loading dye (Table 2.6) and placed into individual gel loading slots of the gel submerged 
already in TAE buffer (Table 2.6). Five microlitres (i.e. 0.5 µg) of the 1 kb Plus DNA Molecular 
Ladder (Table 2.6) were loaded as a size marker as well as a standard for the quantification 
of individual DNA fragments. Before electrophoresis of DNA samples, ~0.5 μl of an EtBr 
solution (2 mg/ml) was placed into the anode chamber of the gel electrophoresis tank to 
ensure uniform EtBr staining of the DNA fragments. Agarose gel electrophoresis was 
performed at 100 V in 1x TAE buffer for 30 min. Concentrations of DNA fragment were 





Table 2.9. DNA oligonucleotide primers used in this study. 




















































































2.2.2 DNA Polymerase Chain Reaction 
The polymerase chain reaction (PCR) was used to amplify DNA fragments. A typical 
50 µl PCR reaction contained 20-50 ng genomic DNA (gDNA) or 1-10 ng plasmid DNA 
template, 5 μl 10× Phusion Hot Start Flex (HF) reaction buffer, 1 μl 10 mM dNTPs (New 
England Biolabs, Ipswich, MA, USA), 8 μl DNA oligonucleotide primers (3.2 μM) and 0.5 μl 
(1 U) third generation high-fidelity Phusion HF DNA polymerase (New England Biolabs, 
Ipswich, MA, USA). Routine PCR reactions were performed with the following cycling 
parameters: 
 Temperature Duration Cycles 
Denaturation 98 ˚C 30 s  
Denaturation 98 ˚C 10 s 35 (gDNA) 
25 (plasmid) 
Annealing 65 ˚C 10 s 
Extension 72 ˚C Xa s 
Final extension 72 ˚C 5 min  
Holding 4 ˚C              infinite  
a 15-30 seconds/kb DNA fragment 
 
2.2.2.1 Colony PCR   
Colony PCR is a rapid method to verify DNA modifications in yeast transformants 
(Figure 2.1). Template DNA was obtained by touching a yeast colony with a pipette tip and 
suspending the cells by pipetting up and down in 10 μl ddH2O. PCR amplification of the 8 
kb expression cassette used to transform yeast was carried out using KOD Fx Neo (Toyobo 
Co. Ltd., Osaka, Japan). A typical 10 µl PCR reaction contained: 5 μl 2× PCR buffer, 2 μl 
dNTPs (2 mM), 0.8 μl oligonucleotide primers (3.2 μM), 0.2 μl KOD Fx Neo DNA polymerase 
(1 U/μl) and 1.2 μl cell suspension. Colony PCR was performed using the following cycling 
parameters: 
 Temperature Duration Cycles 
Denaturation 98 ˚C 30 s  
Denaturation 98 ˚C 10 s 
45 Annealing 65 ˚C 10 s 
Extension 68 ˚C Xa min 
Final extension 68 ˚C 5 min  
Holding 4 ˚C         infinite  
a 1 min/kb DNA fragment 
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The PCR amplified DNA product was analysed by agarose gel electrophoresis and, if 
needed, extracted using the QIAquick® gel extraction kit or purified with the QIAquick® PCR 
purification kit (Qiagen, Clifton Hill, Victoria, Australia) following the manufacturer’s 
instructions.  
 
Figure 2.1. Graphical illustration of colony PCR and agarose gel electrophoresis protocol 
that was used to verify yeast transformants. This illustration was prepared online using 
the Biorender website (Biorender). 
 
2.2.3 Preparation of Transformation Competent Yeast Cells  
Transformation competent S. cerevisiae AD∆∆ or AD∆ cells were used fresh or 
stored at -80 ˚C for subsequent transformations. Competent yeast cells were prepared and 
transformed using adaptations of protocols by Gietz and Schiestl (Gietz et al., 2007). A 25 
ml 2x YPCD (Table 2.7) culture inoculated with a single yeast colony and incubated 
overnight (o/n; 16 h) was used to inoculate 225 ml 2x YPCD medium to an OD600nm of 0.1 – 
1.0. The 250 ml yeast culture was incubated for a further ~6-8 h at 30 ˚C with shaking at 
200 rpm until it reached an OD600nm of ~6-8. These logarithmic-phase cells were harvested 
by centrifugation at 3,000 g for 3 min, washed twice with sterile ddH2O (100 ml and then 
10 ml), harvested again at 3,000 g for 3 min and slowly (periodically over a 30 min time 
period) resuspended in 2.5 ml FCC (Table 2.6) on ice. These transformation competent cells 
were either used immediately or stored long-term by slowly freezing them at -80 ˚C as 
Prepare a cell suspension                         PCR preparation         Colony PCR                  Gel electrophoresis 
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follows. Fifty to 300 µl competent cell aliquots contained in individual 1.5 ml microfuge 
tubes were placed into a 96-compartment plastic storage container which in turn was 
placed in a larger polystyrene container that was closed with a polystyrene lid and placed 
in a -80 ˚C freezer. Slowly freezing was critical for cell survival. 
2.2.4 Yeast Transformation  
Fresh or frozen competent cells, defrosted for 5 min in a 30 ˚C water bath, were 
divided into 50 µl aliquots in 1.5 ml microfuge tubes and harvested by centrifugation for 1 
min at maximum speed (18,000 g). The supernatant was removed and the cell pellet kept 
on ice. Salmon sperm carrier DNA (2 mg/ml) was denatured for 10 min in a boiling water 
bath and kept on ice. Fifty microlitre aliquots of the salmon sperm DNA were then mixed 
with 14 µl (500–2,000 ng) of the appropriate transforming DNA fragments, and the 64 µl 
DNA mixtures were kept on ice until further use. For each transformation, 296 µl mixtures 
of 260 µl 50% polyethylene glycol (PEG 3350) plus 36 µl 1 M LiAc at RT were mixed, by 
repeat pipetting, with the appropriate 64 µl ice-cold DNA mixtures and added immediately 
to the 50 µl competent S. cerevisiae cell pellets. The competent cell pellets were 
resuspended in the 360 µl PEG-LiAc-DNA mixture by thorough vortexing for about 10 s, and 
the transformation of these competent cells was achieved by incubating the cell mixture in 
a 30 ˚C water bath for 1 h. The cells were harvested at 18,000 g for 10 s, the supernatant 
was discarded, and the cell pellet was resuspended in 80 μl ddH2O, and subsequently 
spread onto a CSM-URA agar plate (Table 2.7). The plates were incubated for 2-3 days at 
30 °C until uracil prototroph transformants were clearly visible. To confirm that uracil 
prototroph transformants contained the desired DNA elements at the correct 
chromosomal location, colony PCR and DNA sequencing of the PCR product were 
performed.  
2.2.5 DNA Sequence Analysis  
To confirm correct transformants, the entire ~8 kb CaCDR1 transformation cassette 
was amplified by colony PCR with the primer pair PDR5-up/PDR5-down (Table 2.9). 
Unincorporated DNA oligomer primers were enzymatically removed with 0.1 µl ExoSAP-IT 
(GE Healthcare Life Sciences, Amersham, UK) treatment (i.e. 15 min incubation at 37 ̊ C and 
heat-inactivation of the exonuclease by incubating at 80 ˚C for 15 min) of 5-10 µl of the PCR 
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products. DNA sequencing of DNA fragments was carried out at the Genetic Analysis 
Services facility in the Department of Anatomy, University of Otago, Dunedin, New Zealand. 
DNA sequencing chromatograms were visualised with FinchTV (Geospiza, Inc., Seattle, WA, 
USA), and the sequences were extracted into DNA editing software ApE - A Plasmid Editor 
(by Wayne Davis, (Davis)) to confirm the sequences.  
2.2.6 Determination of Azole Susceptibilities (MIC Assay)  
The minimum growth inhibitory concentration (MIC) assay was used to measure 
the susceptibility of yeast strains to the antifungal drug FLC. Yeast cells were grown in 96-
well microtitre plates in the presence of two-fold serial dilutions of FLC. Since S. cerevisiae 
AD∆∆ cannot grow in Roswell Park Memorial Institute (RPMI) medium, which is usually 
used for yeast microdilution assays ((CLSI), 2018), CSM was used instead (Niimi et al., 2004). 
A portion (100 µl) of a 2 ml CSM (pH 7.0) o/n culture was used to inoculate 2 ml fresh CSM 
(pH 7.0) which was incubated for a further 4 to 6 h at 30 ˚C to generate a logarithmic-phase 
cell culture. These cells were then diluted with fresh CSM (pH 7.0) to an OD600nm of 0.01 
and 100 µl of the cell suspension (~10,000 cells) were used to inoculate individual 
microtitre plate wells containing 100 µl of FLC serially 2-fold diluted (512 to 0.5 mg/l) in 
CSM (pH 7.0). A no-FLC positive growth control was also included. Cell growth was recorded 
after 24 h and 48 h incubation at 30 ˚C. MICs for each ‘yeast construct’ were routinely 
determined as technical duplicates repeated twice for three separate clones. 
2.3 Biochemical Methods 
2.3.1 Determination of Protein Concentrations  
The protein concentration of crude plasma membrane preparations was 
determined with the Lowry assay (Lowry et al., 1951) using a Bio-Rad kit (reducing agent 
and detergent compatible protein assay) and bovine serum albumin (BSA) as a protein 
standard. The BSA standard curve was linear up to a concentration of 10 mg/ml. The 
protein absorbance peak at 280 nm was used to determine the protein concentration of 
detergent-solubilised membrane proteins. In some cases, the absorbance spectra of 
protein samples, between 250 nm and 550 nm, were also monitored to better assess the 
quality of detergent-solubilised Cdr1 samples. A280 nm to A250 nm ratio ≥ 2 was a useful 
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indicator for sample homogeneity. The Beer-Lambert Law was used to calculate protein 
concentrations:  
A280 =  𝜺𝜺 𝒍𝒍 𝒄𝒄 
A280 is the measured absorbance of the protein solution at 280 nm, ε is the 
extinction coefficient, 𝑙𝑙 is the path length of light measured in cm through the protein 
solution, and c is the protein concentration. The extinction coefficient of a protein can be 
predicted, with the following formula, based on the number of tryptophan (W), tyrosine 
(Y) and cysteine (C) residues that absorb light to some extent at 280 nm (Pace et al., 1995).  
𝜺𝜺 = 𝒏𝒏 (𝑾𝑾) × 𝟓𝟓𝟓𝟓𝟓𝟓𝟓𝟓 + 𝒏𝒏(𝒀𝒀) × 𝟏𝟏𝟏𝟏𝟏𝟏𝟓𝟓 + 𝒏𝒏 (𝑪𝑪) × 𝟏𝟏𝟏𝟏𝟓𝟓  
n is the number of the corresponding residues in the protein of interest. The 
extinction coefficient of CaCdr1A-XLmGFPHis was calculated to be 270,255 M-1 cm-1. 
2.3.2 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE, a method developed in the early 70s (Laemmli, 1970), and using a 
protein mini gel system from Bio-Rad, was used to analyse the purity and quantity of 
proteins in samples. The components of the protein stacking gel and the 7% polyacrylamide 
protein separating gel are listed in Table 2.10. For some experiments, undertaken in 
Germany, commercial Mini-PROTEAN® TGX Stain-Free™ Precast Gels (BioRad) with a 4-15% 
polyacrylamide gradient were used. Samples containing 10 to 15 µg of protein were mixed 
with equal volumes of 2x Protein Loading Dye (Table 2.6) and immediately loaded into 
individual gel slots (submerged in running buffer (Table 2.6)). Protein gel electrophoresis 
was performed at 200 V until the blue loading dye reached the bottom of the gel (usually 
45-55 min). Protein molecular weight markers (Table 2.3) were used as standards to 
estimate the size of individual protein fragments. After electrophoresis, gels containing 
GFP-tagged proteins were photographed and examined for in-gel GFP-fluorescence to 
quantify their expression level with the Gel Doc Imaging system (excitation and emission 
wavelengths were 475-485 nm and 520 nm, respectively). When using stain-free precast gels, 
protein bands were detected immediately after SDS-PAGE with a stain-free imaging 
technology. This was achieved using 2,2,2-tricholorethanol in the protein gels that fluoresces 
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when it interacts with protein tryptophan residues and emits fluorescence in the visible range 
that can be visualised on a 300-nm transilluminator (Ladner et al., 2004).  
Following in-gel fluorescence examination, proteins were fixed in the gel by gentle 
agitation of the gel in Protein Gel Fixing Solution (Table 2.6) for 15 min. The gel was rinsed 
twice for 10 min with 10 ml distilled water and protein bands were visualised by staining 
the gel in 10 ml QC Colloidal Coomassie Stain (Table 2.3) with gentle shaking at RT for 1-20 
h. For improved visualisation of protein bands, the gel was de-stained in ~20 ml ddH2O for 
1-3 h before gel images were recorded with the Gel Doc Imaging system. 
Table 2.10. SDS-PAGE components for two gels. 




40% Acrylamide/Bis-acrylamidea 2.1 ml 0.5 ml 
4× Separating Bufferb 3 ml - 
4× Stacking Bufferb - 1 ml 
ASTM type 1 H2O 6.9 ml 2.5 ml 
TEMEDa 8 μl 2 μl 
10% ammonium persulphatea 60 μl 30 μl 
a See Table 2.1. 






3 Cdr1 Mutagenesis and Biochemical Characterisation of Cdr1 
Mutants 
3.1  Introduction 
3.1.1 Structure of ABC Transporters 
Over the past two decades, the crystal structure of a number of type I (Schiefner et 
al., 2002; Oldham et al., 2011) and type II ABC importers (Borths et al., 2005; Korkhov et 
al., 2012) as well as those of a number of type I ABC exporters (Dawson et al., 2006; 
Hollenstein et al., 2007b; Zolnerciks et al., 2007; Hohl et al., 2012; Jin et al., 2012; Shintre 
et al., 2013; Lin et al., 2015) have been solved. More recently, the first two human type II 
ABC exporter structures, namely, ABCG2 (Taylor et al., 2017; Jackson et al., 2018; 
Manolaridis et al., 2018) and ABCG5-G8 (Lee et al., 2016) have also been solved. However, 
at the time of writing no full-size fungal PDR transporter structure is available as yet.  
Existing ABC transporter structures in various conformations that represent 
different steps of the transport cycle have significantly improved our understanding of the 
transport mechanisms of these different types of ABC transporters. However, most of the 
ABC transporter structures were solved in the open conformation, and only a few 
structures have been solved in their closed state – the ATP-bound, conformation. Despite 
the structural information gained so far, many details of how ABC transporters couple ATP-
hydrolysis to substrate transport remain elusive, especially for type II ABC exporters. 
Instead, studies have focused on some basic questions such as the number of ATP 
molecules hydrolysed per transport cycle, for instance of type II ABC exporters. Other 
questions such as whether non-canonical CNBDs of type II ABC exporters hydrolyse ATP 
and how exactly ATP-binding and -hydrolysis is coupled to substrate translocation across 
the plasma membrane in type I and type II ABC exporters remain to be answered. 
The only existing low (25 Å) resolution structure for any full-size fungal PDR 
transporter was determined by negative stain EM for the S. cerevisiae multidrug efflux 
pump Pdr5 (Ferreira-Pereira et al., 2003). The authors provided a 3D reconstruction of a 
Pdr5 dimer that did not agree with existing biological information (Ferreira-Pereira et al. 
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2003). Later, the first predicted 3D model for S. cerevisiae Pdr5 was made based on the 
structure of type I ABC exporters (Rutledge et al., 2011), even though Pdr5 is a type II 
transporter - a prime example of how structural information can be misrepresented for 
modelling purposes (Lamping et al., 2017a). In fact, and perhaps not surprisingly, the first 
type II ABC exporter structure of the human cholesterol transporter, ABCG5-G8 (Lee et al., 
2016), confirmed the presence of the unique TMD-fold and unique TMD-NBD contact 
points characterising type II ABC exporters. 
3.1.1.1 Structure and Mechanism of Action of Bacterial ABC Importers 
Type I – The crystal structure of the Methanosarcina acetivorans type I 
molybdate/tungstate ABC importer revealed that ModB2C2 (Figure 1.7-A) in a trans-
inhibited state was attached to a single periplasmic binding protein (Tong et al.) molecule 
that binds molybdate at the interface of the ModB2 (TMDs) and the substrate-binding site 
of ModA - ModB2C2A (Dawson et al., 2007a; Gerber et al., 2008). Archaeoglobus fulgidus 
ModB2 forms an inverted V-shape conformation with a large cavity accessible to the 
cytoplasm that is shielded from the lipid bilayer (Hollenstein et al., 2007b). Two conserved 
gate regions between TMS3 and TMS5 of the two ModB2 dimers separate the cavity from 
the periplasmic space. A ModB coupling helix in the short cytoplasmic IL2 between TMS4 
and TMS5 connects the TMDs of ModB with a groove region of ModC2 (NBDs) (Hollenstein 
et al., 2007b; Gerber et al., 2008).  
Another well-characterised type I ABC importer is the E. coli maltose transporter 
(MalFGK2E). A structure for an intermediate conformation of the transport cycle was 
captured for the intact MalFGK2E maltose transporter (Oldham et al., 2007). This 
conformation, with ATP bound to the two canonical CNBDs, was stabilised by a mutation 
that prevented ATP hydrolysis. This outward-facing, ATP-bound, conformation provided 
“direct evidence for a concerted mechanism of transport in which solute is transferred from 
the binding protein to the transmembrane subunits when the cassette dimer closes to 
hydrolyse ATP” (Oldham et al., 2007).  
Type II – The E. coli BtuC2D2 vitamin B12 type II ABC importer (Figure 1.7-B) that 
contains 20 TMSs was one of the earliest ABC transporter structures solved (Locher et al., 
2002). BtuCD forms a homodimer of two TMDs (BtuC2) that are attached to a dimer of two 
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cytosolic NBDs BtuD2 (BtuC2D2) (Locher et al., 2002). Vitamin B12 is delivered to the BtuC2D2 
importer by BtuF, the vitamin B12 binding protein that delivers substrate to the periplasmic 
face of the transporter (Borths et al., 2002). In the absence of ATP, the translocation 
pathway of BtuC2D2 between the BtuC2 TMD was open to the periplasmic side of the 
transporter and in direct contact with the vitamin B12 delivering BtuF subunit. With the help 
of these structures, Locher’s team proposed a transport mechanism whereby ATP binding 
catalyses conformational changes that cause the release of vitamin B12 from BtuF through 
a gate into the BtuC translocation pathway where it enters a large gap at the centre of the 
importer (Borths et al., 2002; Locher, 2004). Later, the authors presented additional 
information demonstrating that there was no substrate binding pocket for vitamin B12 in 
the TMDs of BtuC2D2-F and ATP binding and hydrolysis could not lead to an inward facing 
conformation, a scenario quite different from type I ABC importers. Instead, there were 
two cytoplasmic and one periplasmic gate(s) in the BtuC TMD subunit. As a result, in the 
absence of substrate (in both the ATP-bound and the nucleotide-free states), the 
periplasmic gate remained open and the transporter assumed an outward-facing 
conformation. Binding of periplasmic BtuF to the outward-open translocation pathway 
trapped BtuF between the TMD dimer BtuC2. ATP hydrolysis then caused partial opening 
of the NBD dimer BtuD2 which forced cytoplasmic gate 2 to open while, at the same time, 
cytoplasmic gate 1 could not be closed because of the trapped vitamin B12 substrate which 
ultimately forced the substrate to be released into the cytoplasm (Locher, 2016). The 
mechanism of action of type I and II ABC importers has been reviewed in great detail by 
Lewinson and Livnat-Levanon (Lewinson et al., 2017). 
3.1.1.2 Structure and Mechanism of Action of ABC Exporters 
Type I – The first type I ABC exporter structure in the open (inward facing) 
conformation of the E. coli lipid flippase, MsbA, was published in 2001, albeit at rather low 
resolution (4.5 Å) (Chang et al., 2001). The first X-ray structures of the Staphylococcus 
aureus type I bacterial ABC exporter Sav1866 in both the open (Dawson et al., 2007b) and 
closed (outward facing) conformations (Dawson et al., 2006) and at improved (3-3.4 Å) 
resolution were published in 2006-2007. Sav1866 is a multidrug efflux pump that functions 
as a homodimer of two half-transporter units of an NBD fused to a C-terminal TMD (NBD-
TMD)2. The two Sav1866 structures revealed substrate-binding sites, located within the 
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TMDs, that were accessible to either the extracellular or the intracellular space. ATP-
binding and -hydrolysis at either of the two canonical CNBDs was proposed to cause large 
conformational changes in the TMDs that power substrate transport across the plasma 
membrane (Dawson et al., 2006; Hollenstein et al., 2007a; Jones et al., 2009; Rees et al., 
2009; Kerr et al., 2010). This transporter has two intracellular coupling helices that contact 
both NBDs. The ATP-bound state, or outward-facing conformation, showed the two NBDs 
in close contact forcing the two TMDs to expose a centrally located polar cavity to the outer 
leaflet and the release of hydrophobic substrates to the periplasmic space (Dawson et al., 
2006, 2007b; Zolnerciks et al., 2007; Velamakanni et al., 2008). 
Later X-ray structures of MsbA revealed how specific TM helix interactions possibly 
mediated large conformational changes as the transporter switches from the inward to the 
outward facing conformation (Ward et al., 2007). It is thought that MsbA, which is also a 
multidrug efflux pump, contains two different substrate-binding sites (one for the 
physiological substrate, lipid A, and another one for drugs). The authors observed different 
sets of TM helices lining the substrate binding pocket(s) in the inward (TM3/TM6 and 
TM4/TM5) as opposed to the outward facing conformation (TM3/TM6 and TM1/TM2), 
suggestive of a twist-like motion of certain TM helices (Reyes et al., 2006; Ward et al., 2007; 
Siarheyeva et al., 2009; Kaul et al., 2011).  
The type I ABC exporter P-glycoprotein (ABCB1 - Figure 1.8-A) is arguably one of the 
most studied proteins in nature. It is a multidrug efflux pump that pumps a vast array of 
xenobiotics across cell membranes. ABCB1 has a typical ABC transporter domain 
arrangement (TMD-NBD)2. Its importance in cancer treatment, and its ability to transport 
a broad-spectrum of chemically and structurally unrelated compounds have led to many 
structural studies of the apo-, nucleotide-, and drug-bound states. The crystal structure of 
P-glycoprotein from Caenorhabditis elegans (ABCB1) at a resolution of 3.4 Å and P-
glycoprotein from Mus musculus ABCB1 at a resolution of 3.8-4.2 Å have been solved by X-
ray crystallography (Aller et al., 2009; Ravna et al., 2009; Jin et al., 2012; Ward et al., 2013; 
Li et al., 2014). The structure displayed extended loops that may act as hinges to gate the 
drug-translocation pathway and likely mediate drug binding. The interaction of intercellular 
loops with NBDs was shown as well (Rosenberg et al., 2003; Zolnerciks et al., 2007; Aller et 
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al., 2009; Ford et al., 2009; Ravna et al., 2009; Jin et al., 2012; Ward et al., 2013; Li et al., 
2014). The structural data suggested a helix rotation model for transport, and NBD 
dimerisation was disrupted by ATP hydrolysis. However, the large internal cavity with a 30 
Å separation of the two ATP binding domains in apo-structures were later refuted; 
nowadays, we know that physical NBD separation results in inactivation of transporter and 
the closed NBD dimer conformation has been established pivotal for the ATPase activity of 
the full ABC transporters where ATP binding and hydrolysis occurs alternately on either 
nucleotide binding site. This pushing together leads to pulling apart and large 
conformational changes and an opening of the TMDs to the outside via the large swinging-
arm rotation. That exposes the substrates to a lower affinity which releases the 
hydrophobic substrates into the extracellular space. ATP hydrolysis, then, brings the 
transporter back to the open conformation, and another ATP molecule binds on the other 
NBD (Wilkens, 2015; Locher, 2016; Ford et al., 2019).  
Type II – Recently, the first structure of a type II ABC exporter, human cholesterol 
transporter HsABCG5-G8 (Figure 1.8-B) in the open conformation, has been solved (Lee et 
al., 2016). Perhaps not surprisingly, given the unique features characterising PDR 
transporters (Lamping et al., 2010), HsABCG5-G8 exhibited a unique TMD-NBD cis-interface 
with novel connecting-helices and E-helices just before TMS1 and after the Q-loop of 
ABCG5 and ABCG8, respectively (Figure 3.1). There are some conserved salt-bridges 
stabilising contacts between the TMDs (coupling helices (Ch) of G5 and G8, and IL1 of G5 
and G8) and the NBDs (Q-loop of G5 and G8, and E-helices of G5 and G8) of HsABCG5-G8 - 
(Figure 3.1) (Lee et al., 2016). Lamping and colleagues had previously noticed that PDR 
transporter-specific positively charged helices just before TMS1 and TMS7 (Lamping et al., 
2010) align with the two connecting helices of ABCG5 and ABCG8. As all fungal PDR 
transporters also have the conserved E-helices adjacent to their respective Q-loops 
(Lamping et al., 2017a), this suggests that Pdr5 and Cdr1 have the same 
structural/functional constraints as HsABCG5-G8. However, there are also significant 
differences such as an N-terminal fungal-specific 150 amino acid extension (Lamping et al., 




Figure 3.1. The major contact points of type II ABC cholesterol exporter HsABCG5-G8 
(pdb: 5DO7; (Lee et al., 2016)). The lipid bilayer boundary is indicated with dashed grey 
lines. The main contact points between the TMDs (ILs and coupling helices (Ch) in yellow) 
and the Q-loops (dark blue; conserved Qs are shown as red sticks) of the NBDs. The IL1 and 
a conserved positively charged cytosolic Ch preceding TMS1 provide ‘symmetric’ contact 
with their respective NBDs; i.e. the Ch and IL1 of ABCG5 and ABCG8 are in contact with the 
Q-loop and a conserved E-helix (shown in magenta) of their own NBDs (i.e. cis-interface). 
Visible TMS helices are numbered in yellow (N-terminal TMD) and orange (C-terminal 
TMD). Taken from (Lamping et al., 2017a); used with permission from Springer Nature, 
licence no. 4885751453645 (Appendix A4). 
 
3.1.1.3 Transport Mechanism Models 
There are indeed different models for the different types of ABC transporters that 
describe how ATP-binding, and ATP-hydrolysis, and the release of ADP and Pi, at the CNBDs 
are coupled to large conformational changes of the TMDs that promote opening and 
closing of the transporter so that substrates can be translocated across biological 
membranes.  
The alternating-access model described how the substrate binding site switches 
between inward- and outward-facing conformations (Ward et al., 2007) and relies on a 
large separation of the NBDs (Locher, 2016). In the switch model (Higgins et al., 2004), also 
known as the tweezer-like model (Chen et al., 2003), the two NBDs of type I ABC importers 
and exporters are separated and have a low affinity for ATP in the open dimer 
configuration. ATP binding at the high-affinity binding site brings the two NBDs closer 
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together and induces large conformational changes in the TMDs switching access to the 
substrate binding pocket from the inward to the outward facing conformation followed by 
the release of transported substrate. Hydrolysis of ATP followed by the release of Pi and 
ADP then restores the transporter to its basal, inwardly-open, conformation. In these early 
models the NBDs of type I ABC exporters are separated by a surprisingly large distance of 
~20 Å between the ABC signature motif of one NBD and the Walker A motif of the opposite 
NBD (Higgins et al., 2004; Hollenstein et al., 2007a). However, recent models have shown 
that those original models were inaccurate. Indeed, some studies favoured a Constant 
Contact Model in which the NBDs actually remain in contact throughout ATP binding and 
hydrolysis, and ATP binding and hydrolysis alternates between the two CNBDs (Sauna et 
al., 2007; Jones et al., 2009; George et al., 2012; Wilkens, 2015; Locher, 2016; Ford et al., 
2019). In the Constant Contact Model, the two NBDs are in constant contact although the 
ATP-bound active site is closed when ATP is bound while the second, low-affinity ATP-
binding site, is empty and slightly separated. The two CNBDs switch sites after every cycle 
of ATP-binding and -hydrolysis (Ravna et al., 2009; George et al., 2012; Fribourg et al., 2014; 
Locher, 2016; Ford et al., 2019). The next model, the Helix Rotation Model proposed that 
ATP-binding may bring the two NBDs closer and a barrel-like structure is formed by the two 
TMDs that surround a central substrate-binding cavity that is exposed to the outside of the 
cell (Velamakanni et al., 2008; Aller et al., 2009; Ravna et al., 2009; Jin et al., 2012; Ward et 
al., 2013). A twisting motion induced by movements of IL1-4 that are in contact with the Q-
loops of NBD1 and NBD2 cause helix rotations of individual TMSs as the transporter 
switches from the open to the closed conformation (Gutmann et al., 2010). Irrespective of 
the mechanistic details, binding of ATP to the high-affinity CNBD appears to induce large 
conformational changes at the TMDs via unique TMD-NBD contact points that cause 
substrate translocation followed by substrate release. ATP-hydrolysis and the release of Pi 
and ADP then reset the transporter to the open conformation. Then binding of ATP at the 
opposite CNBD initiates a further transport cycle.  
The transport mechanism of type II ABC exporters, and specifically with regard to 
PDR transporters, appears to be quite different from that for type I ABC transporters. PDR 
transporters quite possibly hydrolyse ATP only at the canonical CNBD2, and they perhaps 
bind, but do not hydrolyse ATP at the non-canonical CNBD1 (Ernst et al., 2008; Ernst et al., 
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2010; Golin et al., 2015). Wang, et al, 2011, have shown that this was indeed the case in 
the human cholesterol transporter, ABCG5-G8. They found “that NBD1, although not 
required for ATP hydrolysis, is essential for normal function of G5G8 in sterol transport” and 
that “both the position and structural integrity of NBD2 are essential for sterol transport 
activity” (Wang et al., 2011). The first crystal structure for any type II ABC exporter, the 
inward open apo structure of the human cholesterol transporter ABCG5-G8, confirmed the 
existence of a number of important features including a unique TMD-fold and unique 
contact points between the NBDs and the TMDs that are quite possibly involved in coupling 
ATP-hydrolysis to substrate translocation. Cryo-EM structures for the human multidrug 
efflux transporter, ABCG2, a functional homo-dimer bound to various substrates and 
inhibitors and at different states of the transport cycle followed soon after (Taylor et al., 
2017; Jackson et al., 2018; Manolaridis et al., 2018). After considering these structures, Zein 
and colleagues suggested movement of the TMDs of ABCG5 and ABCG8 after binding of 
ATP as indicated in Figure 3.2. However, despite some significant progress made over the 
last five years, details of the transport mechanism of type II ABC exporters remain unclear 
(Zein et al., 2019). Thus, more efforts are required before we fully understand the detailed 
workings of PDR exporters. Some even argue that a universal model for ABC transporters, 
even for transporters within the same family, may actually be impossible because they all 
appear to behave slightly differently during an entire transport cycle (Moeller et al., 2015; 
Locher, 2016; Ford et al., 2019). Different models may be also used by an individual 




Figure 3.2. Proposed model for ABCG5/G8 transport. A) Molecular dynamics simulations 
indicated a possible upward movement of the TMDs and an inward movement of the NBDs 
(black arrows) as the transporter closes after ATP binds to the hydrolytic CNBD of ABCG8 
(Zein et al., 2019). B) Support for the predicted model comes from residue evolution studies 
that revealed the co-evolution of certain residue pairs in the TMDs that were more than 8 
Å apart in the apo structure (PDB accession number: 5DO7) but came in close contact 
during a simulated transport cycle (Zein et al., 2019). Taken from (Zein et al., 2019); used 
with permission from Portland press (Appendix A4). 
 
3.1.2 C. albicans Cdr1  
C. albicans is a commensal microorganism and is part of the oral microflora of 30% 
to 50% of healthy individuals (Singh et al., 2014). However, it can cause serious, life 
threatening, invasive fungal infections in immunocompromised individuals (White et al., 
1998; Brown et al., 2012b). Azole antifungal drugs are commonly used to treat C. albicans 
infections but drug resistance is an increasing public health threat (White et al., 1998; 
Pfaller et al., 2007; Yapar, 2014). One of the predominant azole resistance mechanisms is 
the over-expression of the plasma membrane multidrug efflux pump Cdr1 (Prasad et al., 
1995; Sanglard et al., 1995; Holmes et al., 2008). Cdr1 is a type II ABC transporter in the 
ABCG subfamily which is one of seven predicted full-size C. albicans PDR transporters 
(Prasad et al., 2014) that was first isolated and characterised in 1995 (Prasad et al., 1995). 
C. albicans Cdr1 has 1501 amino acids, a molecular weight of 170 kDa and the typical PDR 
inverted [NBD–TMD]2 configuration (Figure 3.3) with six ELs and four ILs connecting 12 
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individual TMSs. Type II ABC exporters, including Cdr1, have four small (EL1, -2, -4, -5) and 
two large (EL3 and EL6) ELs and two small (IL2, 4) and two large (IL1, 3) ILs and family-
defining conserved motifs in EL3 and EL6 (Figure 3.4) (Lamping et al., 2010; Lamping et al., 
2017a). The PDR transporter-specific extracellular domains (EDs) are an attractive drug 
target because they are easily accessible to inhibitors (Niimi et al., 2012a), and inhibitors 
targeting them (Hayama et al., 2012) have potentially few side effects because humans lack 
equivalent full-size ABCG transporters (they are only found in plants (Crouzet et al., 2006) 
and fungi (Lamping et al., 2010)). PDR transporters have several characteristic features: i) 
non-inducible ATPase activities; ii) asymmetric CNBDs with only CNBD2 able to hydrolyse 
ATP; iii) a unique TMD-fold; and iv) a unique coupling mechanism between ATP-hydrolysis 
and substrate translocation across the TMDs (Lee et al., 2016; Manolaridis et al., 2018) (see 
Section 1.6.2). 
3.1.3 Biochemical Characterisation of Cdr1 
There are no 3D structures, so far, for full-size PDR transporters, which is part of the 
reason why our knowledge of this important ABC transporter family remains rather limited. 
There are several important questions that have yet to be answered such as: What is the 
function of the large EDs and their family defining motifs? How do the large EDs fold and 
interact with the rest of the molecule during opening and closing of the transporter? What 
is the shape, size and specificity of the drug binding pocket(s)? How is ATP hydrolysis 
coupled to substrate transport? Why are the two CNBDs of PDR transporters asymmetric? 
And how do the two asymmetric CNBDs contribute to ATP binding and/or hydrolysis and 




Figure 3.3. Cdr1 topology and location of ten cytosolic cysteines relative to the hallmark 
NBD1 and NBD2 motifs of full-size fungal PDR transporters. Conserved amino acids in 
brackets are given in the one letter code with X representing any amino acid and h any 
aliphatic amino acid. TMSs are numbered 1–12. N = N-terminus; C = C-terminus; ELs and 
ILs are drawn to scale. The positions (red arrows) of the ten cytosolic cysteines are shown 
in red. The figure is modified from (Lamping et al., 2010); used with permission from 
Elsevier, Licence no. 4885840008306 (Appendix A4). 
 
Figure 3.4. Predicted topology of the Cdr1 TMDs and location of their thirteen cysteine 
residues. ELs (turquois) and ILs (Raad et al.) are drawn to scale. Cysteines are represented 
by yellow circles and their positions are listed underneath individual TMSs or IL4 or beside 
their respective ELs. The four conserved PDR motifs at the beginning of EL3 (PDRA and 
PDRB) and EL6 (EL6 motif and EL6 helix) are shown as green or grey boxes. The plasma 
membrane boundaries are indicated with dashed grey lines. 







3.1.3.1 Alanine Scanning and Site-Directed Mutagenesis of Cdr1 
In the absence of any structural information, biochemical analyses can provide 
many important clues about the structure and function of a protein. Biochemistry is also 
essential for the confirmation of modelled structures. Mutagenesis can provide clues about 
the functional or structural significance of individual residues. Alanine is most frequently 
used as a substitute for individual residues because it is the most frequent amino acid found 
in non-critical protein positions and all forms of secondary structure (Betts et al., 2003). 
Occasionally, bulkier residues such as valine or leucine with slightly larger aliphatic side 
chains or charged residues can be used if the size or charge of a mutated residue needs to 
be retained. Critical residues identified by alanine scanning mutagenesis can then be 
replaced with other residues to provide further clues about the possible contribution of 
individual residues to the folding, function, structure, localisation or stability of a protein.  
A number of alanine scanning and site-directed mutagenesis studies of Cdr1 and 
related type II ABC exporters have provided important insights into the drug binding 
pocket(s) (Rawal et al., 2013), the mechanism of action (Tarling et al., 2011) and how 
substrates (Puri et al., 2009) and/or inhibitors (Saini et al., 2006) interact with this 
important sub-family of multidrug efflux pumps.  
In particular, for example, Ernst et al. (Ernst et al., 2008) revealed non-equivalent 
functions of NBD1 and NBD2 of Pdr5. Their results indicated that Pdr5 functions as an 
uncoupled ABC transporter and substrate selection is not dictated solely by the 
transmembrane domains. They also found that properly folded nucleotide-binding 
domains of Pdr5 are necessary for trafficking to the plasma membrane (de Thozee et al., 
2007). The same group later showed that the S1368A mutation, which is within the putative 
drug-binding pocket of Pdr5, made cells very sensitive to drugs without any changes in 
either ATP hydrolysis, or intradomain signalling (Mehla et al., 2014). A random mutagenesis 
approach to investigate PDR5 found mutations that affected folding, trafficking and 
stability, substrate specificity and inhibitor susceptibility of the mutants and evidence to 
show that substrate binding and transporter inhibition might depend on similar structural 
features (Egner et al., 1998).  
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Prasad’s group has performed random mutagenesis studies of various Cdr1 
domains. For instance, they investigated the role of Cdr1 TMS11 residues in drug efflux 
(Saini et al., 2005). They showed in another study that substituting each of the 252 amino 
acid residues of the 12 TMSs with alanine or glycine reduced resistance to all tested drugs 
completely, or selectively, in about 40% of the variants, and showed also that TMS4 and 
TMS10 did not interact directly with the drug-binding pocket (Rawal et al., 2013). The 
asymmetric non-exchangeable nature of Cdr1 NBDs and involvement of both halves of the 
protein in the drug efflux has also been studied (Saini et al., 2006) where it has been shown 
that exchange of either the N- or the C-terminal half of Cdr1 with the homologous portion 
of Cdr3 led to a non-functional transporter. 
The Otago research group has also analysed which parts of Cdr1 contribute to Cdr1-
specific substrate transport by making chimeras with Cdr2 (Tanabe et al., 2011). They found 
regions of Cdr1 (especially TMS5) that are important for Cdr1-specific substrate and 
inhibitor interactions. It was shown, for example, that FK506- and enniatin B-inhibition was 
reliant on a greater subset of TMSs than beauvericin, and they also showed that NBD1 
indirectly affected pump activity (Tanabe et al., 2011). These studies have revealed many 
important residues that contribute to correct folding, proper localisation, ATPase activity 
and drug transport or transport inhibition of Cdr1. However, as mentioned above many 
aspects of Cdr1 biology remain obscure (Prasad et al., 2012a; Lamping et al., 2017a).  
3.1.3.2 Cysteine Cross-Linking and Cysteine Labelling Studies of Proteins 
Cysteine is a small amino acid with unique chemical properties due to its reactive 
sulphydryl (thiol) side chain (Betts et al., 2003). Extracellular cysteines frequently form 
covalent disulphide bonds that stabilise protein structure, while intracellular cysteines are 
often found in the active sites of proteins like the antifungal drug target, Erg11 (Monk et 
al., 2020), or in cysteine proteases (Turk et al., 2000). Interestingly, evolution seems to 
favour an increased cysteine content with increased organism complexity (2.26% in 
mammals versus 0.4% – 0.5% in Archaebacteria) (Miseta et al., 2000). However, cysteines 
do not always increase protein stability. Iyer and Mahalakshmi, 2019, have recently shown 
that placing cysteines in regions close to the polar surface interface of a lipid-bilayer in the 
model β-barrel membrane protein, PagP, destabilised the protein much more than 
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cysteines placed in regions of the protein that faced the hydrophobic core of the lipid-
bilayer, highlighting the rather hydrophobic nature of cysteines (Iyer et al., 2019). 
Cysteines are useful in protein topology analyses as they are targets for non-
radioactive labelling. An excellent example of the use of cysteine labelling was the 
topological study performed on the major human multidrug efflux pump, ABCB1 (Loo et 
al., 1995). In this pioneering work, the authors used a cysteine-less (Cys-less), but 
functional, ABCB1 mutant that had single cysteine residues placed either into extracellular 
or into intracellular parts of the protein and incubated cells expressing these ABCB1 
mutants with either membrane permeable biotin maleimide (both intra- and extra-cellular 
cysteines were labelled) or membrane impermeable stilbene disulphate maleimide (only 
extracellular cysteines were labelled) (Loo et al., 1995). Cysteine residues can be used to 
study many other aspects of membrane protein biology including the structural and/or 
conformational changes associated with drug transport (Radchenko et al., 2016), the role 
of particular residues in drug binding (Trofimova et al., 2018), or, importantly, for the 
confirmation of high resolution protein structures (Jones et al., 2000; Crisman et al., 2009).  
Cysteine cross-linking studies are a commonly employed tool to explore protein 
structures. This is based on the principle that cysteine-crosslinks can only be formed 
between residues that are in close proximity. Two cysteines are introduced into a Cys-less 
protein and if a disulphide bond is formed it indicates that a carbon to carbon distance in 
the range 4 to 8 Å (Bass et al., 2007), and a sulphur to sulphur atom distance within a 2 Å 
centre-to-centre distance (Akabas, 2004) are present in the protein. However, for 
meaningful results the Cys-less mutant protein has to retain its biological function. The 
inosine-guanosine permease of Crithidia fasciculata (CfNT2) is an example of a protein that 
lost its function when either of two of its ten cysteines was replaced with a serine or 
alanine. However, the authors were able to create a fully functional Cys-less CfNT2 protein 
by using random mutagenesis to determine which residues were required at those two 
positions to obtain a fully functional protein (Arendt et al., 2007). As already mentioned, 
Loo and Clarke used a fully functional Cys-less ABCB1 molecule to reveal the TMD topology 
of this type I ABC exporter with cysteine cross-linking experiments (Loo et al., 1995). They 
also studied the distance between the two NBDs and they found that the ATPase activation 
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switch was turned off when the distance was greater than 20 Å (Loo et al., 2014). Use of a 
Cys-less version of the mouse ABCB1 homolog and double electron resonance 
spectroscopy between pairs of spin labelled cysteine residues helped solve long standing 
controversies about the detailed molecular mechanisms of substrate- versus inhibitor-
induced or basal ATPase hydrolysis mechanisms of this important protein family (Dastvan 
et al., 2019).  
3.1.3.3 Creation of a Cysteine-Less Cdr1 Molecule 
C. albicans Cdr1 contains 23 cysteines, 10 are cytosolic (Figure 3.3) and 13 are 
predicted to be in the TMDs or the extracellular domains (EDs) of Cdr1 (Figure 3.4). Six of 
the seven extracellular cysteines, 2 in EL3 and 4 EL6 (Figure 3.4), are conserved in all fungal 
PDR transporters and predicted to form three extracellular disulphide bonds that quite 
possibly stabilise the structure of the ED of PDR transporters (Lamping et al., 2010). 
Although plant PDR transporters have similar EDs with the same family-defining motifs, 
they do not have any conserved extracellular cysteines and obviously use a different 
stabilisation mechanism for their EDs. The existence of three possible disulphide bonds 
indicates that it may not be quite so easy to create a fully functional Cys-less Cdr1 mutant. 
Prasad and his colleagues reported the creation of a functional Cys-less Cdr1 
molecule in 2012 (Prasad et al., 2012b). Most cysteines were replaced with alanine but the 
intracellular cysteines C1056, C1091, C1106, C1294 and C1336 had to be substituted with 
serine residues to obtain a functional efflux pump when overexpressed in S. cerevisiae. 
Unfortunately, the strain we obtained from Prasad did not yield a functional Cdr1 protein, 
which may have been due to the presence of a number of additional mutations we 
detected, but even after correcting these mutations the Cys-less CDR1 mutant remained 
inactive. To understand why that was so, and to learn which cysteines are most critical for 
Cdr1 function, a number of CDR1 mutants that had the cysteines of individual subdomains 
replaced by alanine or serine were created and characterised. The results of these 
experiments and the creation of four additional CDR1 mutants with disrupted ATPase 
activities are described in this chapter. 
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3.1.4 Heterologous Membrane Protein Expression  
One of the main obstacles for the structural characterisation of membrane proteins 
is the expression of correctly folded and intact membrane protein in quantities required 
for X-ray crystallography or cryo-EM. There are three types of membrane protein 
expression systems: i) homologous (Schertler, 1992; Ahn et al., 2001); ii) heterologous 
(Macauley-Patrick et al., 2005; Grisshammer, 2006); or iii) in vitro expression systems 
(Reckel et al., 2010; Focke et al., 2016). In vitro membrane protein expression technologies 
using mammalian, yeast, or bacterial cell extracts as yet are not optimised for their routine 
use for the production of properly folded and functional membrane protein, hence the 
method needs trial and error for each individual protein to achieve correct folding (Farrokhi 
et al., 2009). Homologous membrane protein expression technology, which refers to the 
overexpression of a gene in the same organism from which it originated, is possibly the 
best choice for producing correctly folded and post-translationally modified membrane 
proteins. However, expression levels can often be quite low and their use can be 
prohibitively cost- and labour-intensive. This leaves a few well characterised heterologous 
expression systems as the preferred option for the production of membrane proteins 
where expression of the gene happens in a host species different from the origin of the 
gene.  
There are a number of different protein expression hosts ranging from bacteria (e.g. 
E. coli), to yeast (e.g. S. cerevisiae and Pichia pastoris), and higher eukaryotes including Sf9 
insect or various mammalian cell lines (Pandey et al., 2016). All protein expression 
technologies have advantages and disadvantages, but E. coli, P. pastoris (Byrne, 2015) and 
S. cerevisiae are most frequently used as hosts for heterologous membrane protein 
expression. Yeast cells are well studied unicellular microorganisms, they are genetically 
tractable, and they can be scaled up cheaply. Major differences between the various 
heterologous membrane protein expression platforms exist, and they must be carefully 
considered when choosing the best host for a particular membrane protein of interest. 
These include criteria such as ease of use, growth rates and costs, but also the ability to 
express complex, post-translationally modified proteins that can be critical for the function 
and/or stability of a protein (Bernaudat et al., 2011; Byrne, 2015). 
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3.1.5 The S. cerevisiae Membrane Protein Hyper-Expression System 
S. cerevisiae is perhaps the best studied eukaryotic model organism. It has many 
versatile applications in genetic engineering, drug discovery, synthetic biotechnology, and, 
importantly, the heterologous expression of eukaryotic membrane proteins (Kingsman et 
al., 1985; Harvey et al., 2018). S. cerevisiae ADΔ (Lamping et al., 2007) and ADΔΔ (Sagatova 
et al., 2016) were used as hosts to overexpress all Cdr1 variants. Both strains are derivatives 
of AD1-8u- (Decottignies et al., 1998) (Figure 3.5) that have either the ura3 (AD∆) or the 
ura3 and his1 (AD∆∆) genes deleted which eliminated the background of false positive 
transformants. Over the past two decades the original yeast membrane protein expression 
technology (Nakamura et al., 2001) was further optimised (Lamping et al., 2007) to 
facilitate the easy one-step cloning of membrane proteins of interest (Lamping et al., 
2017b) tagged at either their N- or C-terminus with various affinity, epitope, or reporter 
tags and, if desired, their expression levels predictably repressed to anywhere between 
50% to as low as 0.1% of the maximum expression level (Lamping et al., 2013). S. cerevisiae 
AD1-8u- (Decottignies et al., 1998) is deleted in seven major ABC transporters as well as the 
transcription factor PDR3, and it contains the gain-of-function Pdr1-3 mutated 
transcription factor that causes the constitutive overexpression of heterologous plasma 






Figure 3.5. Yeast membrane protein hyper-expression system. S. cerevisiae AD1-8u- is 
deleted in seven ABC transporters and transcription factor PDR3. Integration of a 
transformation cassette containing the PDR5 promoter (blue), the gene of interest (e.g. 
CaCDR1; brown), followed by the PGK1 terminator (Raad et al.), the URA3 or HIS1 selection 
marker (light blue) and the PDR5 downstream sequence (blue) into the genomic PDR5 locus 
causes the constitutive overexpression of Cdr1. Figure is taken from (Lamping et al., 2007); 
used with permission from the ASM (Appendix A4). 
 
3.1.6 Aims 
The overall objective of this part of the thesis was to create a Cys-less CDR1 mutant 
with unaltered multidrug efflux pump function.  
Specific aims were to: 
1) Optimise a small-scale yeast plasma membrane preparation protocol. 
2) Create and biochemically characterise CDR1 mutants that can help reveal which 
cysteines are most important for Cdr1 function. 
3) Create a functional Cys-less CDR1 mutant for cysteine-crosslinking studies. 
4) Create and characterise mutants of the catalytic Walker A2 (K901 residue), catalytic 
carboxylate residues of Walker B1 (D327) and Walker B2 (E1027). 
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3.2 Materials and Methods 
The following materials and methods were primarily used in this chapter. A quick 
and easy to use small-scale yeast plasma membrane isolation protocol was developed for 
the efficient and reliable biochemical characterisation of various yeast strains 
overexpressing Cdr1 variants. This involved optimising the number of cell breakage cycles, 
the types of beads used for breaking cells, the growth temperature, the growth phase, and 
the cell density. The effect of acid-precipitation on the quality of the isolated yeast plasma 
membranes and their specific Cdr1 ATPase activities was examined. Following is the 
optimised small-scale plasma membrane isolation protocol. 
3.2.1 Growth and Harvesting of Yeast Cells for the Small-Scale Isolation of Crude 
Plasma Membrane Preparations 
A single yeast colony from a YPD agar plate was used to inoculate 10 ml YPD 
medium which was incubated at 30 °C with shaking at 200 rpm for ~7-8 h. The 10 ml pre-
culture was used to inoculate 40 ml YPD medium and incubated o/n (~16 h) at 30 °C with 
shaking at 200 rpm until the cell density reached an OD600nm of 1-3. Forty OD units (ODU; 
e.g. 1 ml at an OD600nm of 1 = 1 ODU) of these logarithmic cells were harvested by 
centrifugation at 4,200 g for 5 min at 4 ˚C and washed once with 40 ml ice-cold ddH2O. The 
cell pellet was resuspended in 1 ml ice cold ddH2O and transferred to a 1.5 ml microfuge 
tube placed on ice. Cells were harvested by centrifugation at 3,300 g for 3 min at 4 ˚C and 
resuspended in 0.5 ml homogenising buffer (HB) freshly supplemented with 1 mM PMSF 
(Table 2.6). Cell suspensions were stored at -80 °C for future use or kept on ice for 
immediate breakage.  
3.2.2 Small Scale Crude Plasma Membrane Preparation 
Approximately 1 g ice-cold 0.5 mm diameter silica beads were added to 0.5 ml cell 
suspension in a 1.5 ml microfuge tube (either kept on ice or thawed on ice for ~1 h) to reach 
a total volume of ~1 ml. The cells were broken by 6 cycles of vortexing at maximum shaking 
intensity for 1 min and 3 min cooling periods on ice in between. The 0.5 ml broken cell 
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homogenate was transferred into a new ice-cold 1.5 ml microfuge tube by stabbing a tiny 
hole with a hot needle in the bottom of the tube. The tube was placed into a new open 1.5 
ml microfuge tube and the entire 0.5 ml cell homogenate was collected through the small 
opening into the new 1.5 ml microfuge tube with a 10s low speed (~200 rpm) spin; the silica 
beads remained in the original tube. The 0.5 ml cell homogenate was centrifuged at 5,156 
g for 5 min at 4 °C to remove cell debris, unbroken cells, and nuclei. Most of the supernatant 
(450 µl) was transferred into an ice cold 1.5 ml microfuge tube and further diluted with 1 
ml ice-cold HB freshly supplemented with 1 mM PMSF. This dilution step was critical for 
high-quality plasma membrane protein recovery. It enabled: i) ~100% plasma membrane 
protein recovery and; ii) the removal of almost 50% of cross-contamination with unwanted 
microsomal material in the following centrifugation step. The crude plasma membranes 
were harvested by centrifugation at 17,968 g for 1 h at 4 ˚C and resuspended in 100 µl ice-
cold HB (freshly supplemented with 1 mM PMSF).  
3.2.3 Cdr1 ATPase Assay 
The Cdr1 ATPase activity of crude plasma membrane preparations was determined 
spectrophotometrically by capturing the phosphate released by ATP hydrolysis as a blue-
coloured phosphomolybdate complex. The assay was performed in triplicate in the absence 
or presence of Cdr1-ATPase inhibitors oligomycin (20 µM), FK506 (120 µM) or enniatin (10 
µM). The ATPase assay cocktail and Mg-ATP (Table 2.6) were equilibrated to 30 ˚C for ~1 h 
before the ATPase assay was undertaken by distributing 90 µl aliquots of the prewarmed 
ATPase assay cocktail, with or without inhibitor, into wells of a 96-well microtitre plate. 
Aliquots (5 µl) of crude plasma membrane preparations, diluted, if necessary, to obtain the 
desired ~5-10 µg of crude plasma membrane protein, or of phosphate standards (0-100 
nmoles Pi), were added to the appropriate wells. The first and last columns were used for 
phosphate standards. The assay was started by adding 25 µl prewarmed 28.8 mM Mg-ATP 
(the final Mg-ATP concentration was 6 mM) to each well with a multi-channel pipette and 
incubating the reaction for 30 min at 30 ˚C. The ATPase assay was stopped by adding 130 
µl of ATPase assay development reagent (Table 2.6) to each well, and the dye was left to 
develop for 10 min at RT before the A750nm was measured with a microtiter plate reader. It 
was important to develop the dye for exactly 10 min because it continued to develop to an 
ever deeper blue. 
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The total ATPase activities (nmol/min/mg) were measured for the wells with the 
cocktail buffer (Table 2.6) without adding any oligomycin while oligomycin-insensitive 
ATPase activities (nmol/min/mg) were measured in the presence of 20 µM oligomycin. The 
‘oligomycin-sensitive (OS) ATPase activity’ was calculated by subtracting the oligomycin-
insensitive from the total ATPase activity. The OS ATPase activity was expected to represent 
the Cdr1 ATPase activity, but, unfortunately, there was also some background OS ATPase 
activity in the AD∆∆ strain. Thus, the ‘specific Cdr1 ATPase activity’ or the ‘OS Cdr1 ATPase 
activity – corrected, (OSC)’ was determined by subtracting the OS AD∆∆ background 
ATPase activity from the OS ATPase activity of the Cdr1 overexpressing strain. 
3.2.3.1 Quantification of Cdr1 Expression Levels and Determination of Specific Cdr1-
ATPase Activities 
Expression levels of C-terminally GFP tagged Cdr1 variants were quantified by 
measuring the green fluorescence emitted at 512 nm (excitation wavelength = 448 nm) 
from SDS-PAGE separated plasma membrane protein (10 or 20 µg) samples using the 
BioRad Gel-Doc system. The ATPase activities of the Cdr1 variants were quantified spectro-
photometrically by measuring the phosphate released after a certain period of time.  
There are some compounds that have been identified as inhibitors of fungal efflux 
pumps, such as oligomycin, FK506 (Kralli et al., 1996; Tanabe et al., 2019), enniatin B (Hiraga 
et al., 2005), and beauvericin (Tanabe et al., 2011; Szczepaniak et al., 2015; Shekhar-
Guturja et al., 2016; Tong et al., 2016) (Figure 3.6). The ATPase activity measurements for 
Cdr1 and ADΔΔ membranes (with and without acid-precipitation) were performed with and 






Figure 3.6. Structures of Cdr1 efflux pump inhibitors. A) oligomycin, B) FK506, C) enniatin 
B, and D) beauvericin (pubchem: https://pubchem.ncbi.nlm.nih.gov). 
 
3.2.4 Confocal Microscopy of Yeast Cells Overexpressing Cdr1-GFP Variants 
Confocal microscopy of yeast cells expressing GFP tagged proteins is a powerful tool 
to study the localisation of proteins inside living cells. To assess the correct localisation of 
C-terminally tagged Cdr1-GFP mutant constructs expressed in the S. cerevisiae host, 2 ml 
CSM medium (Table 2.7) was inoculated with a single yeast colony and incubated at 30 ˚C 
o/n in a shaking (200 rpm) incubator. An aliquot of the o/n culture was used to inoculate 1 
ml CSM to a cell density of OD600nm of ~ 0.5, and the culture was incubated at 30 °C with 
shaking at 200 rpm for another ~2-4 h to reach a cell density of OD600nm of 1. The logarithmic 
cells were harvested by centrifugation at 18,000 g for 1 min, resuspended in ~ 0.1 ml ice 
cold CSM (OD600nm = 10) and kept on ice until they were subjected to confocal microscopy. 














slides and covered with a cover slip. To avoid movement of cells and to ensure that they 
stick to the surface of the slide, a thin agarose layer was created on the slide surface by 
placing 1-2 ml 0.7% (w/v) melted agarose onto the slide and letting it dry for about 1 hour 
in a laminar flow cabinet. Images of cells and their GFP signals were observed with a Zeiss 
LSM 710 confocal laser scanning microscope at 630x magnification and using a 488 nm 
argon laser for excitation of the GFP fluorophore. GFP fluorescence was detected at an 
emission wavelength window set between 495 and 598 nm. 
3.2.5 Construction of Yeast Strains Overexpressing Cdr1  
The correct Cys-less CDR1PC overexpressing yeast strain AD∆∆-CaCDR1PC-GFP 
(MBL: 2311; P stands for the wild-type allele that Prasad’s research team used to create 
the Cys-less CDR1 mutant (Prasad et al., 2012b) and C stands for Cys-less) lacking any of 
the additional unwanted mutations mentioned above was provided by my supervisor, Dr. 
Erwin Lamping. AD∆∆ strains overexpressing the various CDR1 mutants were created in 
single transformations containing up to five individual PCR fragments that overlapped by 
25 bp (Figure 3.7). The individual DNA fragments were amplified by PCR from various DNA 
sources (either plasmids like pABC3-CaCDR1P-GFP, pABC3-CaCDR1PC-GFP or pABC3-
CaCDR1A-GFP or gDNA extracts from certain yeast strains) and sometimes using 
mutagenesis primers to introduce individual point mutations (yellow lines; Figure 3.7). All 
primer sequences can be found in Table 2.9. A total of 25 different yeast strains 




Figure 3.7. One-step yeast transformation cloning strategy (multi-fragment 
transformation). One-, two-, three-, or four-fragment recombinant transformation 
strategy to create various AD∆∆-CaCDR1 mutants. P are CDR1-specific primers that were 
used to amplify the indicated PCR fragments. The PDR5 promoter and downstream 
sequences, the gene of interest, the PGK1 terminator and the URA3 selection marker are 
in blue, brown, green and light blue, respectively. The homologous cross-over events (2, 3, 
4 or 5) that were necessary to integrate the entire transformation cassette in one piece 
(top), or 2, 3 or 4 pieces (underneath), into the genomic PDR5 locus are indicated with grey 
crosses. The yellow lines depict desired mutations that can easily be introduced by primer 
design of the indicated CDR1-specific -for and -rev primer pairs. Correct transformants 
were verified by colony PCR with a primer pair that binds ~40 bp upstream and downstream 
of the chromosomal integration site. 
 
Figure 3.8 indicates, as an example, the creation of AD∆∆-CaCDR1PC-GFP-NTS12 
(MBL: 2397). Fragment 1 (~3 kb; lane 1) contained the 5’ part of the transformation 
cassette with all cysteines of CDR1P-NBD1-TMD1 up to EL3 (Figure 3.3) replaced with 
alanine or serine. Fragment 3 (~1.5 kb; lane 3) had all cysteines of CDR1P-NBD2-TMD2 up 
to EL6 replaced with alanine or serine, and fragments 2 and 4 contained wild-type CDR1P 
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sequences of EL3 (~0.5 kb; lane 2) and EL6 plus the C-terminus of CDR1P-GFP and the 
remaining 3’ part of the transformation cassette (~3 kb; lane 4). Fragment 1 was amplified 
by PCR with the primer pair pPDR5-pro/pCDR1-2014-rev from gDNA of AD∆∆-CaCDR1PC-
GFP. Fragment 2 was amplified from the same gDNA template using primer pairs pCDR1-
2480-for/pCDR1-C1380A-rev, and fragments 3 and 4 were amplified from gDNA of AD∆∆-
CaCDR1P-GFP using pCDR1-2014-for/pCDR1-2480-rev and pCDR1-C1380A-for/pPDR5-ter, 
respectively. 
 
Figure 3.8. Creation of AD∆∆ strains overexpressing CDR1PC-NTS12 that had all cysteines 
except those for EL3 (2) and EL6 (4) replaced with alanine or serine. DNA fragments in 
lanes 1-4 were amplified by PCR from gDNA of AD∆∆-CaCDR1PC-GFP (lanes 1 and 3) or 
AD∆∆-CaCDR1P-GFP (lanes 2 and 4), respectively. M: 1 kb Plus DNA Ladder. One microlitre 
of each PCR fragment was separated by electrophoresis through a 0.8% agarose gel. Lane 
1: 5’ proximal part of the transformation cassette (PDR5 promoter and N-terminal part of 
CDR1PC up to EL3); lane 2: CDR1P-EL3 and -TMS6; lane 3: C-terminal half of CDR1PC (NBD2-
TMD2 up to EL6); lane 4: 3’ part of the transformation cassette including the C-terminus of 
CDR1P-GFP starting from CDR1P-EL6. Lanes 5-15 contain 1 µl of the transformation 
cassettes that were amplified with the outside primer pairs (up/down; Figure 3.7) by colony 
PCR from three correct AD∆∆-CDR1PC-NTS12 transformants (5-7) and from other AD∆∆-
CDR1PC-GFP constructs: AD∆∆-pABC3 containing the empty transformation cassette (8), 
and AD∆∆-CaCDR1PC-GFP-EL3 (9), -EL36 (10), -N1 (12), -T1 (13), -NT1 (14), NTS1 (15) and 
AD∆∆-CaCDR1P-GFP-∆∆EL36 (11), respectively. The fragment in lane 11 is slightly smaller 
because it had EL3 and EL6 deleted. 
 
Competent S. cerevisiae AD∆∆ cells were transformed with a 14 µl equimolar 
mixture of the four PCR amplified DNA fragments (total 0.5–2 µg), and uracil prototroph 
transformants were selected by plating the transformed cells onto CSM-ura plates (Table 
2.7) and incubating the plates for three days at 30 °C until transformants became clearly 
visible (Figure 3.9). Uracil prototrophic transformants were confirmed by PCR amplification 
(colony PCR - Section 2.2.2.1) of the entire transformation cassette with primer pairs 
PDR5up and PDR5down (Figure 3.8) and DNA sequencing of the (~8 kb) transformation 
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cassettes. Petite mutants that cannot grow on non-fermentable carbon sources and have 
a slow growth phenotype due to the loss of mitochondrial activity are quite common in S. 
cerevisiae (Day, 2013). The AD∆∆ strain is especially prone to acquire the petite phenotype 
with an estimated 1 to 10% of colonies exhibiting the petite phenotype (small colonies) on 
YPD plates. To ensure that the transformants had not become petites, their growth on YPG-
agar plates (Table 2.7) was routinely tested; petite mutants cannot grow on non-
fermentable carbon sources such as glycerol (Figure 3.9-D). 
    
Figure 3.9. Example of a yeast transformation experiment. Selection of uracil prototroph 
transformants by incubating transformed cells for 3 days at 30 ˚C on CSM-ura plates. A) 
Negative (no DNA) control. B) Positive control (10 ng pYES2). C) Yeast transformants (0.5-2 
µg DNA). D) Testing transformants for a petite phenotype on YPG agar plates. Yeast cells 
with a mitochondrial defect grow slower on fermentable carbon sources such as glucose 
(e.g. YPD or CSM-ura), and they cannot grow at all on non-fermentable carbon sources like 
glycerol (e.g. YPG). Examples of petite transformants are encircled in yellow. 
 
3.2.5.1 Construction of ATPase Deficient Cdr1 Mutants 
The CDR1 mutant with an inactive ATPase, CDR1A-K901A (AD∆∆-CaCDR1A-K901A-
GFP; MBL 2410), had the catalytic Walker A2 K901 residue mutated to an alanine residue. 
This CDR1A mutant was created with the one-step, two-fragment, transformation 
technique described above. Plasmid pABC3-CaCDR1A-GFP was used as a template to 
amplify two 25 bp overlapping DNA fragments that contained the K901A mutation in the 
centre of the 25 bp overlap. The 5’ fragment was amplified with primer pair pPDR5-
pro/pCDR1-K901A-rev, and the 25 bp overlapping 3’ fragment was amplified with primers 
pCDR1-K901A-for/pPDR5-ter, respectively. Analogous to the construction of AD∆∆-CDR1A-
K901A-GFP, mutants of the catalytic carboxylate residues of Walker B1 (D327) and Walker 
B2 (E1027) were also created (i.e. AD∆∆-CaCDR1A-D327N-XLmGFPHis, AD∆∆-CaCDR1A-
E1027Q-XLmGFPHis, and AD∆∆-CaCDR1A-D327N-E1027Q-XLmGFPHis). The reason for 
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creating these mutants was to use them at a later stage in the structural studies where they 
can be easily locked in one conformation by adding ATP to the purified protein. ATP will 
bind to the NBDs but the strains will not be able to hydrolyse it and change conformation. 
3.2.5.2 Search for CDR1PC-NTS12 Suppressor Mutations that Could Recover Efflux Pump 
Function 
Natural CDR1 suppressor mutants of cells overexpressing inactive CDR1 ORFs, that 
had regained resistance, were selected by plating 106-107 logarithmic phase cells onto CSM 
agar plates supplemented with high concentrations (~4-8 times higher than their MIC) of 
FLC and isolating clearly visible colonies after incubating the plates for up to two weeks at 
30 ˚C. Individual colonies were tested for possible CDR1 suppressor mutations by 
sequencing the entire CDR1 ORF.  
3.2.6 Determination of Azole Susceptibility (MIC Assay) of Generated Mutants 
The minimum growth inhibitory concentration (MIC) assay (Section 2.2.6) was used 
to assess the FLC susceptibility and, thus, the functionality of the various CDR1 constructs 
overexpressed in S. cerevisiae AD∆∆. Positive (AD∆-CaCDR1A-GFP, AD∆∆-CaCDR1P-GFP, or 
AD∆∆-CaCDR1A-XLmGFPHis; MBL 771, 2308, or 2480, respectively) and negative (AD∆∆-
pABC3; MBL 2411) controls were included in each experiment.  
3.3 Results 
3.3.1 Optimisation of a Small-Scale Plasma Membrane Isolation Protocol 
The following experiments were designed to investigate which parameters of the 
small-scale plasma membrane isolation protocol needed to be modified in order to develop 
a fast, reproducible, and easy to use downscaled protocol that could still achieve the 
highest possible quality of plasma membranes. 
3.3.1.1 Optimisation of Cell Breakage 
The highest yield of plasma membranes with the highest Cdr1 specific ATPase 
activity (OSC; Figure 3.10) involved breaking 40 ODU of logarithmic phase (OD600nm of 1-3) 
cells, resuspended in 0.5 ml HB, with the same volume of silica beads and 6 cycles of 
vortexing for 1 min at maximum shaking intensity followed by 2 min cooling periods on ice. 
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Increasing the number of breakage cycles further had a negative effect on the quality and 
quantity of the isolated plasma membranes (the OS ATPase activity reduced from 170 
nmol/min/mg to ~60 nmol/min/mg), and the yield of the isolated plasma membranes also 
decreased slightly with increased (10 or 14) breakage cycles (Figure 3.10). Because there 
were only subtle differences in the protein patterns of the plasma membranes isolated 
from cells broken with varying breakage cycles (Figure 3.11) it is likely that the almost 3-
fold reduced Cdr1 ATPase activities at 10 or more breakage cycles is either caused by: i) 
partial denaturation of Cdr1 due to exposure to elevated temperature; by ii) post-
translational modifications such as phosphorylation or dephosphorylation; or by iii) 
increased ‘cross-contamination’ of the isolated plasma membrane vesicles with membrane 
fractions of other organelles. The 2 min cooling periods could, however, be extended 
without any noticeable effect on the quality of the isolated plasma membranes (data not 
shown). 
 
Figure 3.10. Effect of changing the number of cell breakage cycles on the OS-ATPase 
activity of isolated plasma membranes. A) Concentration of plasma membrane protein 
preparations of logarithmic phase AD∆∆ or AD∆∆-CaCDR1A-GFP (Cdr1) cells obtained after 
breaking the cells for the indicated number of cycles. B) The respective OS ATPase activities 
of the membrane preparations. The black arrows show the difference between OS ATPase 
activities of AD∆∆-CaCDR1A-GFP and AD∆∆ which are the corrected OSC ATPase activities. 
Six cycles of cell breakage yielded the maximum amount of plasma membrane protein (A) 






Figure 3.11. Effect of the number of cell breakage cycles on the protein profile of isolated 
plasma membranes. Coomassie blue stained SDS-PAGE gel (7%) of samples containing 5 
µg plasma membrane proteins isolated from yeast cells broken with various numbers of 
breakage cycles (top) and detection of the green fluorescence signal of Cdr1-GFP (bottom) 
before Coomassie blue staining. M = Precision Plus Protein size marker; the MW of 
individual bands are indicated. Lane 1 contains plasma membranes isolated from AD∆∆ 
cells broken with six breakage cycles and lanes 2 to 5 contain plasma membrane protein 
samples isolated from AD∆∆-CaCDR1A-GFP cells that were broken for 3, 6, 10 and 14 cycles, 
respectively. The Cdr1 band is indicated with an arrow. 
 
3.3.1.2 Effects of the Bead Material, Temperature, and the Number of Freeze/Thawing 
Cycles on Cdr1 ATPase Activities 
The use of either silica or glass beads for breaking the cells with six breakage cycles 
had no significant effect on the OS ATPase activities of the isolated plasma membranes 
(glass beads gave ~4% higher OS ATPase activities) (Figure 3.12-A). The total ATPase 
activities of freshly isolated plasma membranes reduced by ~5% when they were kept for 
60 min on ice, and they reduced even more (~20%) when they were exposed to an elevated 
temperature (30 ̊ C) (Figure 3.12-B). The reductions in the OS ATPase activities were higher; 
for Cdr1 plasma membranes that were kept for an hour on ice or at 30 °C, 80% or 70%, 
respectively, of the OS ATPase activity of freshly prepared plasma membranes remained. 
For AD∆∆, however, 70% or 40% of the OS ATPase activities of the fresh sample remained 
after an hour kept on ice or at 30 °C, respectively (Figure 3.12-B). The oligomycin-insensitive 
ATPase activities (i.e. total minus OS ATPase activity) were stable and remained similar for 
all samples. Next, it was tested whether repeat freeze-thaw cycles would affect the OS 
ATPase activity of the isolated plasma membranes. The OS ATPase activity of three 
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separate plasma membrane preparations each reduced by ~10% with every freeze-thaw 
cycle as shown in Figure 3.12-C. All three strains after one cycle of freezing and thawing 
still had almost 90% OS ATPase activity of the fresh plasma membranes. Those numbers 
decreased to just 30% OS ATPase activity of the fresh plasma membranes after five freeze-
thaw cycles (i.e. 70% reduction). This is why future plasma membrane samples were split 
into small aliquots to reduce the need for multiple freeze-thawing cycles. 
 
Figure 3.12. Effect of bead material, temperature and number of freeze/thaw cycles on 
the ATPase activities of isolated Cdr1 plasma membranes. The plasma membrane ATPase 
activities were determined as total and as OS ATPase activity. A) Graph of the total (AD∆∆-
CaCDR1A-GFP (Cdr1) and AD∆∆) and the OS (AD∆∆-CaCDR1A-GFP (Cdr1) and AD∆∆) ATPase 
activities of plasma membranes isolated with 6 cell breakage cycles of AD∆∆ and AD∆∆-
CaCDR1A-GFP using either silica (blue) or glass beads (red) to break the cells. B) Effect on 
the ATPase activities by keeping freshly isolated (dark blue) plasma membranes of AD∆∆ 
and AD∆∆-CaCDR1A-GFP cells for 60 min on ice (red) or at elevated temperature (30 °C; 
grey). C) The graph shows how multiple freeze/thaw cycles (labelled with the number of 
cycles, nX) significantly reduced the OS ATPase activities of wild-type Cdr1 or Cdr1 with all 
cysteines of NBD1 (N1) or NBD2 (N2) replaced with serines or alanines. 
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3.3.1.3 Effect of Cell Density at Breakage on the OS ATPase Activity of Isolated Plasma 
Membranes 
Other parameters that may also affect cell breakage and the quality of isolated 
plasma membranes are the density of the cell suspension and the ratio of glass or silica 
beads to the volume of the cell suspension. Breaking 40 ODU of cells in 0.5 ml HB provided 
the highest quality of plasma membranes (i.e. most Cdr1-GFP per 10 µg plasma membrane 
protein; (Figure 3.13)) with highest OS ATPase activities (Figure 3.14-B). Higher (> 40 
ODU/0.5 ml HB) or lower (20 ODU/0.5 ml HB) cell densities reduced the OS ATPase activity 
of the isolated plasma membranes, although, their yield kept increasing proportionately 
with increasing cell densities (Figure 3.14-A). Thus, 40 ODU was the optimum amount of 
cells for the isolation of highest quality of plasma membranes.  
 
Figure 3.13. Effect of cell density at breakage on the quality of isolated plasma 
membranes. Coomassie blue stained SDS-PAGE gel (7%) of 10 µg plasma membrane 
protein samples and green fluorescence signals of Cdr1-GFP of the same gel before 
Coomassie staining of protein. M = Precision Plus Protein Marker; MWs of marker bands 
are indicated. Lanes 1, 3, 5 and 7 are plasma membranes of AD∆∆ and lanes 2, 4, 6 and 8 
are plasma membranes of AD∆∆-CaCDR1-GFP isolated from 20, 40, 60 and 80 ODU of cells, 
respectively. Cdr1 is indicated with an arrow. The relative percentages of the green 




Figure 3.14. Effect of cell density at breakage on the yield of isolated plasma membranes 
and ATPase activity of Cdr1. A) Effect of the cell density (ODU/0.5 ml HB) on the protein 
concentration of the plasma membrane samples isolated from AD∆∆ and AD∆∆-CDR1-GFP 
(Cdr1) cells. B) Effect of the cell density at breakage on the total (Raad et al.) and the OS 
(red) ATPase activities of the plasma membranes isolated from AD∆∆-CDR1-GFP cells. C) 
The total OS ATPase activities of samples obtained after breaking cells at different cell 
densities. The measured (dark blue) total ATPase activities of the 100 µl plasma membrane 
preparations obtained from 20, 40, 60 and 80 ODU of cells were compared with their 
expected values (light blue) that were calculated by multiplying the total ATPase activity of 
20 ODU of cells by 2 (40 ODU), 3 (60 ODU) or 4 (80 ODU), respectively. 
 
Using the optimised protocol for the small scale plasma membrane isolation led to 
2-3 times higher Cdr1 specific ATPase activities (~300 nmol/min/mg) compared to the Cdr1 
specific ATPase activities that were initially obtained (~100 nmol/min/mg; compare Figure 
3.10 with Figure 3.12-A and -B). 
3.3.1.4 Growth Phase Dependency of the OS ATPase Activity  
With the optimised small-scale plasma membrane isolation protocol, the Cdr1 
specific ATPase activities, that had the AD∆∆ OS background ATPase activities subtracted, 
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were highest (~300 nmol/min/mg; Table 3.1, OSC) in logarithmic phase cells (OD600 = 0.2-
3; Figure 3.15) and dropped within 2-4 h by ~40% to ~60% in late-logarithmic (OD600 = 5.9; 
Figure 3.15) and early stationary (OD600 = 7.6) phase cells, although they recovered 
significantly at later stages of diauxic growth (Figure 3.16 and Table 3.1). Interestingly, 
AD∆∆ also had a significant amount of OS ATPase activity, although it was much lower 
(~12%; ~37 nmol/min/mg) than the OS ATPase activity of logarithmic AD∆∆-CDR1-GFP cells. 
The OS AD∆∆ ATPase activity remained more or less the same at all harvesting points 
(Figure 3.16), and represents background ATPase activity in the S. cerevisiae host. Thus, to 
obtain the correct Cdr1 specific ATPase activity the OS AD∆∆ ATPase activity was subtracted 
from the OS activity of AD∆∆-CDR1-GFP cells harvested at the same growth point (OSC; 
Table 3.1). The Cdr1-GFP expression levels, however, did not reflect the measured OS 
ATPase activities. Like the OS ATPase activities, they were highest throughout logarithmic 
growth, although they were even slightly higher at the late-logarithmic growth point (OD600 
= 5.9) at a time point where the OS ATPase activity had already dropped by ~40%, but unlike 
the OS ATPase activities that significantly recovered at the two later harvesting points, the 
fluorescence dropped from their highest levels in late-logarithmic cells down to ~40% at 
the last harvesting point representing cells in the diauxic growth phase (Figure 3.17). Thus, 
to account for the different Cdr1 expression levels at various stages of growth, the Cdr1 
specific ATPase activities were normalised against their Cdr1 expression levels (NOSC; Table 
3.1). From these experiments, it was concluded that the normalised Cdr1 specific ATPase 
activity was highest during logarithmic growth, it then dropped quickly within 4 h to ~40% 
while shifting into the diauxic growth phase, but recovered again later on during diauxic 
growth to levels equal to, if not even significantly higher than that in logarithmic cells, 




Figure 3.15. Growth curve of ADΔΔ and AD∆∆-CDR1-GFP in YPD. The AD∆∆ growth curve 
is shown in red and AD∆∆-CDR1-GFP is in green. Green and red dots are the harvesting 
points of cells that were used to isolate crude plasma membranes from. Cells from these 
harvesting points (up to 26 h) were used to characterise the growth phase dependency of 
the OS Cdr1 ATPase activity (Table 3.1). 
 
 
Figure 3.16. Growth phase dependency of the Cdr1-GFP ATPase activity. The graph shows 
the OS ATPase activities of plasma membrane samples isolated from AD∆∆ (Raad et al.) and 
AD∆∆-CaCDR1-GFP (red) cells harvested at the time points before 26 h, shown in the 













Figure 3.17. Growth phase dependency of Cdr1-GFP expression. Coomassie blue stained 
SDS-PAGE gel (7%) of 5 µg plasma membrane protein samples (top) and quantification (%) 
of the relative fluorescent signals of Cdr1-GFP (bottom) of the same gel before Coomassie 
staining. Lanes 1, 3, 5, 8 and 11 are plasma membrane proteins isolated from AD∆∆ cells 
harvested at OD600 values of 0.2, 0.9, 2.8, 5.9, 7.6 and 13, respectively, and lanes 2, 4, 6, 7, 
9, 10 and 12 are plasma membrane proteins isolated from AD∆∆-CDR1-GFP cells harvested 
at 0.2, 0.9, 2.8, 5.9, 7.6, 8.2 and 13, respectively. M = Precision Plus Protein Marker; MWs 
are shown to the right of the gel. 
 
Table 3.1. Growth phase dependency of the ATPase activities of plasma membrane 
samples isolated from AD∆∆-CDR1-GFP and AD∆∆ cells harvested at the indicated time 
points. 
Strain OD600 0.2 0.9 2.8 5.9 7.6 8.2 13 
CDR1-GFP 
P 3.1 2.9 2.6 2.5 2.5 2.3 2.6 
% Cdr1-GFP 95 85 90 100 85 70 40 
T 434 484 485 292 230 281 304 
O 109 130 140 86 64 66 63 
OS 324 353 344 206 166 215 241 
AD∆∆ 
P 2.4 2.5 2.1 2.1 2.2 nd 2.4 
T 179 153 144 100 133 nd 135 
O 133 116 116 75 86 nd 96 
OS 46 37 28 25 47 nd 39 
 OSC 278 316 316 181 119 nd 202 
 NOSC 293 372 351 181 140 nd 505 
P: plasma membrane protein concentrations (mg/ml); T and OS: total and OS ATPase activities 
(nmol/min/mg); O: ATPase activities (nmol/min/mg) in the presence of 20 µM oligomycin; OSC: the Cdr1 
specific ATPase activities corrected for the AD∆∆ background (nmol/min/mg); NOSC: the normalised Cdr1 
specific ATPase activities (nmol/min/mg) corrected for their different Cdr1-GFP expression levels relative 
to the highest Cdr1-GFP expression level at OD600 = 5.9 (see % Cdr1-GFP row); nd = not determined. 
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3.3.1.5 Effect of Acid Precipitation of Mitochondrial Membranes on the Quality of the 
Isolated Plasma Membranes and their ATPase Activity  
Acid precipitation and removal of mitochondria, at pH 5.2, is used to improve the 
quality of plasma membrane preparations. Although acid precipitation did increase (~2-
fold) the OS ATPase activities (nmol/min/mg) of small-scale plasma membranes, the total 
OS ATPase activities (nmol/min) recovered was, unfortunately, also dramatically (5 times) 
reduced, as at least 80% of the prepared membranes was lost. Thus, although acid 
precipitation of mitochondria may eliminate some unwanted proteins, it also seems to 
inactivate 80% of the OS ATPase activities in the process. It was not clear why the OS 
ATPase activity was so sensitive to acid precipitation, but perhaps phosphorylation or 
dephosphorylation caused by a short exposure of Cdr1 at low pH to kinases or 
phosphatases that were released after cell breakage caused inactivation of the Cdr1-GFP 
ATPase activity. 
3.3.2 Enniatin B Specifically Inhibits the Cdr1 ATPase Activity in the AD∆∆ 
Background 
Yeast cells have many ATP hydrolysing enzymes that, unfortunately, interfere to 
some degree with the OS Cdr1 ATPase activity of plasma membranes isolated from AD∆∆ 
cells overexpressing Cdr1. The Cdr1 ATPase assay cocktail (Table 2.6) contains ammonium 
molybdate, KNO3, and NaN3 that inhibit most interfering phosphatases and vacuolar or 
mitochondrial ATPase activities. However, plasma membrane preparations of AD∆∆ cells 
still had ~40% contextual ATPase activities (Figure 3.18-A, comparing total ATPase activity 
of AD∆∆ and AD∆∆-Cdr1), and, unfortunately, some of it (~ 15% of OS ATPase activity of 
AD∆∆-Cdr1) was also sensitive to oligomycin, even though oligomycin was previously 
reported to specifically inhibit the ATPase activity of Cdr1 (Nakamura et al., 2001; Wada et 
al., 2002). Thus, to obtain the correct Cdr1 ATPase activity (OSC), the OS AD∆∆ background 
ATPase activity (present in the host strain) must also be subtracted from the OS Cdr1 
ATPase activity (Figure 3.18-B). To find a better, more specific, inhibitor that only inhibits 
Cdr1 but not any of the ~40% background ATPase activities of AD∆∆ cells, two other well-
known PDR transporter inhibitors were tested, enniatin B (Hiraga et al., 2005) and FK506 
(Kralli et al., 1996; Tanabe et al., 2019).  
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The FK506-sensitive (20 µM) ATPase activity of AD∆∆-CaCDR1-GFP plasma membrane 
preparations was lower (88%) than their oligomycin-sensitive (OS; 20 µM) ATPase activity 
(data not shown). However, increasing FK506 to 120 µM gave a similar inhibitor-sensitive 
ATPase activity (96%) as 20 µM oligomycin (Figure 3.18-A, top). Interestingly, enniatin B, 
whether used at 10 µM (data not shown) or 110 µM, inhibited the ATPase activities of 
AD∆∆-CaCDR1-GFP plasma membrane preparations to a lesser extent (74% relative to the 
OS ATPase activity (Figure 3.18-A, top)). FK506 (120 µM) inhibited the ATPase activities of 
AD∆∆ plasma membrane preparations to an almost similar degree (~80%) as oligomycin, 
but, interestingly, the AD∆∆ background ATPase activity was insensitive to enniatin B 
(Figure 3.18-A, bottom). Clearly, enniatin B is the best choice to determine the specific Cdr1 
ATPase activity because it only inhibits Cdr1 and not any AD∆∆ background ATPase activity 
(Figure 3.18-A, bottom). As shown in Figure 3.18-B, the corrected OS and FKS ATPase 
activities were very similar. However, the corrected EnS ATPase activity consistently, in 
multiple repeat experiments, ~10-15% lower than the OSC and FKSC ATPase activities 
(Figure 3.18-B). One possible explanation for this unexpected finding was that the 
expression of proteins that caused the OS AD∆∆ background ATPase activity was further 
increased in AD∆∆-CaCDR1-GFP cells. 
A very similar relationship was obtained for the acid-precipitated plasma membrane 
preparations (Figure 3.18-C). For better comparisons between repeat experiments, the 
inhibitor-sensitive ATPase activities of Cdr1 plasma membrane samples (with and without 
acid-precipitation) were compared with their OS ATPase activities, which were set to 100%. 





Figure 3.18. Different inhibitor-sensitive ATPase activities of AD∆∆-CaCDR1-GFP and 
AD∆∆ (background) cells. Plasma membrane preparations treated with no inhibitor are 
shown as Total, and 20 µM Oligomycin-, 120 µM FK506-, and 110 µM enniatin B-sensitive 
ATPase activities are labelled OS, FKS and EnS, respectively. A) Total and inhibitor-sensitive 
ATPase activities of AD∆∆-CaCDR1-GFP (AD∆∆-Cdr1; top) and AD∆∆ (bottom). Background 
OS-, FKS-, and EnS-ATPase activities of AD∆∆ plasma membranes were ~15%, 14%, and 0% 
of AD∆∆-Cdr1 plasma membranes, respectively. B) Corrected inhibitor-sensitive ATPase 
activities (-SC) of AD∆∆-Cdr1 after subtracting the background AD∆∆ ATPase activity of 
each inhibitor. C) Graph of the relative inhibitor-sensitive ATPase activities of AD∆∆-Cdr1 
(non acid-pre) plasma membranes and of acid precipitated (acid-Pre) plasma membrane 
preparations treated with 20 µM oligomycin (set to 100%), 120 µM FK506 (98% and 95%, 
respectively) and 110 µM enniatin B (both 70%).  
 
3.3.3 The OS ATPase Activity Assay Is Linear within a Certain Protein 
Concentration Range 
A reliable, robust, enzyme assay should not be affected by the amounts of plasma 
membrane protein used for the assay and the results presented in Figure 3.19 almost 
confirmed that was indeed the case. The slight variations of the OS Cdr1 ATPase activities 
obtained for 2, 4, and 8 µg of plasma membrane protein of AD∆∆-CDR1-GFP-N1 cells could 
be because of the technical difficulties involved in accurately pipetting small (5 µl) amounts 
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of plasma membrane suspensions, or possibly due to substrate limitations when more Cdr1 
added to the assay. 
 
Figure 3.19. Varying the amount of protein did not affect the OS ATPase activities of 
AD∆∆-CDR1-GFP-N1 plasma membranes. As expected, A) using different amounts of 
plasma membrane protein isolated from AD∆∆-CDR1-GFP-N1 gave almost identical specific 
ATPase activities, while B) the total amount of the OS ATPase activities (red line; nmol/min) 
increased linearly with increasing amounts of plasma membrane protein used in the assay 
(dotted line shows the theoretically expected activity). 
 
3.3.4 GFP Fluorescence as a Reliable Measure for Cdr1 Expression Levels  
Dilution of an AD∆∆-CaCDR1P-GFP plasma membrane preparation, separation by 
SDS-PAGE and visualisation of the GFP showed that there was a linear relationship between 
the amount of CaCdr1-GFP and in-gel fluorescence (Figure 3.20).  
 
Figure 3.20. Quantification with in-gel fluorescence of Cdr1-GFP is very sensitive and 
accurate over a large concentration range. The images to the right show Coomassie-blue 
stained and in-gel fluorescence SDS-PAGE images of the same 0.7% poly-acrylamide gel. 
Lanes 1 to 6 were loaded with 0.75, 1.5, 3, 6, 12 and 24 µg AD∆∆-CaCDR1P-GFP plasma 
membrane protein. M = Precision Plus Protein Marker; MWs are shown to the right. The 
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GFP fluorescence intensities were linear over the entire concentration range tested and 
there was hardly any (~1.5%) background fluorescence detectable (ie. the trendline crossed 
the Y-axis at ~1.5% maximum fluorescence; left). 
 
3.3.5 Creation and Characterisation of Cys-Less CDR1 Variants  
To identify which cysteines were most critical for Cdr1 function, the 21 Cys residues 
present in various Cdr1 sub-domains were replaced with either alanine (A) or serine (S) 
(Figure 3.21 and Table 3.2) based on Prasad’s strategy (Prasad et al., 2012b). AD∆∆-
CaCDR1PC-GFP-N1, for instance, had the first five Cys of NBD1 including its linker region to 
TMD1 replaced with A or S (Figure 3.3 and Figure 3.21), and AD∆∆-CaCDR1PC-GFP-TS1 had 
the two Cys of TMD1 (Figure 3.4 and Figure 3.21) replaced with S.  
Measuring the FLC susceptibilities (MICFLC) of yeast strains overexpressing a range 
of different CDR1 mutants was an easy way to quickly assess the effects of the various 
mutations on the Cdr1 transport function. Attaching a C-terminal GFP tag did not affect the 
function of Cdr1; i.e. the MICFLC of AD∆∆-CaCDR1P (256 mg/l) (Table 3.2) and AD∆∆-
CaCDR1P-GFP (256 mg/l) (Figure 3.22) were indistinguishable. There were also no 
noticeable differences in the MICFLCs of strains overexpressing either of the two different 
CDR1 alleles (CDR1A and CDR1P) that were used throughout these studies. This confirmed 
that the 52 synonymous, and 5 non-synonymous, single-nucleotide polymorphisms (SNPs) 
between C. albicans CDR1A (Holmes et al., 2006) and CDR1P (Prasad et al., 1995) had no 
noticeable effect on the Cdr1 efflux pump function. As expected, the MICFLC of AD∆∆-
CaCDR1A-K901A-GFP, containing a mutation in the catalytic Walker A2 K901 residue, was 
practically indistinguishable from the negative control strain AD∆∆-pABC3 (Figure 3.22) 
that had the empty transformation cassette integrated at the genomic PDR5 locus.  
The MICFLCs of the yeast strains expressing the 21 Cys-deficient CDR1 mutants are 
listed in Table 3.2. It was evident that some replacements affected the MICFLC of the 
constructs dramatically, such as for the T1, T2, and T12 and EL6 and EL36 constructs. 
However, some other Cys-deficient constructs conferred close to the wild type MICFLCs, for 
example N1 and N2 strains.  
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Figure 3.21. Conserved extracellular loop cysteines (Cys) are critical for Cdr1 folding 
and/or function. All Cys of NBD1 (N1; 5 Cys), TMD1 [i.e. TS1, 2 Cys, or EL3 (E3), 2 Cys] or of 
NBD2 (N2; 5 Cys), TMD2 [i.e. TS2, 5 Cys including C1380 between the EL6-motif and EL6-
helix, or EL6 (E6), 4 Cys] were replaced with Ala or Ser. The domains whose Cys have been 
replaced with Ala or Ser are indicated in grey, and their MICFLCs are underneath each 
cartoon of individual AD∆∆-CaCDR1PC-GFP variants. The NTS12 variant was used to select 




Figure 3.22. FLC susceptibilities of some important AD derivative strains. The MICFLCs 
(mg/l) were measured and the graph shows the MIC growth curves after 48 h in the 
presence of different concentrations of FLC. Each point is based on two technical replicates 
of at least three independent experiments (+/- SD). 
 
3.3.6 Protein Expression Levels and ATPase Activities of the Various Cys-
Deficient CaCDR1PC-GFP Mutants 
Plasma membranes were isolated from AD∆∆ cells overexpressing the 21 Cys-
deficient CaCDR1PC-GFP mutant variants. Their Cdr1 expression levels were determined by 
SDS-PAGE and quantified by measuring their in-gel fluorescence signals (Figure 3.23 and 
Table 3.3).  
Significant differences in the Cdr1 expression level of different constructs were 
noticed, and it was realised that it would not be possible to get an accurate interpretation 
of the MICFLCs and ATPase activities if they were not normalised based on the protein 
expression levels. Therefore, the measured MICFLCs (Table 3.2) and the specific Cdr1-
ATPase activities (OSC) (Table 3.3) were normalised to the wild-type CDR1P-GFP expression 
levels (Table 3.4) determined by in-gel fluorescence (Figure 3.23). For instance, the N1 
construct had twice the MICFLC (Table 3.2), and 1.43 times more Cdr1 ATPase activity 
(nmol/min/mg; Table 3.3) than the Cdr1p strain. However, comparing its expression level 
with Cdr1 (Table 3.4 and Figure 3.24) showed that its expression was 14% more. So, to 
enable a more accurate comparison of function and activity, the values were normalised 
(mg/l) 
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to the Cdr1 expression level. With this adjustment, the standardised ATPase activity and 
FLC transport values (indicated by level of FLC resistance) of N1 were 125% and 175%, 
respectively, (Table 3.4) compared to Cdr1 (100%). Other examples are TS2 and N12, both 
displayed the same MICFLC of 128 mg/ml (half the Cdr1 MICFLC). After normalising their 
properties based on their expression levels, the FLC transport values changed to 39% and 
238% of wild-type (Table 3.2 and Table 3.4). In fact, some constructs such as N12 which are 
quite seriously affected in expression level (21% of wild-type) had increased FLC transport 
after normalisation (238% of wild-type). Conversely, TS2 with almost the same protein 
expression level as Cdr1, showed 39% of its function after normalisation. 
 
 
Figure 3.23. SDS-PAGE and in-gel fluorescence of plasma membrane samples isolated 
from AD∆∆ cells overexpressing 21 CDR1PC-GFP constructs. A) SDS-PAGE (7% poly-
acrylamide) of 10 µg plasma membrane protein preparations of AD∆∆ (-), AD∆∆-CaCDR1P-
GFP (+) and AD∆∆ cells overexpressing 21 CDR1PC-GFP constructs 1-21 (the numbers of 
individual constructs are as listed in Table 3.3). B) In-gel fluorescence of the same gel before 




Table 3.2. Phenotypes of AD∆∆ strain overexpressing CDR1P, CDR1PC and 21 CDR1PC-






NBD1 TMD1 NBD2 TMD2 



















































































CDR1P       256 
CDR1PC       1 
N1       512 
TS1       64 
EL3       128 
∆EL3       1 
T1       16 
NTS1       128 
NT1       4 
N2       256 
TS2       128 
EL6       1 
∆EL6       1 
T2       1 
NTS2       64 
NT2       1 
N12       128 
TS12       16 
EL36       1 
∆∆EL36       1 
T12       1 
NTS12        8 
NTS12-S        128 
a Grey areas highlight the various Cdr1 domains in which the indicated Cys have been replaced with A or S. 
Darker grey areas indicate deletions. TS: transmembrane segments of each domain. The position of 
individual Cys and the residue they were replaced with (A or S) are listed above. 
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Table 3.3. Cdr1 expression levels and ATPase activities (nmol/min/mg) of plasma 
membrane samples isolated from AD∆∆ (negative control) or from AD∆∆ strains 
overexpressing CDR1P-GFP (positive control) or the 21 CDR1PC-GFP variants. 
No. of 
CDR1PC-GFP 
Strain % Cdr1a ATPase (nmol/min/mg) Cdr1relc,d 
OS +/- SD OSCb 
AD∆∆ nd 22  9.6 0 0 
CDR1P 100 329  14.0 307 100 
1 N1 114 462  25.3 440 143 
2 TS1 109 114  19.6 92 30 
3 EL3 96 250  41.5 228 74 
4 ∆EL3 48 26  9.5 4 1 
5 T1 73 19  2.7 - - 
6 NTS1 105 222  28.1 200 65 
7 NT1 55 18  1.5 -  - 
8 N2 32 87  18.8 65 21 
9 TS2 96 40  8.9 18 6 
10 EL6 65 6  2.1 -  - 
11 ∆EL6 101 16  5.5 -  - 
12 T2 38 6   1.7 - - 
13 NTS2 29 33  8.0 11 4 
14 NT2 21 14  2.5 -  - 
15 N12 21 97  9.9 75 24 
16 TS12 101 19  6.7 -  - 
17 EL36 45 42 3.3 20 7 
18 ∆∆EL36 69 38 7.6 16 5 
19 T12 36 35 14.7 13 4 
20 NTS12 22 24 1.9 2 1 
21 NTS12-S 59 86 10.8 64 21 
a Cdr1 expression levels (%) relative to wild-type Cdr1P-GFP (data were extracted from Figure 3.23). 
b Cdr1 ATPase activities corrected for the OS AD∆∆ background ATPase activity. 
c Cdr1 ATPase activities (OSC) relative to wild type Cdr1P-GFP (307 nmol/min/mg = 100%). 
d ATPase activities with a - sign were below the detection limit (i.e. these ATPase activities were equal to, 





Figure 3.24. Cdr1 ATPase activities of 21 Cys-deficient CaCDR1PC-GFP variants listed in 
Table 3.3. The values are the means (± SDs) of two technical repeats measured at least 
three independent times. The data are OS values (blue) and the OS ATPase activities 
corrected for the AD∆∆ background (OSC; green). 
 
After normalising the data, it seems that substituting the two EL3 cysteines (Table 
3.4, EL3) does not appear to be particularly detrimental to Cdr1 expression/function but 
combining them with any other mutations (i.e. TS1 or NTS1 to T1 or NT1) inactivates the 
proteins although they still express reasonably well (i.e. > 50%). Replacing EL6 cysteines in 
any construct (e.g. T2 and NT2) led to an inactive protein, as well. In other words, any 
constructs with EL3 or EL6 substitution combinations were inactive, while most other 
constructs had much less of a negative effect.  
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Table 3.4. Normalised Cdr1 ATPase and FLC transport activities of Cys-deficient 
CaCDR1PC-GFP constructs (Cdr1P-GFP = 100%). 
  Normalised Cdr1 functiona 
Number Construct % Cdr1 expression ATPase Transport 
- CDR1PC nd nd 0 
+ CDR1P 100 100b 100 
1 N1 114 125 175 
2 TS1 109 28 23 
3 EL3 96 77 26 
4 ∆EL3 48 2 0 
5 T1 73 0 8 
6 NTS1 105 62 24 
7 NT1 55 0 3 
8 N2 32 66 312 
9 TS2 96 6 39 
10 EL6 65 0 0 
11 ∆EL6 101 0 0 
12 T2 38 0 0 
13 NTS2 29 19 43 
14 NT2 21 0 0 
15 N12 21 114 238 
16 TS12 101 0 6 
17 EL36 45 16 0 
18 ∆∆EL36 69 7 0 
19 T12 36 11 0 
20 NTS12 22 4 14 
21 NTS12-Sb 59 36 85 
a The Cdr1 ATPase activities in Table 3.3 and the FLC transport activities (MICFLCs) in Table 3.2 were 
normalised with respect to the wt Cdr1P-GFP expression levels to account for the different expression 
levels of the various CDR1PC-GFP constructs. 
b Later, renamed to Cdr1P-CID. 
 
It was evident after data normalisation that N1, N2 and N12 substitutions resulted 
in two to three times the transport ability for FLC although the protein’s ATPase activities 
and expression levels were similar to, or even lower than, the wild-type. The opposite was 
seen for EL3 where proteins with EL3 substitutions appeared to express well and have 
reasonably high ATPase activity but were severely affected in FLC transport. 
3.3.7 CDR1PC-NTS12-Supressor as an Almost Cys-Less Cdr1 Molecule 
Cdr1PC-NTS12 had the remaining 17 intracellular cysteines replaced with serine or 
alanine (Figure 3.21). In an attempt to create an almost Cys-less Cdr1 molecule that was 
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functional, natural AD∆∆-CaCDR1PC-NTS12 suppressor mutants that could grow on high 
(30 mg/l), normally growth inhibitory, concentrations of FLC were selected. Isolating and 
sequencing the CDR1 ORF of 3 of the 15 suppressor colonies that appeared on CSM-ura 
agar plates after a few days’ incubation at 30 ˚C revealed point mutations in one particular 
residue, S1106 (S1106C and S1106I; Figure 3.21). Interestingly, C1106 is one of the 23 
cysteines that was replaced with serine (S1106) in NBD2 of CDR1PC-NTS12. Thus, an almost 
Cys-less CDR1 mutant (CDR1PC-NTS12-I1106) was created that had all but the six conserved 
EL cysteines replaced with S, A or I (I1106) and was almost as active as wt (wild-type) Cdr1 
(MICFLC = 128 mg/l; Table 3.2). NTS12-S or actually CDR1PC-NTS12-I1106 was renamed 
CDR1P-CID (CID = Cys-less intracellular domain). Cdr1P-CID had a calculated 85% wt FLC 
transport activity after accounting for its significantly reduced (59%) expression level (Table 
3.4).  
3.3.8 Localisation Patterns of the Various Cdr1PC-GFP Constructs  
Intracellular localisation of the various Cdr1PC-GFP mutants was determined by 
confocal microscopy. A uniform fluorescent ring around the cell periphery indicated correct 
localisation in the plasma membrane (Figure 3.25). Although it may be difficult to 
distinguish localisation at the cortical endoplasmic reticulum that runs parallel to, and just 
underneath, the plasma membrane from proper plasma membrane localisation, cortical 
ER localisation manifests as broken circles around the cell periphery because it covers less 







Figure 3.25. Confocal microscopy of AD∆∆ strains overexpressing wild type Cdr1P-GFP 
and selected Cdr1PC-GFP mutants. Fluorescent images are displayed underneath their 
corresponding bright field images. MICFLC values (mg/l) are indicated in white. A uniform 
ring of fluorescence around the cell periphery indicates plasma membrane localisation of 
wild type Cdr1P (left). Sickle-shaped patches of fluorescence in NT1 and T12 indicate that 
most protein got stuck inside the rough ER surrounding the nucleus and faint fluorescence 
throughout the cell indicates molecules on their way to the cell surface. Patches of 
fluorescence in the cell interior and faint fluorescent rings around the cell periphery 
indicate possible trafficking defects for N2 that did not seem to affect its efflux pump 
function. 
 
3.3.8.1 Confocal Microscopy of the Various Cys-Deficient Cdr1PC-GFP Mutants 
To gain further insights into the contribution of the various cysteine substitutions 
to Cdr1 function, the localisation patterns of all Cys-deficient CDR1PC-GFP mutant 
constructs were studied using confocal microscopy. Replacing all Cys with S or A in 
individual subdomains of the N-terminal half of the protein (i.e. N1, TS1, EL3 and NTS1) had 
no noticeable effect on the plasma membrane localisation of Cdr1 (Figure 3.26). However, 
combining EL3 with TS1 (i.e. CDR1PC-T1) or NTS1 (i.e. CDR1PC-NT1) had quite a detrimental 
effect on plasma membrane localisation (Figure 3.25 and Figure 3.26) and the ATPase 
activity and FLC efflux pump function (Table 3.4) of these constructs. Similarly, replacing all 
Cys with S or A in individual subdomains of the C-terminal half of the protein (i.e. N2 and 
TS2, Figure 3.26) had only minor effects on plasma membrane localisation of Cdr1, but 
substitution of the four Cys in EL6 and any combination of domains that involved EL6 
substitutions gave proteins that were stuck inside cells (Figure 3.26) and had no ATPase 






extracellular cysteines (i.e. in EL3 and EL6 constructs) are key contributors to correct 
folding, trafficking and efflux pump function of Cdr1. Also, as expected, CaCdr1A-K901A-
GFP properly localised to the plasma membrane although it had no measurable efflux 
pump function. 
 
3.3.8.2 EL3 and EL6 and their Six Conserved Cysteines are Critical for Proper Folding, 
Plasma Membrane Localisation and Efflux Pump Function of Cdr1 
EL3 and EL6 contain two and five cysteines, two and four of which, respectively, are 
conserved cysteine residues (Figure 3.4), that quite possibly form three critically important 
disulphide bonds to stabilise the ED of PDR transporters. Confocal microscopy revealed 
similar detrimental effects on intracellular localisation for the deletion of EL3 and/or EL6 
as the substitution of the four conserved EL6 cysteines with serines (Figure 3.27).  
 
Figure 3.26. Confocal microscopy of AD∆∆ cells overexpressing various Cys-deficient 
Cdr1PC-GFP mutants and the catalytic K901 mutant, CDR1A-K901A-GFP. AD∆∆ was 
included as a negative control; see text for further details. 
 
AD∆∆               Cdr1A               Cdr1P               N1                     TS1                    EL3      
EL6                   ∆EL6                  T2                     NTS2                 NT2                   N12 
∆EL3                 T1                     NTS1                 NT1                   N2                     TS2  






Figure 3.27. Effect of deletion of EL3 and/or EL6 of Cdr1 on intracellular localisation. 
Confocal microscopy images of AD∆∆ cells overexpressing CDR1 constructs with the 
indicated changes to EL3 and/or EL6. MICFLC values (mg/l) are shown in white.  
 
3.3.9 HSP72 Protein, Ssa2, is Upregulated in N2 Containing Cdr1PC-GFP Mutants 
Upon closer inspection of the Coomassie blue stained SDS-PAGE gels of the 21 Cys-
deficient CDR1PC-GFP mutants, a prominent ~70 kDa protein band was noticed to be 
dramatically upregulated in some strains (i.e. lanes 8, 13, 14, 15, 20, and 21; Figure 3.28). 
Interestingly, all six of these CDR1PC constructs had substitutions in the N2 domain in 
common. MALDI-TOF-TOF analysis identified the ~70 kDa band as the yeast HSP72 heat 
shock protein (SwissProt search) Ssa2 (score: 2156, protein coverage: 43%; Appendix A1. 
Mass Spectrometry Results). Ssa2 is a highly conserved protein that is involved in protein 
folding and vacuolar import of proteins. The Ssa2 paralog, Ssa1, is 98% identical to Ssa2 
and is also involved in protein folding as well as in nuclear import processes 
(Saccharomyces Genome Database: https://www.yeastgenome.org). 
EL3  
∆EL3  
EL6  EL36  
∆EL6  ∆∆EL36  
64 1 1 
1 1 1 
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Figure 3.28. Plasma membrane protein profiles of AD∆∆ (-), AD∆∆-CDR1P-GFP (+), and 
AD∆∆ overexpressing the indicated Cys-deficient CDR1PC-GFP constructs (numbers are 
as in Table 3.4). The major plasma membrane proton pump, Pma1 (~110 kDa), and Cdr1-
GFP (~200 kDa) bands are indicated with black arrows. Some lanes (8, 13, 14, 15, 20, and 
21; N2, NTS2, NT2, N12, NTS12, and NTS12-S, respectively) had a noticeably upregulated 
~70 kDa protein band (yellow arrow). K is the CDR1-K901A-GFP mutant. M = Precision Plus 
Protein Marker; MWs are shown to the left of the gel. 
 
3.3.10 Cdr1 Mutants of the Catalytic Carboxylate and Lysine Residues 
The expression levels of the GFP-tagged CaCDR1A-E1027Q mutant of the catalytic 
carboxylate of Walker B2, the equivalent of the D327N mutant of Walker B1, the D327N-
E1027Q double mutant and the catalytic K901A mutant of Walker A2 were comparable to 
wild-type CaCDR1A-GFP, although CaCDR1A-K901A-GFP (Figure 3.28 – lane K) was 
expressed at a somewhat higher (~130%) and CaCDR1A-D327N-GFP somewhat lower 




Figure 3.29. SDS-PAGE (8% gel) of plasma membrane proteins isolated from AD∆∆ cells 
overexpressing the four catalytic ATPase mutants of Cdr1. Plasma membrane proteins (10 
µg) of AD∆∆ (-), AD∆∆-CaCDR1A-XLmGFPHis (+), and AD∆∆-CaCDR1A-D327N- (1), -E1027Q- 
(2) and -D327N-E1027Q-XLmGFPHis (3) were separated and their expression levels 
quantified by in-gel fluorescence (bottom) before Coomassie blue staining of all proteins. 
M = Precision Plus Protein Marker; MWs are shown to the left of the gel. 
 
As expected, AD∆∆-CaCDR1A-E1027Q- and -D327N-E1027Q-XLmGFPHis were as 
susceptible to FLC (MICFLC ≤ 1 mg/l) as the negative control strain AD∆∆-pABC3 (Figure 
3.30). Surprisingly, AD∆∆-K901A-GFP consistently gave slightly elevated FLC susceptibilities 
(2 mg/l), although it was near that of the negative control strain and practically within the 
detection limit of the MIC assay (Figure 3.30). AD∆∆-CaCDR1A-D327N-GFP, on the other 
hand, had only slightly lower FLC susceptibilities (MICFLC ≤ 128 mg/l) than AD∆∆-CaCDR1A-
GFP cells (MICFLC ≤ 256 mg/l; (Figure 3.30)). Thus, it would seem, given its also slightly 
reduced expression level, that the Walker B2-E1027-catalytic carboxylate equivalent 
residue Cdr1-D327N of Walker B1 is not involved in ATP hydrolysis or FLC transport. 
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Figure 3.30. Fluconazole susceptibilities of AD∆∆ cells overexpressing the four catalytic 
ATPase mutants of Cdr1. AD∆∆-CaCDR1A-E1027Q-XLmGFPHis (blue), and AD∆∆-CaCDR1A-
D327N-E1027Q-XLmGFPHis (purple) were as susceptible to FLC as the sensitive control 
strain AD∆∆-pABC3 (pink). However, AD∆∆-CaCDR1A-K901A-GFP (grey) had a slightly 
increased (~2x) MICFLC than the sensitive host. AD∆∆-CaCDR1A-D327N-XLmGFPHis (red) 
had an only slightly reduced MICFLC than the positive control strain AD∆-CaCDR1A-GFP 
(Raad et al.).  
 
Cdr1-C193, which is an atypical residue of the Walker A1 motif, equivalent to K901 
in Walker A2, was also one of the residues that was mutated in CDR1PC-N1. CDR1PC-N1 
was unaffected in its expression level and ATPase activity, but its FLC transport was even 
slightly (~2-fold) increased (Table 3.4). The ATPase activities of the four catalytic CDR1 
mutants reflected their FLC transport activities (Table 3.5). The plasma membrane ATPase 
activities of Cdr1-K901A, -E1027Q, and -D327N-E1027Q were only slightly (3%-5%) above 
the background of the OS ATPase activity of AD∆∆-pABC3 (Table 3.5). Whether these 
mutants really have some residual ATPase activity or whether other factors could explain 






Table 3.5. Phenotypes and expression levels of AD∆∆ cells overexpressing the four 
catalytic ATPase CDR1 mutants.  
a The MICFLC and the Cdr1-ATPase activities were normalised with respect to the wt Cdr1A-GFP expression 
level determined from Figure 3.29 to account for the different expression levels of the four indicated 
Cdr1A-XLmGFPHis catalytic mutants. 
 
3.4 Discussion 
In this part of the project, a very reproducible small-scale membrane protein 
preparation protocol that facilitated the rapid analysis of wt Cdr1 and Cdr1 mutants was 
validated and optimised. Additionally, 21 Cys-deficient Cdr1 mutants were generated that 
had the cysteines of individual subdomains, or various combinations of those subdomains, 
replaced with serine or alanine.  
A Cys-less or nearly Cys-less version of a protein provides a powerful avenue to 
assess structural and functional aspects of membrane proteins. After discovering that the 
previously reported Cys-less Cdr1 molecule (Prasad et al., 2012b) was not functional in S. 
cerevisiae, even after the correction of eight additional mutations of the original Cys-less 
CDR1 mutant that was kindly provided by Prof. Prasad, the research was begun by studying 
which of the 23 cysteines of Cdr1 were actually the most critical for its expression, folding 
and/or function. Using the wild-type CDR1P and the corrected Cys-less CDR1PC ORFs as 
DNA templates, 21 Cys-deficient Cdr1 mutants were generated. Results demonstrated that 
the N-terminal cysteines were generally less critical for Cdr1 function than the cysteines of 
the C-terminal half of the transporter. However, combining the CDR1 EL3 Cys substitutions 
with any other Cys-less parts of the N-terminus had strong negative effects on Cdr1 
function. Apart from replacing the four conserved EL6 cysteines, which eliminated plasma 




 % Cdr1 
expression 
ATPase 
activity FLC transport  Total OS OSC 
Cdr1 485 344 319 100 100 100 
ADΔΔ 137 25 - - - - 
K901A 164 45 20 130 5 1 
D327N 208 104 79 75 31 67 
E1027Q 125 35 10 100 3 - 
D327N-E1027Q 127 36 11 100 3 - 
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membrane localisation and destroyed the function of Cdr1, alone, or in combination with 
any other Cys-less subdomains, replacing the cysteines of the other two C-terminal 
subdomains of Cdr1 (i.e. N2 and TS2) had some, but a much less severe, effect on plasma 
membrane localisation and function. The Cdr1-TS1 and -TS2 constructs had good plasma 
membrane localisation and were expressed at wt (wild-type) levels, but their FLC transport 
activities were reduced by ~50-80% (Figure 3.26 and Table 3.4). Combining substitutions in 
both subdomains in Cdr1-TS12 had an additive effect reducing its proper plasma 
membrane localisation (Figure 3.26) and FLC transport even further to an MICFLC = 16 mg/l 
(~10% of wt Cdr1; Table 3.2 and Table 3.4). The story was slightly different for the Cdr1-N1 
and -N2 constructs. Although these two constructs were also not affected in their plasma 
membrane localisation (Figure 3.26), they actually exhibited a 2- (N1) and 3-fold (N2) 
increased FLC transport and more or less unchanged ATPase activities, taking their slightly 
increased (N1) and 3-fold decreased (N2) expression levels into account (Table 3.4).  
Combining substitutions in any two subdomains, apart from EL3 and EL6, with each 
other (i.e. N12, TS12, NTS1, NTS2, NTS12) had an additive effect on plasma membrane mis-
localisation (Figure 3.26), FLC transport and the ATPase activity (Table 3.4). This was quite 
different from the strongly synergistic effects observed for all of the EL3 combinations, 
especially the NTS1-EL3 combination in the Cdr1-NT1 construct (Figure 3.26 and Table 3.4). 
Any combinations with the EL6 subdomain (EL36, T2, NT2, T12) were also mis-localised and 
inactive (Figure 3.26 and Table 3.4). Interestingly, however, they were not as severely 
affected (40-60%) in their expression levels, apart from NT2, as any N2 subdomain 
combinations that had the most severely affected expression levels (Figure 3.23 and Table 
3.4) even though the Cdr1PC-N2 and -N12 molecules per se had wt ATPase activities and 
were even more efficient (~2-3 times) FLC efflux pumps than wt Cdr1 (Table 3.4). Careful 
analysis of the plasma membrane protein profile of N2 subdomain-containing Cdr1PC 
constructs showed that all had a strongly upregulated ~70 kDa protein band that mass-
spectrometry clearly identified as HSP72 heat-shock protein, Ssa2 (Figure 3.28). S. 
cerevisiae Ssa2 is a subunit of the chaperonin-containing T-complex (CCT) and an important 
HSP72 family member that is involved in protein folding and ubiquitin-dependent 
degradation of short-lived proteins. Thus, it would seem that one, or perhaps two or more, 
of the NBD2 cysteines are important for correct folding of Cdr1, and replacing that 
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cysteine(s) with alanine or serine causes Cdr1 misfolding and increased, possibly ubiquitin-
mediated, degradation. It may be that those Cdr1PC-N2 containing molecules that can 
escape the protein folding machinery and reach their destination at the plasma membrane 
are correctly folded and function with an increased FLC transport activity.  
In summary, these data suggest that the six conserved extracellular cysteines are 
key contributors to correct trafficking and efflux pump function of Cdr1, in line with the 
hypothesis that three extracellular disulphide bonds are critical for Cdr1 efflux pump 
function. There are, however, few reports on the significance of these conserved EDs of 
fungal PDR transporters (Egner et al., 1998; Lamping et al., 2017a). It is tempting to 
speculate that the two EL3 cysteines form one and the remaining four EL6 cysteines form 
two disulphide bonds. Perhaps eliminating one disulphide bond (EL3 construct) is not as 
detrimental as eliminating two (EL6 construct) or three (EL36 construct) disulphide bonds. 
A model of Cdr1 with these three predicted disulphide bonds has recently been published 
by our research team (Tanabe et al., 2019). 
Cdr1P-CID as an intracellular domain Cys-less Cdr1 molecule had just the six 
conserved cysteines of ELs remaining with a different point mutation at residue C1106I. 
Perhaps C1106 is the one cysteine residue that caused the severe misfolding defects 
observed for all Cdr1PC-N2 constructs, as discussed above. Interestingly, C1106 located 
only three amino acids away from the NPAE motif, at the N -terminus, which was recently 
recognised as a critical contact point between the two NBDs of type II ABC transporters 
(Lee et al., 2016). The importance of this residue for proper expression and localisation of 
Cdr1 was also previously reported by Prasad’s team (Prasad et al., 2012b). Some more 
evidence to confirm the importance of C1106 was achieved after repeating the experiment 
on finding CaCDR1PC-NTS12-GFP chimera suppressors by Dr. Erwin Lamping, my 
supervisor, and he found eight non-petite suppressor-colonies that separated very clearly 
into two groups based on their MICFLC values (64 and 128 mg/l, compared to the MICFLC 
NTS12-GFP chimera which had an MICFLC of 8 mg/l) (unpublished results; Figure 3.21). 
Sequencing those colonies gave a very exciting result: all four colonies of the first group 
(with MICFLC of 64 mg/l) had either a 2-nucleotide deletion (∆GA4488-9) or a 1-nucleotide 
insertion (iA4489) between the CDR1 ORF and the GFP tag, which caused an early stop 
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codon and, thus, the removal of the C-terminal GFP tag (Figure 3.21). The second group 
(with MICFLC = 128 mg/l) was similar to the NTS12-S suppressor that I found; all had a 
S1106C reversion or S1106I substitution (Figure 3.21). Those data clearly showed that 
although a GFP tag does not affect the wt Cdr1 function, it does affect the less stable Cdr1-
NTS12 chimeras because of the substitution of certain residues (e.g. C1106A); by getting 
rid of the GFP tag (Figure 3.21), the chimera can recover functionality. However, as having 
a GFP tag was helpful for our experiments, the second group of suppressors were of more 
interest. CDR1P-CID is ready to be used for cysteine-crosslinking studies. The three 
predicted extracellular disulphide bonds are not expected to interfere in cysteine-
crosslinking experiments because they are unlikely to react with sulphydryl reactive agents 
used in cysteine-crosslinking studies. 
The significance of the two asymmetric NBDs and how they contribute to ATP-
binding and hydrolysis remains controversial (Saini et al., 2006; Ernst et al., 2008; Wang et 
al., 2011; Lee et al., 2016). The conserved Walker B1 Cdr1-D327 was proposed to function 
as a catalytic base in ATP hydrolysis, a role normally reserved for an E residue adjacent to 
the conserved D in canonical Walker B motifs (Payen et al., 2003; Rai et al., 2006; Prasad et 
al., 2015). The canonical Walker B2 Cdr1-E1027 was previously shown to be important for 
its ATPase activity and drug efflux in Cdr1 (Rai et al., 2006) and Pdr5 (Ernst et al., 2008). 
Mutations of both these residues, D327N and E1027Q, and the double mutant Cdr1-
D327N-E1027Q were generated. A similar controversy existed for the catalytic Walker A1 
(C193) and the equivalent Walker A2 (K901) residues. Although it was claimed that C193 as 
well as K901 are catalytically active (Jha et al., 2003; Jha et al., 2004), a study of the 
equivalent PDR5 residues (i.e. Pdr5-C199A and -K911A) showed that only K911 of Walker 
A2 was catalytically active (Ernst et al., 2008). Interestingly, I too could not detect any 
significant effect of the C193A mutation on Cdr1 function in the Cdr1PC-N1 mutant. As 
expected, all four CDR1A mutants expressed well, apart from CDR1A-D327N which was 
modestly affected (75% expression; Figure 3.29 and Table 3.5). Only CDR1A-D327N had 
significant ATPase activity (30%) and FLC transport function (67%; Table 3.5). However, the 
OS ATPase activities of CDR1A-K901A, -E1027Q and -D327N-E1027Q and the FLC transport 
activity of CDR1A-K901A were unexpectedly slightly above background values (Table 3.5) 
and this needs to be analysed more carefully in the future. 
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Another important aspect of this study was the use of a C-terminal GFP or 
XLmGFPHis double tag (Section 4.3.4.1). Neither tag interfered with Cdr1 function or 
localisation, yet they were extremely useful for the accurate quantification (in-gel 
fluorescence) of the Cdr1 expression levels and the assessment of the localisation of the 
various Cdr1 mutant constructs. The C-terminal XLmGFPHis double tag had the extra 
advantage that it could also be used for protein purification with nickel affinity resin, 
described in Chapter 4 (Section 4.3.4.1). In addition, C-terminal GFP-tags can be very 
helpful in detergent screens as an indicator that represent the proper folding of a 
membrane protein (Section 4.1.4.3), and for quality control and thermal stability 
experiments of protein preparations which will be discussed in the next chapter (Geertsma 
et al., 2008; Crivat et al., 2012; Bird et al., 2015; Bird et al., 2016). 
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CHAPTER FOUR  
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4 Cdr1 Expression and Purification 
4.1 Introduction 
4.1.1 Challenges of Membrane Protein Research 
It has been estimated that 20–30% of a typical genome encodes membrane 
proteins (Wallin et al., 1998; Krogh et al., 2001; Liu et al., 2002), and the majority (50–60%) 
of all drug targets are integral membrane proteins (Overington et al., 2006; Yin et al., 2016). 
Despite their importance, our knowledge of membrane protein structure and function is 
rather rudimentary compared to what we know about soluble proteins. There are a 
number of reasons for the lack of structural information about integral membrane 
proteins, most of which are related to their hydrophobic nature and the difficulties of 
expressing properly folded and functional membrane proteins in a suitable heterologous 
host (Wiener, 2004; Newby et al., 2009; Parker et al., 2016).  
An efficient expression system is important to successfully produce sufficient 
amounts of protein for crystallography and the study of membrane protein biology (Junge 
et al., 2008). There are many factors affecting the successful overexpression of membrane 
proteins. The yield of properly folded and functional membrane protein can be improved 
by optimising the growth conditions of the heterologous host and by optimising the 
membrane protein solubilisation and purification protocols. Detergent selection and 
optimising the buffer composition (pH, salt and other factors) of detergent solubilised 
membrane proteins can help stabilise the proteins in their native conformation and avoid 
protein aggregation (Hjelmeland, 1990; Neugebauer, 1990). Post-translational 
modifications like phosphorylation or glycosylation create additional heterogeneity 
complicating matters even further (Tokmakov et al., 2012; Emery et al., 2018). Genetic 
engineering is frequently used to remove post-translational modification sites, but this is 
only possible if the changes do not affect the function of the protein. Using the right 
detergent at the right concentration to keep the hydrophobic membrane protein in 
solution throughout the purification process without destroying their structural integrity is 
also a major challenge in membrane protein crystallography (Tulumello et al., 2012; Bagag 
et al., 2013). However, over the past two decades we have seen the development of many 
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new and improved technologies, developments that have revolutionised the solubilisation, 
purification and structural biology of membrane proteins (Zhang et al., 2011; Rawson et al., 
2016; Bonnete et al., 2017).  
4.1.2 The Saccharomyces cerevisiae Membrane Protein Expression System 
The original S. cerevisiae expression host AD1-8u- created by Anabelle Decottignies 
in 1998 (Decottignies et al., 1998) was further improved by Kenjirou Nakamura for the 
characterisation of C. albicans Cdr1 (Nakamura et al., 2001). The patented S. cerevisiae 
membrane protein expression system (Monk et al., 2014) with its improved expression 
host, AD∆, and additional helper plasmids, pABC3 and pABC5’, further increased the 
cloning efficiency (Lamping et al., 2007). Since then further improvements included the 
creation of AD∆∆ (Sagatova et al., 2015), a strain with both the ura3 and his1 auxotrophic 
markers deleted, additional helper plasmids and optimised cloning strategies that enabled 
one step cloning protocols of improved speed, accuracy and efficiency (Lamping et al., 
2017b). S. cerevisiae is arguably the best-characterised eukaryotic model organism, it has 
a short generation time, and use of the AD1-8u- host system has the additional advantage 
of having the membrane protein expression cassettes stably integrated into the genome, 
so that no expensive selective media are required for plasmid maintenance and growth of 
yeast cells.  
4.1.3 Detergent Solubilisation of Membrane Proteins 
The extraction of integral membrane proteins from their native environment can 
dramatically affect their structural and functional integrity (Arachea et al., 2012; Luckey, 
2014). The complex lipid composition of biological membranes ensures that critically 
important protein-lipid interactions can occur. Lipids maintain the structural integrity of 
membrane proteins, thus, enabling them to function correctly in their destined membrane 
compartment(s) (Dowhan, 1997; Lee, 2003). Therefore, a critical first step in membrane 
protein purification is the extraction of the protein from its native environment without 
affecting its structural and/or functional integrity so that the protein remains in its native 
conformation throughout the purification process. 
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4.1.3.1 Detergents  
Detergent solubilisation is typically the first step in structural studies of membrane 
proteins (le Maire et al., 2000; Seddon et al., 2004; Kotov et al., 2019). However, ensuring 
the stability of membrane proteins in detergent micelles or membrane-like environments 
is a major challenge (Kotov et al., 2019). Detergents are amphiphilic molecules that keep 
membrane proteins water-soluble outside of their native lipid bilayer environment 
(Neugebauer, 1990; Linke, 2009), but a detergent that is suitable for extraction may not 
necessarily be suited for purification and/or biochemical studies of the extracted proteins 
(Linke, 2009; Kotov et al., 2019). Equally, a detergent that is suitable for the extraction of 
one membrane protein may well not be the right choice for another membrane protein 
(Seddon et al., 2004; Orwick-Rydmark et al., 2016). Amphiphilic detergents comprise two 
distinct polar and apolar domains (Figure 4.1). The polar or charged hydrophilic part is 
referred to as the “hydrophilic head group” while the nonpolar hydrophobic domain is 
often called the “hydrophobic tail” (Neugebauer, 1990; Linke, 2009). Yet, other detergents 
like the bile acid derivatives CHAPS and CHAPSO have a bean-like molecular shape divided 
into a polar and nonpolar face (Figure 4.1; (Hjelmeland, 1980)).  
 
 
Figure 4.1. Schematic diagram of detergent monomers. Most detergent molecules contain 
a hydrophilic head (blue) and a hydrophobic tail (red; left). However, bile acids are 
detergents that have a bean-like molecular shape (Laxminarayan et al.) with both polar 
(blue) and nonpolar (red) faces as indicated (taken from Anatrace (Anatrace)). 
 
Lipids also have hydrophilic head groups and nonpolar hydrophobic tails (Garavito 
et al., 2001). The difference, however, is that traditional detergents are roughly cone 
shaped with the head group occupying a larger space than the thin hydrophobic tail that 
usually comprises a single hydrophobic alkyl side-chain, whereas lipids of biological 
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membranes are typically cylindrically shaped comprising two hydrophobic alkyl side-chains 
(Figure 4.2-A and -B). The detergent concentration above which monomers self-assemble 
into non-covalent aggregates (micellisation) is called the critical micelle concentration 
(CMC) (le Maire et al., 2000; Seddon et al., 2004; Arachea et al., 2012; Stetsenko et al., 
2017). Detergents aggregate into spherical or ellipsoidal micelles with the tails pointing 
towards the interior and the hydrophilic head groups facing the aqueous environment 
(Figure 4.2-A). In contrast, membrane lipids aggregate into planar lipid bilayers (Garavito 
et al., 2001; Alberts et al., 2002a) as shown in Figure 4.2-B. Micelles are dynamic structures 
of a few nanometres in diameter (Lipfert et al., 2007; Oliver et al., 2013) and a molecular 
weight of <100 kDa (Stetsenko et al., 2017; Anatrace). Detergent molecules can freely 
exchange between micelles and monomers in solution while membrane lipids remain 
tightly bound to the lipid bilayer. 
 
Figure 4.2. Detergents and glycerophospholipids form different three-dimensional 
arrangements in solution. A) Cartoon depiction of a cone shaped detergent monomer and 
their tendency to aggregate as spherical or ellipsoidal micelles at elevated concentrations. 
B) Cartoon depiction of cylindrically shaped glycerophospholipid monomers that aggregate 
into phospholipid bilayers at elevated concentrations. C) Cartoon model of a detergent 
solubilised membrane protein with the hydrophobic tails of individual detergent molecules 
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forming a hydrophobic torus around the hydrophobic transmembrane domains (taken 
from Anatrace (Anatrace)).  
 
Detergents extract membrane-embedded proteins by inserting their hydrophobic 
tails into the lipid bilayer (le Maire et al., 2000; Garavito et al., 2001; Orwick-Rydmark et 
al., 2016) and forming a protective layer surrounding the hydrophobic part of membrane 
proteins while their polar groups provide water solubility (Figure 4.2-C). For complete 
membrane protein solubilisation and the creation of a homogeneous membrane protein-
micelle preparation devoid of endogenous membrane lipids, high detergent concentrations 
are required (le Maire et al., 2000), but unfortunately, this also often inactivates the 
membrane protein (le Maire et al., 2000; Lee, 2003; Opekarova et al., 2003; Seddon et al., 
2004). 
Detergents are grouped into ionic, zwitterionic and non-ionic detergents 
(Neugebauer, 1990; Linke, 2009; Sadaf et al., 2016; Stetsenko et al., 2017). Ionic detergents 
can disrupt ionic bonds and hydrogen bonds of membrane proteins. Strong ionic 
detergents like SDS usually denature proteins by binding to amino acid side-chains. Non-
ionic detergents like the maltosides, glucosides and the polyoxyethylene glycols are milder 
detergents characterised by uncharged hydrophilic head groups. These detergents “disrupt 
protein-lipid and lipid-lipid interactions rather than protein-protein interactions” (Seddon 
et al., 2004). Short chain (C7-C10) non-ionic detergents are typically more denaturing than 
longer chain non-ionic detergents (> C12) (le Maire et al., 2000; Seddon et al., 2004; Sadaf 
et al., 2016; Anatrace)). They are a common choice for the purification of membrane 
proteins  (Arachea et al., 2012; Yang et al., 2014; Feroz et al., 2018). DDM, DM and OG are 
most frequently used for membrane protein crystallography (Stetsenko et al., 2017), 
CYMAL and Fos-choline are more frequently used to extract inner membrane proteins, DM 
is often used successfully for the extraction and structural characterisation of outer 
membrane proteins and LDAO is more frequently used for the solubilisation of transport 
proteins (Arachea et al., 2012). Zwitterionic detergents contain both a positive and a 
negative charge in their hydrophilic head group. Their detergent properties place them in 
between the ionic and non-ionic groups of detergents. They are mild detergents as are non-
ionic detergents because they are electrically neutral, but like the ionic detergents they are 
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capable of disrupting protein-protein interactions (Arachea et al., 2012; Tulumello et al., 
2012). Interestingly, most successful NMR-based structural investigations of membrane 
proteins have been carried out with zwitterionic detergents such as dodecyl-
phosphocholine (Fos-choline-12; Figure 4.3) (Chipot et al., 2018). 
The properties of detergent monomers and their aggregation in solution are 
affected by the physical properties of the hydrophobic tail; the length and branching of the 
alkyl chain, the presence of an aromatic nucleus or fluoroalkyl side chain, or the number of 
polyloxyethylene units all influence the detergent properties. Long hydrophobic side-
chains reduce detergent solubility and cause tighter packing while branched or unsaturated 
side-chains have the opposite effect causing looser packing of detergent micelles. 
Polyoxyethylene side-chains decrease the hydrophobic interior of micelles while fluoroalkyl 
side-chains increase the hydrophobicity of a detergent. Thus, longer acyl chain detergents 
are preferred for the solubilisation and stabilisation of membrane proteins while shorter 
side-chain detergents, generally, cause tighter packing of crystals and improve X-ray 
diffraction (Newstead et al., 2008a; Newstead et al., 2008b). Detergent screening is an 
important first step to determine a suitable detergent for membrane protein solubilisation, 
and purification. 
4.1.3.2 Amphipols  
Amphipols are a new class of amphiphilic detergent consisting of hydrophilic 
polyacrylate polymers grafted with various hydrophobic side chains that makes them 
ideally suited to wrap around membrane proteins tightly (Figure 4.4) and stabilise them in 
aqueous solution (Tribet et al., 1996). This unique property of amphipols increases 
membrane protein stability in aqueous solutions for long periods of time (Tribet et al., 
1996; Gorzelle et al., 2002; Dahmane et al., 2009). Amphipol A8-35 is the most commonly 
used amphipol for membrane protein stabilisation (Dahmane et al., 2009; Huynh et al., 





Figure 4.3. Frequency of the successful use of membrane-mimicking environments for 
determining the structures of membrane proteins (MPs). A) Detergents used to 
determine MP crystal structures. B) Detergents used to determine MP structures by 
electron microscopy. C) Detergents used to determine structures by solution-state NMR. 
D) shows that in solution-state NMR dodecyl phosphocholine (DPC) has been used to 
determine about 40% protein structures, irrespective of whether the proteins are integral 
MPs, short peptides, β-barrels, or α-helical proteins. Taken from (Chipot et al., 2018); used 
with permission from ACS, chemistry for life (Appendix A4). 
 
4.1.4 Membrane Protein Purification  
Most detergent solubilised membrane proteins are more stable at lower 
temperatures (4-8 °C) and near neutral pH 6-8. Glycerol is also frequently added to help 
stabilise proteins, and protease inhibitor cocktails protect detergent solubilised membrane 
proteins from proteolytic degradation (Hjelmeland, 1990; Yasui et al., 2010). Detergents 
(Figure 4.4) are still the method of choice for membrane protein solubilisation and 
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purification (Rigaud et al., 2000; Chami et al., 2001; Prive, 2007). However, more advanced 
methods have been developed over the past two decades that place detergent solubilised, 
purified, membrane proteins in environments that better mimic their native lipid 
environment. These methods include the reconstitution of purified membrane proteins 
into liposomes (Rigaud et al., 2003), replacing detergents with amphipols (Pocanschi et al., 
2006; Popot, 2010) or nanodiscs (Ritchie et al., 2009; Popot, 2010), or the use of lipid-
bicelles (Sanders et al., 1998) (Figure 4.4). The basic principles of protein chromatography 
also apply to the purification of detergent solubilised membrane proteins. However, 
chromatography buffers must contain excess detergent at all times during the purification 
process to avoid aggregation of detergent solubilised membrane protein (Seddon et al., 
2004; Orwick-Rydmark et al., 2016). 
 
Figure 4.4. Schematic representation of some possible environments for membrane 
proteins after their extraction from biological membranes. The membrane proteins, 
detergent micelles, and lipids are shown in yellow, blue, and green, respectively. Figure is 
taken from (Milic et al., 2015); CC-BY licence (Appendix A4).  
 
4.1.4.1 Ion Affinity Chromatography 
Affinity chromatography is usually the first step in membrane protein purification 
after solubilisation. It exploits strong binding affinities of the protein of interest to an 
affinity resin to retain the protein on the affinity column. In ion metal affinity 
chromatography (IMAC) the six-histidine tag which is usually attached to the C-terminus of 
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the protein of interest binds with high affinity to the immobilised Ni-NTA Ni2+-cation resin. 
After binding and washing the column with an excess of detergent-containing 
chromatography buffer, the protein of interest is eluted off the column with a buffer that 
contains high concentrations of a cation, such as imidazole or histidine, that out-competes 
binding of the 6-His tag to the affinity resin (Seddon et al., 2004). 
4.1.4.2 Size Exclusion Chromatography 
Size exclusion chromatography (Henderson et al.) separates proteins according to 
their size and hydrodynamic radius (Burgess, 2018). SEC columns are tightly packed with 
tiny porous bead particles of defined average pore size that allow smaller proteins to freely 
diffuse throughout the porous bead particles whereas larger proteins are excluded from 
entering the pores. This causes size-separation of proteins below a certain size cut-off value 
above which all proteins elute in the ‘void’ volume of the column (Uliyanchenko, 2014; 
Burgess, 2018). Thus, large proteins elute first in the void volume of the column. Proteins 
of decreasing size then elute next and proteins below a certain size cut-off value all elute 
together in the total column volume. Proteins eluted from the column are detected by 
measuring protein absorbance with a light detector at 280 nm at the column exit. Buffer 
characteristics such as ionic strength, detergent concentration, pH, glycerol content or the 
presence or absence of reducing agents can significantly affect aggregation of detergent 
solubilised membrane proteins as they are being separated by SEC (Orwick-Rydmark et al., 
2016). A calibration curve plotting the log10 MW of reference proteins of various sizes 
divided by the ‘void’ volume of the column against the elution time enables size 
determination of an unknown protein from its elution time (Some et al., 2019). However, 
SEC cannot accurately determine the MW of detergent-solubilised membrane proteins 
(Hayashi et al., 1983; Slotboom et al., 2008; Gimpl et al., 2016). Column characteristics and 
buffer compositions are additional factors influencing the elution volumes of charged or 
hydrophobic proteins (Hong et al., 2012). 
4.1.4.3 Fluorescence Size Exclusion Chromatography (FSEC) 
FSEC (Kawate et al., 2006) is a simple method designed to monitor the extraction 
efficiency, mono-dispersity, and stability of membrane proteins in detergent micelles. 
Nanogram quantities of membrane proteins are sufficient for this purpose. The method 
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was developed by Drew and colleagues (Drew et al., 2001; Drew et al., 2006). It uses the 
fluorescence signal of C-terminally GFP-tagged proteins as an indicator for proper folding 
of a membrane protein. This is because the fluorescent signal of a correctly folded GFP 
molecule depends on the proper membrane integration and folding of the N-terminally 
attached membrane protein (Drew et al., 2001; Drew et al., 2006). A C-terminal GFP tag 
can be used for the quantification of membrane protein expression levels either in whole 
cell suspensions or by measuring their green fluorescence intensities in polyacrylamide gels 
immediately after SDS-PAGE separation of proteins. In addition, using a second, 
fluorescence, detector for SEC with the FPLC system provides an excellent opportunity to 
learn more about the quality and behaviour of the GFP-tagged membrane protein as it is 
being separated by SEC. The size, position and shape of the fluorescence peak is a good 
indicator for the amount, oligomeric state and integrity of the fluorescently labelled 
membrane protein. FSEC has been applied successfully with many different heterologous 
membrane protein expression systems. Examples include E. coli (Kawate et al., 2006), yeast 
(Newstead et al., 2007; Drew et al., 2008; Mizutani et al., 2011) and insect cells (Chen et 
al., 2013). FSEC has also been used successfully to screen large sets of different detergent 
and buffer conditions to optimise membrane protein extraction and purification protocols, 
and it can also be used to measure the thermostability of membrane proteins. Membrane 
proteins with increased thermostability are significantly more likely to give X-ray diffracting 
crystals (Hattori et al., 2012). 
4.1.4.4 Size Exclusion Chromatography with Multi-Angle Light Scattering (SEC-MALS)   
SEC-MALS is a combination of size exclusion chromatography with multi-angle light 
scattering analysis that can accurately determine the MW of membrane proteins in 
detergent micelle solutions, thus, overcoming the limitations of SEC for estimating the 
MWs of protein-detergent micelle complexes (Kendrick et al., 2001; Kwan et al., 2019; 
Some et al., 2019) (Figure 4.5). SEC-MALS (Some et al., 2019) simultaneously measures 
three different parameters of the SEC eluates: “on-line” static laser light scattering (LS), 
the refractive index (RI) and ultraviolet (UV) absorption (Kendrick et al., 2001; Folta-
Stogniew, 2006). SEC-MALS can be used to accurately determine the MW of proteins 
(Hayashi et al., 1989). It can also determine the oligomeric state of protein complexes 
(Folta-Stogniew, 2006; Gimpl et al., 2016), reveal possible protein aggregation (Philo, 2009) 
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and even help determine the degree of post-translational protein modification (Wen et al., 
1996; Micoli et al., 2018). SEC-MALS can even determine the amount of sugar residues, 
lipid, or detergent bound to proteins (Some et al., 2019) and it can also determine the 
amount of empty detergent micelles present in purified membrane protein/micelle 
solutions that could negatively affect protein crystallisation efforts (Dorwart et al., 2010; 
Moraes et al., 2015). 
 
Figure 4.5. Schematic setup of SEC-MALS with triple-detector. A high-performance liquid 
chromatography (HPLC) system provides constant flow through a SEC column to separate 
polypeptide mixtures. UV absorbance and RI detectors monitor changes in protein and 
detergent concentrations, while an LS detector follows changes in light scattering intensity 
at multiple angles. The detectors’ output signals are combined and analysed by a software 
package. Numbers 1 to 10 indicate solvent reservoir (1), degasser (2), pump (3), 
autosampler or manual injector (4), columns (5), UV detector (6), differential refractive 
index detector (7), multi-angle light scattering detector (8), waste disposal (9), and 
software (10; modified from Wyatt Technology website (Wyatt). 
 
4.1.5 Protein Quantification Assays 
Protein concentrations are determined with various colourimetric assays or by 
measuring the UV absorbance of pure protein solutions (Olson et al., 2016). The UV 
absorbance method cannot be used if detergents like Triton X-100 are present because its 
aromatic rings also absorb UV light. Detergents may also interfere with some colourimetric 
assays. Thus, protein standards and baseline measurements need to be performed in the 













4.1.6 Aims  
The aim of this chapter was to create protocols for the expression, solubilisation 
and purification of Cdr1 suitable for crystallography.  
Specific aims were to:  
1) Upscale the small-scale yeast plasma membrane preparation protocol. 
2) Screen detergents to find those suitable for Cdr1 solubilisation and purification. 
3) Optimise a stable, mono-disperse, Cdr1 purification protocol.  
4) Optimise a C-terminal Cdr1-GFPHis double tag for maximum protein yields. 
5) Determine the oligomeric state of mono-disperse Cdr1 preparations. 
6) Purify Cdr1-D327N, -E1027Q and -D327N-E1027Q mutants. 
4.2 Methods 
The following methods were primarily used in this chapter. 
4.2.1 Overexpression of C. albicans Cdr1A-His in S. cerevisiae AD∆  
C. albicans Cdr1 fused to a C-terminal His-tag was overexpressed in S. cerevisiae 
AD∆-CaCDR1A-HIS. AD∆∆ overexpressing Cdr1 with an improved C-terminal double tag, 
CaCDR1A-XLmGFPHis, was also created (mGFP is a monomeric GFP mutant; L is a GGSGS 
linker; X is a TEV protease cleavage site). The creation of AD∆∆-CaCDR1A-D327N-
XLmGFPHis, AD∆∆-CaCDR1A-E1027Q-XLmGFPHis and AD∆∆-CaCDR1A-D327N-E1027Q-
XLmGFPHis were described in Chapter 3 (Section 3.2.5.1). 
4.2.2 Growth and Harvesting of Yeast Cells for the Upscaled Isolation of Crude 
Plasma Membrane 
I developed midi- and large-scale plasma membrane isolation protocols based on 
the optimised small-scale plasma membrane isolation protocol described in Section 3.2.2. 
Midi-scale protocol - A single yeast colony from a YPD agar plate was used to 
inoculate 10 ml YPD liquid medium and incubated o/n (~16 h) at 30 °C with shaking at 200 
rpm. This logarithmic phase cell culture was used to inoculate 1 l flasks containing 0.5 l YPD 
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medium to an OD600nm of ~ 0.005. The cultures were incubated o/n at 30 °C with shaking at 
200 rpm until the cell culture reached an OD600nm of 6. The late-logarithmic phase cells were 
harvested by centrifugation at 5,524 g for 5 min at 4 °C, washed twice with 100 ml ice-cold 
ddH2O and resuspended in 40 ml ice cold HB freshly supplemented with 1 mM PMSF. 
Large scale protocol - A single yeast colony from a YPD agar plate was used to 
inoculate 10 ml YPD medium which was incubated o/n (~16 h) at 30 °C with shaking at 200 
rpm. The culture was used to inoculate 40 ml YPD medium and incubated at 30 °C with 
shaking at 200 rpm for a few hours until the cell density reached an OD600nm of 3-5. Aliquots 
of the logarithmic phase cell culture were used to inoculate 3 baffled 5 l flasks containing 
2 l YPD medium each to a cell density of OD600nm ~ 0.005. The cultures were incubated o/n 
at 30 °C with shaking at 200 rpm until they reached an OD600nm of 6. The late-logarithmic 
phase cells were harvested by centrifugation at 3,820 g for 5 min at 4 °C, washed twice with 
400 ml ice-cold ddH2O and resuspended in 60-70 ml ice cold HB (Table 2.6) freshly 
supplemented with 1 mM PMSF. Cell suspensions were stored at -80 °C for future use or 
kept on ice for immediate breakage. 
4.2.3 Upscaled Crude Plasma Membrane Preparation 
Midi-scale protocol - Cell suspensions were transferred into a 100 ml Bead-beater 
chamber half-filled with 40 g ice-cold 0.5 mm diameter silica beads. The chamber was filled 
to the top with additional HB freshly supplemented with 1 mM PMSF. Cells were broken 
with the Bead-beater (chamber surrounded with ice water) for three 1 min periods 
interspersed by 2 min cooling intervals. The cell homogenate (almost 55 ml) was 
transferred to an ice-cold centrifuge beaker and the pH of the homogenate quickly 
readjusted to pH 7.5 with a few drops of 100 mM Tris. Nuclei, unbroken cells, and cell debris 
were removed by centrifugation at 5,524 g for 5 min at 4 °C. Crude plasma membrane 
proteins in the supernatant were harvested by centrifugation at 18,000 g for 2 h at 4 °C. 
After aspiration of the supernatant the crude plasma membrane pellets were resuspended 
with a paint brush in 1 ml GTED-20 buffer (Table 2.6) and stored at -80 °C. 
Large scale protocol - The frozen 60-70 ml large-scale cell suspensions were thawed 
on ice for about 1 h and transferred into a 350 ml Bead-beater chamber half-filled with 250 
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g ice-cold 0.5 mm diameter silica beads. The chamber was filled to the top with additional 
HB freshly supplemented with 1 mM PMSF to avoid air bubbles from forming in the next 
step. Cells were broken with the Bead-beater (the chamber was surrounded by ice water) 
for seven 1 min periods interspersed with 4 min cooling intervals. The cell homogenate, 
and an extra 50 ml HB used to wash the silica beads, were transferred to an ice cold 250 ml 
centrifuge beaker and the pH of the homogenate was readjusted to pH 7.2 with 1 M Tris. 
Nuclei, unbroken cells, and cell debris were removed by centrifugation at 3,820 g for 5 min 
at 4 °C, and the supernatant was centrifuged again at 3,820 g for 5 min at 4 °C to remove 
remaining nuclei, unbroken cells and cell debris. Crude plasma membrane proteins were 
harvested from the supernatant by centrifugation at 18,000 g for 2 h at 4 °C. After 
aspiration of the supernatant the crude plasma membrane pellet was resuspended with a 
paint brush in a minimum volume (20-25 ml) of GTED-20 buffer, split into five 15 ml Falcon 
tubes, and stored at -80 °C.  
4.2.4 Membrane Protein Solubilisation 
The most common method to extract membrane proteins from biological 
membranes is solubilisation with detergent. The challenge, however, is to find the right 
detergent that has the minimum effect on protein stability and/or folding characteristics. 
4.2.4.1 Small Scale Detergent Screen  
Two milligram portions of membrane preparations were mixed with GTED-20 (Table 
2.6) containing various test detergents (Table 2.2 and Table 4.1) at a final concentration of 
1% (w/v), and the mixture was inverted for 2 h at 4 °C with a rotation device. The mixture 
was centrifuged at 141,000 g for 1 h at 4 °C, and the supernatants containing solubilised 
material were transferred to a fresh tube. GTED-20 supplemented with 2% SDS (w/v) (0.5 
ml) was added to each pellet and incubated o/n at 30 °C in a shaking incubator to extract 
all detergent-insoluble membrane proteins. To identify the most suitable detergent(s) for 
Cdr1 solubilisation the supernatant and extracted pellet fractions were analysed by SDS-
PAGE and fluorescence size exclusion chromatography (FSEC; see Section 4.2.9).  
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Table 4.1. Properties of detergents used in this study.  
Detergent MW (g/mol) CMC (mM) 1x CMC (mg/ml) 
LDAO 229.4    ~ 1-2 ~0.34 
Anzergent 3-8 279.6 390 109 
Anzergent 3-12 335.5 2.8 0.9 
Anzergent 3-18 419.7   
CYMAL-1 438.5 ~ 340 149.1 
CYMAL-4 480.5 ~ 7.6 3.7 
CYMAL-7 522.5 0.19 0.1 
OG 292.4       ~ 18-20 5.6 
NG 306.4 ~ 6.5 2 
HEGA-10 379.5 ~ 7.0 2.7 
Mega-10 349.5 ~ 6-7 2.3 
CHAPS 614.9 8 4.9 
CHAPSO 630.9 ~ 8 5.1 
Fos-choline-8 295.4 ~ 114 33.7 
Fos-choline-10 323.4 ~ 11 3.6 
Fos-choline-13 365.5 ~ 0.75 0.3 
Fos-choline-14 379.5 ~ 0.12 0.05 
NM 468.5 ~ 6 2.8 
DM 482.6 ~ 1.8 0.9 
UDM 496.6 0.59 0.29 
β-DDM 510.6 0.17 0.09 
α-DDM 510.6 0.152 0.08 
n-Tridecyl-β-D-Maltoside 524.6 0.033 0.02 
DDS 524.6 ~ 0.3 0.16 
TDM 538.6 0.01 0.005 
MNG-OG 568.7 ~ 1.02 0.6 
MNG-DM 949.08 ~ 0.036 0.3 
LMNG 1005.2 ~ 0.01 0.01 
PCC-α-M 548.67 0.036 0.02 
Digitonin 1229.3 0.25–0.5 0.4 
SDS 288.4 8.2 2.4 
TRITON X-100 647  0.13 
TWEEN 80 1310 ~ 0.012 0.02 
 
4.2.4.2 Large Scale Membrane Protein Solubilisation  
Isolated crude plasma membrane preparations (see Section 4.2.3) were adjusted to 
5 mg/ml protein concentrations and solubilised in GTED-20 buffer freshly supplemented 
with 1 mM PMSF and containing the desired detergent (1%; w/v) by incubating for 2 h at 4 
°C on a rotating mixer. Detergent-insoluble material was removed by high-speed 
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centrifugation at 140,000 g for 1 h at 4 °C. The supernatant, containing detergent 
solubilised Cdr1 was subjected to SDS-PAGE and affinity chromatography. 
4.2.5 Affinity Chromatography (Ion Metal Affinity Chromatography; IMAC) 
HisTrap HP protein purification columns (Table 2.5) were used to purify detergent 
solubilised Cdr1 that was fused to a C-terminal His-tag. These ready-to-use columns were 
prepacked nickel-charged IMAC columns for the preparative purification of His-tagged 
proteins. Solubilised membrane proteins were filtered through a 0.45 μm syringe filter 
before passing it through the HisTrap HP column(s) equilibrated with GTED-20 
supplemented with 1 mM PMSF and 1% (w/v) of the desired detergent at a flow-rate of 0.3 
ml/min. All purification steps were performed at 8 °C with the HisTrap HP column(s) 
connected to an ÄKTA pure protein purification system. Non-specifically weakly bound 
proteins were removed from the column by washing it with 20x bed volumes (column 
volume or CV)of IMAC buffer (Table 2.6) supplemented with 1 mM PMSF, 25 mM imidazole 
and the desired detergent at 4× the critical micelle concentration (CMC; Table 4.1). Strongly 
bound proteins were eluted with 10x bed volumes of IMAC buffer supplemented with 1 
mM PMSF, 200 mM imidazole, and 4× CMC of the desired detergent. Peak fractions, 
monitored by the ÄKTA system, were pooled and subjected to size exclusion 
chromatography (Henderson et al.). Portions of the collected IMAC fractions were analysed 
by SDS-PAGE to determine whether the target protein bound to, and eluted efficiently 
from, the affinity resin. 
4.2.6 Size Exclusion Chromatography  
Further purification of pooled IMAC fractions was achieved by SEC using the ÄKTA 
pure protein purification system. A Superose 6 Increase 10/300 GL or a HiLoad 16/600 
Superdex 200 pg (Table 2.5) column were pre-washed with filtered and degassed ddH2O 
and equilibrated with 2x bed volumes SEC buffer with or without detergent. Proteins were 
loaded in, and eluted with, SEC buffer (Table 2.6) containing 2× CMC of the desired 
detergent. For best possible resolution no more than 0.5 ml (Superose 6 Increase 10/300) 
or 5 ml (HiLoad 16/600 Superdex 200 pg) of affinity purified fractions were filtered through 
a 0.45 μm syringe filter and injected onto the equilibrated columns. The target protein was 
eluted at flow rates of 0.5 ml/min (Superose 6 Increase 10/300) or 1 ml/min (HiLoad 16/600 
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Superdex 200 pg), and 0.5 ml eluant aliquots were collected. If higher protein 
concentrations were needed (e.g. for crystallography), fractions of Cdr1-GFPHis were 
concentrated by centrifugation at 2,000 g through a 100 kDa MWCO Amicon Ultra-
Centrifugal Filter (Table 2.3). For some detergent screening experiments, 100 µl solubilised 
Cdr1-GFPHis samples were separated by SEC using a Superose 6 Increase 10/300 column 
and GFP fluorescence was detected at an emission wavelength of 510 nm using an 
excitation wavelength of 475 nm. 
4.2.7 Detergent-Amphipol Exchange for Purified Cdr1-GFPHis  
Although detergents are commonly used to extract membrane proteins from their 
natural lipid environment, detergent micelles often affect the structural and/or functional 
integrity of membrane proteins. Detergents can also interfere with protein crystallisation 
efforts or hinder the formation of homogeneous vitrified ice in single-particle cryo-electron 
microscopy (cryo-EM). To avoid some of these pitfalls, detergent purified membrane 
proteins can be reconstituted with membrane-mimetics such as amphipols. Amphipols are 
amphiphilic polymers that can be used to stabilise membrane proteins in detergent-free 
aqueous solutions (Tribet et al., 1996). 
Detergent solubilised and IMAC, or IMAC plus SEC, purified Cdr1-GFPHis eluates 
were mixed with a seven-fold excess (w/w protein) of amphipol A8-35 (Table 2.1) and 
incubated at 4 °C with gentle rotation for 2-3 h. A twenty-fold excess of activated Bio-Beads 
SM-2 Resin (Table 2.3; i.e. 20 mg/mg detergent) was added to remove the detergent and 
allow its exchange with amphipol A8-35 by slowly rotating the sample at 4 °C o/n. After 
removal of the Bio-Beads by centrifugation at 4,000 g, the soluble amphipol A8-35 
stabilised Cdr1-GFPHis particles in the supernatant were further purified to remove traces 
of detergent. This was achieved by SEC through a Superose 6 increase 10/300 column 
equilibrated with detergent-free SEC Buffer (Table 2.6). Successful detergent exchange was 
confirmed by the presence of a sharp Gaussian-shaped peak for the amphipol A8-35 
stabilised Cdr1-GFPHis particles as they were eluted from the size-exclusion column.  
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4.2.8 Size Exclusion Chromatography-Multiangle Light Scattering (SEC-MALS) 
Analysis of Detergent Solubilised and Partially Purified Cdr1-GFPHis  
The initial solubilisation of membrane proteins requires high detergent 
concentrations, well above the CMC, to solubilise lipids as well as proteins. Due to the 
presence of detergent micelles, solubilised membrane protein-detergent complexes 
require more careful size measurement protocols compared to standard globular proteins 
when separated by SEC. Therefore, standard SEC calibration methods cannot provide 
accurate molecular weight (MW) estimations for membrane protein-micelle complexes. In 
particular, it is difficult to divide the estimated MW for the entire membrane protein-
detergent micelle particle into its detergent-micelle and membrane protein components. 
SEC-MALS is a method that can accurately separate these two parts from each other, which 
makes it possible to determine the correct oligomeric state of detergent solubilised 
membrane proteins (Some et al., 2019). SEC-MALS can accomplish this by measuring the 
light scattered by the protein or protein/micelle solutions at discrete angles as illustrated 
in Figure 4.6. To determine the correct MW of detergent solubilised Cdr1-GFPHis particles 
after SEC (Section 4.2.6), UV280nm absorption, multiangle light scatter (MALS) and 
differential refractive indices (DRI) of eluates were measured with standard UV detectors 
combined with specially designed MALS (DAWN® detector), and Optilab DRI detectors. 
Careful analysis of the MALS, UV absorption, and DRI data (ASTRA software offers options 
such as particle analysis) yielded the MW for the membrane protein and the detergent 
micelle components of the solubilised Cdr1-GFPHis protein-detergent complex 
(Korepanova et al., 2012; Le Roy et al., 2014).  
 
Figure 4.6. Schematic representation of multiangle light scattering measurement. Figure 
taken from the Wyatt Technology website (Wyatt). 
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4.2.9 FSEC Screening 
FSEC experiments were performed with the NGC Chromatography Medium 
Pressure system from Bio-Rad. The system was equipped with a fluorescence detector, an 
autosampler, a fractionator and Superose 6 Increase 10/300 GL columns (Figure 4.7). A 
flow rate of 0.35 ml/min was used. Before sample application the SEC column was washed 
with two bed- or column-volumes (CVs) of ddH2O and equilibrated with at least 1.5 CV SEC 
buffer filtered through a 0.22 μm Millipore filter, degassed, and cooled prior to application. 
The autosampler and the injection loop were also equilibrated with the same buffer prior 
to sample application. The detergent solubilised plasma membrane samples were filtered 
through a 0.22 μm Millipore filter at 4 °C before 100 μl of each sample were automatically 
injected with the autosampler into the size exclusion column. The UV detector measured 
the protein absorption peak at 280 nm and the fluorescence detector (excitation 475 nm 
and emission at 510 nm) traced the GFP signals. The sensitivity and gain parameters of the 
fluorescence detector were adjusted according to the amounts of protein injected. 
Fractions between 4 to 24 ml elution volumes were collected with a Bio-Frac Fraction 
Collector and, together with the detergent-solubilised samples that were used for the FSEC 
experiments, analysed by “semi-denaturing” SDS-PAGE (i.e. samples were not heat 
inactivated before loading onto the polyacrylamide gel).  
 
 
Figure 4.7. FSEC of Cdr1-GFPHis containing plasma membranes. Cdr1-GFPHis containing 
plasma membranes were solubilised with detergent-buffer and loaded automatically onto 
Solubilised sample 
with a GFP-tag 







the SEC column. The eluent passed through a flow-cell where a fluorometer detected GFP 
fluorescence and a UV detector the protein concentration before eluents were collected 
with an automated fraction collector. The fluorescence graph shows a hypothetical elution 
pattern and the UV absorbance panel shows a typical UV absorbance pattern of a crude 
plasma membrane protein sample. Made using Biorender website (Biorender). 
 
4.3 Results 
4.3.1 Optimisation of Cell-Breakage for the Midi-Scale Plasma Membrane 
Isolation Protocol and Upscaling for the Large-Scale Protocol 
In a midi-scale plasma membrane preparation, 3,000 ODU of late logarithmic phase 
yeast cells (OD600nm = 6) were resuspended in 40 ml ice cold GTED-20, supplemented with 
fresh 1 mM PMSF (Table 2.1), and transferred into a 100 ml Bead-beater chamber that 
contained 40 g of ice cold 0.5 mm silica beads. The chamber was topped up with a little 
more GTED-20 buffer and the yeast cells were broken with three cycles of bead-beating for 
1 min followed by 3 min cooling periods in between. Although increasing the bead-beating 
cycles to four increased the yield of crude plasma membrane protein by 40% (from 20 to 
28 mg/ml) it actually reduced the specific Cdr1 ATPase activity of the plasma membrane 
preparations from 116 nmol/min/mg to 60 nmol/min/mg meaning the total recovered OS 
Cdr1 ATPase activity reduced from 2320 to 1680 nmol/min when, in theory, it should have 
increased by 40% to 3248 nmol/min. In other words, increasing the cell breakage cycles to 
four significantly increased (~40%) the yield of crude plasma membranes but, 
unfortunately, it also caused a significant decrease (~28%) in the total recovered Cdr1 
ATPase activity. In another experiment, 500 ml cells harvested from a culture with an 
OD600nm of 6 (3,000 ODU) and broken with 4 cycles, had a greater OS activity (84 
nmol/min/mg) than 500 ml cells harvested from a culture with an OD600nm of 3 (1,500 ODU), 
also broken with 4 cycles (60 nmol/min/mg). Thus, cells at an OD600nm of 6 were routinely 
harvested and broken with three 1 min breaking cycles interspersed with 3 min cooling 
periods in order to isolate crude plasma membranes of the highest possible quality.  
For large-scale plasma membrane preparations, the midi-scale protocol was 
upscaled, but because a larger bead beater chamber was needed, modifications of the 
protocol were required, as described in section 4.2.3, above. Although the optimised mini-
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scale preparation developed in Chapter 3 gave OS specific Cdr1 ATPase activities of up to 
300 nmol/min/mg, the midi-scale preparations gave OS specific Cdr1 ATPase activities of 
only 60 to 120 nmol/min/mg, and the large-scale preparations gave activities of 140 to 160 
nmol/min/mg, respectively. This was probably due to inevitable differences in the breakage 
conditions, such as changes in the ratio of surface area to volume, as a larger Bead-Beater 
chamber was needed rather than microfuge tubes.  
4.3.2 Detergent Screening 
Thirty-one detergents with various properties for their ability to solubilise Cdr1 
from crude plasma membranes of S. cerevisiae AD∆∆-CDR1-XLmGFPHis were screened. The 
desired detergent should solubilise as much Cdr1-XLmGFPHis as possible without altering 
its structure and/or function. The crude plasma membrane proteins were solubilised for 2 
h with 1% (w/v) detergent and aliquots of the soluble and insoluble fractions were analysed 
by SDS-PAGE (Figure 4.8) and later also by FSEC (Figure 4.11). 
 
Figure 4.8. Detergent screening. SDS-PAGE of 10 µl aliquots of the total (T) solubilisation 
mixture, the pellet (P) after solubilisation and the solubilised supernatant (S) fractions of 
detergent solubilised crude plasma membranes of AD∆∆-Cdr1-XLmGFPHis (top) and in-gel 
fluorescence of Cdr1-XLmGFPHis before Coomassie blue staining of the same gel (bottom). 
T = total proteins present after solubilising plasma membranes for 2 h with 1% detergent; 
S = supernatant containing solubilised membrane proteins after centrifugation at 140,000 
g for 1 h; and P = aliquot of the pellet fraction of membrane proteins not solubilised by the 
detergent, but extracted with 2% SDS-containing GTED-20 buffer in a similar volume as the 
supernatant fraction (S). M = broad MW pre-stained protein ladder (Abcam; 245, 180, 135, 
100, 75, 63 and 48 kDa bands); the 200 kDa Cdr1-XLmGFPHis band is indicated with a red 
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arrow and a 75 kDa band with a green arrow. Lanes A to L and N to Q are the T, S and P 
fractions for DM (A), β-DDM (B), α-DDM (C), TDM (D), LMNG (E), OGNG (F), OG (G), LDAO 
(H), Hega (I), Mega (J), Triton-X100 (K), CHAPS (L), NM (N), Tween80 (O), Fos-choline-13 (P) 
and SDS (Q), respectively. Note: SDS denatures Cdr1-XLmGFPHis which is why no green 
fluorescence signals are visible in lanes P and Q. 
 
I scored the detergents with a score of 1 to 4 by directly comparing the green 
fluorescence intensities of Cdr1-XLmGFPHis in lanes S (soluble) and P (insoluble) with those 
in T (total; 100%) (Figure 4.8). If the Cdr1-XLmGFPHis band in the P lane on the Coomassie 
stained gel was equal to, or higher than, the soluble (S) fraction, the detergent was given 
the lowest possible score of 1. If, however, the majority of Cdr1-XLmGFPHis was recovered 
in the soluble supernatant fraction, S (i.e. the signal was>80% in S and <20% in P), the 
detergent was given the highest possible score of 4. Detergents that gave 20-30% insoluble 
Cdr1-XLmGFPHis material in the pellet fraction P were scored 3 and those resulting in 30-
50% insoluble material in P were scored a 2. The scores shown in Table 4.2 were based on 
at least three independent experiments. DDM and Fos-choline-13 appeared to be the best 
detergents for the solubilisation of intact Cdr1-XLmGFPHis (Table 4.2), however, the use of 
Fos-choline-13 seemed to cause partial proteolysis of Cdr1-XLmGFPHis. LMNG, PCC-α-M 
and possibly also DM were the next best detergents.  
The detergent screen also showed that glucosides, CHAPS, and Anzergents are bad 
choices for the solubilisation of Cdr1-XLmGFPHis (Figure 4.8). There was a clear trend of 
higher detergent scores for detergents with longer aliphatic side-chains of 12 or 13 carbon 
residues; e.g. DDM > DM > NM (12, 10 or 9 carbons), Fos-choline-13 > 10 > 8 (13, 10 or 8 
carbons) and LMNG > DMNG > OGNG (12, 10 or 8 carbons), respectively. Thus, detergents 
with hydrophobic tails of less than 12 carbons were far less suitable detergents for 
solubilisation of Cdr1 than detergents with longer hydrophobic tails of 12 or 13 carbons, 
and non-ionic detergents (DDM, LMNG) seemed generally more suitable for solubilisation 
of Cdr1 than zwitterionic detergents (Table 4.2). 
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Table 4.2. Ability of detergents to solubilise intact Cdr1-XLmGFPHis. 
Type Group Abbreviation Scorea 
Non-ionic 
General purpose SDS (Ionic) 4b 
TRITON X-100  2 
TWEEN 80  1 
Digitonin 2 
Glucosides OG 1 
NG 1 
Glucamides HEGA-10 3 
MEGA-10 2 
Maltosides NM 2 
 DM 3 
 UDM 3 
 β-DDM 4 
 α-DDM 4 
 Tridecyl-Maltoside 1 
 TDM 3 
 PCC-α-M 4 
Sucroside DDS 2 
Neopentyl-glycosides OGNG 1 
DMNG 2 
LMNG 4 




Amine oxide LDAO 1 
Ammonio-1-propanesulphonates Anzergent 3-8 1 
Anzergent 3-12 1 
Anzergent 3-18 1 
Fos-cholines Fos-choline-8 1 
Fos-choline-10 2 
Fos-choline-13 4 
Sterol derivatives CHAPS 1 
a Detergent scores (4 is the best score) are based on at least three independent experiments. 
b SDS solubilised all Cdr1-XLmGFPHis but it also denatured most protein in the process (GFP fluorescence 
is a good indicator for the structural integrity of proteins). 
 
4.3.2.1 A Minimum Detergent to Protein Ratio of Two is Required for Efficient 
Solubilisation of Cdr1 
Next, the optimum DDM concentration required for the solubilisation of Cdr1-
XLmGFPHis was determined. To achieve this, the parameters that were most important for 
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the optimum detergent concentration were investigated; was it the concentration of the 
detergent (x CMC) or was it simply the detergent/membrane protein ratio that determined 
how much detergent was required for the most gentle but efficient solubilisation of Cdr1-
XLmGFPHis?  
Figure 4.9-A shows how the CMC is not the best parameter to consider when it comes to 
choosing the ‘right’ amount of detergent for the efficient solubilisation of membrane 
proteins. Large differences in the solubilisation efficiencies of Cdr1-XLmGFPHis were 
observed when using fixed concentrations of 10x or 80x CMC of DDM. The solubilisation 
efficiencies varied between 40 and 80% or 60 and 90% depending on the amounts of crude 
plasma membranes used in the various solubilisation experiments. However, choosing 
detergent to protein ratios (w/w) of 2 (Figure 4.9-B) gave reproducibly good results with 
>85% of Cdr1-XLmGFPHis being solubilised no matter the amount of plasma membrane 
protein used. So, in later experiments, using the more commonly employed approach of 
simply choosing 1 or 2% (w/v) detergent for the solubilisation of Cdr1-XLmGFPHis, the 
detergent to protein ratio was always kept above 2.  
4.3.2.2 Two-Step Protein Purification of Selected Detergent Solubilised Cdr1-XLmGFPHis 
Samples 
Next, the detergents with the highest solubilisation scores (DDM, LMNG, PCC-α-M, 
DM, TDM, Hega, NM, OGNG, and Fos-choline-13) were used to solubilise and purify small 
test amounts of Cdr1-XLmGFPHis with nickel affinity [HisTrap HP column, Table 2.5] 
followed by SEC [Superose 6 Increase 10/300 GL, Table 2.5]. The IMAC and the SEC buffers 
(Table 2.6) included 2x CMC of the selected detergent. The SEC chromatograms (Figure 
4.10) seemed to confirm the major findings of the detergent screen with DDM, PCC-α-M 
and LMNG showing least aggregation (as there was no, or only a small, peak in the void 
volume) and a major protein peak at 15.5 ml for Cdr1-XLmGFPHis. Interestingly, the SEC 
chromatogram for Fos-choline-13 was quite different from the other three chromatograms 
displaying a rather smooth, but significantly broader, protein peak with its maximum at 
around 13.5 ml, indicating a much higher oligomeric state for Cdr1-XLmGFPHis particles 
contained in Fos-choline-13 micelles. The chromatograms of the remaining lower scoring 
detergents DM, TDM, Hega, NM and OGNG showed mostly large protein precipitates and 
 142 
no obvious peaks of properly folded and possibly mono-disperse Cdr1-XLmGFPHis 
particles. These experiments confirmed the detergent screen results indicating that DDM, 
PCC-α-M and LMNG are the best detergents to solubilise and purify Cdr1-XLmGFPHis.  
 
Figure 4.9. Solubilisation of Cdr1-XLmGFPHis requires at least twice as much DDM. A) The 
amount of DDM required for the solubilisation of Cdr1 (%) from crude plasma membrane 
preparations does not depend on the concentration of the detergent used (x CMC) per se. 
B) The solubilisation efficiency of Cdr1-XLmGFPHis with DDM was clearly a function of the 
ratio of the amount of DDM relative to the amount of crude plasma membrane protein 
used. A detergent to crude plasma membrane protein ratio of 2 (w/w) was sufficient to 






Figure 4.10. SEC profiles of Cdr1 solubilised and purified with different detergents. SEC 
chromatograms of small amounts of detergent solubilised (30 mg crude plasma membrane 
protein solubilised in a total volume of 6 ml) and Nickel-affinity purified Cdr1-XLmGFPHis 
samples separated on a Superose 6 increase 10/300 column for A) OGNG (blue), Hega 
(fuchsia), NM (purple), TDM (Oliver et al.), DM (lavender) and LMNG (teal) and B) Fos-
choline 13 (fuchsia), PCC-α-M (purple) and DDM (blue). 
 
4.3.2.3  Detergent Screening with FSEC 
FSEC enables monitoring the behaviour of GFP-tagged membrane proteins directly 
in crude detergent solubilised membrane protein mixtures (Figure 4.7), but FSEC has many 
other applications. For example, it can be used to measure the thermostability of proteins, 
or it can help optimise purification protocols by monitoring the effects of buffer additives, 
or the addition of specific lipids or ligands on the behaviour of the membrane protein of 
interest. As part of the DAAD Postgraduate exchange program, the detergent screen with 
FSEC was repeated at the Max Planck Institute of Molecular Physiology in Dortmund, 
Germany, under the supervision of Prof. Stefan Raunser. This method of in-line affinity 
chromatography and FSEC (Figure 4.11-A) was markedly faster but, as expected, the results 
were very similar to the detergent screens described in the previous sections (Figure 4.10). 
The FSEC chromatograms of the total Cdr1-XLmGFPHis containing crude plasma membrane 
protein mixture solubilised with DDM or LMNG (Figure 4.11-B) were very similar to those 
obtained for the double-step purified Cdr1-XLmGFPHis fractions shown in Figure 4.10-A 
and -B, respectively. There was a main peak of possibly mostly Cdr1-XLmGFPHis monomer 
containing detergent micelles and a small shoulder of possibly Cdr1-XLmGFPHis dimers or, 
alternatively, they too were mostly Cdr1-XLmGFPHis monomers that were contained 
within detergent micelles that had significant amounts of membrane lipid contaminations. 
Elution volume (ml) Elution volume (ml) 
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A slight deviation from the previous detergent screen, performed in NZ, was the fact that 
Tridecyl- and Tetradecyl-Maltoside (Figure 4.11-B) gave a larger Cdr1-XLmGFPHis 
monomeric peak with an even smaller shoulder, the same improved solubilisation and peak 
distribution trend that was observed for detergents with larger hydrophobic tails (compare 
the chromatograms of TDM with Tridecyl-Maltoside or DDM with shorter side-chain 
detergents UDM, DM and NM; Figure 4.11-A and -B). Similar trends were also observed for 
the CYMAL or Anzergent detergents (Figure 4.11-D). Unlike LMNG, the shorter Neopentyl-
glycosides OGNG and DMNG were also unsuitable for the solubilisation of Cdr1-XLmGFPHis 
(Figure 4.11-C). Unlike the detergent screen performed in NZ where digitonin scored only 
2, digitonin seemed to perform quite well for the solubilisation and purification of Cdr1-
XLmGFPHis in the FSEC experiments (Figure 4.11-E), and like in Figure 4.8, Fos-choline-13 
caused a smooth but broader Cdr1-XLmGFPHis peak at ~14 ml that indicated larger 
particles than the possibly mostly Cdr1 monomer containing peak usually observed at 15.5 
ml (Figure 4.11-F). 
 145 
 
Elution volume (ml) 
Elution volume (ml) 
Elution volume (ml) 
 146 
 
Elution volume (ml) 
Elution volume (ml) 
Elution volume (ml) 
 147 
Figure 4.11. Detergent screening with FSEC. A) Compilation of all the FSEC chromatograms 
of 100 μl crude plasma membrane proteins from AD∆∆-CaCDR1A-XLmGFPHis (2 mg/ml) 
solubilised with 1% of the detergents indicated in panels B-E and separated with a 
Superpose 6-increase column. The chromatograms depict the mGFP fluorescence (475 nm 
excitation and 520 nm emission wave lengths) as relative fluorescence units (FU) of one CV 
(25 ml) of collected elution buffer. The peak at 9 ml elution volume represents mostly 
aggregated protein that elutes in the void volume. The two main Gaussian-shaped peaks 
at about 13 ml and 15.5 ml elution volume are present in most detergent solubilised 
samples. B) FSEC chromatograms of maltosides and LMNG show most of Cdr1-XLmGFPHis 
eluting as a nicely shaped Gaussian peak at 15.5 ml with a small shoulder eluting slightly 
earlier at 14 ml. These samples have no Cdr1-XLmGFPHis eluting in the void volume. The 
blank sample (control) is the buffer plus DDM control that gave no mGFP signal. C) These 
FSEC chromatograms highlight the importance of the type of sugar headgroup for the 
quality of the detergent solubilised Cdr1-XLmGFPHis. Glucose containing detergents (OG, 
NG, OGNG) performed worse than sucrose containing detergents (DDS) which in turn 
performed worse than maltose containing detergents (NM, DMNG, DDM). Cdr1-
XLmGFPHis solubilised with glucose containing detergents eluted as an aggregated (OG) or 
broad aggregated peak (NG, OGNG). Although the DMNG chromatogram was qualitatively 
similar to the DDM chromatogram, the higher peaks for DDM indicate that a large portion 
of DMNG solubilised Cdr1-XLmGFPHis may actually be denatured. D) FSEC chromatograms 
for cyclohexyl-maltosides (Cymal1, Cymal4, Cymal7) and the zwitterionic detergents 
Anzergent 3-8, Anzergent 3-12, Anzergent 3-18 and LDAO. Only Cymal7, with the longest 
hydrophobic tail, showed an elution profile similar to DDM, whereas all the others gave 
mostly broad aggregate peaks (Cymal4, Anzergent 3-12, Anzergent 3-18, LDAO) or had no 
mGFP signal at all (Cymal1, Anzergent 3-8). E) and F) show the FSEC chromatograms for the 
zwitterionic Fos-cholines (Fos-choline-8, Fos-choline-12, Fos-choline-13) and two non-ionic 
detergents (digitonin, Triton-X100). In F) twice as much (200 μl) crude plasma membrane 
protein was solubilised with the indicated Fos-cholines and DDM. Only digitonin gave a 
similar chromatogram to DDM and although Fos-choline-13 gave a symmetrical sharp 
shaped peak, it again eluted with a significantly lower elution volume (14 ml) than that for 
DDM (15.5 ml). 
 
4.3.2.4 Cdr1-XLmGFPHis ATPase Activity After Solubilisation and Purification 
It is critical for structural studies to demonstrate that the purified membrane 
protein has kept its native activity. Thus, the ATPase activities of Cdr1 after solubilisation 
with various detergents were measured. However, the ATPase activities of the isolated 
crude plasma membranes varied significantly depending on which purification protocol 
was used (mini-, midi- or large-preparation), and the OS Cdr1 ATPase activities recovered 
after detergent solubilisation were not very reproducible (Figure 4.12). As indicated above, 
the mini plasma membrane preparation protocol gave highest OS Cdr1 ATPase activities, 
whereas the OS Cdr1 ATPase activities of the midi- and large-scale protocols were much 
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lower. Despite these difficulties, it was clear that using either 10x CMC of DDM or 2% or 
even 3% of DDM (230x or 345x CMC) for the solubilisation of crude plasma membrane 
proteins recovered almost 40% of the expected OS ATPase activity of Cdr1 (Figure 4.12). 
Using 10x CMC of DM also recovered about 30% of the OS Cdr1 ATPase activity. Although 
solubilisation of crude plasma membranes with 400x CMC LMNG, 34x CMC UM, 4x CMC 
Hega and 1.7x CMC OG recovered only about 20% of the OS Cdr1 ATPase activities, more 
experiments are needed to confirm those results and to see whether the optimum 
detergent concentrations had been used. After IMAC purification of Cdr1-XLmGFPHis from 
crude plasma membrane preparations solubilised with 115x CMC of DDM and eluted with 
4x CMC of DDM, hardly any OS Cdr1 ATPase activity was detectable above background 
(Figure 4.12). The OS ATPase activity of crude plasma membranes of the AD∆∆ strain 
solubilised with 10x CMC DDM or 10x CMC DM were close to zero (2 and -2 nmol/min/mg), 
or in other words less than 3% of the OS Cdr1 ATPase activity of crude AD∆∆-Cdr1-
XLmGFPHis plasma membranes. Most detergent solubilised crude plasma membrane 
protein samples had significantly higher OS ATPase activities than the AD∆∆ background 
ATPase activity, strongly suggesting that the OS ATPase activities measured after DDM and 
DM solubilisation of crude plasma membranes were real Cdr1 ATPase activities. However, 
practically all OS Cdr1 ATPase activity was lost after IMAC purification (Figure 4.12) and no 
OS ATPase activity could be detected for any SEC-purified Cdr1 samples (data not shown). 
  
Figure 4.12. ATPase activity of detergent solubilised Cdr1-XLmGFPHis. Graph of the 
relative OS ATPase activities of 2 mg crude AD∆∆-CDR1-XLmGFPHis plasma membrane 











to detergent ratio = 2), 200x CMC PCC (protein to detergent ratio = 2), 11x CMC DM, 34x 
CMC UM, 4x CMC Hega, 1.7x CMC OG, 10x CMC Fos-choline 13, and IMAC purified Cdr1-
XLmGFPHis (in 4x CMC DDM), respectively. Data are means ± SD. 
 
4.3.3 The Oligomeric State of Purified Cdr1-XLmGFPHis 
SEC can only provide rough estimates for the molecular weight and the possible 
oligomeric state of detergent solubilised and purified Cdr1 samples. This is why multi-angle 
light scattering analysis was used to determine, accurately, the size distribution of DDM 
solubilised and affinity purified Cdr1-XLmGFPHis detergent/micelle particles as they were 
eluted off a size-exclusion column. Then, 0.1 ml of a SEC-fraction containing Cdr1-
XLmGFPHis was taken and subjected to SEC (2x CMC of DDM in SEC buffer) with a MALS 
detector to determine the size, peak shape and heterogeneity of the eluted sample. The 
experiment was repeated three times with very similar results; once at the University of 
Auckland (Figure 4.13-A), once at the University of Otago (not shown), and once at the 
Wyatt Technology Corporation in Germany (Figure 4.13-B). Cdr1-XLmGFPHis eluted as a 
sharp uniform peak indicating that Cdr1 was almost mono-disperse and clearly a stable 
monomer.  
All three experiments of three different Cdr1-XLmGFPHis samples showed a main 
peak of DDM-solubilised Cdr1 with a calculated MW for the detergent/protein complex of 
almost 300 kDa with a single Cdr1-XLmGFPHis molecule of 200-210 kDa surrounded by a 







Figure 4.13. SEC-MALS analysis of Cdr1-XLmGFPHis. Plot of molar mass vs. elution volume. 
A) Results from the University of Auckland; and B) results from the MPIMP in Germany; UV 
signal is plotted as an overlay. The monomer peak revealed a protein MW of 201.0 ± 10 
kDa and a detergent MW of 104.4 ± 20 kDa. 
 
4.3.4 Large-Scale Expression and Ni-affinity Purification of Cdr1 
DDM and LMNG were identified as the best detergents for extracting Cdr1 from the 
plasma membrane. However, there was always a shoulder to the left of the main Cdr1-
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XLmGFPHis monomer peak that could not be eliminated even after many optimisation 
attempts, as described below. 
4.3.4.1 Batch Method 
The initial Cdr1 DDM solubilisation and purification attempts were performed with 
a slurry of Ni-NTA-agarose beads (Qiagen) following the manufacturer’s instructions and 
using a six-histidine (His) tag attached to the C-terminus of Cdr1-His. However, this resulted 
in low binding efficiencies (~50%; Figure 4.14 compare lanes 1 and 2), a significant loss of 
Cdr1-His in the three washing steps (lanes 3-5; Figure 4.14), and a gradual rather than sharp 
elution of bound Cdr1-His off the column (lanes 6-9; Figure 4.14). It was hypothesised that 
Cdr1-His could not bind properly to the affinity resin because the His tag was partially 
hidden from the Nickel affinity resin by protein folding. Thus, the improved AD∆∆-
CaCDR1A-XLmGFPHis strain, kindly provided by Dr. E. Lamping (unpublished results), was 
used to test this hypothesis. Cdr1-XLmGFPHis had an eight amino acid HRV 3C protease 
cleavage site (X), a five amino acid linker (L), and a monomeric mGFP tag separating the His 
tag from the Cdr1 molecule. Using the new Cdr1-XLmGFPHis double tagged construct for 
IMAC purification of Cdr1 resulted in a much improved affinity purification (lanes 10-24; 
Figure 4.14) confirming our hypothesis that the C-terminal His tag of Cdr1-His was not in a 
position to bind to the nickel affinity resin; much more Cdr1 (compare lane 11 with lane 
10) was more tightly bound (little Cdr1 was lost washing the affinity resin; lanes 12 and 13) 
as shown in Figure 4.14. 
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Figure 4.14. Improving affinity purification of Cdr1 by adding a linker between the protein 
and the His-tag. Coomassie blue stained SDS-PAGE gel (7% polyacrylamide) of 1% DDM-
solubilised plasma membrane protein and 10 µl aliquots of the indicated IMAC elution 
fractions. Lane 1 is a 10 µl aliquot of 35 ml AD∆-Cdr1-His crude plasma membrane protein 
(171 mg) solubilised with 1% DDM; lane 2 to 4 are 10 µl aliquots of three separate 7.5 ml 
washing steps using 25 mM imidazole in IMAC buffer containing 4x CMC of DDM; and lanes 
5 to 9 are 10 µl aliquots of five 0.8 ml elution fractions using 200 mM imidazole in the same 
elution buffer. Lanes 10 to 24 show the IMAC purification results of AD∆∆-Cdr1-XLmGFPHis. 
Lane 10 is an 11 µl aliquot of 30 ml of AD∆∆-Cdr1-LXmGFPHis crude plasma membrane 
protein (150 mg) solubilised with 1% DDM; lane 11 is an 11 µl aliquot of unbound protein 
of 30 ml flow through; lanes 12 and 13 are 11 µl aliquots of two separate 7.5 ml washing 
steps using the 25 mM imidazole washing buffer; and lanes 14 to 24 are 11 µl aliquots of 
eleven 0.5 ml elution fractions using 200 mM imidazole in the elution buffer. For Cdr1-
XLmGFPHis the GFP fluorescence signals of the same gels are also shown. M = Pre-stained 
Protein Ladder – Broad MW (10-245 kDa) (ab116028); MWs are to the right of the figure. 
Notice the slightly increased size of the Cdr1-XLmGFPHis construct. 
 
The SDS-PAGE gels in Figure 4.14 also highlighted another interesting observation. 
Membrane proteins, after removal from the lipid environment, tend to aggregate due to 
strong, non-specific, hydrophobic interactions between their hydrophobic parts that 
become exposed upon denaturation with SDS or exposure to higher temperatures. These 
higher MW aggregates are the proteins that get stuck in the wells or stacking gel or run as 
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smears in the higher MW range. Detergents or high salt concentrations can also interfere 
with the proper resolution of protein bands by SDS-PAGE; cationic and zwitterionic 
detergents can precipitate in the presence of SDS, or they can modify the negative charge 
of proteins supplied by binding of SDS to the peptides (Gallagher, 2012; Orwick-Rydmark 
et al., 2016).  
4.3.4.2 His-Trap Column Purification 
To further improve the affinity purification of Cdr1, Cdr1 was routinely purified 
using pre-packed IMAC columns (HisTrap, Table 2.5) that were low cost, simple to use, 
amenable to automation with the ÄKTA system and enabled reproducible purification 
results. Two representative chromatograms for the automated use of HisTrap columns, one 
with a 1 ml and another with a 5 ml CV, are shown in Figure 4.15. 
4.3.5 SEC of IMAC Purified Cdr1-XLmGFPHis 
HiLoad 16/600 Superdex 200 pg (Table 2.5) and/or Superose 6 increase size-
exclusion (Table 2.5) columns were used for SEC of the nickel-affinity purified Cdr1-
XLmGFPHis samples as well as for analysing the purity and homogeneity of the purest Cdr1-
XLmGFPHis fractions collected from the size-exclusion columns. Before sample loading the 
size-exclusion columns were equilibrated with 2 CV of the SEC buffer. Up to one or five ml 
of the best peak fractions of IMAC purified Cdr1-XLmGFPHis protein samples were then 
loaded onto the Superose 6 increase or HiLoad 16/600 Superdex 200 column, respectively, 
and SEC was performed at 8 ˚C with the FPLC system using one CV of SEC buffer to size-
fractionate the sample; mGFP fluorescence was recorded at 500 nm and the absorbance at 
280 nm and 250 nm were also recorded. Usually, small amounts of Cdr1-XLmGFPHis 
aggregates would elute first in the void volume followed by a broad peak of higher order 
oligomers or partially denatured protein and then the monomeric Cdr1-XLmGFPHis micelle 
complex peak. Ten to 20% glycerol is commonly used as a chemical chaperone for 
detergent solubilised membrane proteins; however, the use of glycerol can be problematic 
for cryo-EM. Surprisingly, removal of glycerol from the SEC buffer had, if anything, a 
positive effect on the size-exclusion chromatogram of Cdr1-XLmGFPHis, independent of 
the type of size-exclusion column used (Figure 4.16).  
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Next, adding salt to the solubilisation and/or SEC buffer was tested to see if it would 
help improve the quality of the detergent solubilised Cdr1-XLmGFPHis/micelle mixtures by 
reducing the amount of higher order Cdr1-XLmGFPHis oligomer containing micelles in 
favour of stable, properly folded, Cdr1-XLmGFPHis micelle monomers. However, adding 
100 mM, 150 mM or 400 mM NaCl to the SEC buffer had no noticeable effect on the 
resulting SEC chromatograms (data not shown). Using IMAC buffer (20 mM Tris, 100 mM 
NaCl, 10% glycerol; pH 7.5) instead of GTED-20 buffer (10 mM Tris, 0.5 mM EDTA, 20% 
glycerol; pH 7.5) for the solubilisation of 5 mg/ml Cdr1-XLmGFPHis crude membrane with 
1% DDM resulted in a slightly larger aggregation peak compared to the monomeric peak 
when the sample was run on the HiLoad 16/600 Superdex 200 column with SEC buffer 
without glycerol (compare fuchsia chromatogram in Figure 4.16-C with the blue 
chromatogram in Figure 4.16-B). Again, running the IMAC purified samples into the column 
using the SEC buffer with no glycerol (Figure 4.16-C; fuchsia) gave more of the monomeric 
Cdr1 peak compared to the sample separated by SEC column using the buffer including 5% 
glycerol (Figure 4.16-C; purple). Based on this result, it was hypothesised that either the 
100 mM NaCl in the IMAC buffer caused more aggregation or the small amount of EDTA in 
the GTED-20 buffer prevented Cdr1 precipitation. So next, adding 100 mM NaCl to the 
GTED-20 buffer was tested for the solubilisation of 5 mg/ml Cdr1-XLmGFPHis crude 
membranes with 1% DDM and then IMAC purifying and size-separating Cdr1-
XLmGFPHis/DDM micelle particles with SEC buffer that was not supplemented with 
glycerol. It was found that this protocol caused significant aggregation of Cdr1-XLmGFPHis 
micelle particles compared with the sample that had no salt added to GTED-20 (Figure 4.16-
D). Based on these results, it was decided to use GTED-20 buffer for 1% DDM solubilisation 
of 5 mg/ml crude plasma membranes, and then purifying the solubilised sample first with 
IMAC (with IMAC buffer supplemented with 4x CMC detergent). Then the peak fraction of 
Cdr1 molecules eluted from the HisTrap column were injected onto the SEC column that 
had been equilibrated with the SEC buffer containing no glycerol and supplemented with 




Figure 4.15. Chromatography of Cdr1-XLmGFPHis using His-trap IMAC columns connected 
to the ÄKTA system. A) A typical chromatogram obtained for the purification of Cdr1-
XLmGFPHis using a 1 ml His-trap column that was loaded with 6 ml DDM-solubilised (1% 
DDM) AD∆∆-CDR1-XLmGFPHis (30 mg) crude plasma membrane proteins, washed with 20 
CV of 25 mM imidazole in IMAC buffer, and eluted with 200 mM imidazole elution buffer 
containing 4x CMC of DDM. Cdr1-XLmGFPHis eluted as a narrow symmetrical sharp peak. 
B) This chromatogram was obtained after binding 120 ml of 1% DDM-solubilised crude 
plasma membrane protein (600 mg) onto a 5 ml His-trap column, washing with 15 CV of 25 
mM imidazole buffer, and eluting Cdr1-XLmGFPHis with 200 mM imidazole. As for the 1 ml 
column, Cdr1-XLmGFPHis eluted as a uniform sharp peak. The dashed maroon lines mark 
the ends of sample application and the washing period which was immediately followed by 
the elution of Cdr1-XLmGFPHis. The protein absorption measured at A280nm is shown in blue 
and the mGFP fluorescence of Cdr1-XLmGFPHis, measured at 500 nm, is shown in green. 
Elution volume (ml) 





Figure 4.16. Effect of glycerol and high NaCl concentrations in the SEC buffer on SEC of 
detergent solubilised IMAC purified Cdr1-XLmGFPHis samples. A) An overlay of three 
separate SEC chromatograms of 1% DDM-solubilised AD∆∆-Cdr1-XLmGFPHis crude plasma 
membrane proteins (5 mg/ml, volume of 30 ml) size-separated with a Superose 6 increase 
column that was equilibrated and eluted with 1 CV of SEC buffer with either 10% (cyan), 
3% (lime) or 0% (lavender) glycerol. Eluting Cdr1-XLmGFPHis samples with no or 3% glycerol 
gave slightly improved chromatograms than SEC buffer containing 10% glycerol (the signal 
heights varied because different amounts of Cdr1-XLmGFPHis were loaded). B) Similar 
results were obtained for 1% DDM-solubilised AD∆∆-Cdr1-XLmGFPHis crude plasma 
membrane proteins (5 mg/ml, volume 45 ml) that were IMAC purified and size-separated 
with a HiLoad 16/600 Superdex 200 pg column. Although the SEC chromatograms had more 
of the higher order Cdr1-XLmGFPHis oligomer peaks than those obtained with the Superose 
6 increase column in A, supplementing the SEC buffer with 10% glycerol (red) resulted in 
more of the higher order oligomer and less of the monomer peaks compared with the 
chromatogram for 0% glycerol (blue) in the SEC buffer. Again, the signal heights varied 
because different amounts of Cdr1-XLmGFPHis were loaded. C) Replacing GTED-20 buffer 
with the IMAC buffer (contains 100 mM NaCl) for 1% DDM solubilised AD∆∆-Cdr1-
XLmGFPHis crude plasma membranes (5 mg/ml), and then IMAC and SEC purifying the 
solubilised sample, gave the purple chromatogram when the SEC buffer contained 5% 
glycerol and the fuchsia chromatogram when Cdr1-XLmGFPHis was eluted with SEC buffer 
with no glycerol. D) Adding 100 mM NaCl to the GTED-20 solubilisation buffer caused more 
volume (ml) Elution volume (ml) 
Elution volume (ml) Elution volume (ml) 
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aggregation of IMAC purified Cdr1-XLmGFPHis samples that were size-separated without 
glycerol in the SEC buffer. Solubilising 5 mg/ml AD∆∆-Cdr1-XLmGFPHis crude plasma 
membrane protein with 1% DDM in GTED-20 buffer plus 100 mM NaCl (total volume of 74 
ml) caused more Cdr1-XLmGFPHis aggregation (orange) than solubilising the protein with 
regular GTED-20 buffer without NaCl (jade). 
 
 
Figure 4.17. Example of typical IMAC and SEC of DDM solubilised Cdr1-XLmGFPHis 
detergent micelle particles after protocol optimisation. A) Coomassie blue stained 
polyacrylamide gel (7%) of: lane 1, 10 µg DDM-solubilised (1% DDM) AD∆∆-CDR1-
XLmGFPHis crude plasma membrane protein (5 mg/ml); lane 2 is the same volume as lane 
1 (6 µl) of 30 ml flow through of unbound protein; lane 3 is a 3 µl aliquot of 15 ml washing 
solution (IMAC buffer + 25 mM imidazole + 4x CMC DDM); lanes 4 to 8 are 3 µl aliquots of 
1.2 ml elution fractions (IMAC buffer + 200 mM imidazole+ 4x CMC DDM). Fractions relating 
to lanes 5 to 7 were combined and subjected to SEC (SEC buffer with no glycerol, containing 
2x CMC DDM). B) The corresponding SEC chromatogram is shown to the right. The 
experiment was carried out with a Superose 6 increase column attached to the ÄKTA 
system. Lanes 9 to 13 are 6 µl aliquots of 1 ml elution fractions collected at 10 ml, 13 ml, 
15 ml, 16 ml and 18 ml elution volumes, respectively, analysed by SDS-PAGE. M = Pre-
stained Protein Ladder – Broad molecular weight (10-245 kDa; ab116028). 
 
After many further trials (not all data are shown) the optimised purification protocol 
using the Superose 6 increase column for SEC gave Cdr1-XLmGFPHis/DDM micelles with 
the majority (~80%) of DDM micelles containing Cdr1-XLmGFPHis monomers but, despite 
A 
B 
Elution volume (ml) 
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all efforts, there was also a small amount of mostly dimer and some higher order oligomers 
(Figure 4.18). In an attempt to upscale the purification yield, but also to possibly improve 
the separation of overlapping peaks, switching to using the larger HiLoad 16/600 Superdex 
200 pg column for Cdr1-XLmGFPHis/detergent micelle purification was tried. However, the 
switch caused major problems and in initial experiments the majority of Cdr1 aggregated. 
Only about a third of DDM-solubilised Cdr1-XLmGFPHis/detergent micelles eluted as Cdr1 
monomers with the peak monomer fraction eluting at ~55-56 ml elution volume (Figure 
4.19-A). However, the Cdr1-XLmGFPHis/DDM micelle monomers were stable (Figure 4.19-
B). 
 
Figure 4.18. Optimised SEC of DDM-solubilised Cdr1-XLmGFPHis/detergent micelle 
particles using a Superose 6 increase column. The optimised solubilisation and purification 
protocol gave an almost uniform sharp peak with a maximum at ~15.5 ml elution volume 
and a small shoulder to the left; very similar chromatograms were obtained when different 
amounts of protein were loaded. The probable Cdr1-XLmGFPHis monomer, dimer and 
aggregate peaks are indicated with arrows. Absorbance was recorded at 280 nm (protein; 
blue), 500 nm (mGFP; green) and 250 nm (red). 
 
One reason for the large Cdr1 aggregate peak was related to the IMAC purification 
step. Binding the DDM-solubilised crude plasma membrane protein preparations once, 
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and elution off the IMAC column, significantly improved the quality of the SEC purified 
protein samples, although some loss of final monomer product was observed (Figure 4.20). 
 
Figure 4.19. Optimised SEC of DDM-solubilised Cdr1-XLmGFPHis/detergent micelle 
particles using a HiLoad 16/600 Superdex 200 pg column. A) SEC chromatograms for DDM 
solubilised IMAC purified Cdr1-XLmGFPHis/DDM micelle samples (5 mg/ml); the IMAC 
column was loaded twice by repeat-loading the column with the unbound DDM solubilised 
fraction of the flow-through. B) Repeat SEC of the Cdr1-XLmGFPHis monomer peak 
fractions (54.5 – 56 ml) confirmed that the monomeric Cdr1-XLmGFPHis/DDM micelle 
particles were stable once they had been separated by SEC from higher order oligomers 
and Cdr1-XLmGFPHis/DDM micelle aggregates. Absorbance was recorded at 280 nm 
(protein; blue), 500 nm (mGFP; green) and 250 nm (red), respectively.  
 
 
Figure 4.20. Multiple loading of IMAC column. SEC chromatograms of DDM solubilised 
Cdr1-XLmGPFHis/detergent micelle particles differed somewhat if the IMAC flow through 
was reapplied a second time onto the IMAC column to increase the yield of protein. 
Absorbance was recorded at 280 nm (protein; blue) and 500 nm (mGFP; green). Continuous 
lines are for samples applied once and dashed lines are for samples that were applied twice 
to the IMAC column. A) IMAC elution profiles of Cdr1-XLmGPFHis/DDM micelle particles 
eluted from the 5 ml His-trap column after applying IMAC elution buffer containing 200 
mM imidazole and 4x CMC DDM. The dashed lines indicated that ~40% of DDM solubilised 
(1% DDM) Cdr1-XLmGFPHis/detergent micelle particles did not bind to the IMAC column 
Monomer 
Void volume 
Elution volume (ml) Elution volume (ml) 
Elution volume (ml) Elution volume (ml) 
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at the first binding step. The slightly shifted elution profiles are an artefact due to a slight 
difference in the volumes of washing steps used in those two experiments. B) The 
corresponding SEC chromatograms (HiLoad 16/600 Superdex 200 pg column) indicated 
that the DDM solubilised Cdr1-XLmGFPHis fraction that bound immediately to the IMAC 
column (~60%; continuous line) comprised mostly (~60-70%) Cdr1-XLmGFPHis/DDM 
micelle monomer whereas the flow through sample (~40%; dashed line) that only bound 
to the IMAC column when applied for a second time contained less (~50%) Cdr1-
XLmGFPHis/DDM micelle monomer. 
 
After further optimisation attempts (data not shown), the best possible DDM-
solubilised and IMAC purified preparations after SEC with the HiLoad 16/600 Superdex 200 
pg column still showed significant aggregation of Cdr1. However, the proportion of 
aggregation was significantly reduced and routinely ~50-60% of the protein was recovered 
in the monomeric peak (Figure 4.21). The SEC buffer used was identical to that used for the 
Superose 6 increase column (no glycerol and supplemented with 2x CMC DDM) and the 
solubilisation was performed the same with 5 mg/ml crude membrane preparation 
solubilised with 1% DDM (detergent to protein ratio of 2 (w/w)). One factor that caused 
the significantly improved SEC separations shown in Figure 4.21 as opposed to the results 
obtained in initial trials shown in Figure 4.19-A was the realisation that the binding capacity 
of the 5 ml HisTrap column may have been compromised. So, the column was stripped and 
recharged with Ni2+ ions according to the manufacturer’s instructions. This resulted in 
significantly improved SEC chromatograms with less of an aggregation peak, however, the 
results were still not as good as what had been obtained by using the smaller Superose 6 
increase column (e.g. comparing Figure 4.21-A and -B). It is noteworthy that in all the IMAC 
and SEC purification experiments, where the absorbance at 250 nm and 500 nm in addition 
to A280 were measured, the monomeric peak had a higher ratio of A500 to A250, compared 
to the shoulder peak or any other peak of oligomeric Cdr1. For instance, this difference is 
evident in Figure 4.21-A, and -B. The profile of the GFP absorbance was almost the same 
for both samples, yet, the absorbance at 280 nm and 250 nm were different. Both of those 
samples after eluting the purified IMAC fractions had A280/A250 values ≥ 2 (2 and 2.2, 
respectively, for Figure 4.21-A, and -B). The importance of this ratio will be discussed in 
Section 4.3.6. It is noteworthy that the ratio of the mGFP fluorescence (green trace) relative 
to the absorbance at 250 nm (red trace) for the Cdr1 monomer was higher than the ratio 
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for Cdr1 oligomers and much higher than the ratio for Cdr1 aggregates, in both graphs of 
Figure 4.21 and a very interesting similarity between both GFP graphs was seen. Binding 
the solubilised sample twice to the IMAC column or binding the flow through for the second 
time were stopped, based on the results shown in Figure 4.20.  
 
Figure 4.21. Optimised SEC of DDM-solubilised Cdr1-XLmGFPHis/detergent micelle 
particles using a HiLoad 16/600 Superdex 200 pg column. A) SEC (HiLoad 16/600 Superdex 
200 pg column) of 1.5 ml of the IMAC purified peak fractions of Cdr1-XLmGFPHis/DDM 
micelles, bound only once, and eluted off the SEC column with SEC buffer containing 2x 
CMC DDM gave an improved Cdr1-XLmGFPHis/DDM micelle chromatogram with ~50% of 
protein eluting as a monomeric peak (56 ml) and two lesser peaks of partially denatured 
higher order oligomers (50 ml) and partially denatured Cdr1-XLmGFPHis aggregate (~47 ml; 
the green mGFP absorbance line was much reduced relative to the two protein absorbance 
lines). B) A similar, repeat, experiment of (A) gave the best Cdr1-XLmGFPHis/DDM micelle 
chromatogram with ~60% eluting as a monomer (56 ml) and two lesser peaks of partially 
denatured higher order oligomers (50 ml) or partially denatured Cdr1-XLmGFPHis (~47 ml). 
Absorbance was recorded at 280 nm (protein; blue), 500 nm (mGFP; green) and 250 nm 
(red), respectively. 
 
4.3.6 The A280/A250 Ratio is a Useful Measure to Assess the Quality of Membrane 
Protein-Detergent Solutions 
I routinely measured the absorption spectra (∼230-530 nm - Figure 4.22) of 
relevant IMAC and SEC fractions to gain additional information about the quality of the 
purified Cdr1 samples. The absorption spectrum of neutral or acidic protein solutions 
should have a deep trough at 250 nm, an absorption maximum at 280 nm, and absorb little 
light above 310 nm, but Cdr1-XLmGFPHis solutions should also have a light absorption 
maximum at ~500 nm (because of the mGFP - Figure 4.22). UV absorbance ratios between 
Elution volume (ml) Elution volume (ml) 
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these absorption maxima (280 nm) and minima (250 nm) can be used to determine the 
purity or aggregation state of proteins (Lovrien et al., 2005). The peak/trough ratio 
(A280/A250) for proteins in neutral pH should be ≥2 (Lovrien et al., 2005). Thus, lower 
absorption ratios due to increased absorption at 250 nm is a strong indicator of the 
presence of aggregated protein that could possibly interfere with the A280 measurements 
and result in the inaccurate calculation of protein concentrations.  
In this project, the A280/A250 ratios, generally, correlated well with the quality (i.e. 
homogeneity) of the detergent solubilised Cdr1-XLmGFPHis/DDM micelle samples 
assessed by other means; the A280/A250 ratios were generally lower (from 1.3 to 2.2) for 
IMAC fractions (Figure 4.22) than for SEC fractions of the stable Cdr1-XLmGFPHis monomer 
(from 1.8 to 2.6). Also, as expected, the A280/A250 ratios of Cdr1-XLmGFPHis/DDM micelle 
monomer fractions were higher than those of the oligomeric peak (mostly < 1.8). Similarly, 
the ratio for IMAC fractions of Cdr1-XLmGFPHis/DDM micelle particles that had bound to 
the column just once was higher than for IMAC fractions from Cdr1-XLmGFPHis/DDM 
micelle particles that were reloaded onto the IMAC column with the flow-through fractions 
(e.g. 1.9 and 1.6, respectively). Also, the A280/A250 ratio decreased after concentrating the 
sample (e.g. from 2 to 1.8). Using this simple method enabled me to predict the quality of 
SEC chromatograms based on this ratio; an A280/A250 ratio <2 for IMAC purified Cdr1 
samples always resulted in more of the oligomeric peak(s) and less of the monomer. Thus, 
measuring the A280/A250 ratio is a good indicator for the quality of detergent solubilised 
membrane protein. 
 
Figure 4.22. Absorption spectra of Cdr1-XLmGFPHis/DDM IMAC purified fractions. The 
Cdr1-XLmGFPHis/DDM spectrum has a deep trough at 250 nm, an absorption maximum at 
280 nm, and a light absorption maximum at ~500 nm for mGFP. The A280/A250 ratio is a good 
indicator of sample quality. Three examples of the IMAC fractions of different experiments 
with different qualities are shown; lower ratios correlated with less monomeric peak and 
more aggregation or higher molecular weight peaks. 
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4.3.7 Amphipol Exchange 
To keep membrane proteins stably in solution and prevent aggregation, the 
detergent concentration of purification buffers should always be kept above the CMC (e.g. 
2x CMC), yet, not too high to avoid unnecessary empty detergent micelles. However, 
detergents can negatively affect the generation of homogeneous vitreous ice that is 
required for grid preparation in cryo-EM, and high concentrations of detergents can also 
reduce the contrast in electron micrographs. One way of overcoming these problems is to 
replace the detergent of Cdr1-XLmGFPHis/DDM micelle particles with amphipols. After 
amphipol exchange and removal of excess detergent, membrane proteins can be handled 
in detergent-free solution similar to soluble proteins (Tribet et al., 1996; Popot, 2010). 
Amphipol-exchange was performed on DDM- or LMNG-solubilised and IMAC-purified Cdr1-
XLmGFPHis samples (Figure 4.23-D, and -F) or on the monomeric SEC peak of DDM-
solubilised and IMAC purified Cdr1-XLmGFPHis (Figure 4.23-A, and B). SEC of the amphipol-
Cdr1-XLmGFPHis particles was performed in detergent-free SEC buffer with no glycerol. 
The amphipol-exchanged Cdr1-XLmGFPHis particles from DDM- and LMNG-solubilised and 
IMAC purified samples eluted as non-symmetric peaks that had shifted to higher apparent 
MW (i.e. ~14 ml elution volume; Figure 4.23-D and -F) compared to the samples without 
amphipol exchange (15.5 ml elution volume; Figure 4.23-C, and -E). The shift to lower 
elution volumes upon exchange with amphipol has been reported previously (Zoonens et 
al., 2007) and is not well understood. Interestingly, the elution peaks after amphipol 
exchange were also slightly broader with a small left shoulder possibly indicating some level 
of aggregation or protein amphipol heterogeneity. 
 164 
 
Figure 4.23. Amphipol exchange of DDM with Amphipol A8-A35 for stable Cdr1-
XLmGFPHis monomer/DDM micelles. A) Size-exclusion chromatogram (Superose 6 
increase column) of DDM-solubilised and IMAC purified Cdr1-XLmGFPHis. B) SEC (Superdex 
200 10/300 GL column (performed at the University of Auckland)) of amphipol A8-A35-
exchanged Cdr1-XLmGFPHis monomer fractions from A (15.1-15.8 ml elution volume) and 
removal of excess detergent. C) and D) show the SEC chromatograms (Superose 6 increase 
column) of half each of DDM-solubilised (1% DDM) and IMAC purified Cdr1-XLmGFPHis 
samples before C), and after D), amphipol A8-A35-exchange and detergent removal. E) and 
F) show the SEC chromatograms (Superose 6 increase column) of half each of LMNG-
solubilised (1% LMNG) and IMAC purified Cdr1-XLmGFPHis samples before E) and F) after 
amphipol A8-A35-exchange and detergent removal. 
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4.3.8 Non-Hydrolysing Mutant Purification 
I used FSEC to test whether some of the catalytic Cdr1-XLmGFPHis mutants (see 
Chapter 3, Section 3.3.10) behaved differently from wild type Cdr1 when extracted with 
detergents. Mini-scale crude plasma membrane preparations of AD∆∆-CaCDR1A-D327N-
XLmGFPHis, AD∆∆-CaCDR1A-E1027Q-XLmGFPHis and AD∆∆-CaCDR1A-D327N-E1027Q-
XLmGFPHis were used for these tests. FSEC of DDM-solubilised (1% DDM) CaCDR1A-
D327N-XLmGFPHis containing crude plasma membrane protein (2 mg) gave a sharp single 
peak with hardly any noticeable shoulder (trace 1; Figure 4.24-A). Cdr1-XLmGFPHis-E1027Q 
and -D327N-E1027Q mutants showed some aggregation in the void volume and a non-
symmetric monomeric peak with a broader shoulder of higher order oligomers (trace 2 and 
3; Figure 4.24-A), indicating increased heterogeneity for these two mutants. FSEC 
chromatograms of LMNG-solubilised (1% LMNG) of the two Cdr1-XLmGFPHis-D327N and -
E1027Q mutants gave almost identical results of a single and almost symmetrical 
monomeric peak (trace 1 and 2; Figure 4.24-B). Thus, LMNG looks to be a much better 
choice than DDM for the solubilisation and purification of these mutants; a comparison 
between DDM and LMNG as suitable detergents for the solubilisation of the catalytically 








Figure 4.24. FSEC chromatograms (Superose 6 increase) of three ATPase-catalytic Cdr1-
Walker B-mutants. The chromatograms show the mGFP fluorescence signals, expressed as 
relative fluorescence units (FU), as a function of the elution volume. A) 100 μl DDM-
solubilised (1% DDM) AD∆∆-CaCDR1A-D327N-XLmGFPHis (1), AD∆∆-CaCDR1A-E1027Q-
XLmGFPHis (2) and AD∆∆-CaCDR1A-D327N-E1027Q-XLmGFPHis (3). B) 100 μl LMNG-
solubilised (1% LMNG) AD∆∆-CaCDR1A-D327N-XLmGFPHis (1), and AD∆∆-CaCDR1A-
E1027Q-XLmGFPHis (2). C) An overlay of the DDM- and LMNG-solubilised FSEC 
chromatograms of the ATPase-inactive AD∆∆-CaCDR1A-E1027Q-XLmGFPHis mutant. The 
LMNG solubilised Cdr1-E1027D-XLmGFPHis mutant gave a sharp uniform shaped 
chromatogram of, possibly, the Cdr1-E1027D monomer. 
4.4 Discussion 
Despite many recent technological advances, membrane proteins remain 
challenging targets for structural biologists, and obtaining enough pure, stable, correctly 
folded and mono-disperse membrane protein is still a major bottleneck for determining 
high resolution structures of many membrane proteins, such as Cdr1. The aim of this part 
of the thesis was to establish robust purification protocols that could yield milligram 
quantities of detergent solubilised, stable, mono-disperse Cdr1 in its native conformation 
that are suitable for crystallography and cryo-EM.  
The first difficulty with the optimisation of robust protocols for Cdr1 purification 
was upscaling the optimised mini-scale protocol, which was necessary for structural 
studies. The OS ATPase activity of crude plasma membrane preparations by the mini-scale 
method was far higher than that for the midi- and large-scale methods (3 times and 2 times 
higher, respectively). More optimisation of the large-scale membrane preparation protocol 
is recommended for the purification of stable and correctly folded Cdr1 molecules.  
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One of the early conclusions about solubilisation of Cdr1 from crude plasma 
membrane preparations was that the detergent to protein (weight to weight) ratio was a 
far better, more reliable, measure for the efficient solubilisation of Cdr1 than using the 
CMC as a guide. A detergent to protein ratio (w/w) of 2 (Figure 4.9-B) was selected as it 
gave reproducibly good results with >85% of Cdr1-XLmGFPHis being solubilised. So, for the 
solubilisation experiments in this project, 5 mg/ml Cdr1-XLmGFPHis crude membrane 
protein preparations were combined with GTED-20 buffer supplemented with 1% (w/v) 
detergent to achieve a detergent to protein ratio of 2. This was necessary to ensure that 
there was sufficient detergent to dissolve the membrane lipids as well.  
The ideal detergent extracts membrane proteins from their native lipid bilayer and 
keeps them stable in solution without affecting their native conformation. However, the 
immense complexity and highly organised micro-compartmentalisation of biological 
membranes means that testing many different detergents for their suitability to solubilise 
and/or purify membrane proteins of interest is critically important, even though it can, at 
times, be very time-consuming. To identify detergents or classes of detergents that could 
be used (or should be avoided) for extracting monomeric Cdr1 molecules, various 
detergent screens were performed; DDM, empirically often the first detergent chosen in 
labs working on membrane proteins, seemed to be a very good starting point for 
extraction, solubilisation and purification of Cdr1. An SDS-PAGE screen of detergents for 
Cdr1 solubilisation indicated that DDM, LMNG, and PCC-α-M solubilised more than 85% of 
Cdr1 from crude plasma membranes. DDM and LMNG also gave good results for the 
purification of monomeric Cdr1-XLmGFPHis/detergent micelle particles. However, using 
the much less time-consuming FSEC screen, at the MPI-MP in Dortmund, Germany, gave 
comparable results. Clearly, FSEC is a better choice for detergent screening, however, there 
is one drawback with this technique, it does require rather expensive equipment. 
Of the 31 detergents chosen for the detergent screen members of the glucoside, 
Cymal and anzergent families did not perform well for Cdr1 solubilisation and/or 
purification, instead they induced Cdr1 aggregation and destabilisation. Protein aggregates 
can be caused by partial protein unfolding of regions that take part in non-specific covalent 
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or noncovalent interactions. However, the lack of aggregation with other detergents does 
not necessarily indicate a properly folded protein.  
There was a very clear preference for the type of headgroup and side-chain evident 
in the detergent screening results. Maltosides were better than glucosides or sucrosides in 
solubilising Cdr1, and detergents with longer aliphatic side-chain detergents (C12 to C14) 
were best. Zwitterionic detergents such as Fos-choline, Anzergents, LDAO and CHAPS 
appeared to be ‘harsh’ detergents for Cdr1 solubilisation. However, OG, a non-ionic 
detergent was also not a good choice for Cdr1 solubilisation. This left the non-ionic 
detergents DDM, LMNG and TDM best suited for solubilising and purifying Cdr1, but even 
these detergents gave a broad or asymmetric main elution peak after SEC. This may 
indicate that a small proportion experienced partial aggregation of two or three separate 
protein/detergent micelle monomers, or perhaps reflects different oligomeric states of 
Cdr1 within a single detergent micelle, or possibly Cdr1 detergent/micelle monomers that 
were partially contaminated with endogenous lipids that bound quite strongly to Cdr1. 
The ATPase activity of crude plasma membranes solubilised in different detergents 
still had some enzyme activity (20-40%) after solubilisation by most of the detergents, 
especially DM and DDM. However, the ATPase activity dropped below 10% (near 
background levels) after IMAC purification when Cdr1 probably had all its natural lipids fully 
replaced with detergent.  
DDM was selected as the first-choice detergent to establish a full two step protocol 
to purify enough mono-disperse Cdr1 for further studies. SEC-MALS of DDM purified 
samples confirmed that the main SEC peak at an elution volume of 15.5 ml from a Superose 
6 increase column consisted of Cdr1-XLmGFPHis/DDM micelle particles each containing a 
single Cdr1 monomer. 
The optimisation process yielded findings that helped establish protocols for the 
purification of Cdr1 molecules. For instance, for the IMAC purification step, using a HisTrap 
column produced much better, more reliable results, than using a batch purification 
protocol. Based on the comparisons in this project, binding the solubilised plasma 
membrane solution just once to the IMAC column further improved the quality of purified 
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Cdr1/detergent micelle particles, even though almost 40% of Cdr1 was lost in the process. 
Replacing the C-terminal His-tag with the XLmGFPHis double tag was also a significant 
improvement for the IMAC purification step. The five amino acid-linker between Cdr1 and 
the mGFPHis double tag allowed Cdr1 to have better access to the nickel-affinity resin 
which resulted in much improved yields. The mGFP tag was also a very useful addition for 
monitoring the behaviour of purified Cdr1-XLmGFPHis/detergent micelle particles, and the 
protease cleavage site placed between the double-tag and the protein meant that those 
tags could be removed whenever necessary. Removal of the mGFPHis double tag, that is 
separated from Cdr1 with a flexible linker region, may quite possibly be essential for X-ray 
crystallography or cryo-EM studies.  
The optimised two-step purification protocol for the smaller Superose 6 Increase 
10/300 column gave a well-shaped Gaussian peak for Cdr1-XLmGFPHis/detergent micelle 
monomer with either DDM or LMNG, as the detergent of choice. However, there was still 
a small high-molecular weight shoulder to the left of the monomer peak. Adding more salt 
to the glycerol containing SEC buffer did not improve the purification of Cdr1. After further 
tests the optimised SEC buffer contained 100 mM NaCl, no glycerol, and 2x CMC of 
detergent. Again, upscaling this protocol by using the larger 5 ml HisTrap column for the 
IMAC purification step and the larger HiLoad 16/600 Superdex 200 pg column for SEC to 
generate more purified sample for the structural studies was problematic, but it did lead 
to a much-improved large-scale preparation of Cdr1-XLmGFPHis/detergent micelle 
particles. Although the SEC results clearly showed that glycerol adversely affected gel 
filtration purification of Cdr1, in terms of crystallisation, and further biophysical studies, 
the inclusion of glycerol may need to be considered and examined more carefully. It seems 
that having some lipids associated with the Cdr1 molecule surrounded by the detergent 
micelle is pivotal for keeping the molecule active and in the correct conformation, and 
maybe the loss of activity after purification is because of losing the lipids. “Lipids play a 
major role in preserving the native environment of membrane proteins” (Kotov et al., 2019). 
It has been shown for example that ABC transporter conformation, transport and ATPase 
activity are dramatically affected by lipids, and often reconstitution in liposomes or lipid 
bilayers is necessary to regain activity (Neumann et al., 2017). It has also been shown that 
eukaryotic membrane proteins are more sensitive to de-lipidation than their bacterial 
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homologues (Nji et al., 2018). So, adding lipids to extracted Cdr1 could be an option for 
future studies. Another helpful finding was that the ratio between A280 and A250 for a 
protein sample can clearly distinguish a mono-disperse protein (ratio > 2) from a mixed 
aggregate sample, even before performing gel filtration. 
It can be concluded that the construct structure, expression, solubilisation, and 
purification strategy should be selected, designed and carried out carefully for membrane 
proteins of interest. In order to have enough purified mono-disperse Cdr1, the individual 
parameters mentioned above need to be taken into account. In this chapter, a robust 
purification protocol was created for Cdr1-XLmGFPHis, that led to the purified, stable, more 
or less mono-disperse protein sample ready for X-ray crystallography and cryo-EM. 
Typically, this optimised Cdr1 purification protocol (double step purification by HisTrap and 
Superose 6 Increase 10/300 columns) provided 3 mg of mono-disperse Cdr1 protein of six 
litres of yeast culture (Table 4.3). 
 
Table 4.3. Summary of Cdr1 purification yields from a 6 L YPD culture.  
No. of cells 
(cells/ml) 
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5 X-ray Crystallography and Cryo-EM Studies of Cdr1 
5.1 Introduction 
X-ray crystallography and cryo-EM are techniques frequently used to solve 
structures of proteins or protein complexes at atomic or near-atomic resolution (Delmar et 
al., 2015; Vinothkumar, 2015). It is notable that less than 4% of all protein structures are 
for membrane proteins (PDB website, https://www.rcsb.org), emphasising the difficulty of 
determining structures of membrane proteins. The increase of the annual rate of solved, 
unique membrane protein structures deposited in public repositories (dark red bars; Figure 
5.1) is approximately linear with a total of 985 unique membrane protein structures (pink; 
Figure 5.1) published by the end of 2019 (MPStruc database, 
https://blanco.biomol.uci.edu/mpstruc/). 
 
Figure 5.1. Number of unique membrane protein structures since the first structure 
solved in 1985. The graph depicts the cumulative number (pink; 985) as well the annual 
rate (dark red) of unique membrane protein structures deposited over the past 35 years. 
Data extracted from the Stephen White Lab on 27th Dec, 2019; (White, Dec 2019). 
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5.1.1 Membrane Protein Structure Determination  
5.1.1.1 X-ray Crystallography  
One of the biggest challenges in X- ray crystallography of membrane proteins is to 
obtain well-ordered crystals that diffract to high resolution (Holcomb et al., 2017). 
Unfortunately, crystallisation of membrane proteins remains largely an empirical process 
(Birch et al., 2018). As discussed in previous chapters, the problem starts with the detergent 
extraction that can destabilise membrane proteins in various ways. One of which is the fact 
that detergent micelles that shield the hydrophobic transmembrane domains from their 
aqueous surroundings possess a certain degree of disorder that in many cases can hinder 
crystallisation. In the classical vapor diffusion crystallisation method, the purified 
membrane protein solution is mixed with the ‘precipitant’ (e.g. polyethylene glycol (PEG) 
or ammonium sulphate) in reservoir solution. This ‘hanging’ or ‘sitting’ drop of membrane 
protein/precipitant mixture is then slowly equilibrated with a large volume of reservoir 
solution containing pure precipitant (Figure 5.2). Over time, water molecules from the 
protein drop diffuse through the gas phase to the reservoir until an equilibrium is reached. 
This diffusion process leads to the steady increase in protein and precipitant concentration 
in the ‘hanging’ or ‘sitting’ drop; the protein drop is slowly transformed into a 
supersaturated state (Figure 5.3) that can lead to nucleation of protein crystals 
(McPherson, 2004; McPherson et al., 2014). Nucleation causes the removal of protein 
molecules from the liquid phase and the system enters a metastable zone where crystal 
growth eventually takes place. Crystal contacts between individual membrane protein 
molecules can only be formed between hydrophilic components that are not shielded by 
lipid or detergent (Prive, 2007). 
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Figure 5.2. Protein crystallisation by the vapor diffusion method in the hanging or sitting 
drop arrangement. MP = membrane protein. Made with Biorender, (Biorender). 
 
 
Figure 5.3. Phase diagram of protein crystallisation. An increase in the protein and/or 
precipitant concentrations causes the protein to transition through various stages: the 
metastable (supersaturated) phase, the labile (highly supersaturated) phase and the 
precipitation phase (too supersaturated to support ordered aggregation). Protein nuclei 
may develop into larger crystals in the metastable zone, while the labile zone is where both 
nucleation and crystal growth can occur. In the precipitation zone, however, the protein is 
in such a supersaturated state that it usually ends up as an amorphous protein precipitate. 
Figure is modified from (McPherson et al., 2014; Holcomb et al., 2017). 
 
A specialised vapor diffusion method, the use of which in membrane protein 
crystallography has increased considerably over the past few years, grows detergent 
solubilised membrane protein crystals in a lipid cubic phase (LCP) of neutral 
monoacylglycerol lipid mixtures of mono-palmitoleyl and mono-oleyl fatty acid side chains. 
The LCP lipid bilayer can also accommodate phospholipids and cholesterol, membrane 
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proteins and a large variety of buffer constituents. The structure and composition of the 
LCP mimic biological membranes and favours functionality and crystallisation of membrane 
proteins. This method was first introduced in 1996 (Landau et al., 1996). It uses a 
lipid/water phase system that spontaneously forms a 3D continuous lipid bilayer matrix 
into which detergent solubilised membrane proteins can diffuse freely and form well-
ordered membrane protein crystals (Landau et al., 1996; Caffrey, 2015).  
5.1.1.2 Transmission Electron Microscopy (TEM) 
Despite the availability of many commercial crystallisation screens and the wide 
applicability of the method, many membrane proteins are not easily amenable to X-ray 
crystallography. TEM is an alternative technique for structural studies of membrane 
proteins, without the need for 3D crystals. With TEM, one can apply a single particle 
analysis using negative staining for low-resolution studies and cryo-EM for high-resolution 
studies.  
Due to ease of specimen preparation, negative stain imaging of a purified 
membrane protein solution is a very useful method to analyse the purity of the sample 
preparation. Advantages of this method are the ease with which stained single particle 
images can be produced compared to cryo-preservation of purified membrane protein 
solutions. The disadvantage is that the resolution of a protein structure is usually limited 
to ~20 Å, a resolution far too low to resolve alpha-helices or beta-sheets, let alone amino 
acid side chains. Different heavy metal solutions can be used for negative staining and fixing 
of protein particles (e.g. uranyl acetate, uranyl formate, sodium phosphotungstate). They 
differ in their grain size, pH range, stability and quality of contrast. Uranyl formate and 
uranyl acetate are used routinely, however, both are highly toxic and must be handled with 
care and all material that comes into contact with the stain is considered a hazardous 
waste. Regions of the grid with thinner stain, such as those covering the specimen particles, 
scatter fewer electrons than regions with a thick stain (areas in between). The 
proteinaceous regions of the structure are overlaid with relatively less stain than crevices 
or gaps in the structure where stain accumulates. This leads to a brighter appearance of 
the particles on a darker background; hence the name negative stain EM. Sometimes, 
negatively stained proteins can aggregate or deform due to the low pH of the stain and the 
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drying process leading to artefacts in the image. Nevertheless, negative stain imaging is an 
invaluable tool to gain a first glimpse of the quality of purified biological samples. 
TEM uses the scattering of a beam of accelerated electrons to reveal the structure 
of small objects including biological samples. To prevent possible interference of electron 
scatter by air or volatile compounds like water, TEM is performed under high vacuum, and 
samples must be either dry or vitrified. EM gives ‘2D projection pictures’ of individual 3D 
protein particles. In single particle analysis, images of particles in different orientations are 
selected and aligned to make 2D classifications which leads to a low-resolution initial 3D 
model which is then refined to produce final reconstruction. Recent breakthroughs in 
specimen preparation, instrumentation and data processing have led to the “resolution 
revolution” of cryo-EM (Kuhlbrandt, 2014a; Moreau et al., 2014). It is being claimed by 
some that cryo-EM is about to overtake crystallography for the determination of high-
resolution membrane protein structures, and will dramatically improve our understanding 
of biological macromolecules (Fribourg et al., 2014; Kim et al., 2015a; Vinothkumar, 2015; 
Frank et al., 2016; Manolaridis et al., 2018).  
The major advantage of single particle analysis with cryo-EM is that no protein 
crystals are required (Henderson, 1995). Single particle cryo-EM is now used worldwide to 
determine high-resolution protein structures (Cheng, 2018b). Cryo-EM provides direct 
observation of protein samples frozen in vitrified ice that closely mimics their state in 
amorphous liquid water (Danev et al., 2019). Only a small amount of purified membrane 
protein is required for cryo-EM experiments. Even sample heterogeneity is less of a 
problem that can be solved with maximum-likelihood approaches for the classification of 
individual protein particles or complexes in various conformations and/or states; several 
structures of highly dynamic or flexible complexes can be solved at near atomic resolution. 
A disadvantage of cryo-EM, however, is the low contrast of the sample images (Wang et 
al., 2006; Henderson, 2015; Cheng, 2018a; Quentin et al., 2018; Vilas et al., 2018).  
The electron lenses that focus the electron beam in TEM microscopes (Figure 5.4) 
are magnetic fields produced by electromagnetic coils, and an exceptionally high vacuum 
is needed to ensure electron scattering only by the specimen. Because biological samples 
are sensitive to electron damage, limiting electron dosage is critical. There are different 
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electron sources in use. The JEOL JEM-1400 electron microscope, a very similar model to 
the one shown in Figure 5.5, that was used in this study for negative stain electron 
microscopy uses heated LaB6 filaments (Otago) or Tecnai 12 (Mosser et al.) with LaB6 
(Auckland) as the electron source. A drawback of LaB6 filaments is the broad energy 
distribution of the emitted electrons. For high-resolution structures a narrower energy 
distribution is required. This is usually achieved with field emission guns (FEGs) such as 
those used in high-end electron microscopes like the Titan Krios and Talos Arctica cryo-EMs 
from Thermo Fisher Scientific. Electrons of FEGs are accelerated usually with 200 kV-300 
kV to yield much brighter and more coherent beams than LaB6 filaments (Orlova et al., 
2011). Although lower electron energies (120 keV) provide a higher amplitude contrast, 
higher electron energies are less sensitive to sample charging and therefore advantageous. 
Radiation damage is also reduced at higher acceleration voltages (Orlova et al., 2011; 
McMullan et al., 2014). The electron beam is focussed with the condenser lens system with 
parallel illumination of the biological sample in high-end microscopes; non-parallel sample 
illumination would introduce an unwanted phase shift (Smith et al., 1983). Brightness and 
size of the illuminated area are also determined by the condenser lenses. Specimen 
insertion at the centre of the objective lens is also critical for image quality (Orlova et al., 
2011).  
Electrons scatter either elastically or inelastically when passing through a sample. 
Inelastically scattered electrons lose energy by interacting with the biological sample, 
thereby causing specimen damage. These electrons can be filtered out at high scattering 
angles by using apertures installed after the objective lens, and with in-column energy 
filters that increase overall contrast. Image magnification of a 2-dimensional projection 
image of the 3-dimensional object is determined by the objective lens and the system of 
intermediate and projection lenses. This can be observed on the fluorescent screen or with 
a detector (JEOL manual (JEOL) and (Orlova et al., 2011)). Because biological samples 
consist mostly of atoms with low atomic number (carbon, oxygen, nitrogen or hydrogen), 
they are considered ‘weak phase objects’ that produce little contrast. Thus, to increase 
phase contrast, during data acquisition of biological samples, defocus is applied (Zhu et al., 
1997). The Volta phase plate inserted into the TEM instead of an objective aperture is used 
to cause an additional phase shift that enhances contrast. These features enabled solving 
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protein structures routinely as small as 200 kDa (Fan et al., 2017; Khoshouei et al., 2017; 
von Loeffelholz et al., 2018) and occasionally down to 39 kDa (Fan et al., 2019). 
The movement of protein molecules due to the breaking of covalent bonds by high 
energy electron beams generates blurred images. The development of new generation 
direct electron detectors that are much more sensitive than previously used charge-
coupled device cameras (CCD cameras) or photographic films is another cornerstone of the 
‘high-resolution revolution’ of cryo-EM. They use active pixel sensor technology (same as 
the cell phone camera chips, but radiation-hard) and the sensors are about half the 
thickness of a paper sheet, minimising scattering of electrons that would otherwise make 
blurred images (Kuhlbrandt, 2014b; Danev et al., 2019). The combination of next 
generation direct electron detection devices (DDDs) (Bammes et al., 2012), the ability to 
freeze samples in amorphous vitrified ice, automatic data acquisition and the development 
of high-speed computers and software packages for image acquisition and single particle 
analysis have made it possible to solve protein structures to near atomic resolution with 
TEM. A structure at 1.62 Å resolution was recently reported for the mouse heavy-chain 




Figure 5.4. Example of TEM column exterior. The figure was taken from JEOL manual 






Figure 5.5. Example of a cross-section of a TEM column. The figure was taken from JEOL 
manual (JEOL); used with permission from JEOL Ltd. (Appendix A4). 
 
5.1.2 Aims  
After the successful purification of milligram quantities of properly folded, stable, 
and homogeneous Cdr1-XLmGFPHis, the next challenge was to determine the 3-
dimensional structure of Cdr1 by X-ray crystallography or cryo-EM. The aims of this chapter 
were to: 
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1) Perform X-ray crystallography of detergent purified Cdr1. 
2) Undertake cryo-EM of detergent solubilised purified Cdr1-XLmGFPHis. 
3) Optimise protocols that could lead to a high-resolution structure of Cdr1.  
5.2 Materials and Methods 
5.2.1 Hanging Drop Vapor Diffusion Crystallography of Purified Cdr1-XLmGFPHis 
Initial crystallisation trials were performed with the commercially available buffer 
screens MbClass I and II Suite (Qiagen) and MemGold™ and MemGold2™ from Molecular 
Dimensions (Chapter 2; Table 2.3). Individual buffer solutions contained a range of different 
buffers at different concentrations and pH values, various precipitants (salts or PEG), and 
additives known to help the crystal formation of membrane proteins. The buffer 
compositions of the various buffers that were provided as 1 ml aliquots in individual wells 
of four separate 96 well microtiter plates are listed in the appendix A2. The hanging-drop 
vapour-diffusion method was used for all Cdr1-XLmGFPHis crystallisation trials. 
Immediately before setting up the crystallisation trials, the detergent solubilised, purified, 
and concentrated Cdr1-XLmGFPHis samples (10-15 mg/ml) were centrifuged at 4 °C for 15 
min at 10,000 g to remove insoluble protein aggregates. Following this aggregate removal 
step, individual wells of a 96-well corning 3550 crystallisation plate were filled with 75 µl 
of the 96 different buffers provided by one of the four above mentioned buffer screens 
(Table 2.3). Droplets (400 nl) of the purified Cdr1-XLmGFPHis sample were then applied 
with a mosquito crystal pipetting robot (Table 2.4) onto the hanging drop screen and mixed 
with an equal volume (400 nl) of the 96 different test buffers. The screen was then placed 
upside down and sealed onto the prepared crystallisation plates by pressing the sticky 
surface of the screen onto the corresponding crystallisation plates. The tightly sealed plates 
were stored at 16 °C in an automated imaging system (Rock Imager (Table 2.4)) that 
recorded images of the hanging drops at chosen time intervals. Image processing and 
inspection of individual crystallisation conditions was performed with the help of the Rock 
Maker (Formulatrix) software package (RockMaker). 
The first two crystallisation trials were performed with DDM solubilised Cdr1-
XLmGPHis samples that were purified by SEC using a buffer that still contained 10% glycerol 
and 6x CMC of DDM. The monomeric peak fractions of different SEC runs (Figure 5.6-A, left) 
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were pooled and concentrated (15-fold) to 1 ml (12 mg/ml). The concentrated sample, 
however, showed signs of aggregation on an SDS-PAGE gel. Possible aggregation was also 
reflected in a reduced A280/A250 ratio (1.7). Thus, the entire sample was size separated once 
more by SEC which resulted in a large monomeric Cdr1-XLmGFPHis peak of 1,000 mAU280 
and a small left shoulder of protein aggregates (Figure 5.6-A, right). The fractions of the 
monomeric peak were combined (2 ml; 6.2 mg; A280/A250 = 1.9) and concentrated with an 
Amicon Ultra filter (100 kDa MW cut-off) by centrifugation at 2,000 g and 4 °C to a volume 
of 0.2 ml (25 mg/ml).  
The second monomeric Cdr1-XLmGFPHis sample for crystallisation trials was 
prepared by combining the monomeric peak fractions of several purification experiments 
(Figure 5.6-B) and concentrating the combined SEC fractions (11 ml) to 0.25 ml (16 mg/ml; 
A280/A250 = 1.9). Each Cdr1-XLmGFPHis sample was used in independent hanging-drop 
vapour-diffusion crystallisation trials using four 96 well MbClass I and II Suite and 
MemGold™ and MemGold2™ screens (i.e. 384 different buffer conditions). 
 
Figure 5.6. SEC on Superose 6 increase 10/300 of DDM-solubilised Cdr1-
XLmGFPHis/detergent micelle particles used for crystallography trials. A) SEC 
chromatograms of Cdr1-XLmGFPHis samples used for the first crystallisation trial. The 
monomeric peak fractions (15-17.5 ml elution volume; grey dotted lines; two typical SEC 
chromatograms are shown as examples; left) of a number of independent SEC runs were 
combined, concentrated, and separated once more by SEC (middle trace). The Cdr1-
XLmGFPHis monomer peak fractions (grey dotted lines) were collected and concentrated 
(25 mg/ml) for crystallisation trials. B) For the second crystallisation trial the monomeric 
peak fractions of a number of independent SEC runs (three SEC chromatogram examples 
in grey, blue and turquois are shown) were combined, concentrated (16 mg/ml), and used 
directly for the second crystallisation trial. 
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After optimisation of the SEC buffer (removal of glycerol and using 2x CMC of DDM) 
and upscaling the detergent solubilisation and purification protocols, as described in 
Chapter 4, the HiLoad 16/600 Superdex 200 pg column fractions of the monomeric Cdr1 
peak were pooled (12 ml; A280/A250 = 2.2) and concentrated to 0.35 ml (15 mg/ml; A280/A250 
of 1.9) by centrifugation at 2,000 g and 4 ˚C with a 100 kDa MWCO Amicon Ultra filter. To 
lock Cdr1 in the open conformation and to improve the chance of obtaining protein crystals 
the following experiments were performed in the presence of a 3.2-fold molar excess of 
beauvericin, a potent inhibitor of Cdr1 efflux pump function (Shekhar-Guturja et al., 2016; 
Tong et al., 2016). The beauvericin and Cdr1-XLmGFPHis concentrations chosen for these 
experiments were 240 µM and 75 µM, respectively. After incubating the purified Cdr1-
XLmGFPHis sample (75 µM) with beauvericin (240 µM) on ice for 1 h, a third crystallisation 
trial was performed with the same four buffer screens of 384 unique crystallisation 
conditions. The same sample was also used for negative stain electron microscopy (see 
below). 
5.2.2 Transmission Electron Microscopy (TEM) of Purified Detergent-Solubilised 
Cdr1-XLmGFPHis Particles 
5.2.2.1 Cryo-EM Grid Preparation 
Samples for EM studies are mostly applied on small (few mm) copper discs or grids. 
Standard copper grids of 3.05 mm diameter sub-partitioned into square grids of 200 to 400 
mesh (i.e. holes per inch; Figure 5.7) are usually used as specimen holders. For negative 
stain experiments, the grids are covered with a continuous carbon layer (usually 8 nm 
thick), whereas for cryo-TEM grids, a holey carbon layer is used. In this case, each grid 
square, for instance, contains 30-50 holes with a diameter of 1-2 μm each (Figure 5.8). This 
information is reflected in the names given to the various commercially available grids. For 
instance, a “Quantifoil 1.2/1.3” grid has a hole size and hole spacing of 1.2 μm and 1.3 μm, 
respectively. EM grids are commercially available either with a continuous or a holey 
carbon layer (e.g. from Quantifoil®, C-flatTM). However, a continuous carbon layer EM grid 
can be created manually on an empty grid (see Section 5.2.2.1).  
In cryo-EM the sample is flash-frozen by plunging the particle-coated grid into a 
cryogen, usually liquid ethane. This method has revolutionised protein structure 
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determination because it preserves the native conformation of proteins. Optimal ice 
thickness is a crucial factor for the success of high resolution cryo-EM. Ice layers thinner 
than the sample cause dislocation of the protein from the holes, while flash-freeze image 
contrast, on the other hand, reduces with increasing ice layer thickness. Holey carbon layer 
grids used in cryo-EM vary in mesh size, hole size and hole spacing to accommodate the 
different size and shape of particles. Protein distribution can be dramatically affected by 
ice thickness and detergent micelles surrounding embedded protein particles. The air-
water interface can also induce unwanted particle orientation bias further impacting the 
process of 3-dimensional reconstruction of the target protein. Obtaining the best possible 
sample distribution and image contrast needs optimisation of ice thickness and sample 
preparation. 
 
Figure 5.7. TEM grids for creating negative stain images of Cdr1-XLmGFPHis. Carbon-
coated copper grid (left) and two different size square mesh TEM copper grids of mesh 
sizes 200 and 400, respectively. 
 
 
Figure 5.8. A schematic representation of a typical EM carbon grid used for single particle 
cryo-EM of Cdr1-XLmGFPHis. Figure taken from Wang et al. (Wang et al., 2006); used with 




5.2.2.2 Carbon Coating of Negative Stain EM Grids 
Bare 200 mesh copper grids (G2400C, Plano GmbH, Wetzlar, Germany) were coated 
with a thin plastic film (Ohi et al., 2004; Booth et al., 2011). Three drops of collodion 
solution (Table 2.1) were placed onto the surface of ddH2O contained in a glass beaker 
(diameter ~30 cm). Collodion is a solution of nitrocellulose in ether that enables the 
creation of continuous supportive polymer films. To avoid dust settling on the thin polymer 
film, the glass beaker was covered with aluminium foil for a few minutes until the polymer 
film had formed on the water/air interface after evaporation of the volatile ether. The film 
was removed with a pipette tip, and the process repeated twice or three times to avoid 
any unwanted dust particles on the thin polymer film. After these cleaning steps, about 40 
to 60 bare copper grids were placed, shiny side down, one by one onto the floating polymer 
layer and carefully covered with a circular piece of Whatman filter paper (9 cm diameter). 
To avoid wrinkles, the filter paper should not absorb water quickly. The thin collodion 
polymer film surrounding the wet filter paper was disrupted with a pipette tip and the filter 
paper with the grids attached to the polymer film were carefully lifted off the water surface 
with a pair of forceps and transferred into a dry petri-dish. After air drying for three days, 
the grids were coated with an 8 nm carbon layer using a carbon evaporator chamber. After 
creating a high vacuum (~ 10-4 Pa) in the carbon coating chamber, carbon evaporation from 
a carbon rod was initiated by flowing a high current through the rod until the desired 
thickness set for the chamber was achieved. 
5.2.2.3 Negative Staining of Cdr1-XLmGFPHis Particle Grids and Electron Microscopy 
Negative stain electron microscopy (EM) is a valuable technique to evaluate the 
homogeneity and composition of purified proteins and to get a first glimpse of the 3D shape 
of a protein in various projected views. Prior to sample application and staining, the carbon 
coated grids created above were made more hydrophilic by glow-discharge treatment for 
0.5 min in a Femto Plasma discharger (Table 2.4) with the current set to 15 mA. Glow-
discharged grids should be used within 2 h to utilise the temporary hydrophilic character 
of the carbon film. Reverse-force anti-capillary forceps were used when handling grids with 
the coated side facing up. Next, two drops (each ~10 μl) of detergent-free SEC buffer and 
two drops (each ~10 μL) of stain solution (e.g. 1% uranyl acetate or freshly prepared 0.75% 
uranyl formate in ddH2O) were placed near each other on a clean piece of Parafilm® for 
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later washing and staining the grid. Then, 4 μl of the purified detergent solubilised Cdr1-
XLmGFPHis sample was applied onto the glow-discharged grid surface. The grid holding the 
protein sample was incubated at room temperature for 1 min, after which excess fluid was 
removed with a piece of filter paper (Whatman No. 4) by touching the edge of the grid. 
Various protein concentrations (0.001-1 mg/ml) were tested to obtain optimum particle 
distribution (≤0.004 mg/ml concentration was the best). The grid surface to which the 
protein particles were attached was washed twice with the two detergent-free SEC buffer 
droplets prepared above. This was achieved by bringing the grid surface into contact with 
the droplet and then blotting excess liquid off by gently touching the edge of the grid with 
filter paper. Negative staining was carried out by immediately placing the washed grid onto 
one of the droplets of the desired heavy metal stain solution, quickly blotting off excess 
liquid, but avoiding the grid drying out, and placing the grid in the second stain droplet for 
1 min. After blotting off excess liquid, the grids were allowed to air-dry for a couple of 
minutes before visualisation of protein particles by EM and data acquisition. Electron 
micrographs were acquired using a JEOL JEM 1400 TEM operated at 120 kV, and images 
were recorded with a 4k x 4k CMOS Camera TemCam-F416 (TVIPS) at 60,000-fold 
magnification corresponding to a pixel size of 1.844 Å/pixel and a defocus of -1 to -2 µm.  
5.2.2.4 Cdr1-XLmGFPHis Specimen Preparation for Single Particle Cryo-EM 
The major limitation of EM and 3D reconstruction of negatively stained particle 
images is its limited resolution [>20 Å] mostly due to the grain size of the stain and other 
possible artefacts caused by the loss of the hydration shell (Scarff et al., 2018). Cryo-EM 
avoids most of these problems by freezing protein samples extremely quickly and 
preserving an amorphous vitrified layer of ice. After careful assessment of samples with 
negative stain EM, the most promising detergent solubilised, purified, Cdr1-XLmGFPHis 
samples were used for cryo-EM. For the collection of a high-resolution dataset, it was 
essential to get the highest possible quality of cryo-grid images. Several parameters 
required optimisation: the concentration of the purified protein sample, the type and 
concentration of the detergent used for the purification, the volume of the sample applied 
onto the grid, the waiting time after sample application, the blotting time and force, the 
drain time, and even the type of holey grid used (Drulyte et al., 2018; Sgro et al., 2018). 
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Vitrification was performed with an FEI Vitrobot plunge freezer set to 4 °C and 100% 
humidity after glow-discharge treatment of the holey carbon grids with a plasma 
discharger. Three and a half microlitres of detergent solubilised and purified Cdr1-
XLmGFPHis at an optimised concentration of 0.3-0.5 mg/ml were placed onto the grid for 
1 min and then automatically blotted for 3 s with a blotting force set to -3 to remove excess 
buffer from the grid surface. Afterwards, the grid was plunged into a liquid ethane-filled 
container pre-cooled to -183 °C with liquid nitrogen. Initial screening and data collection 
were performed on a Talos™ Arctica cryo-EM equipped with two cameras, a digital FluCam 
and a Ceta 16M camera, and a Volta Phase Plate (VPP) for visualising protein particles with 
the highest possible contrast (Danev et al., 2016; Danev et al., 2017; von Loeffelholz et al., 
2018).  Single-particle reconstruction was performed with the SPHIRE (Sparx for High 
Resolution Electron Microscopy) software package (SPHIRE). After semi-automatic particle 
selection using CrYOLO (YOLO; You Only Look Once - a deep-learning based automated 
particle picker (Wagner et al., 2019)), particles were extracted, aligned and classified using 
iterative stable alignment and clustering [ISAC, 2D classification] (Yang et al., 2012), after 
which the best class averages were selected and used for initial 3D-reconstruction using 
the VIPER (Validation of Individual Parameter Reproducibility) software package (Moriya et 
al., 2017; Wagner et al., 2019).  
5.2.3 Negative Staining of Amphipol-Exchanged Cdr1-XLmGFPHis Samples 
(Undertaken at Auckland University by Professor Nam-Chul Ha) 
Grid Preparation - A 2% solution of filtered (0.22 µm filter) uranyl acetate (UA) was 
used for negative stain experiments using 300 mesh copper EM grids that had been 
formvar-carbon coated and rendered hydrophilic by glow discharge treatment. A drop (4 
µl) of the amphipol-exchanged Cdr1-XLmGFPHis sample (Section 4.2.7 and Figure 4.23-B) 
was placed on the grid and incubated at room temperature for 90 s. The grid was washed 
3 times by floating it for a few seconds in turn on 3 separate 80 µl ASTM type 1 water 
droplets sitting on a strip of Parafilm®. Excess liquid was removed by touching the edge of 
the grid with a piece of Whatman No. 5 filter paper. Negative staining of Cdr1-XLmGFPHis 
particles was performed by placing the grid on two 4 µl UA droplets in succession for 45 
and 25 s, and excess UA stain was removed in between the two staining steps by touching 
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the grid edge with filter paper. The grids were then air dried for a couple of minutes and 
examined by TEM.  
Image acquisition - Low dose images were acquired using an FEI Tecnai 12 TEM at 
120 kV that was equipped with a Gatan Ultrascan 1,000 4-Mpixel digital camera and a LaB6 
filament (Mosser et al.). The total electron dose did not exceed 20 e/Å2/s per micrograph. 
Defocus values ranged from 0.4-2.5 µm and the magnification of images was 52k which 
corresponded to 2 Å/pixel in the acquired image.  
Image processing protocol using RELION - Image processing was performed with 
the RELION software package 3.0 (Scheres, 2012; He et al., 2017). The following settings 
were used for data collection: the contrast transfer function (CTF), which is used to 
estimate a suitable defocus and astigmatism value, was set to ctffind4.1 (Rohou et al., 
2015); the amplitude contrast was set to 0.7; an FFT (fast Fourier transform) box size of 512 
pixels; the minimum and maximum defocus values were set to 0.3 µm and 5 µm, 
respectively; and the defocus step size and the amount of astigmatism were set to 500 Å 
and 100 Å, respectively. The typical workflow of the image processing protocol included 
particle picking (manual or automated), setting different parameters such as amplitude 
contrast, FFT box size (Fourier Transform window size, which has to be an even number as 
requirements of some programs), and defocus. This was followed by creating 2D class 
averages of Cdr1-XLmGFPHis particle images that represented the various orientations of 
the molecule in 3-dimensional space and selecting representative subsets for creating an 
initial low-resolution 3D model that could be used as a guide for future model refinements. 
A 20 Å lowpass filter and a particle diameter boundary of 170 Å were used for manual 
particle selection. The following optimised parameters were chosen for ‘auto picking’ 
individual particles: a picking threshold of 0.85; 100 Å for minimum inter-particle distance; 
a maximum standard deviation parameter of 1.1 for noise exclusion; minimum average 
noise parameter option switched off; and a particle diameter of 160 Å.  
2D class averages of the selected particles were created with 25 iterations and a 
mask diameter of 200 Å. C1 symmetry and a mask diameter of 200 Å were chosen for the 
creation of an initial 3D model. The model was auto-refined by choosing the following 
software parameters: 1 for the number of expected classes; a mask diameter of 200 Å; C1 
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symmetry; 25 initial, 100 in-between, and 25 final iterations; and 7.5˚ for initial angular 
sampling. For more details please check the software package tutorial (Scheres, 2018). 
5.2.4 Negative Staining of Amphipol-Exchanged Cdr1-XLmGFPHis Samples 
(Germany) 
The amphipol A8-35-exchanged Cdr1-XLmGFPHis samples were investigated by 
negative staining at the MPI of Molecular Physiology, Dortmund, Germany. Images of 
negatively-stained samples were visualised with a JEOL JEM-1400 electron microscope that 
was operated at 120 kV using a LaB6 filament as an electron source and choosing a 60K 
magnification for obtaining the EM images. For that experiment, Cdr1-XLmGFPHis was 
extracted and purified with DDM which was exchanged with amphipol A8-35 immediately 
after the affinity purification step (see Chapter 4 for further details). The amphipol A8-35 
exchanged Cdr1-XLmGFPHis sample was then further purified by SEC using a Superose 6 
increase 10/300 column and a detergent-free SEC buffer (Figure 5.22). Two 0.5 ml eluant 
fractions from the left (fractions 36 and 37), one from the central part (fraction 39) of the 
major, non-Gaussian, monomeric Cdr1-XLmGFPHis peak and one from the second peak 
(fraction 45) that did not show any absorbance at 500 nm (i.e. no GFP fluorescence), which 
possibly comprised excess amphipol and/or empty DDM micelles, were collected (the 
fractions collected are indicated with red dots in Figure 5.22), and small, diluted, portions 
of these fractions were negatively stained with 1% [w/v] uranyl acetate and visualised by 
EM. For optimum particle densities the fractions were diluted to concentrations ≤0.004 
mg/ml. This was achieved by diluting individual fractions to 6-8 mAU280 using their peak 
absorbance monitored by the ÄKTA system as a guide (e.g. fraction 39 (almost 500 mAU 
height) was diluted 1:60 to 1:80). This simple rule correlated surprisingly well with the 
spectrophotometrically determined protein concentrations. 
The EM images were recorded at 60k magnification, which corresponded to a pixel 
size of 1.844 Å, and particles were automatically ‘picked’ with the crYOLO, a software that 
was developed at the MPI of Molecular Physiology (Wagner et al., 2019). The selected 
particles were extracted with square boxes of 160 pixels (29.5 nm) and classified into 2D 
class averages with ISAC, which is part of the SPHIRE software package (Moriya et al., 2017) 
to reliably calculate 2D class averages of the dataset. After deleting the “junk” class 
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averages, which were blurry class averages, the RVIPER program generated the initial low-
resolution 3D reconstruction volumes using a small subset of class averages produced by 
ISAC. The output of this step can later be used as the reference for the refinement of the 
final model when there is no initial model, as was the case for Cdr1.  
5.3 Results 
The protein-linker (L) and the mGFP fluorescent tag with the C-terminal His tag were 
not removed from the Cdr1 molecule by protease cleavage at the HIV-3C protease cleavage 
site (X) in any of the preliminary structural studies described in this chapter. Although an 
increased particle size may help particle recognition in cryo-EM, the ‘loosely’ attached GFP 
tag also quite possibly affected the resolution of 3D reconstructions of the 2D class 
averages. Equally, if not even more, problematic was the potential detrimental effect of 
the tag on the initial crystallisation trials described below. This is because the C-terminal -
XLmGFPHis tag was specifically designed not to interfere with the structural and functional 
integrity of Cdr1. This allowed free movement of protein domains meaning increased 
heterogeneity of Cdr1 molecules and reduced likelihood of crystal formation.  
5.3.1 Crystallisation of Purified, Detergent-Solubilised Cdr1 
The crystallisation process depends on numerous factors and is, unfortunately, still 
very much a trial and error process. It may result in no precipitation at all (when saturation 
conditions are not met) or it can, more often than not, produce various types of 
precipitates rather than clearly defined crystals. However, the types of precipitates can 
provide valuable clues about which conditions may be more favourable for crystal growth. 
In the first trial, 0.4 µl Cdr1-XLmGFPHis (25 mg/ml in SEC buffer containing 6x CMC 
of DDM) were combined with 0.4 µl of the various buffers provided in the MemGold and 
MemGold2 panels. Immediately after setting up, 85% of the MemGold and 70% of the 
MemGold2 crystallisation conditions gave different types of protein precipitates, indicating 
that the protein concentration was possibly too high and mostly in the precipitation zone 
to begin with. The drops that were not clear gave various types of appearances ranging 
from granular precipitates (Figure 5.9-B) to precipitates distributed throughout the drop 
(Figure 5.9-C and -D), and from phase separated droplets (Figure 5.9-E) to brown 
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amorphous precipitates (Figure 5.9-F). Over time, the appearances of some drops changed 
and on the day 35 the number of clear drops (Figure 5.9-A) dropped from 15%-30% to just 
5-10%, respectively. Some of the initially clear drops developed salt crystals (Figure 5.9-G) 
or contaminants (Figure 5.9-H). The salt crystals were not fragile by poking, and later their 




Figure 5.9. Classification of different drop appearances of the first hanging drop crystal 
trials performed at 16 ˚C with purified, DDM-solubilised, Cdr1-XLmGFPHis (25 mg/ml). A) 
Clear drop, B) granular precipitate, C) and D) heavy, continuous, precipitate throughout, E) 
phase separation, F) brown amorphous precipitate, G) salt crystals, and H) contaminants. 
Scale bars are shown at the top left corners. 
Drops with precipitates that changed their appearance over time presented more 
encouraging types of protein precipitates. An example of such types of small clusters of 
translucent round-shaped and brownish or flocculent precipitates was observed in 
MemGold well A5 (10 mM Tris, pH 8, 300 mM NaCl, 27.5% w/v PEG 4,000; Figure 5.10). At 
A                                                  B                                                  C 
D                                                  E                                                  F 
G                                                   H 
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day 0, a slightly brownish, globular, precipitate was formed (Figure 5.10-A). Over time (after 
7 days) some translucent round-shaped precipitates emerged (yellow arrows; Figure 5.10-
C,E) that grew until day 35 (Figure 5.10-D,F), when observation stopped. The MemGold A5 




Figure 5.10. An example of potentially useful Cdr1-XLmGFPHis (25 mg/ml) crystallisation 
conditions identified in well A5 of the MemGold screen. Images A-D show the changes 
that were observed over a 35-day time period in well A5 (MemGold; A = 0, B = 7, C = 21, D 
= 35 days). E) and F) are the enlarged rectangular portions of C) and D). Yellow arrows 
indicate encouraging protein precipitates that appeared over time. Scale bars are 500 μm. 
 
A                                                                        B 
C                                                                        D 
E                                                                     F 
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Micro-crystalline precipitates can be a sign for potential protein crystal formation. 
Such ‘hits’ should be further optimised by lowering the nucleation events by reducing the 
protein and/or precipitant concentration or by lowering the incubation temperature. Using 
UV rather than visible or cross polarised light imaging gave many bright spots distributed 
throughout ~25% of the drops of the MemGold screen. Small UV absorbing particulate 
precipitates may be a sign of protein nucleation. However, none of these precipitates 
showed any sign of growth over a 35-day incubation period. Examples of some of these 
drops are shown in Figure 5.11-A to -C. The type and concentration of buffer in these ~25% 
of wells varied, they also contained various salts at various concentrations (50-400 mM 
NaCl or 100 mM MgCl2 or 200 mM KCl), some of the wells of the MemGold2 screen 
contained no salt at all (Figure 5.11-D and -E), and most of these wells had a pH between 
pH 6 and pH 8. While the MemGold2 and MemGold screening results were quite similar, 
the MbClass I screen produced 25% clear drops, many of which started to precipitate after 
1-2 days of incubation. There was also a limited range of precipitate types obtained with 
the MbClass I screen; most were of the brownish type. However, phase separation (Figure 
5.9-E) was seen in some of the wells. In several wells (Figure 5.12), potential crystals 
became visible after day 28 under three very different conditions (Figure 5.12-C, -I, and -
K). The UV absorbance was not very bright (Figure 5.12-E, and -L), suggesting that these 
crystals were possibly salt or DDM crystals. In well A11 (100 mM ADA [N-(2-
Acetamido)iminodiacetic acid], pH 6.5, 1 M (NH4)2HPO4) some well-shaped elongated 
square pyramid crystals (biggest one around 40 µm to 45 µm at the base) appeared within 
one day of incubation (Figure 5.13). However, these crystals did not grow any further until 
day 21, when the crystals were collected for further investigation. Although these crystals 
appeared protein-like in the UV images (Figure 5.13-E), they were also coloured when 
imaged with polarised light (Figure 5.13-D). Some of these crystals were ‘fished’ and placed 
in the in-house X-ray source at the Macromolecular X-ray Crystallography Suite in the 
Department of Biochemistry (University of Otago, New Zealand), but the X-ray diffraction 








Figure 5.11. Representative examples of the ~25% of wells of the MemGold and 
MemGold2 screens of Cdr1-XLmGFPHis (25 mg/ml) that produced UV absorbing 
precipitates. Images on the left are visible light images and those on the right are their 
corresponding UV images. A) Well B1 (100 mM NaCl, 20 mM Na3Citrate pH 5.6, 11% w/v 
PEG 3350). B) Well B5 (100 mM MgCl2, 300 mM Tris pH 8.2, 19% w/v PEG 4,000). C) Well 
F6 (200 mM Na3Citrate, 800 mM NaH2PO4 pH 6.2, 18% w/v PEG 2,000). D) Well C6 (100 
mM magnesium formate, 100 mM MOPS pH 7, 17% w/v PEG 3350). E) Well G7 (100 mM 
ADA pH 5.5, 14% w/v PEG 6,000). Images A-C are from the indicated wells of the MemGold 







    
 
Figure 5.12. Potential protein crystals appeared in some wells of the MbClass I screen of 
purified, DDM-solubilised, Cdr1-XLmGFPHis (25 mg/ml) after 28 days of incubation at 16 
˚C. A) to E) are well A3 (100 mM Na-acetate pH 4.6, 200 mM CaCl2, 30% w/v 2-propanol 
and 20% w/v glycerol). A, B, and C are images taken on day 0, 21, and 28, respectively. D 
and E are polarised and UV light images of C, respectively. F) to J) are images of well A4 
(100 mM Tris pH 8.5, 500 mM (NH4)2SO4) taken on days 0, 7, 14, and 28, respectively. There 
A                                                  B                                                 C 
F                                                  G                                                 H 
D                                                  E 
I                                                                               J 
K                                                  L 
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was some precipitation immediately after setting up the drops. This precipitation 
disappeared a week later and the potential protein crystals appeared after day 21. J is a 
magnified portion of the indicated part of image I. K and L are visible and UV light images, 
respectively, of well A5 (100 mM NaK phosphate pH 7.5, 700 mM (NH4)2SO4) taken on day 




Figure 5.13. Crystals in well A11 (100 mM ADA, pH 6.5, 1 M (NH4)2HPO4) of the MbClass I 
screen. A) to C) are visible light images taken at day 0, 1, and 21, respectively. D) and E) are 
the polarised and UV light images of well A11 at day 21, respectively. F) Polarised light 
image of similar crystals obtained in the same well using the second Cdr1-XLmGFPHis 
purified protein sample of lower protein concentration (16 mg/ml). Scale bars are shown 
at the top left corners. 
 
A second set of crystallisation screens of MbClass I and II and MemGold and 
MemGold2 was performed with a second preparation of DDM-solubilised purified Cdr1-
XLmGFPHis at a reduced protein concentration (16 mg/ml), and 500 nl sample droplets. 
Unexpectedly, and despite the reduced protein concentration, the percentage of clear 
drops in the second set of screens was even lower. Perhaps using 0.5 µl protein mixed with 
0.5 µl buffer for each hanging drop rather than the 0.4 µl plus 0.4 µl was one of the reasons 
for this unexpected result. Many drops gave strong brown precipitates (Figure 5.14). 
However, some of the drops also showed signs of micro-nucleation presenting small 
D                                                 E                                                  F 
A                                                  B                                                 C 
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dispersed precipitates that absorbed UV. MbClass II gave similar results with many wells 
showing dark brown or black amorphous precipitates of presumably denatured protein 
(data not shown).  
 
Figure 5.14. Overview of the 96-well canvas of the MemGold2 screen using 16 mg/ml 
purified Cdr1-XLmGFPHis in the second crystallisation trial, after 3 days. Most drops gave 
dark brown precipitates. 
 
The third crystallisation experiment was performed in the presence of a 3.2-fold 
molar excess of beauvericin. Unfortunately, this approach did not improve the results. 
Again, mostly large precipitates were obtained, similar to the previous two experiments. 
Crystals in well A11 of the MbClass I screen were similar to both previous experiments, 
however, this time no crystals appeared in well A3, unlike in the first two experiments with 
Cdr1-XLmGFPHis samples that were purified with 6x CMC of DDM in the SEC buffer 
containing 10% glycerol. This strengthens the possibility that the previous micro-crystals 
that appeared after day 28 (Figure 5.12) were DDM crystals. 
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This time, however, more potential small Cdr1-XLmGFPHis crystals with beauvericin 
bound were observed under two different conditions (Figure 5.15 and Figure 5.16). 
Unfortunately, most of these crystals were very fragile and rather small to extract for 
further analysis by X-ray diffraction. Despite those problems some crystals were fished, 
mounted onto cryo-loops, and exposed to X-ray radiation at the Macromolecular X-ray 
Crystallography Suite in the Department of Biochemistry (University of Otago, New 
Zealand). The copper X-ray radiation anode tube and the Rigaku R-AXIS IV++ area detector 
were used to pre-screen the potential crystals. However, the small size of these possible 
crystals precluded the detection of any diffraction patterns.  
 
 
Figure 5.15. Possible Cdr1-XLmGFHPHis crystals with beauvericin bound formed in the 
hanging drop of well H1 of the MemGold2 screen (50 mM Tris-Cl, pH 8.5, 28% v/v PEG 
400). A) Image of the drop of well H1 immediately after setting up the hanging drop, and 
B) is an image of the same drop under UV light. C) Image of the same drop on day 5 (a small 
crystal started to emerge; indicated by an orange arrow). D) and E) The crystal appeared to 
grow by days 7 and 14, respectively. F) The UV image of the crystal (arrow) taken on day 
35 did not show any sign of further growth. Scale bars are shown at the top left corners. 
 
A                                                  B                                                   C 
D                                                 E                                                  F 
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Figure 5.16. Another possible Cdr1-XLmGFHPHis crystal with beauvericin bound 
appeared by day 4 in the hanging drop of well G10 of the MemGold2 screen (50 mM ADA, 
pH 6.5, 24% v/v PEG 400). A) Light precipitation was visible at day 0. B) Image of the same 
drop under UV light. C) An image taken at day 4 showed two small emerging crystals 
(indicated by orange arrows in D). D) Magnification of the indicated part of C) that 
contained the emerging crystal, and E) is an image of C) obtained under UV light. F) The 
crystals on day 35 obscured by increased precipitation. The crystals stopped growing after 
day 7 and were too small to be analysed. Scale bars are shown at the top left corners. 
 
A                                                                       B 
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5.3.2 Negative Stain Electron Microscopy of Cdr1-XLmGFPHis  
Negative stain electron microscopy was performed to evaluate the homogeneity of 
detergent solubilised purified Cdr1-XLmGFPHis samples at three different facilities, the 
University of Auckland, the University of Otago, and the Max Planck Institute of Molecular 
Physiology in Dortmund, Germany. 
5.3.2.1 Detergent Solubilised Cdr1-XLmGFPHis Particles Exchanged with Amphipol A8-
35 
The DDM solubilised purified sample was sent to our collaborators at the University 
of Auckland where they performed DDM exchange with the amphipol A8-35 (for more 
details see Section 4.3.7), as detergents can lead to a high background of EM micrographs 
of negatively stained protein/micelle particles causing a number of possible artefacts 
(Gewering et al., 2018). This background problem is significantly reduced with amphipol 
stabilised membrane proteins, and excess amphipol can also be easily eliminated by SEC. 
Amphipols enable the handling of membrane proteins in detergent-free solutions similar 
to soluble proteins (Tribet et al., 1996; Popot, 2010; Le Bon et al., 2018). The electron 
micrographs (Figure 5.17 and Figure 5.18) of amphipol A8-35 exchanged Cdr1-XLmGFPHis 
particles showed a homogeneous particle distribution. These initial experiments were 
performed by Prof. Nam-Chul and Dr. Bogomolny under the supervision of Associate Prof. 
Alok K. Mitra.  
   
Figure 5.17. Negative stain EM images of amphipol A8-35 Cdr1-XLmGFPHis particles. The 
large circles in the background are deformities in the plastic support of the carbon film. 
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Figure 5.18. Raw EM images of negatively stained amphipol A8-35 exchanged Cdr1-
XLmGFPHis particles that were used for data collection and 3D reconstructions. These 
images were taken at three different defocus values. 
 
The collection of the data set from 155 micrographs comprised almost 18,000 
individual particles and image processing was performed with the RELION software 3.0 (He 
et al., 2017). Particles were manually selected. Initial reference-free 2D class averages were 
created of ~3,000 manually selected particles from an initial subset of 56 micrographs. In 
the next step, 11 of the initially created 2D class averages were used as templates for a 
reference-based selection of particles using the ‘auto picking’ option. A total of 18,424 
particles were selected in this way (Figure 5.19). With this dataset, 50 2D class averages 
were created with 25 iterations and a mask diameter set at 200 Å. From these initial 
iterations 10,959 particles were used to create 21 2D class averages, depicted in Figure 




Figure 5.19. Example of auto-picked (green circles), negatively stained, EM images of 
individual amphipol A8-35 exchanged Cdr1-XLmGFPHis particles. 
 
    
Figure 5.20. 2D classification of negatively stained amphipol A8-35 exchanged Cdr1-
XLmGFPHis particles. (Left): 50 2D class averages were created from 18,424 ‘auto picked’ 
particles. (Laxminarayan et al.): the best resolved 21 2D class averages (red bordered 
images on the left), representing 10,959 particles, were selected for the final 3D 




Figure 5.21. 3D reconstruction of 10,959 negatively stained, amphipol A8-35 exchanged, 
Cdr1-XLmGFPHis EM particle images and the Fourier Shell Correlation plot (FSC). A) The 
estimated resolution was ~22-24 Å (pointed by the arrow), based on 0.143 criterion 
(Rosenthal et al., 2003). FSC measures similarity shell-by-shell in Fourier space both 
amplitudes and phases (Frank et al., 1982; Saxton et al., 1982; Harauz et al., 1986; 
Grigorieff, 2000). B) CDR1 map sides views. 
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The experiment was repeated at the MPI of Molecular Physiology, Dortmund, 
Germany, with an amphipol A8-35 exchanged Cdr1-XLmGFPHis sample (Figure 5.22). The 
SEC run did not give a satisfactory, homogeneous, distribution of individual particles 
suitable for creating 3D reconstructions (Figure 5.22). The negatively stained particles of 
the EM images of fractions 36 and 37 had an average diameter of 10-20 nm, most of which 
>15 nm. These fractions had quite a heterogenous particle distribution with a significant 
proportion of larger and smaller than the average size particle. These were quite possibly 
aggregated or partially degraded protein particles, or particles that were not completely 
exchanged with amphipol A8-35. Fraction 39 was more homogenous with generally smaller 
particles (10-15 nm diameter) than the negatively stained EM images of fractions 36 and 
37. There was, however, a staining problem which made it quite difficult to analyse the 
entire grid. Fraction 45 of the smaller, ~17 ml, elution peak contained mostly smaller 
particles (< 10 nm), which was consistent with a fraction that was expected to contain 
largely excess amphipol A8-35 and DDM micelles. 
 
Figure 5.22. Negative stained EM images of four fractions of DDM solubilised Cdr1-
XLmGFPHis after exchange with amphipol A8-35. SEC profile of the amphipol A8-35 
exchanged Cdr1-XLmGFPHis sample that was separated with a Superose 6 increase 10/300 
column. The four fractions that were selected for EM examination are labelled with red 
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dots, and the negative stained EM images of the correlating fractions are shown. Specimens 
were visualised, at 60k magnification, with a JEOL JEM-1400 EM microscope.  
 
The repeat negative stain EM of fraction 39, that represented the major, 
monomeric, Cdr1-XLmGFPHis peak, gave images of improved particle size distribution 
(Figure 5.23). Those images were used for data collection and the 3D reconstruction of 
amphipol A8-35 exchanged Cdr1-XLmGFPHis particles. Two hundred EM images were 
recorded at 60k magnification, and ~12,000 particles were automatically ‘picked’ with 
crYOLO (Wagner et al., 2019). Initial 3D volumes (three example volumes are shown in 
Figure 5.23) obtained for amphipol A8-35 stabilised Cdr1-XLmGFPHis particles had 
dimensions of 10 nm by 12 nm by 15 nm. These 3D volumes produced more electron 
density in regions that may possibly correspond to the NBDs of Cdr1-XLmGFPHis (Figure 
5.23). However, it was not feasible to progress any further with those data and produce a 
reliable 3D model. For that, higher quality homogeneous class averages were required. In 
fact, to run RVIPER successfully for negative stain data, at least 60 to 80 high quality 
averages with about 100 members each were needed and the input class averages had to 
include as many orientations of the particle, as possible. The lack of consistency between 
the models (Figure 5.21 and Figure 5.23) indicated that more work was required to further 
improve the quality of the protein samples.  
 
Figure 5.23. Example negative stained EM grid and three low-resolution 3D 
reconstruction volumes of amphipol A8-35 exchanged Cdr1-XLmGFPHis particles. 
Representative micrograph of negatively stained amphipol A8-35 exchanged Cdr1-
XLmGFPHis particles visualised at 60k magnification with a JEOL JEM-1400 electron 
microscope. Three example 3D reconstruction low resolution models are shown in blue. 
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5.3.2.2 Cdr1 in DDM/LMNG Detergent Micelles 
Although detergents can negatively affect sample quality and reduce contrast in 
negative stain and cryo-EM due to the presence of protein-free detergent micelles 
(Gewering et al., 2018), many detergent-solubilised membrane protein structures have 
been solved with cryo-EM (Orwick-Rydmark et al., 2016; Sgro et al., 2018). Thus, negative 
stain EM of purified Cdr1-XLmGFPHis solubilised with DDM or LMNG was performed. For 
this purpose, monomeric SEC peak fractions of DDM or LMNG solubilised and purified Cdr1-
XLmGFPHis samples, diluted to 6 mAU280, were used for negative stain EM using the JEOL 
JEM-1400 electron microscope. A dataset was only collected if the samples were of 
sufficient quality. Figure 5.24 shows EM images of two negatively stained LMNG solubilised, 
SEC purified, Cdr1-XLmGFPHis fractions, one (Figure 5.24-A) eluted with SEC buffer (Table 
2.6) that contained 2x CMC of LMNG at 13.5 ml (presumed dimer) and the other (Figure 
5.24-B) eluted at 15 ml (presumed monomer) elution volume. The Cdr1-XLmGFPHis 
particles in Figure 5.24-A were more heterogenous (a mix of monomers and dimers) than 
the particles in Figure 5.24-B which were homogenous and contained mostly smaller sized 
particles. Repeating the experiment, but by eluting the LMNG purified samples with SEC 
buffer that also contained 5% glycerol, gave similar results for the corresponding peak 





   
Figure 5.24. EM of negatively stained LMNG-solubilised and purified Cdr1-
XLmGFPHis/detergent micelle particles (SEC without glycerol). A) An electron micrograph 
of the negatively stained fraction that eluted at 13.5 ml (presumed dimer). B) An image of 
the negatively stained fraction that eluted at 15 ml (monomer) from the Superose 6 
increase 10/300 column. Both micrographs were taken at the same (60k) magnification; 
scale bar at bottom left of B) also relates to A). 
 
   
Figure 5.25. EM of negatively stained LMNG-solubilised and purified Cdr1-
XLmGFPHis/detergent micelle particles (SEC buffer with 5% glycerol). Representative 
images of the negatively stained presumed dimer (A) and presumed monomer (B) fractions 






Performing the second SEC (SEC buffer without glycerol) of the LMNG purified, 
monomeric peak fraction, that was used to generate the EM image in Figure 5.24, gave a 
sharp symmetrical monomer peak with a minor left shoulder (Figure 4.23-E). This LMNG-
solubilised and purified Cdr1-XLmGFPHis sample was also investigated with negative 
staining and EM (Figure 5.26). The vast majority of particles were similar in size (~13-16 
nm) and shape, suggesting a monodisperse homogenous sample. Two-hundred and four 
micrographs were collected with the JEOL JEM-1400 microscope and 94,758 particles were 
‘picked’ with crYOLO (Wagner et al., 2019). The particles were extracted with a square box 
size of 160 pixels and 2D class averages were generated with ISAC (Moriya et al., 2017). 
Some 2D class averages indicated the possible presence of LMNG micelles surrounding 
individual Cdr1-XLmGFPHis particles. Some potential top views were also observed (Figure 
5.27). The initial 3D-volume reconstruction model (by VIPER) gave an estimated resolution 
of ~17 Å (data not shown).  
 
Figure 5.26. EM images of negatively stained LMNG-solubilised and purified Cdr1-
XLmGFPHis/detergent micelle particles of the twice SEC-purified, monomer, peak 
fraction. The micrograph on the right is a magnification of the highlighted part in the left 




       
Figure 5.27. 2D class averages and 3D model of the negatively stained particle data set 
obtained from micrographs like the one shown in Figure 5.26. The top left panel shows all 
the 2D class averages obtained from 94,758 particles, and the top right panel shows the 
selected best 2D class averages. The bottom panel shows magnified side-on views of some 
of the most revealing 2D class averages. White arrows point towards the presumed LMNG 
micelle surrounding the embedded Cdr1-XLmGFPHis particle. The numbers indicate how 
many particles contributed to creating each of these 2D class averages. A 3D model of the 
Cdr1-XLmGFPHis/LMNG micelle particle is shown in the top right corner.  
 
Negative staining and EM of DDM solubilised and purified Cdr1-XLmGFPHis particles 
were also attempted. A similar trend of increased heterogeneity and larger particle size 
was observed in fractions obtained from the presumed dimer peak compared to the 
presumed monomer peak (data not shown). Figure 5.28 shows three representative 
examples of negative stained images obtained for Cdr1 monomers within a DDM micelle 
shell. Although quite similar to the images of LMNG solubilised Cdr1-XLmGFPHis monomers 
(Figure 5.26), they had a tendency to ‘stick’ together more and aggregate. The CMC of DDM 
(240–360 µM) is much higher than that of LMNG (22 nM) which means that the DDM 
solubilised Cdr1-XLmGFPHis sample may also contain significantly more, empty, DDM 





   
Figure 5.28. Representative EM images of negatively stained (1% uranyl acetate) DDM 
solubilised and purified Cdr1-XLmGFPHis particles (scale bars at bottom left are 200 nm). 
 
Amorphous carbon films can cause considerable background in EM images 
especially when studying small protein complexes (<200 kDa). Monomolecular layers of 
crystalline carbon, such as graphene (Geim et al., 2007), have gained popularity as an 
alternative support material. Because graphene is extremely hydrophobic, graphene oxide 
(GO) films (Pantelic et al., 2010) are preferred, although GO is less electron-transparent 
and more difficult to apply, reproducibly, as a monolayer on EM grids (Boland et al., 2017) 
(Pantelic et al., 2010; Pantelic et al., 2012). The application of DDM solubilised and purified 
Cdr1-XLmGFPHis particles on a Quantifoil 1.2/1.3, holey carbon, grid with a manually 
applied graphene layer, kindly provided by Dr. Tobias Raisch, was tried to see if it would 
improve the quality of the negatively stained EM images. However, the particle distribution 
and homogeneity obtained on these grids were discouraging (Figure 5.29). The particles 
tended to aggregate more and the background was also not reduced. Some studies have 
suggested that GO can affect particle orientation, distribution and on-grid concentration 
(Pantelic et al., 2010; Pantelic et al., 2012; Drulyte et al., 2018). 
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Figure 5.29. Representative negatively stained EM images of DDM solubilised and 
purified Cdr1-XLmGFPHis particles applied onto a holey carbon grid coated with a 
continuous GO monolayer. Using a GO monolayer rather than a carbon-coated grid did not 
improve image quality (scale bars at bottom left are 70 nm). 
 
A negative stain EM experiment for DDM solubilised and purified Cdr1-XLmGFPHis 
with beauvericin bound (in a 3.2-fold molar excess) was also performed at the Otago Micro 
and Nanoscale Imaging Centre (a portion of the same sample that was used for the hanging-
drop vapour-diffusion crystallisation trial). The samples showed reasonably homogenous 
particles distributed on the grid (Figure 5.30), although the grid contrast was not ideal. The 
most prominent particles were 10 nm by 15 nm in size. Three thousand five hundred 
particles were manually ‘picked’ and the ISAC software was used for 2D alignments and 
classification. A common V shaped structure appeared in most 2D class averages. Although 
there were too few particles to obtain 2D class averages, a low resolution 3D model (Figure 
5.30) was produced; but as it is hardly likely to generate a structure from images dominated 
by one (or a few) preferred orientation(s), the model was not accurate.  
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Figure 5.30. 2D class averages and 3D model of negatively stained EM images of DDM-
solubilised Cdr1-XLmGFPHis particles with the inhibitor beauvericin bound. A) A 
representative electron micrograph taken at 60k magnification (scale bar at bottom right 
is 100 nm). B) 2D class averages of 3,600 manually picked particles (numbers indicate the 
number of particles contributing to each 2D class average). C) A magnified 2D class average 
that shows a potential side-on view of the particle. D) The 3D model that was created based 
on the 2D class averages. Phosphotungstic acid with a near neutral pH, was used for 
negative staining and generated inferior contrast compared to the typically used uranyl 
salts. 
 
5.3.3 Cryo-EM of Purified Cdr1-XLmGFPHis/Detergent Micelle Particles 
Despite all efforts, the protocol for cryo-EM of purified Cdr1 needs further 
optimisation; ice thickness and equal sample distribution, for example, are still an issue, as 
demonstrated in Figure 5.31. Even optimised grid plunging and double blotting conditions 
with the optimised blotting time and blotting force still resulted in holes with a gradient of 
vitrified ice thickness. Grid areas with thinner ice turned out to be generally more suitable 
for creating high quality cryo-EM images. Protein particles tended to be absent from the 
thinner layers of vitrified ice that usually formed in the central parts of the holes (Figure 
5.31). Instead, most protein particles accumulated, and were more evenly distributed, in 
the thicker parts of the ice near the edges of the holes (Figure 5.31). To check particle 
distribution, several grids were screened using the VPP to increase contrast. For initial test 
screens less-pure detergent solubilised Cdr1-XLmGFPHis samples eluted from the nickel-
affinity column in IMAC buffer containing 4x CMC of LMNG (1.8 mg/ml; A280/A250 = 2.1) 
were applied directly onto the cryo-grids and visualised. The particle concentration was too 
high and the micrographs (Table 5.1; first row) showed mostly aggregated particles. 





dataset even though there was a heterogenous particle distribution of different sizes and 
shapes, including some aggregated particles and other impurities. Despite that, the 2D class 
averages obtained from 84,842 individual particles that were selected from 794 images 
provided useful 2D class averages (Figure 5.32-A). Another data set of 15,000 particles was 
collected from 520 cryo-EM micrographs that were prepared with LMNG solubilised and 
purified Cdr1-XLmGFPHis, a sample similar to the one that generated the images in Figure 
5.24. Although the majority of particles aggregated near the edge of the hole and ice 
thickness was still an issue (hardly any protein particles were seen in the centre, instead 
many small, unidentified, black dots could be found in that region), the 2D class averages 
gained from these cryo-EM grids were less revealing with a tendency to produce averages 
biased towards side-on views (Figure 5.32-B), which was quite possibly related to problems 
associated with uneven ice thickness. So, in order to run RVIPER successfully for cryo data, 
it was necessary to have at least 60 to 80 high quality averages with about 100 to 200 
members each, including as many orientations of the particle, as possible. Yet, as this 
number of images was not available, it was not possible to create 3D models based on 
those data.  
 
Table 5.1. Examples of cryo-EM micrographs obtained with different Cdr1-XLmGFPHis 
preparations (chosen EM defocus values are also listed). A Talos Arctica cryo-EM was used 
at 100k magnification. The yellow scale bars represent 20 nm. 
Cdr1-XLmGFPHis sample Defocus -3 VPP (defocus -1.2) 





Cdr1-XLmGFPHis sample Defocus -3 VPP (defocus -1.2) 
IMAC purified in 4x CMC of LMNG (diluted) 
(0.3 mg/ml) 




Amphipol A8-35 exchanged  
(1.3 mg/ml) 
A280/A250 = 2 
  
SEC purified in 2x CMC of LMNG  
(0.08 mg/ml)  
GO  
  




Cdr1-XLmGFPHis sample Defocus -3 VPP (defocus -1.2) 
SEC purified in 2x CMC of LMNG (diluted)  
(0.4 mg/ml) 
  
SEC purified in 2x CMC of LMNG (diluted) 
(0.3 mg/ml) 
  
SEC purified in 2x CMC of LMNG (diluted) 
(0.2 mg/ml) 
used for data collection without VPP  
(520 micrographs) 
  








    
    
    
     
Figure 5.31. Examples of cryo-EM vitrified ice thickness and particle distribution problems 
encountered for detergent solubilised Cdr1-XLmGFPHis particles. A) Cryo-EM grid at very 
low-magnification shows individual squares with an ice-gradient from thick (top left) to thin 
ice (bottom right). B) to D) Uneven ice distribution inside the grids (low-magnification). 
Darker parts are thick ice. E) to G) Uneven ice distribution inside holes. H) Uneven ice 
thickness across the hole, with thick ice on the edge and thin ice in the centre. I) Even ice 
distribution inside the hole, but the ice was too thick. A big ice contaminant was also 
present on the right-hand side (red circle). J) to L) High-magnification images (yellow scale 
A                                                   B                                                    C 
 
G                                                    H                                                   I 
 
J                                                    K                                                    L 
 
D                                                   E                                                    F 
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bars represent 20 nm) with protein particles visible in the ice background. In (J), again 
uneven protein particle distribution was visible. There was thicker ice at the edge and 
thinner ice in the middle which forced Cdr1 molecules away from the thin layer of ice, near 
the centre, to the thicker ice regions at the edge of the hole. This increased the amount of 
aggregation and made it difficult to analyse the data set. In (K), uneven protein distribution 
was also evident. Although (L) showed a good even distribution of ice, the ice was thick 
and, even though the particles were nicely distributed, the lack of contrast made analysis 
difficult. Some ice contaminants are highlighted with red circles. Dark blue arrows point to 




Figure 5.32. 2D class averages of two cryo-EM data sets. A) 2D class averages of 84,842 
particle images collected from the diluted, IMAC purified, LMNG solubilised (4x CMC of 
LMNG), Cdr1-XLmGFPHis sample (0.3 mg/ml). B) 2D class averages of 15,000 particle 
images collected from the diluted, LMNG-solubilised (2x CMC of LMNG), and purified Cdr1-
XLmGFPHis sample (0.2 mg/ml). The numbers in the bottom left corners indicate how many 






Of all membrane protein structures deposited in the protein database, 81% were created 
with X-ray crystallography, 8% with cryo-EM, and ~10% were solved with solution NMR 
(http://www.rcsb.org/pdb/results/results.do?tabtoshow=Current&qrid=FA5F4D63). Pure, 
mono-disperse, detergent solubilised Cdr1-XLmGFPHis was obtained in amounts, and at 
concentrations (15-25 mg/ml), that were suitable for X-ray crystallography and cryo-EM. 
However, further optimisation of the purification, crystallisation, and cryo-EM protocols 
are required to ultimately succeed in solving the structure of Cdr1 at high resolution. 
Although DDM has been used quite successfully in X-ray crystallography and single particle 
analysis to obtain important ABC transporter structures in the past, the addition of lipids in 
different experiments helped (Galian et al., 2011; Shintre et al., 2013; Shukla et al., 2017). 
Lee et al, 2016, obtained X-ray diffracting human ABCG5/ABCG8 crystals only after 
exchanging DDM for DMNG (Lee et al., 2016). Replacing DDM with LMNG or adding lipids 
to the detergent solubilised and purified Cdr1 sample are possible options for improving 
the purification protocol. Removing the C-terminal GFP fluorescent tag with HIV-3C 
protease may also help obtain Cdr1 crystals. The promiscuous nature of the Cdr1 pump, 
with its ability to transport a vast array of xenobiotics of various chemical properties, means 
that it is also a very flexible protein which can be quite detrimental for crystal formation. 
The attempt to lock the DDM solubilised and purified Cdr1 molecule in the open 
conformation with the Cdr1 inhibitor, beauvericin, did show signs of potential crystal 
formation in the MemGold2 screen. For instance, Cdr1-XLmGFPHis crystals appeared to 
grow in wells G10 (50 mM ADA, pH 6.5, 24% v/v PEG 400) and H1 (50 mM Tris.HCl, pH 8.5, 
28% v/v PEG 400). However, as the putative crystals did not grow big enough for X-ray 
analysis, it is uncertain whether they were Cdr1 crystals. So, future crystallisation trials 
around these initial, rather promising, ‘lead conditions’ (24-28% PEG 400; pH 6.5-8.5) are 
warranted. Subtle changes in temperature or in the buffer composition may induce crystal 
formation by slowing down or increasing crystal packing. The concentrations of the purified 
Cdr1 samples may also have been too high as indicated by sudden precipitation in more 
than 70% of the test conditions. Thus, reducing the protein concentration to <10 mg/ml 
may provide favourable conditions for Cdr1 crystal formation. Another possibility for 
improving the chance of obtaining suitable crystals for X-ray crystallography is using a 
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catalytically inactive Cdr1 mutant which could be locked with ATP in the ATP-bound 
conformation. Initial activity assays and trials with LMNG solubilised and purified Cdr1-
D1027Q samples showed promising results that warrant further investigations in future 
crystallisation trials (see Section 3.3.10). 
The ‘resolution revolution’ of cryo-EM has led to a significant increase in the 
number of membrane protein structures solved in the past few years. Initial negative stain 
and cryo-EM results were obtained for purified Cdr1-XLmGFPHis, either solubilised with 
LMNG or stabilised with amphipol. This project resulted in some 2D class averages and 3D 
models, for amphipol A8-35 exchanged and/or detergent solubilised Cdr1-XLmGFPHis 
particles. However, it should be acknowledged that the model resolutions were too low 
and the results too preliminary to make any firm conclusions. The somewhat smaller model 
(7.8-10 nm by 15 nm) obtained for amphipol A8-35 stabilised Cdr1-XLmGFPHis particles 
compared to the slightly ‘bulkier’ Cdr1-XLmGFPHis/detergent micelle particles (12.5 nm by 
14.5 nm) was perhaps not surprising, as the detergent-micelle surrounds the TMDs of 
membrane proteins while amphipols act more like a tight belt surrounding membrane 
proteins (Figure 4.4). The highest contrast in the 2D class averages was, unfortunately, 
observed in the detergent micelle region surrounding, and thus obscuring, the 
transmembrane domain of Cdr1. This is a general problem observed for most membrane 
proteins, irrespective of whether they are solubilised by detergent or reconstituted into 
amphipols or nanodiscs.  
The persistent problems with the plunging and freezing steps and the 
inconsistencies in the particle density between repeat experiments severely limited the 
number of useful particles that could be selected for the reconstruction of a high-resolution 
3D map of Cdr1-XLmGFPHis. For that purpose, hundreds of thousands of evenly distributed, 
clearly separated, particles in all possible orientations are required. However, hydrophobic 
regions of membrane proteins favour binding to the air-water interface rather than staying 
in contact with water (D'Imprima et al., 2019). This may explain the partial 
denaturation/aggregation or preferential orientation encountered in the presented cryo-
EM grid images. Detergent molecules accumulate at the air-water interface with their 
hydrophobic tails facing the interior, thus shielding the air-water interface and enabling 
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membrane protein particles to assume random orientations. So, perhaps the purified Cdr1 
solution did not contain enough free LMNG detergent to enable the Cdr1-XLmGFPHis 
particles to be displayed in all possible orientations. Adding more LMNG or Triton X-100 
should be tested in the future. The use of hydrophobic graphene coated grids has been 
suggested to help membrane protein orientation and distribution (Sgro et al., 2018; 
D'Imprima et al., 2019). However, using cryo-EM graphene grids did not improve the quality 
of the cryo-EM images of the LMNG solubilised and purified Cdr1-XLmGFPHis particles 
obtained in this study (data not shown). The removal of the C-terminal -XLmGFPHis tag and 
locking Cdr1 in the open conformation (by binding it to beauvericin), or the closed 
conformation (by using the catalytically inactive Cdr1-D1027Q mutant in the presence of 
ATP) are some of the possible ways for generating a high resolution cryo-EM structure for 
Cdr1, in the future.  
LMNG appeared to be a better detergent choice for the cryo-EM studies of Cdr1 
than DDM; DDM solubilised and purified Cdr1 particles tended to aggregate much more 
than their LMNG counterparts, and they also accumulated more around the edges of 
individual grid holes. This observation is consistent with previous reports of LMNG having 
the tendency to stabilise ‘fragile’ membrane proteins, even in the absence of detergent 
micelles below the CMC (Hauer et al., 2015). 
The 3D model of the LMNG solubilised Cdr1-XLmGFPHis molecule obtained from 
negatively stained EM images is the first 3D model for Cdr1, although its resolution is rather 
low. Thus, more experimentation is required to obtain a high-resolution cryo-EM 
reconstruction of Cdr1.  
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CHAPTER SIX   
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6 Concluding Remarks 
C. albicans is one of the major human fungal pathogens of immunocompromised 
and vulnerable population groups. The dearth of antifungals available to the clinician and 
the increasing threat of drug resistant isolates is an urgent wake-up call to develop novel 
antifungals or multidrug efflux pump inhibitors that could be used in combination therapy 
to treat infections caused by multidrug resistant strains. One of the major mechanisms of 
azole resistance in clinical C. albicans isolates is the overexpression of the plasma 
membrane multidrug efflux pump, Cdr1 (Cannon et al., 2009). Detailed structural and/or 
functional information of drug targets, such as Cdr1, is essential for improving existing, or 
developing new, drugs (Lundstrom, 2007). Yet, understanding the structure of Cdr1 or, 
indeed, any other efflux pump of this important ABC transporter subfamily remains elusive. 
However, even in the absence of any direct structural information, valuable indirect 
evidence on the possible structure of a protein can be gained from the detailed biochemical 
characterisation of a protein. Such information could not only provide useful insights into 
important structural features of a protein and its mechanism of action, but it is also 
essential for validating any existing structure. With this in mind, a two-pronged approach 
was undertaken to investigate the structure of Cdr1. The first approach was to create a 
functional, Cys-less recombinant Cdr1 molecule as an invaluable tool for, among many 
other things, cysteine cross-linking studies to scrutinise existing models. Although a 
previous study reported the creation of just such a molecule (Prasad et al., 2012b), that 
report turned out to be incorrect; the Cys-less Cdr1 was inactive. This was the reason why 
various versions of partially Cys-less Cdr1 mutants were created. Studies on these Cdr1 
variants ultimately demonstrated that the six conserved extracellular cysteines were 
essential for correct folding, proper localisation and function of Cdr1. With the help of 
these mutants, a specific partially Cys-less Cdr1 mutant, Cdr1P-CID, was created. Cdr1P-CID 
was functional and had all but the six conserved extracellular cysteines replaced with serine 
or alanine, except for C1106 which was replaced with isoleucine. It was proposed that these 
six extracellular cysteines form three conserved disulphide bonds that stabilise PDR 
transporters, including Cdr1 (Lamping, et al, unpublished results). Since covalently linked 
cysteines involved in disulphide bonds do not interfere with cysteine cross-linking studies, 
 224 
this partially Cys-less and functional Cdr1P-CID mutant can now be used for cysteine-
crosslinking studies. 
The second major objective of this thesis was to overexpress Cdr1 in S. cerevisiae 
and purify enough mono-disperse, detergent solubilised, protein suitable for X-ray 
crystallography and cryo-EM studies. The S. cerevisiae membrane protein expression 
system (Lamping et al., 2007; Sagatova et al., 2015) provided sufficient Cdr1 in the plasma 
membrane to produce enough (0.5 mg/l cell culture) of the purified, detergent solubilised, 
and mono-disperse efflux pump for preliminary X-ray crystallography, negative stain EM 
and cryo-EM studies. The main purpose of this part was to optimise a Cdr1 purification 
protocol and use that purified protein solution to optimise crystallisation and cryo-EM 
conditions and make as much progress, as time would allow, towards the ultimate goal of 
solving the structure of Cdr1. Upscaling the robust and reproducible mini-scale plasma 
membrane preparation protocol for large-scale preparations did not result in an equally 
active plasma membrane preparation of Cdr1 (i.e. ~2-fold lower Cdr1 specific ATPase 
activities), although it too was reproducible and created enough raw material for the 
purification of Cdr1 (3 mg purified Cdr1 from a 6 L culture). Although further optimisation 
of the large-scale plasma membrane preparation protocol may increase the specific Cdr1 
ATPase activity, it is unlikely that it would improve any downstream purification processes. 
Initial detergent screens identified DDM and LMNG as the two best candidates for 
the solubilisation of Cdr1. Detergents with larger hydrophobic sidechains (>13 carbons) 
gave noticeably better solubilisation efficiencies, possibly because Cdr1 preferentially 
associates with lipid raft like microdomains of increased biolayer thickness (Pasrija et al., 
2008; Simons et al., 2010). For efficient (90-100%) solubilisation of Cdr1, the weight ratio 
between the detergent and the isolated plasma membranes had to be kept to 2 or higher. 
Maintaining this ratio is important because it takes into account the need for complete 
solubilisation of plasma membrane lipids as well as the protein. It was also demonstrated 
that using glycerol in the buffers to maintain the stability of purified Cdr1 was not 
necessary, which can be quite beneficial for cryo-EM experiments because glycerol can 
reduce image contrast of particles. After optimising the two-step (nickel affinity 
chromatography followed by SEC) purification protocol, Cdr1 remained as a stable 
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monomer in detergent micelles. However, there is still room for improvement of the 
purification protocol. For example, optimising the buffer a little more to get rid of the left 
(dimer) shoulder, or optimising the volume of the sample injected onto the size-exclusion 
column for optimum separation of protein peaks.  
Adding a five amino acid linker with a protease cleavage site (XL) between Cdr1 and 
the double tag (-XLmGFPHis) was also a very useful modification which improved binding 
of Cdr1 to the nickel-affinity column and prevented possible steric interference of the 
mGFPHis double tag with Cdr1 function. The mGFP tag had a number of other advantages; 
it enabled quantification of Cdr1 expression levels (in-gel GFP fluorescence), monitoring 
Cdr1 localisation, and detergent solubilisation screening (FSEC). FSEC can also be used to 
study the impact of other parameters on the behaviour of a membrane protein, 
parameters like for instance ionic strength, reducing agents or any other buffer 
supplements.  
Despite my best efforts at optimising the SEC purification conditions, even with the 
larger HiLoad 16/600 Superdex 200 column that was expected to provide a better peak 
separation, the chromatograms had a small shoulder of possibly higher order Cdr1 
oligomers to the left of the main Cdr1 monomer peak. However, it should be mentioned 
that the monomeric peak was stable and after subjecting it to a second SEC, the signal in 
the shoulder peak was reduced. The Superdex 200 column gave more of the higher 
‘oligomeric’ peak than the Superose 6 increase 10/300 column, but this was possibly 
related to the usual problems encountered when upscaling protocols. To ensure Cdr1 
molecules remained solubilised in detergent micelle particles, the detergent concentration 
was kept above its CMC (4x CMC for IMAC; 2x CMC for SEC) throughout the purification 
steps. But, as a consequence, excess micelles may have interfered with some downstream 
applications, specifically X-ray crystallography and cryo-EM. To overcome such issues, 
purified Cdr1 preparations that had the detergents replaced with amphipols were also 
generated. Although initial results of negatively stained EM images of amphipol-exchanged 
preparations were encouraging, they were also not very reproducible; further optimisation 
of the amphipol exchange protocol is required. 
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For the successful crystallisation of membrane proteins a concentration of a very 
pure protein between 5 and 15 mg/ml is recommended (Newby et al., 2009). Although the 
concentrations of the purest DDM solubilised Cdr1 were within that range, initial 
crystallisation trials produced few crystals big enough to be ‘fished’. Some of the conditions 
showed signs of possible protein micro-crystals, but they could as easily have been 
crystallisation artefacts. Clearly, important factors such as: A) removal of the C-terminal -
XLmGFPHis tag; B) stabilising a particular conformation of the catalytically inactive Cdr1-
D1027Q mutant by binding it to ATP; C) stabilising a particular conformation of the Cdr1 
molecule by the inhibitor (beauvericin); D) considering the possible influence of glycerol on 
crystallisation; and E) the use of different detergents, are all important factors that could 
help in future crystallisation trials. 
Structure determination by cryo-EM has the advantage that protein molecules are 
visualised closer to physiological conditions than those used in crystallography, and also a 
considerably smaller amount of protein is required to obtain a high-resolution structure. 
Further optimisation is required to obtain cryo-EM grids of sufficient quality to get good 
Cdr1 images. In addition, protocol improvements are necessary to generate reproducible 
grid-preparations of well distributed Cdr1/detergent micelle particles presenting in all 
possible orientations (Drulyte et al., 2018). The negatively stained EM images of Cdr1-
XLmGFPHis/LMNG micelle particles revealed a first glimpse of the 3D structure of Cdr1 at 
low resolution. Although Cdr1 clearly ‘prefers’ detergents with longer hydrophobic tails, 
shorter detergents are generally more likely to provide high-quality structural information 
in cryo-EM, and also crystallography, because of an increased probability of better protein-
protein contacts necessary for lattice formation (Alegre et al., 2015). Thus, optimisation of 
the amphipol exchange protocol, or exploring the suitability of other detergents with 
shorter alkyl side-chains that preferably produce smaller Cdr1-encapsulating micelles may 
also have to be considered for cryo-EM and X-ray crystallography studies of Cdr1. 
In conclusion, a functional, Cys-less, Cdr1 mutant has been created that can be used 
for cysteine crosslinking studies. A catalytically inactive Cdr1-D1027Q mutant has also been 
created as an alternative source for crystallisation and cryo-EM studies. This mutant had 
practically no ATPase activity, which implicates a less dynamic molecule and theoretically, 
 227 
it should enable us to lock the molecule, in the presence of ATP, in the closed conformation. 
So, using this mutant might be the key for determining the structure of Cdr1, especially 
after cleaving the linker to make the molecule more stable. Locking the protein with ATP in 
a certain conformation can significantly increase the chance of obtaining X-ray diffracting 
crystals. The optimised two-step purification protocol permits the isolation of milligram 
quantities of homogeneous, monodisperse, Cdr1. With these purified Cdr1 preparations, it 
was possible to create a first, low-resolution, 3D model of Cdr1, and there were some 
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A1. Mass Spectrometry Results 
Heat Shock Proteins are Upregulated in N2-containing CDR1PC-GFP mutants and 
the Coomassie blue stained SDS-PAGE gels of the six Cys-deficient CDR1PC-GFP mutants 
with substitutions in the N2 domain presented a prominent ~70 kDa protein band 
dramatically upregulated in those strains (Chapter three; Figure 3.28). MALDI-TOF-TOF 
analysis are shown: 
MASCOT search results identified the ~70 kDa band as the yeast HSP72 heat shock 
protein Ssa2 (score: 2156, protein coverage: 43%) and the ~70 kDa band as the yeast HSP71 
heat shock protein Ssa1 (score: 2026, protein coverage: 39%). 
 
A) Protein View: HSP72_YEAST 
Heat shock protein SSA2 OS=Saccharomyces cerevisiae (strain ATCC 204508 / 
S288c) GN=SSA2 PE=1 SV=3 
Database: SwissProt 
Score: 2156 
Nominal mass (Mr): 69427 
Calculated pI: 4.95 
Taxonomy: Saccharomyces cerevisiae S288c 
 
Protein sequence coverage: 43% 
Type of search         : MS/MS Ion Search 
Enzyme                 : Trypsin, cuts C-term side of KR unless next residue is P. 




Matched peptides shown in bold. 
1 MSKAVGIDLG TTYSCVAHFS NDRVDIIAND QGNRTTPSFV GFTDTERLIG 
51 DAAKNQAAMN PANTVFDAKR LIGRNFNDPE VQGDMKHFPF KLIDVDGKPQ 
101 IQVEFKGETK NFTPEQISSM VLGKMKETAE SYLGAKVNDA VVTVPAYFND 
151 SQRQATKDAG TIAGLNVLRI INEPTAAAIA YGLDKKGKEE HVLIFDLGGG 
201 TFDVSLLSIE DGIFEVKATA GDTHLGGEDF DNRLVNHFIQ EFKRKNKKDL 
251 STNQRALRRL RTACERAKRT LSSSAQTSVE IDSLFEGIDF YTSITRARFE 
301 ELCADLFRST LDPVEKVLRD AKLDKSQVDE IVLVGGSTRI PKVQKLVTDY 
351 FNGKEPNRSI NPDEAVAYGA AVQAAILTGD ESSKTQDLLL LDVAPLSLGI 
401 ETAGGVMTKL IPRNSTIPTK KSEVFSTYAD NQPGVLIQVF EGERAKTKDN 
451 NLLGKFELSG IPPAPRGVPQ IEVTFDVDSN GILNVSAVEK GTGKSNKITI 
501 TNDKGRLSKE DIEKMVAEAE KFKEEDEKES QRIASKNQLE SIAYSLKNTI 
551 SEAGDKLEQA DKDAVTKKAE ETIAWLDSNT TATKEEFDDQ LKELQEVANP 





B) Protein View: HSP71_YEAST 
Heat shock protein SSA1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / 
S288c) GN=SSA1 PE=1 SV=4 
Database: SwissProt 
Score: 2026 
Nominal mass (Mr): 69615 
Calculated pI: 5.00 
Taxonomy: Saccharomyces cerevisiae S288c 
Enzyme: Trypsin: cuts C-term side of KR unless next residue is P. 
 
Protein sequence coverage: 39% 
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Matched peptides shown in bold. 
1 MSKAVGIDLG TTYSCVAHFA NDRVDIIAND QGNRTTPSFV AFTDTERLIG 
51 DAAKNQAAMN PSNTVFDAKR LIGRNFNDPE VQADMKHFPF KLIDVDGKPQ 
101 IQVEFKGETK NFTPEQISSM VLGKMKETAE SYLGAKVNDA VVTVPAYFND 
151 SQRQATKDAG TIAGLNVLRI INEPTAAAIA YGLDKKGKEE HVLIFDLGGG 
201 TFDVSLLSIE DGIFEVKATA GDTHLGGEDF DNRLVNHFIQ EFKRKNKKDL 
251 STNQRALRRL RTACERAKRT LSSSAQTSVE IDSLFEGIDF YTSITRARFE 
301 ELCADLFRST LDPVEKVLRD AKLDKSQVDE IVLVGGSTRI PKVQKLVTDY 
351 FNGKEPNRSI NPDEAVAYGA AVQAAILTGD ESSKTQDLLL LDVAPLSLGI 
401 ETAGGVMTKL IPRNSTIPTK KSEIFSTYAD NQPGVLIQVF EGERAKTKDN 
451 NLLGKFELSG IPPAPRGVPQ IEVTFDVDSN GILNVSAVEK GTGKSNKITI 
501 TNDKGRLSKE DIEKMVAEAE KFKEEDEKES QRIASKNQLE SIAYSLKNTI 
551 SEAGDKLEQA DKDTVTKKAE ETISWLDSNT TASKEEFDDK LKELQDIANP 
601 IMSKLYQAGG APGGAAGGAP GGFPGGAPPA PEAEGPTVEE VD 
 
 
A2. Buffer Compositions of Four Commercial Screens Used in this Project for 
the Crystal Trials 
These 96 well microtiter plates are based on crystallisation conditions data mined 
from the Protein Data Bank, which provide four separate matrix screens containing 96 
conditions covering a range of pH, PEGs and salt additives (MbClass I and II Suite (Qiagen) 
and MemGold™ and MemGold2™ (Molecular Dimensions). The compositions of the 

















BICINE; N,N-Bis(2-hydroxyethyl)glycine, HEPES; N-(2-hydroxyethyl)-piperazine-N'-2-ethanesulphonic acid, 
KMES; 2-(N-morpholino)ethanesulphonic acid potassium salt, MES; 2-(N-morpholino)ethanesulphonic 
acid, MME; Monomethylether, PEG; Polyethylene glycol, Tricine; N- [Tris(hydroxymethyl)methyl]glycine, 





Abbreviations: ADA; N-(2-Acetamido)iminodiacetic Acid, BICINE; N,N-Bis(2-hydroxyethyl)glycine, Bis-Tris; 
2,2'-(Propane-1,3- diyldiimino)bis[2-(hydroxymethyl)propane-1,3-diol]. CHES; 2-(N-Cyclohexylamino)ethane 
sulphonic Acid, HEPES; N-(2- hydroxyethyl)-piperazine-N'-2-ethanesulphonic acid, MES; 2-(N-
morpholino)ethanesulphonic acid, MME; Monomethylether, MOPS; 3-morpholinopropane-1-sulphonic acid, 
PEG; Polyethylene glycol, PEG DME; Poly(ethylene glycol) bis(carboxymethyl) ether, Tricine; N-
[Tris(hydroxymetl)methyl]glycine, Tris; 2-Amino-2-(hydroxymethyl)propane-1,3- diol.  
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